<SEC-DOCUMENT>0001513160-12-000090.txt : 20121121
<SEC-HEADER>0001513160-12-000090.hdr.sgml : 20121121
<ACCEPTANCE-DATETIME>20121121152748
ACCESSION NUMBER:		0001513160-12-000090
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20120930
FILED AS OF DATE:		20121121
DATE AS OF CHANGE:		20121121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OXIS INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-08092
		FILM NUMBER:		121221120

	BUSINESS ADDRESS:	
		STREET 1:		468 N. CAMDEN DR.
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90210
		BUSINESS PHONE:		(310) 551-4020

	MAIL ADDRESS:	
		STREET 1:		468 N. CAMDEN DR.
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>oxis10q09302012.htm
<DESCRIPTION>OXIS QUARTERLY REPORT
<TEXT>
<html>
<head>
    <title>oxis10q09302012.htm</title>
    <!--Licensed to: OXIS International, Inc,-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">U. S. SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, DC 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">&#254;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the quarterly period ended <font style="DISPLAY: inline; FONT-WEIGHT: bold">September 30, 2012.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">&#168;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the transition period from <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font> to <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Commission File Number 0-8092</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Exact name of small business issuer as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(State or other jurisdiction of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">incorporation or organization)</font></div>
</td>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">94-1620407</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(I.R.S. employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">identification number)</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">468 N. Camden Dr., 2nd Floor, Beverly Hills, CA 90210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Address of principal executive offices and zip code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(310) 860-5184</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Registrant&#8217;s telephone number, including area code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font> No <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font> No&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font> (<font style="DISPLAY: inline; FONT-SIZE: 10pt">Do not check if a smaller reporting company)</font></font></div>
</td>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
</tr><tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).<font id="TAB1" style="MARGIN-LEFT: 12pt"></font>Yes <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font>No <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">At September 30, 2012, the issuer had outstanding the indicated number of shares of common stock:&#160;&#160;457,207,313.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Quarter Ended September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table of Contents</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART I&#160;&#160;FINANCIAL INFORMATION</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" colspan="2" valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Page</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial Statements</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Balance Sheets as of September 30, 2012 (Unaudited) and December 31, 2011</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Operations for the three months and nine months ended September 30, 2012&#160;&#160;and 2011 (Unaudited)</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statement of Stockholders&#8217; Deficit</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 and 2011 (Unaudited)</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Condensed Notes to Consolidated Financial Statements</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 2.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;22</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 3.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Quantitative and Qualitative Disclosures About Market Risk</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;28</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 4.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Controls and Procedures</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 29</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td colspan="5" valign="bottom" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART II&#160;&#160;OTHER INFORMATION</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Legal Proceedings</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 30</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1A.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk Factors</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 30</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 2.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unregistered Sales of Securities and Use of Proceeds</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 30</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 3.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Defaults Upon Senior Securities</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;31</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 4.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mine Safety Disclosures</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;31</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 5.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other Information</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;31</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 6.</font></div>
</div>
</td>
<td valign="bottom" width="58%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibits</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 31</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td colspan="2" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SIGNATURES</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;32</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I.&#160;&#160;FINANCIAL INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC. AND SUBSIDIARIES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Balance Sheets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">As of September</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">30, 2012 and December 31, 2011</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">September</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">30, 2012</font></font></div>
</td>
<td valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current Assets:</font></div>
</div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">92,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventories</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Current Assets</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">73,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">104,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patents, net</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Other Assets</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TOTAL ASSETS</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">88,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">129,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current Liabilities:</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">858,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">806,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued interest</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,225,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,598,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,049,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">607,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Line of credit</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant liability</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">514,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">158,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Demand notes payable, net of discount of $0 and $54,000</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">63,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">266,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible debentures, net of discount of $0 and $0, current portion</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,966,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">775,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible debentures</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">625,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">995,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Current Liabilities</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,326,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,230,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; Deficit:</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized:</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series C - 96,230 and 96,230 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series H &#8211; 25,000 and 25,000 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series I &#8211; 1,666,667 and 1,666,667 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock - $0.001 par value; 600,000,000 shares authorized;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">457,207,313<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>and 269,299,838 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">457,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">269,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,634,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,422,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated deficit</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(88,205,000</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(83,795,000</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Minority interest</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(127,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Stockholders&#8217; Deficit</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,238,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,101,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</font></div>
</div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">88,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">129,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The accompanying condensed notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC. AND SUBSIDIARIES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three Months and Nine Months Ended September 30, 2012 and 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.55pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.55pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">120,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">123,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TOTAL REVENUE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">120,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">123,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost of Product Revenue&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gross profit (loss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">88,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">90,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(25,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating Expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative<font id="TAB1" style="MARGIN-LEFT: 12pt"></font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,438,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">535,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,865,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,806,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,438,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">535,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,865,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,855,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss from Operations&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,350,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(541,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,775,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,880,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in value of warrant and derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">681,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(358,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">783,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense/income&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(65,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(117,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,305,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(465,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Other Income (Expense)<font id="TAB1" style="MARGIN-LEFT: 12pt"></font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(65,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">564,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,663,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">318,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss before minority interest and provision for income taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,415,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,438,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Minority interest in subsidiary</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income (loss) before provision for income taxes<font id="TAB1" style="MARGIN-LEFT: 12pt"></font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,400,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,410,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,562,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provision for income taxes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net gain&#160;(loss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,400,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,410,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,562,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss Per Share, basic and diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted Average Shares Outstanding, basic and diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">397,553,268</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">213,511,550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">336,824,712</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">183,038,141</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The accompanying condensed notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC. AND SUBSIDIARIES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statement of Stockholders&#8217; Deficit</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Nine Months Ended September 30, 2012 (unaudited) and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="98%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="21%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="4" valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Preferred Stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="4" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="14%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Additional Paid-in</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="21%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Capital</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deficit</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance, December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,787,897</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">149,571,976</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">149,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,474,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(80,095,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of stock options</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">307,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for services</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,210,498</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,355,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of debt</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">77,734,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,286,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise of warrants</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,783,364</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="21%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,700,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance at December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,787,897</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">269,299,838</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">269,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,422,000</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(83,795,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of stock options</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">699,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of debt</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,107,475</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,438,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for services</font></div>
</td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,800,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">754,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="21%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,410,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="21%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance at September 30, 2012</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1,787,897</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$3,000</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">457,207,313</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">457,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">81,634,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(88,205,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="21%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The accompanying condensed notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC. AND SUBSIDIARIES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Cash Flows</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Nine Months Ended September 30, 2012 and 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="98%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="68%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="5" valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine months Ended September 30,</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>
</td>
<td align="left" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,410,000</font></div>
</div>
</td>
<td valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,562,000</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of intangible assets</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></div>
</div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock compensation expense for options and warrants&#160;issued to employees and non-employees</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">699,000</font></div>
</div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">126,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of shares for services</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">782,000</font></div>
</div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,597,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of debt discounts</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,000</font></div>
</div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">306,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in value of warrant and derivative liabilities</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">356,000</font></div>
</div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(783,000</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,000</font></div>
</div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,000</font></div>
</div>
</td>
<td valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,000</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">667,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(773,000</font></div>
</div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(639,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from the exercise of options and warrants</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from notes payable</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">615,000</font></div>
</div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">621,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Repayment of note payable</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></font></td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">615,000</font></div>
</div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">585,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Minority Interest</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">127,000</font></div>
</div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NET DECREASE IN CASH AND CASH EQUIVALENTS</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(31,000</font></div>
</div>
</td>
<td valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(54,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH AND CASH EQUIVALENTS - Beginning of period</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">92,000</font></div>
</div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="68%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH AND CASH EQUIVALENTS - End of period</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,000</font></div>
</div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The accompanying condensed notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 1 -- The Company and Summary of Significant Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OXIS International, Inc. (collectively, &#8220;OXIS&#8221; or the &#8220;Company&#8221;) is engaged in the research, development and sale of products that counteract the harmful effects of &#8220;oxidative stress&#8221; and inflammation.&#160;&#160;Oxidative stress refers to the situations in which the body&#8217;s antioxidant and other defensive abilities to combat free radicals (a.k.a. highly reactive species of oxygen and nitrogen) are overwhelmed and normal healthy balance is lost.&#160;&#160;The Company&#8217;s current finished product and finished product candidates include therapeutic nutraceutical products, cosmeceutical products, functional foods and functional beverages. The Company also possesses intellectual property covering a number of proprietary compounds and formulations that may be out-licensed to biotech and pharmaceutical companies as drug candidates.&#160;&#160;The Company&#8217;s primary focus currently is on products that incorporate the unique amino acid naturally occurring compound, L-Ergothioneine (&#8220;ERGO&#8221;), as a key component. Ergothioneine is produced only by microorganisms in soil and is not synthesized by humans, animals or plants.&#160;&#160;The Company has spent approximately $75 million in researching and developing ERGO, and now owns a patented process to synthesize commercial quantities of ERGO in a highly stable form that is highly soluble and tasteless, making it suitable for use in combination with other nutraceuticals and botanicals in a wide variety of dietary supplements, functional foods and beverages, and topical anti-aging products including lotions and creams.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In 1965, the corporate predecessor of OXIS, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic Data changed its incorporation to the State of Delaware in 1972; and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Going Concern</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $88,205,000 through September 30, 2012.&#160;&#160;On a consolidated basis, the Company had cash and cash equivalents of $61,000 at September 30, 2012. The Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are many factors that may prevent the Company from reaching its goal of profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The current rate of cash usage raises substantial doubt about the Company&#8217;s ability to continue as a going concern, absent any sources of significant cash flows.&#160;&#160;In an effort to mitigate this near-term concern the Company intends to seek additional equity or debt financing to obtain sufficient funds to sustain operations.&#160;&#160;The Company plans to increase revenues by introducing new nutraceutical products primarily based on its ergothioneine assets.&#160;&#160;However, the Company cannot provide assurance that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company will generate future product related revenues.&#160;&#160;The Company&#8217;s financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue in existence.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Use of Estimates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue Recognition</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Product Revenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based upon historical data, current economic conditions and the underlying contractual terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">License Revenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-refundable, up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&#160;&#160;We defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research and development services that are required because our know-how and expertise related to the technology is proprietary to us, or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments related to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Segment Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company operates in one reportable segment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock Based Compensation to Employees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 718.&#160;&#160;The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees over the related vesting period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company granted stock options to purchase 26,384,193 and 2,066,491 shares of the Company&#8217;s common stock to employees and directors during the nine months ended September 30, 2012 and 2011, respectively.&#160;&#160;The fair values of employee stock options are estimated for the calculation of the pro forma adjustments at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions during 2012: expected volatility of 116%; average risk-free interest rate of 1.04% to 2.04%; initial expected life of 5 to 10 years; no expected dividend yield; and amortized over the vesting period of typically one to four years.&#160;&#160;The Company reported an expense for share-based compensation for its employees and directors of $699,000 and $307,000 for the nine months ended September 30, 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock Based Compensation to Other than Employees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with ASC 718. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably determinable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. The Company recognized no expense in share-based compensation for non-employees for the nine months ended September 30, 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earnings Per Share</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic earnings per share is computed by dividing the net income or loss for the period by the weighted average number of common shares outstanding during the period.&#160;&#160;Diluted earnings per share is computed by dividing the earnings for the period by the weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion of outstanding stock options and warrants during the period.&#160;&#160;Since the Company incurred a net loss for the six months ended June 30, 2012 and 2011, all instruments convertible into shares of common stock are excluded from net diluted loss per share because of their anti-dilutive effect.&#160;&#160;Total potentially dilutive shares excluded from the calculation of earnings per share at September 30, 2012 totaled 538,285,943.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Recent Accounting Pronouncements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s financial position or results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair Value Measurements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest.&#160; The three levels are defined as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Company&#8217;s Level 2 liabilities consist of two liabilities arising from the issuance of convertible securities and in accordance with EITF 00-19: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured on a quarterly basis. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table represents the Company&#8217;s assets and liabilities by level measured at fair value on a recurring basis at September 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets</font></div>
</div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant liability</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">514,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 2 &#8211; Patents</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capitalized patent costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">640,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">640,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated amortization</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(625,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(615,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Periodically, the Company reviews its patent portfolio and has determined that certain patent applications no longer possessed commercial viability or were abandoned since they were inconsistent with the Company's business development strategy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table presents expected future amortization of patent costs as of December 31, 2011 that may change according to the Company's amortization policy upon additional patents being issued or allowed:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,000</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,000</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,000</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2015</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,000</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2016</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,000</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 3 &#8211; Debt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible debentures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On October 25, 2006, the Company entered into a securities purchase agreement (&#8220;2006 Purchase Agreement&#8221;) with four accredited investors (the &#8220;2006 Purchasers&#8221;). In conjunction with the signing of the 2006 Purchase Agreement, the Company issued secured convertible debentures (&#8220;2006 Debentures&#8221;) and Series A, B, C, D, and E common stock warrants (&#8220;2006 Warrants&#8221;) to the 2006 Purchasers, and the parties also entered into a security agreement (the &#8220;2006 Security Agreement&#8221;) pursuant to which the Company agreed to grant the 2006 Purchasers, pari passu, a security interest in substantially all of the Company&#8217;s assets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the terms of the 2006 Purchase Agreement, the Company issued the 2006 Debentures in an aggregate principal amount of $1,694,250 to the 2006 Purchasers. The 2006 Debentures are subject to an original issue discount of 20.318% resulting in proceeds to the Company of $1,350,000 from the transaction. The 2006 Debentures were due on October 25, 2008. The 2006 Debentures are convertible, at the option of the 2006 Purchasers, at any time prior to payment in full, into shares of common stock of the Company. As a result of the full ratchet anti-dilution provision the current conversion price is $0.01 per share (the &#8220;2006 Conversion Price&#8221;). Beginning on the first of the month beginning February 1, 2007, the Company was required to amortize the 2006 Debentures in equal installments on a monthly basis resulting in a complete repayment by the maturity date (the &#8220;Monthly Redemption Amounts&#8221;). The Monthly Redemption Amounts could have been paid in cash or in shares, subject to certain restrictions. If the Company chose to make any Monthly Redemption Amount payment in shares of common stock, the price per share would have been the lesser of the Conversion Price then in effect and 85% of the weighted average price for the 10-trading days prior to the due date of the Monthly Redemption Amount. The Company did not make any of the required monthly redemption payments.</font></div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the provisions of the 2006 Debentures, such non-payment was an event of default and penalty interest has accrued on the unpaid redemption balance at an interest rate equal to the lower of 18% per annum and the maximum rate permitted by applicable law. In addition, each of the 2006 Purchasers has the right to accelerate the cash repayment of at least 130% of the outstanding principal amount of the 2006 Debenture (plus accrued but unpaid liquidated damages and interest) and to sell substantially all of the Company&#8217;s assets pursuant to the provisions of the 2006 Security Agreement to satisfy any such unpaid balance. On June 6, 2008, the Company received notification from Bristol Investment Fund, Ltd (&#8220;Bristol&#8221;), that the collateral held under the 2006 Security Agreement would be sold to the highest qualified bidder on Thursday, June 19, 2008. On June 19, 2008, the Company received a Notice of Disposition of Collateral from Bristol in which Bristol notified the Company that Bristol, acting as the agent for itself and the three other 2006 Purchasers, purchased certain assets held as collateral under the 2006 Security Agreement. Bristol purchased 111,025 shares of common stock of BioCheck, Inc., the Company&#8217;s majority owned subsidiary, on a credit bid of $50,000, and Bristol also purchased 1,000 shares of the capital stock of OXIS Therapeutics, Inc., a wholly owned subsidiary of OXIS, for a credit bid of $10,000. In December 2005, OXIS purchased the 111,025 shares of common stock of BioCheck, Inc. for $3,060,000. After crediting the aggregate amount of $60,000 to the aggregate amount due under the 2006 Debentures, plus fees and charges due through June 19, 2008, Bristol notified the Company that the Company remains obligated to the 2006 Purchasers in a deficiency in an aggregate amount of $2,688,000 as of June 19, 2008. As a result of the disposition of the collateral, the Company recorded a net loss aggregating $2,978,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the 2006 Purchase Agreement, the 2006 Purchasers also have a right of first refusal to participate in up to 100% of any future financing undertaken by the Company until the 2006 Debentures are no longer outstanding. In addition, the Company is also prohibited from effecting any subsequent financing involving a variable rate transaction until such time as no 2006 Purchaser holds any of the 2006 Debentures. Furthermore, so long as any 2006 Purchaser holds any of the securities issued under the 2006 Purchase Agreement, if the Company issues or sells any common stock or instruments convertible into common stock which a 2006 Purchaser reasonably believes is on terms more favorable to such investors than the terms pursuant to the 2006 Debentures or 2006 Warrants, the Company is obligated to permit such 2006 Purchaser the benefits of such better terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Of the 2006 Warrants issued by the Company to the 2006 Purchasers, only the Series A Warrants remain outstanding. The Series A Warrants, which now expire in October 2014, permit the holders to purchase 2,420,357 shares of common stock at an original exercise price of $0.35 per share. Such exercise price is adjustable pursuant to a full ratchet anti-dilution provision and upon the occurrence of a stock split or a related event.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During 2009, Bristol converted $177,900 of the principal amount of 2006 Debentures for 17,790,000 shares of the Company&#8217;s common stock. During 2010, Bristol converted an additional $401,000 of the principal amount of 2006 Debentures for 40,100,000 shares of the Company&#8217;s common stock. During 2011, an additional $605,000 of the principal amount of 2006 Debentures was converted into 60,500,000 shares of the Company&#8217;s common stock. Of the $605,000 converted in 2011, $53,125 was converted into 5,312,500 shares of the Company&#8217;s common stock during the first quarter of 2011. During the nine months ended September 30, 2012, an additional $372,000 of the principal amount of 2006 Debentures was converted into 37,200,000 shares of the Company&#8217;s common stock.</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The 2006 Debentures do not meet the definition of a &#8220;conventional convertible debt instrument&#8221; since they are not convertible into a fixed number of shares. The Monthly Redemption Amounts can be paid with common stock at a conversion price that is a percentage of the market price; therefore the number of shares that could be required to be delivered upon &#8220;net-share settlement&#8221; is essentially indeterminate. Therefore, the 2006 Debentures are considered &#8220;non-conventional,&#8221; which means that the conversion feature must be bifurcated from the debt and shown as a separate derivative liability. This beneficial conversion liability has been calculated to be $690,000 on October 25, 2006. In addition, since the 2006 Debentures are convertible into an indeterminate number of shares of common stock, it is assumed that the Company could never have enough authorized and unissued shares to settle the conversion of the 2006 Warrants issues in this transaction into common stock. Therefore, the 2006 Warrants have a fair value of $2,334,000 at October 25, 2006. The value of the 2006 Warrant was calculated using the Black-Scholes model using the following assumptions: Discount rate of 4.5%, volatility of 158% and expected term of 1 to 6 years. The fair value of the beneficial conversion feature and the 2006 Warrant liability will be adjusted to fair value on each balance sheet date with the change being shown as a component of net loss. The fair value of the beneficial conversion feature and the 2006 Warrants at the inception of the 2006 Debentures were $690,000 and $2,334,000, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The first $1,350,000 of these discounts has been shown as a discount to the 2006 Debentures which will be amortized over the term of the 2006 Debenture and the excess of $1,674,000 has been shown as financing costs in the accompanying statement of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">At September 30, 2012 and December 31, 2011, the Company determined the fair value of the 2006 Warrants was $79,000 and $39,000, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On October 1, 2009, the Company entered into a financing arrangement with several accredited investors (the &#8220;2009 Investors&#8221;), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $2,000,000 (the &#8220;2009 Financing&#8221;). In connection with the 2009 Financing, the Company issued the following securities to the 2009 Investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0% Convertible Debentures in the principal amount of $2,000,000 due 24 months from the date of issuance (the &#8220; 2009 Debentures&#8221;), convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.05 per share;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series A warrant to purchase such number of shares of the Company&#8217;s common stock equal to 50% of the principal amount invested by each 2009 Investor (the &#8220;2009 Class A Warrants&#8221; ) resulting in the issuance of Class A Warrants to purchase 20,000,000 shares of common stock of the Company.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series B warrant to purchase such number of shares of the Company&#8217;s common stock equal to 50% of the principal amount invested by each 2009 Investor (the &#8220;2009 Class B Warrants&#8221;) resulting in the issuance of Class B Warrants to purchase 20,000,000 shares of common stock of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Class A Warrants and Class B Warrants (collectively, the &#8220; 2009 Warrants&#8221;) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. The 2009 Debentures and the 2009 Warrants are collectively referred to herein as the &#8220;2009 Securities&#8221;.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with the sale of the 2009 Securities by the Company, the Company and Bristol entered a Standstill and Forbearance Agreement, pursuant to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect to (i) the 2006 Debentures and (ii) certain demand notes (the &#8220;Bridge Notes&#8221;) issued by the Company on October 8, 2008, March 19, 2009, April 7, 2009, April 28, 2009, May 21, 2009 and June 25, 2009 and discussed under the caption &#8220;Demand Notes&#8221; below. In connection with the sale of the 2009 Securities by the Company, the Company and Bristol have also entered into a waiver agreement (the &#8220;Waiver Agreement&#8221;) pursuant to which Bristol waived certain rights with respect to the 2006 Debentures and Bridge Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The conversion price of the 2009 Debentures and the exercise price of the 2009 Warrants are subject to full ratchet anti-dilution adjustment in the event that the Company thereafter issues common stock or common stock equivalents at a price per share less than the conversion price or the exercise price, respectively, and to other normal and customary anti-dilution adjustment upon certain other events. So long as the 2009 Debentures are outstanding, if the Company effects a subsequent financing, the October 2009 Investors may elect, in their sole discretion, to exchange all or some of the October 2009 Debentures (but not the 2009 Warrants) for any securities or units issued in a subsequent financing on a $1.00 for $1.00 basis or to have any particular provisions of the subsequent financing legal documents apply to the documents utilized for the October 2009 Financing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company also agreed that if it determines to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others, then it shall include the shares of common stock underlying the 2009 Securities on such registration statement. The 2009 Investors have contractually agreed to restrict their ability to convert the 2009 Debentures and exercise the 2009 Warrants and receive shares of our common stock such that the number of shares of the Company common stock held by a 2009 Investor and its affiliates after such conversion or exercise does not exceed 4.9% of the Company&#8217;s then issued and outstanding shares of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During 2010, 2009 Investors converted $1,335,000 of the principal amount of 2009 Debentures for 26,700,000 shares of the Company&#8217;s common stock. During 2011, 2009 Investors converted $610,000 of the principal amount of 2009 Debentures for 12,200,000 shares of the Company&#8217;s common stock. Accordingly, at September 30, 2012, $55,000 in aggregate principal amount of 2009 Debentures remained outstanding. In addition, as of September 30, 2012, 14,900,000 of the 2009 Class A Warrants and 16,750,000 of the 2009 Class B Warrants remained outstanding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On June 1, 2011, the Company entered into a financing arrangement with several accredited investors (the &#8220;June 2011 Investors&#8221;), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $500,000 (the &#8220;June 2011 Financing&#8221;). In connection with the June 2011 Financing, the Company issued the following securities to the June 2011 Investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12% Convertible Debentures in the principal amount of $500,000 due April 15, 2012, convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.10 per share; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants to purchase 5,000,000 of shares of the Company&#8217;s common stock. The warrants are exercisable, on a cash or cashless basis, for up to two years from the date of issue at a per share exercise price equal to $0.15.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In November, 2011, the Company entered into a financing arrangement with several accredited investors (the &#8220;November 2011 Investors&#8221;), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the &#8220;November 2011 Financing&#8221;). In connection with the November 2011 Financing, the Company issued the following securities to the November 2011 Investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8% Convertible Debentures in the principal amount of $275,000 due in two years, convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.05 per share; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants to purchase 5,500,000 of shares of the Company&#8217;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#8220;Warrants&#8221;) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In March, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $617,500 (the &#8220;March 2012 Financing&#8221;). In connection with the March 2012 Financing, the Company issued the following securities to the investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8% Convertible Debentures in the principal amount of $617,500&#160;&#160;due in two years, convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.05 per share; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants to purchase 12,350,000 of shares of the Company&#8217;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#8220; March 2012 Warrants&#8221;) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In April 2012, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company.&#160;&#160;Pursuant to the anti-dilution provisions in the convertible instruments, the conversion price of certain convertible instruments is now $0.01 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $0.01 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In May, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the &#8220;May 2012 Financing&#8221;). In connection with the May 2012 Financing, the Company issued the following securities to the investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8% Convertible Debentures in the principal amount of $275,000 due May 2014, convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.05 per share; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants to purchase 5,500,000 of shares of the Company&#8217;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#8220; May&#160;&#160;2012 Warrants&#8221;) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 8, 2012, a Settlement Agreement and Mutual General Release ("Agreement") was made by and between OXIS and Bristol Investment Fund, Ltd., in order to settle certain claims regarding certain convertible debentures held by Bristol.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the Agreement, OXIS shall pay Bristol (half of which payment would redound to Merit Capital Limited (&#8220;Merit&#8221;)) a total of $1,119,778 as payment in full for the losses suffered and all costs incurred by Bristol in connection with the Transaction. Payment of such $1,119,778 shall be made as follows: OXIS shall issue restricted common stock to each of Bristol and Merit, in an amount such that each Bristol and Merit shall hold no more than 9.99% of the outstanding shares of OXIS (including any shares that each may hold as of the date of issuance). The shares so issued represent $417,475.65 of the $1,119,778 payment (27,831,710 shares at $0.015 per share, of which 9,168,750 will be retained by Bristol and 18,662,960 will be issued to Merit). The remaining balance of the payment shall be made in the form of two convertible promissory notes in the respective amounts of $422,357.75 for Bristol and $279,944.60 for Merit (collectively, the &#8220;Notes&#8221;) with a maturity of December 1, 2017 having an 8% annual interest rate, with interest only accruing until January 1, 2013, and then level payments of $3,750 each beginning January 1, 2013 until paid in full on December 1, 2017. In the event a default in the monthly payments on the Notes has occurred and is continuing each holder of the Notes shall be permitted to convert the unpaid principal and interest of the Notes into shares of OXIS at $.01 cents per share.&#160;&#160;In the absence of such continuing default no conversion of the Notes will be permitted. OXIS will have the right to repay the Notes in full at any time without penalty.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Demand Notes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On May 15, 2009, the Company entered into a convertible demand promissory note with Bristol Capital, LLC for certain consulting services totaling $100,000. The note does not provide for any interest and is due upon demand by the holder. The note has been converted into common stock of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On June 22, 2009, the Company entered into a convertible demand promissory note with Theorem Group (&#8220;Theorem&#8221;) pursuant to which Theorem purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#8220; 2009 Theorem Note&#8221;). The 2009 Theorem Note was subsequently sold as described below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Simultaneously with the issuance of the 2009 Theorem Note, the Company issued Theorem a seven-year warrant (the &#8220;2009 Theorem Warrant&#8221;) to purchase 3,137,500 shares of common stock of the Company at a price equal to the lower of (i) $0.01 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Theorem Note (the &#8220;Exercise Price&#8221;). The 2009 Theorem Warrant may be exercised on a cashless basis if the shares of common stock underlying the 2009 Theorem Warrant are not then registered pursuant to an effective registration statement. In the event the 2009 Theorem Warrant is exercised on a cashless basis, we will not receive any proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 1, 2009, Theorem sold the 2009 Theorem Note to Net Capital Partners, Inc. (&#8220;Net Capital&#8221;). In December 2009, Net Capital converted $24,000 of the principal for 2,400,000 shares of the Company&#8217;s common stock. In January 2010, Net Capital converted the remaining $7,375 of principal amount for an additional 737,500 shares of the Company&#8217;s common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On February 7, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#8220;February 2011 Bristol Note&#8221;). The February 2011 Bristol Note is convertible into shares of common stock of the Company at a price equal to $0.05 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Simultaneously with the issuance of the February 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the &#8220;February 2011 Bristol Series A Warrants&#8221;) to purchase 313,750 shares of the Company&#8217;s common stock at a per share exercise price of $0.0625, and a Series B Warrant (the &#8220;February 2011 Bristol Series B Warrants&#8221; and, together with the February 2011 Bristol Series A Warrants, the &#8220;February 2011 Bristol Warrants&#8221;) to purchase 313,750 shares of the Company&#8217;s common stock at a per share exercise price of $0.075. The February 2011 Warrants are exercisable for up to seven years from the date of issue. The February 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the February 2011 Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Bristol Warrants are exercised on a cashless basis, the Company will not receive any proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On February 7, 2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#8220;February 2011 Net Capital Note&#8221;). The February 2011 Net Capital Note is convertible into shares of common stock of the Company at a price equal to $0.05 per share. As of September, 2012, the February 2011 Net Capital Note had been converted into shares of the Company&#8217;s common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Simultaneously with the issuance of the February 2011 Net Capital Note, the Company issued Net Capital a Series A Warrant (the &#8220;February 2011 Net Capital Series A Warrants&#8221;) to purchase 313,750 shares of the Company&#8217;s common stock at a per share exercise price of $0.0625, and a Series B Warrant (the &#8220;February 2011 Net Capital Series B Warrants&#8221; and, together with the February 2011 Net Capital Series A Warrants, the &#8220;February 2011 Net Capital Warrants&#8221;) to purchase 313,750 shares of the Company&#8217;s common stock at a per share exercise price of $0.075. The February 2011 Net Capital Warrants are exercisable for up to seven years from the date of issue. The February 2011 Net Capital Warrants may be exercised on a cashless basis if the shares of common stock underlying the February 2011 Net Capital Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Net Capital Warrants are exercised on a cashless basis, the Company will not receive any proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 4, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#8220;March 2011 Bristol Note&#8221;). The March 2011 Bristol Note is convertible at the option of the holder at any time into shares of common stock, at a price equal to $0.05.</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Simultaneously with the issuance of the March 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the &#8220;March 2011 Bristol Series A Warrants&#8221;) to purchase 313,750 shares of the Company&#8217;s common stock at a per share exercise price of $0.0625, and a Series B Warrant (the &#8220;March 2011 Bristol Series B Warrants&#8221; and, together with the March 2011 Bristol Series A Warrants, the &#8220;March 2011 Bristol Warrants&#8221;) to purchase 313,750 shares of the Company&#8217;s common stock at a per share exercise price of $0.075. The March 2011 Warrants are exercisable for up to seven years from the date of issue. The March 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the March 2011 Warrants are not then </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">registered pursuant to an effective registration statement. In the event the March 2011 Warrants are exercised on a cashless basis, the Company will not receive any proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On April 4, 2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#8220;April 2011 Net Capital Note&#8221;). The April 2011 Net Capital Note is convertible into shares of common stock of the Company, at a price equal to $0.05 per share.&#160;&#160;As of September, 2012, April&#160;&#160;2011 Net Capital Note had been converted into shares of the Company&#8217;s common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Simultaneously with the issuance of the Net Capital Note, the Company issued Net Capital a Series A Warrant (the &#8220;April 2011 Net Capital Series A Warrants&#8221;) to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.0625, and a Series B Warrant (the &#8220;April 2011 Net Capital Series B Warrants&#8221; and, together with the April 2011 Net Capital Series A Warrants, the &#8220;April 2011 Net Capital Warrants&#8221;) to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.075. The April 2011 Net Capital Warrants are exercisable for up to seven years from the date of issue. The April 2011 Net Capital Warrants may be exercised on a cashless basis if the shares of common stock underlying the April 2011 Net Capital Warrants are not then registered pursuant to an effective registration statement. In the event the April 2011 Net Capital Warrants are exercised on a cashless basis, we will not receive any proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On October 26, 2011 the Company entered into a convertible demand promissory note with Theorem pursuant to which Theorem purchased an aggregate principal amount of $200,000 of convertible demand promissory notes for an aggregate purchase price of $157,217 (the &#8220;October 2011 Theorem Note&#8221;). The October 2011 Theorem Note is convertible into shares of common stock of the Company, at a price equal to $0.05 per share. As of September, 2012, the October&#160;&#160;2011 Theorem&#160;&#160;Capital Note had been converted into shares of the Company&#8217;s common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Simultaneously with the issuance of the October 2011 Theorem Note, the Company issued Theorem a Series A Warrant (the &#8220;October 2011 Series A Warrant&#8221;) to purchase 10,000,000 shares of common stock of the Company at a per share exercise price of $0.0625, and a Series B Warrant (the &#8220;October 2011 Series B Warrants&#8221; and, together with the October 2011 Series A Warrants, the &#8220;October 2011 Warrants&#8221;) to purchase 10,000,000 shares of common stock of the Company at a per share exercise price of $0.075. The October 2011 Warrants are exercisable for up to seven years from the date of issue. The October 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the October 2011 Warrants are not then registered pursuant to an effective registration statement. In the event the October 2011 Warrants are exercised on a cashless basis, we will not receive any proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All of the foregoing securities were issued in reliance upon an exemption from the registration requirements pursuant to Section 4(2) of the Securities Act of 1933, as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financing Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The aggregate amount of outstanding Advances available to the Company under the Line of Credit may not exceed $750,000.00 at any time. The credit amounts available to the Company will be tiered, starting at $250,000 and will ramp up to $500,000 and then $750,000 upon achievement of determined milestones. The Advances requested under the Line of Credit may only be used for purchases of products and inventory from Gemini Pharmaceuticals.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The outstanding principal of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In partial consideration of the commitment made by Gemini Pharmaceuticals under the Line of Credit, the Company has issued to Gemini, non-callable 5-year warrants to purchase 300,000 additional shares of Common</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock at a share price of $0.12. The warrants contain a cashless exercise provision. The warrants vest as follows: 50% immediately, 25% when the credit line is increased to $500,000, and the remaining 25% when the credit line is increased to $750,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Joint Ventures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In March 2011, the Company agreed to form a joint venture with engage:BDR, Inc., an on-line marketing company that offers both premium and placement-specific display marketing solutions and the ability to distribute campaigns through its own display platforms and channels.&#160;&#160;engage:BDR partners with most of comScore's top 1000 websites (globally) for the most advanced display marketing capabilities.&#160;&#160;Under the joint venture agreement, engage:BDR will provide a full range of online marketing services to the joint venture, including developing brand strategy, the design of all digital media and interfaces, online media planning and buying, leveraging and integrating social media, and customer analysis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In March 2012 the Company signed a term sheet with engage:BDR that further evidences its arrangement and that permits both parties to commence operations under the arrangement.&#160;&#160;The parties contemplate that the existing binding arrangement will be evidenced by a formal limited liability company agreement that the parties are preparing. The following is a summary of the principal provisions of our joint venture arrangement (the &#8220;Joint Venture&#8221;) with engage:BDR, Inc.:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has agreed to grant the Joint Venture an exclusive license for the on-line marketing of products containing EGT&#8482;.&#160;&#160;The first product to be marketed and sold through the Joint Venture shall be Oxis&#8217; ErgoFlex&#8482; product, which product was successfully test marketed in mail offering in late 2010 and early 2011.&#160;&#160;Additional Oxis products designated by the Company will be offered by the Joint Venture.&#160;&#160;If both parties agree, third party products may also be offered through the Joint Venture.&#160;&#160;However, nothing in the Joint Venture is intended to prohibit the Company from marketing, distributing and selling ErgoFlex&#8482; or any of its other current or future products by means other than through online sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Oxis and engage:BDR have agreed to make the following&#160;&#160;contributions to the Joint Venture:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Oxis will contribute up to $240,000 during the first year following the formation of the Joint Venture.&#160;&#160;These funds will be provided if, when and as needed by the Joint Venture.&#160;&#160;OXIS&#8217; cash capital contribution will be used (i) to purchase ErgoFlex and other products from Oxis, at OXIS&#8217; cost, without any markup, (ii) to purchase website media inventory from engage:BDR, at engage:BDR&#8217;s cost, plus a 15% administrative mark-up, and (iii) to fund the Joint Venture&#8217;s other operating costs.&#160;&#160;engage:BDR has agreed to waive the 15% administrative mark-up through December 31, 2012.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition to the cash, OXIS&#8217; contribution to the Joint Venture includes the exclusive license for the on-line marketing of any products created by Oxis which utilize its proprietary EGT&#8482;.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;engage:BDR , at its own cost and expense, is designing, developing and providing to the Joint Venture, on a turnkey basis, all online product offering systems and technologies, including website layouts, landing pages, graphic designs, display advertising, rich media, in-banner and in-stream video development.&#160;&#160;During the initial start-up phase of the Joint Venture, engage:BDR will, at its own cost and expense, also manage all day-to-day online activities of the Joint Venture.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash from operations in excess of the amounts needed for its operations and for reasonable reserves, shall be distributed by the Joint Venture in the following order:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;First, to Oxis on a cumulative basis, an amount equal to the cash that OXIS contributed to the Joint Venture, and</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Thereafter, all excess net operating cash will be distributed 50.1% to Oxis and 49.9% to engage:BDR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The administrative affairs of the Joint Venture shall be managed by a committee consisting of one representative of each Joint Venture member.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As additional consideration for engage:BDR entering into the Joint Venture and for contributing its services in designing, developing and implementing the advertising platform, at the time that the Joint Venture operating agreement is signed, OXIS will grant engage:BDR a two-year option to purchase Oxis securities.&#160;&#160;The option shall entitle engage:BDR to purchase the type of securities sold by us in a future $6,000,000 or more financing, on the same terms and conditions, and at the same price, as such securities are sold to third party investors in such financing.&#160;&#160;The number of such securities that engage:BDR may purchase upon the exercise of the option (determined by assuming all convertible securities are converted and all exercisable securities are exercised) shall be equal to 4.99% of the Company&#8217;s common stock issued and outstanding on the date the Joint Venture agreement is signed.&#160;&#160;If the Company has not raised $6,000,000 by December 31, 2012, commencing on that date, engage:BDR will have a two-year right to purchase Oxis&#8217; common stock at a price equal to $.03.&#160;&#160;OXIS has also agreed to issue to engage:BDR a warrant to purchase up to 5,000,000 shares of its common stock if the Joint Venture, through engage:BDR efforts, attains certain revenue and profits targets.&#160;&#160;The warrant will have an exercise price of $.03 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On June 29, 2011 the Company entered into a Joint Venture Agreement (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Joint Venture Agreement</font>&#8221;) with John E. Repine, M.D. (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Dr. Repine</font>&#8221;), a member of the Company&#8217;s advisory board.&#160;&#160;Under the terms of the Joint Venture Agreement, the Company formed a Delaware limited liability company, Ergo ARDS, LLC (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">ARDS Venture</font>&#8221;), in which the Company holds a 60% membership interest and Dr. Repine holds a 40% membership interest.&#160;&#160;The ARDS Venture was formed to develop, acquire and market dietary supplements, cosmeceutical products, nutraceutical products, medical foods and pharmaceuticals using EGT&#8482; for treating, diagnosing and preventing acute respiratory distress syndrome and other lung disorders (collectively &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">ARDS</font>&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Concurrently with the execution of the Joint Venture Agreement, Dr. Repine assigned his interest in the patent applications relating to the use of ERGO in treating ARDS (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Assigned IP</font>&#8221;) to the ARDS Venture.&#160;&#160;In consideration for the Assigned Interest, Dr. Repine was issued a 40% membership interest in the ARDS Venture.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oxis will be responsible for supplying EGT&#8482; to the ARDS Venture at no cost in connection with the ARDS Venture&#8217;s animal studies. Oxis will also pay all patent prosecution and maintenance costs relating to the Assigned IP.&#160;&#160;The ARDS Venture is required to make payments to Dr. Repine upon the achievement of certain milestones by the ARDS Venture.&#160;&#160;Any future payments to Dr. Repine shall be made based on the achievement of following milestones with respect to products to be commercialized using the Assigned IP:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The ARDS Venture shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Licensing the Assigned IP to a pharmaceutical company -- $1,000,000;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Completion of Phase I Clinical Trial -- $250,000;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Completion of Phase II Clinical Trial -- $1,000,000;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Completion of pivotal Phase III Clinical Trial -- $1,500,000; and</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Receipt of FDA Marketing approval -- $3,000,000</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The ARDS Venture shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Licensing the Assigned IP to, or entering into a distribution agreement with, a nutraceutical or similar company -- $100,000; and</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross sales of products utilizing EGT&#8482; in the field &#8211; 5% of annual gross sales by the ARDS Venture or any licensee or distributor (including Oxis).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Following the successful completion of the animal studies, Oxis and Dr. Repine will make a joint decision to commence human clinical trials. If the parties do not agree to proceed, the Joint Venture Agreement will terminate and the intellectual property belonging to the ARDS Venture will be assigned to the party that elected to proceed.&#160;&#160;In the event both parties agree to not proceed, the ARDS Venture will continue to hold the intellectual property.&#160;&#160;If the parties agree to proceed, Oxis will use its best efforts to raise $3 million for the ARDS Venture.&#160;&#160;Once the $3 million in funds have been successfully raised by Oxis, Oxis will no longer be responsible for paying the ARDS Venture&#8217;s operating costs, including costs related to the ARDS Venture&#8217;s intellectual property.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The ARDS Venture will be managed by Dr. Repine as Manager, who will also serve as the ARDS Venture&#8217;s Chief Executive Officer and Treasurer. The ARDS Venture will also have a board of five members, consisting of Dr. Repine and a designee of Dr. Repine, and three designees of Oxis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note&#160;4 -- Stockholders&#8217; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Under the Company's Second Amended and Restated Certificate of Incorporation, the Company was authorized to issue a total of 150,000,000&#160;shares of Common Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 5, 2011, the Company's Board of Directors approved an amendment to its Second Amended and Restated Certificate of Incorporation to increase the shares of Common Stock that are authorized for issuance by 450,000,000 shares, bringing the total number of common shares authorized for issuance to 600,000,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The approval of the Amendment required the consent of no less than at least a majority of the voting power of the Company.&#160;&#160;Theorem Group, LLC owns, in addition to other of our securities, 25,000 shares of Series H Convertible Preferred Stock.&#160;&#160;The Certificate of Designation of Preferences, Rights and Limitations of the Series H Convertible Preferred Stock provides that each outstanding share of Series H Convertible Preferred Stock entitles the holder thereof to a number of votes equal to (A) the number of shares of Common Stock that such share of preferred stock could, at such time, be converted into (B) multiplied by 100.&#160;&#160;The Series H Convertible Preferred Stock is currently convertible into 2,500,000 shares of Common Stock.&#160;&#160;Accordingly, Theorem Group, LLC has the voting power of 250,000,000 shares, which represents more than a majority of voting power of all of the Company's outstanding voting shares.&#160;&#160;Theorem Group, LLC approved the Amendment on January 5, 2011 by an action taken by written consent.&#160;&#160;The amendment was filed with the Delaware Secretary of State in February 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each share of common stock is entitled to one vote at the Company's annual meeting of stockholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the nine months ended September 30, 2012 and 2011, the Company issued a total of 160,107,475 and 61,831,683 shares of common stock, respectively for retirement of debt valued at $2,382,281 and $1,144,000, respectively.</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The 96,230 shares of Series C preferred stock are convertible into 27,800 shares of the Company's common stock at the option of the holders at any time. The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than .20 or more than .2889 common shares for each Series C preferred share. The conversion ratio may be adjusted under certain circumstances such as stock splits or stock dividends. The Company has the right to automatically convert the Series C preferred stock into common stock if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company's common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $13.00. Each share of Series C preferred stock is entitled to the number of votes equal to .26 divided by the average closing bid price of the Company's common stock during the fifteen consecutive trading days immediately prior to the date such shares of Series C preferred stock were purchased. In the event of liquidation, the holders of the Series C preferred stock shall participate on an equal basis with the holders of the common stock (as if the Series C preferred stock had converted into common stock) in any distribution of any of the assets or surplus funds of the Company. The holders of Series C preferred stock are entitled to noncumulative dividends if and when declared by the Company's board of directors. No dividends to Series C preferred stockholders were issued or unpaid through September 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On December 4, 2008, the Company entered into and closed an Agreement (the &#8220;Bristol Agreement&#8221;) with Bristol Investment Fund, Ltd. pursuant to which Bristol agreed to cancel the debt payable by the Company to Bristol in the amount of approximately $20,000 in consideration of the Company issuing Bristol 25,000 shares of Series&#160;G Convertible Preferred Stock, which such shares carry a stated value equal to $1.00 per share (the &#8220;Series&#160;G Stock&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Series&#160;G Stock is convertible, at any time at the option of the holder, into common shares of the Company based on a conversion price equal to the lesser of $.01 or 60% of the average of the three lowest trading prices occurring at any time during the 20 trading days preceding the conversion.&#160;&#160;&#160;The Series&#160;G Stock, as amended,&#160;shall have voting rights on an as converted basis multiplied by 100.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the event of any liquidation or winding up of the Company, the holders of Series&#160;G Stock will be entitled to receive, in preference to holders of common stock, an amount equal to the stated value plus interest of 15% per year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Series G Stock restricts the ability of the holder to convert the Series&#160;G Stock and receive shares of the Company&#8217;s common stock such that the number of shares of the Company common stock held by Bristol and its affiliates after such conversion does not exceed 4.9% of the Company&#8217;s then issued and outstanding shares of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Series G Stock was previously referred to in an 8-K filed by the Company on December 10, 2008 in error as the &#8220;Series E Stock&#8221;. Further, the Series G Stock initially incorrectly provided that it voted on an as converted basis multiplied by 10.&#160;&#160;This incorrectly reflected the intent of the Company and the holder.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On October 13, 2009, the Company was informed by Theorem Group, LLC that it had purchased all of the outstanding Series G Preferred Stock and Theorem gave notice to the Company that it intended to exercise its ability to vote on all shareholder matters utilizing the super voting privileges provided by the Series G Stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective February 10, 2010, the Company issued 25,000 shares of its new Series H Convertible Preferred Stock (the &#8220;Series H Preferred&#8221;) to Theorem Group, LLC, a California limited liability company (the &#8220;Stockholder&#8221;), in exchange for the 25,000 shares of Series G Stock then owned by the Stockholder.&#160;&#160;The foregoing exchange was effected pursuant to that certain Exchange Agreement, dated February 10, 2010, between the Company and the Stockholder (the &#8220;Exchange Agreement&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Certificate of Designation of the Series H Preferred is based on, and substantially similar to the form and substance of the Certificate of Designation of the Series G Preferred.&#160;&#160;Some of the corrections, changes and differences between the Certificate of Designation of the Series G Preferred and the Certificate of Designation of the Series H Preferred include the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As previously disclosed, the holder of the Series H Preferred is entitled to vote with the common stock, and is entitled to a number of votes equal to (i) the number of shares of common stock it can convert into (without any restrictions or limitations on such conversion), (ii) multiplied by 100.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The holder of the Series H Preferred cannot convert such preferred stock into shares of common stock if the holder and its affiliates after such conversion would own more than&#160;9.9% of the Company&#8217;s then issued and outstanding shares of common stock.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Series G Preferred contained a limitation that the holder of the Series G Preferred could not convert such preferred shares into more than 19.999% of the issued and outstanding shares of common stock without the approval of the stockholders if the rules of the principal market on which the common stock is traded would prohibit such a conversion.&#160;&#160;Since the rules of the Company&#8217;s principal market did not require such a limitation, that provision has been deleted.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On November 8, 2010, Gemini Pharmaceuticals purchased 1,666,667 shares of the Company&#8217;s Series I Preferred Stock, $.001 par value, at a price of $0.15 per share ($250,000).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As the holder of the Series I Preferred Stock, Gemini Pharmaceuticals will be entitled to receive, out of funds legally available, dividends in cash at the annual rate of 8.0% of the Preference Amount ($0.15), when, as, and if declared by the Board.&#160;&#160;No dividends or other distributions shall be made with respect to any shares of junior stock until dividends in the same amount per share on the Series I Preferred Stock shall have been declared and paid or set apart during that fiscal year. Dividends on the Series I Preferred Stock shall not be cumulative and no right shall accrue to the Series I Preferred Stock by reason of the fact that the Company may fail to declare or pay dividends on the Series I Preferred Stock in the amount of the Dividend Rate per share or in any amount in any previous fiscal year of the Company, whether or not the earnings of the Company in that previous fiscal year were sufficient to pay such dividends in whole or in part.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Each share of Series I Preferred Stock shall entitle the holder thereof to such number of votes per share as shall equal the number of shares of Common Stock (rounded to the nearest whole number) into which such share of Series I Preferred Stock is then convertible.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Upon any liquidation of the Company, subject to the rights of any series of Preferred Stock that may from time to time come into existence, before any distribution or payment shall be made to the holders of any Junior Stock, the holders of the shares of Series I Preferred Stock then outstanding shall be entitled to receive and be paid out of the assets of the Company legally available for distribution to its stockholders liquidating distributions in cash or property at its fair market value as determined by the Board in the amount of $0.15 per share (as adjusted for any stock dividends, combinations or splits with respect to such shares).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares of Series I Preferred Stock may, at the option of the holder thereof, be converted at any time or from time to time into fully paid and non-assessable shares of Common Stock.&#160;&#160;The number of shares of Common Stock which a holder of shares of Series I Preferred Stock shall be entitled to receive upon conversion of such shares shall be the product obtained by multiplying the Conversion Rate by the number of shares of Series I Preferred Stock being converted.&#160;&#160;Initially, the Series I Preferred Stock is convertible into 1,666,667 shares of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the event that the per-share Market Price of the Common Stock over a period of 20 consecutive trading days is equal to at least 130% of the initial conversion price (130% of $0.15), all outstanding shares of Series I Preferred Stock shall&#160;&#160;be converted automatically into the number of shares of Common Stock into which such shares of Series I Preferred Stock are then convertible without any further action by the holders of such shares and whether or not the certificates representing such shares of Series I Preferred Stock are surrendered to the Company or its transfer agent.</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note&#160;5 -- Stock Options and Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Following is a summary of the stock option activity:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options Outstanding</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted Average Exercise Price</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding as of December 31, 2011</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,078,979</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.19</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,384,193</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.04</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,679,027</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.17</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding as of September 30, 2012</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38,784,145</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.08</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable as of September 30, 2012</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,415,441</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.08</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Following is a summary of the warrant activity:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants Outstanding</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted Average Exercise Price</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding as of December 31, 2011</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105,001,252</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.06</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">462,300,546</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52,500,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,300,000)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding as of September 30, 2012</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">499,501,798</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In April 2012, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company.&#160;&#160;Pursuant to the anti-dilution provisions in the warrants, the exercise price of certain warrants is now $0.01, and the number of shares underlying the warrants has increased such that the number of shares underlying each warrant is equal to the aggregate exercise price in effect prior to the adjustment divided by the new exercise price of $0.01.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 6 &#8211;Advisory and Consulting Agreements Obligations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advisory Agreements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company entered into a two-year Scientific Advisory Board Services Agreement with L. Stephen Coles on March 4, 2010.&#160;&#160;Mr. Coles receives an advisory fee for $9,000 per quarter.&#160;&#160;Upon entering into the agreement, the Company granted Mr. Coles an initial option to purchase 250,000 shares of the Company&#8217;s common stock under its 2003 Stock Incentive Plan.&#160;&#160;The options vest and become exercisable in four equal quarterly installments beginning June 4, 2010.&#160;&#160;Pursuant to the terms of the agreement, a second option to purchase 500,000 shares of the Company&#8217;s common stock under our 2003 Stock Incentive Plan was granted on March 4, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OXIS INTERNATIONAL, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(UNAUDITED)</font></div>
</div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company entered into a two-year Scientific Advisory Board Services Agreement with Rajan Shah on July 15, 2010.&#160;&#160;Mr. Shah receives an advisory fee for $9,000 per quarter.&#160;&#160;Upon entering into the agreement, the Company granted Mr. Shah an initial option to purchase 250,000 shares of the Company&#8217;s common stock under its 2003 Stock Incentive Plan.&#160;&#160;The options vested and become exercisable in four equal quarterly installments beginning October 15, 2010.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company entered into a two-year Advisory Board Services Agreement with Sandep Rahi on July 15, 2010.&#160;&#160;Mr. Rahi receives an advisory fee for $9,000 per quarter.&#160;&#160;Upon entering into the agreement, the Company granted Mr. Rahi an initial option to purchase 250,000 shares of the Company&#8217;s common stock under its 2003 Stock Incentive Plan.&#160;&#160;The options vested and become exercisable in four equal quarterly installments beginning October 15, 2010.&#160;&#160;Pursuant to the terms of the agreement, a second option to purchase 500,000 shares of the Company&#8217;s common stock under its 2003 Stock Incentive Plan was granted on July 15, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consulting Agreements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 1, 2011, we entered into a consulting agreement with Bristol Capital, LLC whereby Bristol will assist us in general corporate activities including but not limited to strategic and financial planning, management and business operations, final projections and investor relation materials. As compensation for these services, we issued 5,000,000 shares of our common stock. The term of the agreement is for six months unless terminated or extended in accordance with subsequent agreements between the parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On January 1, 2011, the Company entered into a consulting agreement with Piter Korompis, whereby Mr. Korompis will assist the company in general corporate activities including but not limited to strategic and financial planning, management and business operations, final projections and investor relation materials. As compensation for these services, the Company will issue 5,000,000 shares of common stock of the Company. The term of the agreement is for six months unless terminated or extended in accordance with subsequent agreements between the parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with a joint venture agreement, the Company entered into a consulting agreement with John E. Repine, M.D. on June 28, 2011, whereby Dr. Repine will provide advisory services to OXIS and Ergo ARDS and serve as Ergo ARDS&#8217; Chief Executive Officer.&#160;&#160;OXIS&#8217; payments to Dr. Repine under the consulting agreement will be made in shares of OXIS common stock. OXIS agreed to issue shares of Common Stock to Dr. Repine as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On July 6, 2011 OXIS issued to Dr. Repine 2,777,778 shares of common stock (valued at $250,000) for various services relating to the terms of the consulting agreement;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OXIS agreed to issue to Dr. Repine additional shares of common stock valued at $50,000 upon completion of the first animal study and Dr. Repine&#8217;s delivery to Ergo ARDS of a summary presentation of the findings of the study; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OXIS agreed to issue Dr. Repine additional shares of common stock valued at $100,000 upon the completion of such second animal study and Dr. Repine&#8217;s delivery to Ergo ARDS of a summary presentation of the findings of the study.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If the value of these shares decreases at the end of the 6-month period following the date of issuance of such shares, OXIS will be obligated to issue additional shares of common stock to Dr. Repine so that the market value of the shares previously issued to Dr. Repine on that date will equal to $250,000, $50,000 or $100,000, as the case may be.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Some of the statements in the Form 10-Q are forward-looking statements about what may happen in the future. Forward-looking statements include statements regarding our current beliefs, goals, and expectations about matters such as our expected financial position and operating results, our business strategy, and our financing plans. The forward-looking statements in the Form 10-Q are not based on historical facts, but rather reflect the current expectations of our management concerning future results and events.&#160;&#160;The forward-looking statements generally can be identified by the use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;foresee,&#8221; &#8220;likely&#8221; or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are or may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements.&#160;&#160;We cannot guarantee that our forward-looking statements will turn out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations for various reasons. You should review carefully all information, including the discussion of risk factors under &#8220;Item 1A: Risk Factors&#8221; and &#8220;Item 7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Form 10-K for the year ended December 31, 2011.&#160;&#160;Any forward-looking statements in the Form 10-Q are made only as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements contained in this Form 10-Q to reflect subsequent events or circumstances.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Throughout this Quarterly Report on Form&#160;10-Q, the terms &#8220;OXIS,&#8221;&#160;&#160;&#8220;we,&#8221; &#8220;us,&#8221;&#160;&#160;&#8220;our,&#8221; &#8220;the company&#8221; and &#8220;our company&#8221; refer to OXIS International, Inc., a Delaware corporation formerly known as DDI Pharmaceuticals, Inc. and Diagnostic Data, Inc, together with our subsidiaries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OXIS&#8217; focus is on the development and sale/licensing of products and/or proprietary formulations that can be classified generally into four main business sectors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dietary supplements, functional foods and functional beverages;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Personal care products, including skin care and cosmetic products;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Veterinary products for companion animals, livestock and performance animals such as race horses; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proprietary compounds that may be out-licensed to biotechnology and/or pharmaceutical companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Of late, our commercial operations have been focused on developing a line of dietary supplements containing EGT&#8482;.&#160;&#160;A limited release of a joint health product named &#8220;ErgoFlex&#8482;&#8221; in December 2010, by means of a long-form direct mail program, produced a very favorable response rate. In support of ErgoFlex&#8482;, we carried out a pilot human trial examining the effect of the product in reducing mild to moderate chronic joint pain and in improving compromised range of motion.&#160;&#160;The results of the trial were highly favorable and produced statistically significant improvements in both measures in one week.&#160;&#160;We currently intend to commercially release a number of additional EGT&#8482; based products commencing in 2012, including, but not limited to, skin care products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are working on establishing several marketing channels to commercialize our planned products.&#160;&#160;Our primary marketing initiative consists of an on-line global sales program to be effected through a joint venture with engage:BDR, as described in further detail below in &#8220;Marketing, Sales and Distribution.&#8221;&#160;&#160;Other marketing channels may include non-traditional, direct to consumer channel (i.e.&#160;&#160;multi-level-marketing (MLM), infomercials, and direct-mail) as well as traditional channels of mass retail and specialty retail.&#160;&#160;We plan to develop products internally and seek complementary acquisitions that may provide additional products, expand our customer base and/or add to our distribution capabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Recent Developments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In April 2012, we agreed to an adjustment as negotiated through this time to enable inducement of further financing of the Company.&#160;&#160;Pursuant to the anti-dilution provisions in the convertible instruments and warrants, the conversion price of all convertible instruments is now $0.01 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $0.01 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion), and the exercise price of certain warrants is now $0.01, and the number of shares underlying the warrants has increased such that the number of shares underlying each warrant is equal to the aggregate exercise price in effect prior to the adjustment divided by the new exercise price of $0.01.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In May, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the &#8220;May 2012 Financing&#8221;). In connection with the May 2012 Financing, the Company issued the following securities to the investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8% Convertible Debentures in the principal amount of $275,000 due May 2014, convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.05 per share; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants to purchase 5,500,000 of shares of the Company&#8217;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#8220; May&#160;&#160;2012 Warrants&#8221;) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 8, 2012, a Settlement Agreement and Mutual General Release was made by and between OXIS and Bristol Investment Fund, Ltd., in order to settle certain claims regarding certain convertible debentures held by Bristol.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the Agreement, OXIS shall pay Bristol (half of which payment would redound to Merit Capital Limited (&#8220;Merit&#8221;)) a total of $1,119,778 as payment in full for the losses suffered and all costs incurred by Bristol in connection with the Transaction. Payment of such $1,119,778 shall be made as follows: OXIS shall issue restricted common stock to each of Bristol and Merit, in an amount such that each Bristol and Merit shall hold no more than 9.99% of the outstanding shares of OXIS (including any shares that each may hold as of the date of issuance). The shares so issued represent $417,475.65 of the $1,119,778 payment (27,831,710 shares at $0.015 per share, of which 9,168,750 will be retained by Bristol and 18,662,960 will be issued to Merit). The remaining balance of the payment shall be made in the form of two convertible promissory notes in the respective amounts of $422,357.75 for Bristol and $279,944.60 for Merit (collectively, the &#8220;Notes&#8221;) with a maturity of December 1, 2017 having an 8% annual interest rate, with interest only accruing until January 1, 2013, and then level payments of $3,750 each beginning January 1, 2013 until paid in full on December 1, 2017. In the event a default in the monthly payments on the Notes has occurred and is continuing each holder of the Notes shall be permitted to convert the unpaid principal and interest of the Notes into shares of OXIS at $.01 cents per share.&#160;&#160;In the absence of such continuing default no conversion of the Notes will be permitted. OXIS will have the right to repay the Notes in full at any time without penalty.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues/Cost of Product Revenues</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In December 2010, we initiated a direct mail test market for ErgoFlex&#8482;, which generated $23,000 of revenues in fiscal 2011 (mostly in the first quarter of 2011).&#160;&#160;In July 2012 we launched our initial products Prograce and Reverge with our partners at Engage BDR. The following table presents the changes in revenues from 2011 to 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -5.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase from 2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase from 2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">120,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">118,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">123,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">120,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Assuming that we are able to raise the capital needed, we plan to continue marketing our products in 2012 and anticipate revenues for 2012 to significantly increase compared to the prior year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table presents the changes in cost of product revenues from 2011 to 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -5.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase from 2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase from 2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost of product revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr>
<td valign="bottom" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the nine months ended September 30, 2012, we purchased products for the launch of our new consumer products products Prograce and Reverge.&#160;&#160;&#160;The cost of products in 2011 exceeded our product revenues due to the high start-up costs of manufacturing a limited amount of our products for the test marketing initiative.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and Development Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the nine months ended September 30, 2012, we incurred $0 in research and development expenses, compared to $49,000 in the nine months ended September 30, 2011.&#160;&#160;These expenditures were incurred in connection with the testing and obtaining certification for EGT&#8482; related to the release of ErgoFlex&#8482; and the launch of our new products Prograce and Reverge. We anticipate that research and development expenses will increase in subsequent fiscal quarters as we increase our product research and development activities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following table presents the changes in selling, general and administrative expenses from 2011 to 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -5.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended September 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase from 2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase from 2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,438,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">535,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">903,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,865,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,806,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The increase in selling, general and administrative expenses for the nine months ended September 30, 2012 is primarily attributable to an increase in wages of $105,300 compared to $0 in 2011, to an increase in non cash stock compensation of $599,300.&#160;&#160;In fiscal 2011, we incurred non-cash stock compensation expense of $98,900 for services rendered.&#160;&#160;&#160;We also had a decrease in costs associated to a conference put on in fiscal 2011 of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ 261,200, a decrease in investor relations expense of $ 57,600 and advertising expenses of $65,900, a decrease in legal fees of 43,000 as well as a decrease in marketing of $25,600, professional fees of 159,300.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in value of warrant and derivative liabilities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The change in the value of warrant and derivative liabilities relates to the change in fair value of these liabilities recorded by us as a result of the convertible debentures issued in October 2006, October 2009 and June 2011.&#160;&#160;When we entered into the convertible debentures with the warrants on October 25, 2006, the beneficial conversion feature was valued at $690,000 and the warrants were valued at $2,334,000.&#160; When we entered into the convertible debentures with the warrants on October 9, 2009, the beneficial conversion feature and the warrants were valued at $2,000,000.&#160; We recognized an increase in expense of $0 and $681,000 compared to $(358,000( and $783,000 for the three months and nine months ended September 30, 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense was $65,000 and $1,305,000 compared to $117,000 and $465,000 for the three months and nine months ended September 30, 2012 and 2011, respectively.&#160;&#160;The increase is primarily due to the settlement of certain claims by Bristol in the amount of $1,120,000 (see Note 7).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net Loss</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We had a net (income) loss of $1,400,000 and $4,410,000, compared to $(23,000) and $633,000 for the three months and nine months ended September 30, 2012 and 2011, respectively.&#160;&#160;The net loss in the first nine months of 2012 was primarily the result of selling, general and administrative expenses of $2,865,000, interest expense of $1,305,000, and a change in value of warrant and derivative liabilities of $358,000.&#160;The net loss in the first nine months of 2011 was primarily the result of general and administrative expenses of $2,806,000 and interest expense of $465,000, which expenses were partially offset by a change in value of warrant and derivative liabilities of $783,000.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On a consolidated basis, we had cash and cash equivalents of $61,000 at September 30, 2012.&#160;&#160;However, we also had $6,326,000 of current liabilities (of which $5,812,000 represented current cash obligations and $514,000 represented non-cash warrant liabilities).&#160;&#160;As a result, as of September 30, 2012, we had a working capital deficit of $6,148,000.&#160;&#160;In addition, we incurred a net loss of $4,410,000 for the nine months ended September 30, 2012, and have an accumulated deficit of $88,205,000 through September 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In November 2011, we received $275,000 from the sale of our 8% convertible debentures, which funds were used to position ourselves for the commercial release of a line of products.&#160;&#160;As of September 30, 2012, we have received an additional $614,000 of funding from selling additional 8% convertible debentures.&#160;&#160;In addition, our investors have indicated that they will purchase approximately $317,500 of additional 8% convertible debentures.&#160;&#160;These funds, including the remaining $111,000, were provided to us on the condition that these funds be used primarily for the commercial release and on-line sales of skin care products.&#160;&#160;The commercial release of our products through the engage:BDR joint venture commenced in July, 2012.&#160;&#160;As a result of the commitment to fund the remaining $111,000 balance of the $1,000,000 commitment for these on-line activities, we had sufficient funds to roll out our new product lines.&#160;&#160;However, our future liquidity and capital needs will thereafter depend on the revenues and profits, if any, that we receive from these new products and upon any additional funding that we may have to raise.&#160;&#160;Although we anticipate that we will generate significant revenues the 2012 fiscal year from the on-line sales of our products through engage:BDR, we are unable to predict the amount and timing of such sales.&#160;&#160;No assurance can be given that the revenues and profits generated through the engage:BDR joint venture will be significant or will be sufficient to fund our future working capital and other financial needs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The sale of our 8% convertible debentures includes the issuance of warrants to purchase up to a total of 20,000,000 shares of our common stock if we sell the $1,000,000 we expect to sell.&#160;&#160;As of September 30, 2012, we have received $889,000 from the sale of our debentures and thus have issued warrants to purchase a total of 17,780,000 shares.&#160;&#160;Our 8% convertible debentures are convertible into shares of our common stock at a conversion price equal to $0.05 per share and mature in October 2013.&#160;&#160;The warrants consist of Class A Warrants and Class B Warrants that are exercisable for up to two&#160;years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In order to fund our purchases of product inventory, on October 13, 2010 we obtained a revolving line of credit of up to $750,000 from Gemini Pharmaceuticals, Inc. (&#8220;Gemini&#8221;), which credit facility can only be used for nutraceutical product and inventory purchases from Gemini.&#160;&#160;The amount of advances available to us under the credit facility is tiered, starting at $250,000, and upon us meeting certain milestones, will be increased to $500,000, and then $750,000.&#160;&#160;Advances will be made to us so long as the representations and warranties we made remain true at the time that we request an advance.&#160;&#160;All advances under this credit facility will bear interest equal to the prime rate plus two percent per annum, calculated based on 360-day year.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font> This credit facility initially expired on October 13, 2011, but has been extended by Gemini.&#160;&#160;However, the credit facility currently may be terminated by Gemini at any time in its sole discretion.&#160;&#160;In consideration for this credit facility, we issued to Gemini a five-year warrant to 300,000 shares of our common stock at an exercise price of $0.12 per share, of which 150,000 shares are vested.&#160;&#160;An additional 75,000 shares will vest under the warrant if and when the credit line is increased to $500,000, and the remaining 75,000 will vest when the credit line is increased to $750,000. The warrants contain a cashless exercise provision.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We commenced on-line sales of ErgoFlex&#8482;, our first EGT&#8482; product in July 2012.&#160;&#160;Based on internally prepared estimates, we believe that the on-line sales will generate certain operating revenues for us.&#160;&#160;However, the amount and timing of such revenues is unknown.&#160;&#160;In addition to funding the engage:BDR joint venture&#8217;s initial capital requirements, we also will be incurring other costs, including the costs of developing, producing and marketing a new line of skin care products.&#160;&#160;Because our revenues from the sale of ErgoFlex and other products that we may release through the engage:BDR joint venture are uncertain, we may need additional capital in order to continue operations until, if ever, we are able to achieve positive operating cash flow.&#160;&#160;In addition, we will need capital in order to expand our operations and fund the increases in our administrative expenses that we expect will occur in 2012 if our business expands as anticipated.&#160;&#160;However, other than the Gemini inventory credit facility, we presently have no bank financing or other external sources of liquidity.&#160;&#160;There is no assurance that we will be successful in obtaining additional funding if, and when, we need such additional funding.&#160;&#160;We expect that we will try to obtain additional funding through the sale of debt or equity securities, or possibly through joint ventures or strategic relationships with unaffiliated third parties, or other financing approaches.&#160;&#160;No assurance can be given that we will be able to obtain sufficient capital to meet our requirements.&#160;&#160;The downturn in the equity and debt markets for small-cap public companies is expected to make it more difficult to obtain financing through the issuance of equity or debt securities.&#160;&#160;Even if we are able to raise the funds required, we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek additional financing.&#160;&#160;Furthermore, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock.&#160;&#160;If additional financing is not available or is not available on acceptable terms, we will not be able to fund our planned level of operations and product releases, and we may have to curtail our operations or possibly even abandon our business plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We consider the following accounting policies to be critical given they involve estimates and judgments made by management and are important for our investors&#8217; understanding of our operating results and financial condition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Basis of Consolidation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The consolidated financial statements contained in this report include the accounts of OXIS International, Inc. and its subsidiaries.&#160;&#160;All intercompany balances and transactions have been eliminated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Revenue Recognition</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product Revenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based upon historical data, current economic conditions and the underlying contractual terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License Revenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License arrangements may consist of non-refundable upfront license fees and various performance or sales milestones and future product royalty payments.&#160;&#160;Some of these arrangements are multiple element arrangements.&#160;&#160;Non-refundable, up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&#160;&#160;We defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of our performance under the other elements of the arrangement.&#160;&#160;In addition, if we have continuing involvement through research and development services that are required because our know-how and expertise related to the technology is proprietary to us, or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-Lived Assets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our long-lived assets include property, plant and equipment, capitalized costs of filing patent applications and goodwill and other assets.&#160;&#160;We evaluate our long-lived assets for impairment in accordance with SFAS No.&#160;&#160;144, &#8220;Accounting for the Impairment or Disposal of Long-Lived Assets&#8221; whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.&#160;&#160;Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management&#8217;s judgment.&#160;&#160;If any of our intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying amount of the assets over its fair value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Applicable long-lived assets are amortized or depreciated over the shorter of their estimated useful lives, the estimated period that the assets will generate revenue, or the statutory or contractual term in the case of patents.&#160;&#160;Estimates of useful lives and periods of expected revenue generation are reviewed periodically for appropriateness and are based upon management&#8217;s judgment.&#160;&#160;Goodwill and other assets are not amortized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Certain Expenses and Liabilities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On an ongoing basis, management evaluates its estimates related to certain expenses and accrued liabilities.&#160;&#160;We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of liabilities that are not readily apparent from other sources.&#160;&#160;Actual results may differ materially from these estimates under different assumptions or conditions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Derivative Financial Instruments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During the normal course of business, from time to time, we issue warrants as part of a debt or equity financing. We do not enter into any derivative contracts for speculative purposes. We recognize all derivatives as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. During the nine months ended September 30, 2012 and 2011, we issued warrants to purchase 463,250,546 and 6,882,500 shares of common stock, respectively, in connection with equity transactions. In accordance with ASC Topic 815-40, &#8220;Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Stock&#8221; (&#8220;ASC 815-40&#8221;), the value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to us in certain events, as defined.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inflation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We believe that inflation has not had a material adverse impact on our business or operating results during the periods presented.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-balance Sheet Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have no off-balance sheet arrangements as of September 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This company qualifies as a smaller reporting company, as defined in 17 C.F.R. &#167;229.10(f) (1) and is not required to provide information by this Item.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 4.<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font>Controls and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Evaluation of Disclosure Controls and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our principal executive officer and principal financial officer evaluated the effectiveness of our &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act of 1934, as amended), as of September 30, 2012.&#160;&#160;Based on that evaluation we have concluded that our disclosure controls and procedures were not effective as of September 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Management&#8217;s Report on Internal Control over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance that the objectives of the control system are met.&#160;&#160;Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.&#160;&#160;Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.&#160;&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of September 30, 2012, management of the company conducted an assessment of the effectiveness of the company&#8217;s internal control over financial reporting.&#160;&#160;In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework.&#160;&#160;In the course of the assessment, material weaknesses were identified in the company&#8217;s internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management determined that fundamental elements of an effective control environment were missing or inadequate as of September 30, 2012.&#160;&#160;The most significant issues identified were: 1) lack of segregation of duties due to very small staff and significant reliance on outside consultants, and 2) risks of executive override also due to lack of established policies, and small employee staff.&#160;&#160;Based on the material weaknesses identified above, management has concluded that internal control over financial reporting was not effective as of September 30, 2012.&#160;&#160;As the company&#8217;s operations increase, the company intends to hire additional employees in its accounting department.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in Internal Control over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other than as described above, no changes in our internal control over financial reporting were made during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II.&#160;&#160;OTHER INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.&#160;&#160;Legal Proceedings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There have been no material changes from the disclosure provided in Part I, Item 3 of our Annual Report on Form 10-K for the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1A.&#160;&#160;Risk Factors</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There have been no material changes from the disclosure provided in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2.&#160;&#160;Unregistered Sales of Securities and Use of Proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From January 1, 2012 through September 30, 2012, we issued 160,107,475 shares of common stock that were not registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), upon conversion of $2,166,031 of convertible debentures and demand notes and&#160;&#160;$216,250 of accrued interest payable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In March, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $617,500 (the &#8220;March 2012 Financing&#8221;). In connection with the March 2012 Financing, the Company issued the following securities to the investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8% Convertible Debentures in the principal amount of $617,500&#160;&#160;due in two years, convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.05 per share; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants to purchase 12,350,000 of shares of the Company&#8217;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#8220; March 2012 Warrants&#8221;) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In May, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the &#8220;May 2012 Financing&#8221;). In connection with the May 2012 Financing, the Company issued the following securities to the investors:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8% Convertible Debentures in the principal amount of $275,000 due May 2014, convertible into shares of the Company&#8217;s common stock at a per share conversion price equal to $0.05 per share; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants to purchase 5,500,000 of shares of the Company&#8217;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#8220; May&#160;&#160;2012 Warrants&#8221;) are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All of the foregoing<font style="BORDER-BOTTOM: 1pt double; DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>were effected without registration under the Securities Act in reliance on the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation D there under.&#160;&#160;The purchasers were accredited investors, no general solicitation or advertising was used in connection with the sale of the shares, and the Company has imposed appropriate limitations on resales.&#160;&#160;There was no underwriter involved in these sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3.&#160;&#160;Defaults Upon Senior Securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There have been no material changes from the disclosure provided in Part I, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 4.&#160;&#160;Mine Safety Disclosures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 5.&#160;&#160;Other Information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 8, 2012, a Settlement Agreement and Mutual General Release ("Agreement") was made by and between OXIS and Bristol Investment Fund, Ltd., in order to settle certain claims regarding certain convertible debentures held by Bristol.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the Agreement, OXIS shall pay Bristol (half of which payment would redound to Merit Capital Limited (&#8220;Merit&#8221;)) a total of $1,119,778 as payment in full for the losses suffered and all costs incurred by Bristol in connection with the Transaction. Payment of such $1,119,778 shall be made as follows: OXIS shall issue restricted common stock to each of Bristol and Merit, in an amount such that each Bristol and Merit shall hold no more than 9.99% of the outstanding shares of OXIS (including any shares that each may hold as of the date of issuance). The shares so issued represent $417,475.65 of the $1,119,778 payment (27,831,710 shares at $0.015 per share, of which 9,168,750 will be retained by Bristol and 18,662,960 will be issued to Merit). The remaining balance of the payment shall be made in the form of two convertible promissory notes in the respective amounts of $422,357.75 for Bristol and $279,944.60 for Merit (collectively, the &#8220;Notes&#8221;) with a maturity of December 1, 2017 having an 8% annual interest rate, with interest only accruing until January 1, 2013, and then level payments of $3,750 each beginning January 1, 2013 until paid in full on December 1, 2017. In the event a default in the monthly payments on the Notes has occurred and is continuing each holder of the Notes shall be permitted to convert the unpaid principal and interest of the Notes into shares of OXIS at $.01 cents per share.&#160;&#160;In the absence of such continuing default no conversion of the Notes will be permitted. OXIS will have the right to repay the Notes in full at any time without penalty.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 6.&#160;&#160;Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</font></div>
</td>
<td align="left" valign="bottom" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of Exhibit</font></div>
</td>
</tr><tr>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.1</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Principal Executive Officer and Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.1</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer and Chief Financial Officer).</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Instance Document</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Calculation Linkbase</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.DEF</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Linkbase</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Label Linkbase</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td align="left" valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Extension Presentation Linkbase</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="31%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="24%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="31%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OXIS International, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="31%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">November 21, 2012</font></div>
</td>
<td align="left" valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;&#160;</font></div>
</td>
<td align="left" colspan="3" valign="top" width="38%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;David Saloff</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Saloff</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer (Principal Executive Officer)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="31%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="31%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="31%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="31%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">November 21, 2012</font></div>
</td>
<td align="left" valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;&#160;</font></div>
</td>
<td align="left" colspan="3" valign="top" width="38%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ David Saloff</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David Saloff</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acting Chief Financial Officer (Principal Financial and Accounting Officer)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
32

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>ex311.htm</title>
    <!--Licensed to: OXIS International, Inc,-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 189pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, David Saloff, Chief Executive Officer and Acting Chief Financial Officer of OXIS International, Inc., certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have reviewed this Quarterly Report on Form 10-Q of OXIS International, Inc;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated:&#160;&#160;November 21, 2012</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline">/s/ David Saloff</font></font></div>
</td>
</tr><tr>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">David Saloff</font></div>
</td>
</tr><tr>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Executive Officer and Acting Chief Financial Officer</font></div>
</td>
</tr></table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>ex321.htm</title>
    <!--Licensed to: OXIS International, Inc,-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 189pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Quarterly Report on Form&#160;10-Q of OXIS International, Inc. (the &#8220;Company&#8221;) for the quarter ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), David Saloff, Chief Executive Officer and Acting Chief Financial Officer of the Company, hereby certifies, pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated:&#160;&#160;November 21, 2012</font></div>
</td>
<td align="left" valign="top" width="53%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline">/s/ David Saloff</font></font></div>
</td>
</tr><tr>
<td valign="top" width="27%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="53%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">David Saloff</font></div>
</td>
</tr><tr>
<td valign="top" width="27%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="53%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Executive Officer and Acting Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This certification accompanies each Report pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>oxis-20120930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- QXInteractive -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:OXIS="http://oxis.com/20120930">
    <link:schemaRef xlink:href="oxis-20120930.xsd" xlink:type="simple" />
    <xbrli:context id="From2012-01-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-09-30_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-09-30_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-09-30_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-09-30_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-09-30_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-09-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-01to2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-01</xbrli:startDate>
        <xbrli:endDate>2011-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2012-01-01to2012-09-30">OXIS INTERNATIONAL INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2012-01-01to2012-09-30">0000109657</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2012-01-01to2012-09-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2012-01-01to2012-09-30">2012-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2012-01-01to2012-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2012-01-01to2012-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2012-01-01to2012-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2012-01-01to2012-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2012-01-01to2012-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2012-01-01to2012-09-30">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2012-01-01to2012-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2012-01-01to2012-09-30">2012</dei:DocumentFiscalYearFocus>
    <us-gaap:InventoryNet contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">12000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">0</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">12000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">104000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">73000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">25000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">15000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">129000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">88000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">806000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">858000</us-gaap:AccountsPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1598000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">1225000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">607000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">1049000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LineOfCredit contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">25000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">26000</us-gaap:LineOfCredit>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">158000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">514000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <OXIS:DemandNotesPayableNetOfDiscountOf54000And0 contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">266000</OXIS:DemandNotesPayableNetOfDiscountOf54000And0>
    <OXIS:DemandNotesPayableNetOfDiscountOf54000And0 contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">63000</OXIS:DemandNotesPayableNetOfDiscountOf54000And0>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2012-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">15000000</us-gaap:PreferredStockSharesAuthorized>
    <OXIS:SeriesCPreferredStockIssuedShares contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">96230</OXIS:SeriesCPreferredStockIssuedShares>
    <OXIS:SeriesCPreferredStockIssuedShares contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">96230</OXIS:SeriesCPreferredStockIssuedShares>
    <OXIS:SeriesCPreferredStockOutstandingShares contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">96230</OXIS:SeriesCPreferredStockOutstandingShares>
    <OXIS:SeriesCPreferredStockOutstandingShares contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">96230</OXIS:SeriesCPreferredStockOutstandingShares>
    <OXIS:SeriesHPreferredStockIssuedShares contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">25000</OXIS:SeriesHPreferredStockIssuedShares>
    <OXIS:SeriesHPreferredStockIssuedShares contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">25000</OXIS:SeriesHPreferredStockIssuedShares>
    <OXIS:SeriesHPreferredStockOutstandingShares contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">25000</OXIS:SeriesHPreferredStockOutstandingShares>
    <OXIS:SeriesHPreferredStockOutstandingShares contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">25000</OXIS:SeriesHPreferredStockOutstandingShares>
    <OXIS:SeriesIPreferredStockIssuedShares contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">1666667</OXIS:SeriesIPreferredStockIssuedShares>
    <OXIS:SeriesIPreferredStockIssuedShares contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">1666667</OXIS:SeriesIPreferredStockIssuedShares>
    <OXIS:SeriesIPreferredStockOutstandingShares contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">1666667</OXIS:SeriesIPreferredStockOutstandingShares>
    <OXIS:SeriesIPreferredStockOutstandingShares contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">1666667</OXIS:SeriesIPreferredStockOutstandingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">269299838</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">457207313</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">269299838</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">457207313</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">5230000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">6326000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">995000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">625000</us-gaap:ConvertibleDebtCurrent>
    <OXIS:ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">775000</OXIS:ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion>
    <OXIS:ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">1966000</OXIS:ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-83795000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">-88205000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">78422000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">81634000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">269000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">457000</us-gaap:CommonStockValue>
    <OXIS:ConvertiblePreferredStockSeriesI contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2000</OXIS:ConvertiblePreferredStockSeriesI>
    <OXIS:ConvertiblePreferredStockSeriesI contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">2000</OXIS:ConvertiblePreferredStockSeriesI>
    <OXIS:ConvertiblePreferredStockSeriesH contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">0</OXIS:ConvertiblePreferredStockSeriesH>
    <OXIS:ConvertiblePreferredStockSeriesH contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">0</OXIS:ConvertiblePreferredStockSeriesH>
    <OXIS:ConvertiblePreferredStockSeriesC contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1000</OXIS:ConvertiblePreferredStockSeriesC>
    <OXIS:ConvertiblePreferredStockSeriesC contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">1000</OXIS:ConvertiblePreferredStockSeriesC>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-5101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">-6238000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_PreferredStockMember" unitRef="USD" decimals="0">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_PreferredStockMember" unitRef="USD" decimals="0">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-09-30_PreferredStockMember" unitRef="USD" decimals="0">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_CommonStockMember" unitRef="USD" decimals="0">149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_CommonStockMember" unitRef="USD" decimals="0">269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-09-30_CommonStockMember" unitRef="USD" decimals="0">457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">74474000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">78422000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">81634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2010-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-80095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-83795000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-09-30_RetainedEarningsMember" unitRef="USD" decimals="0">-88205000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">129000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">88000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">-127000</us-gaap:MinorityInterest>
    <OXIS:DemandNotesPayableNetOfDiscount contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">54000</OXIS:DemandNotesPayableNetOfDiscount>
    <OXIS:DemandNotesPayableNetOfDiscount contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">0</OXIS:DemandNotesPayableNetOfDiscount>
    <OXIS:ConvertibleDebenturesNetOfDiscount contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">0</OXIS:ConvertibleDebenturesNetOfDiscount>
    <OXIS:ConvertibleDebenturesNetOfDiscount contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">0</OXIS:ConvertibleDebenturesNetOfDiscount>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;OXIS International,&#13;Inc. (collectively, &amp;#147;OXIS&amp;#148; or the &amp;#147;Company&amp;#148;) is engaged in the research, development and sale of products&#13;that counteract the harmful effects of &amp;#147;oxidative stress&amp;#148; and inflammation.&amp;#160;&amp;#160;Oxidative stress refers to&#13;the situations in which the body&amp;#146;s antioxidant and other defensive abilities to combat free radicals (a.k.a. highly reactive&#13;species of oxygen and nitrogen) are overwhelmed and normal healthy balance is lost.&amp;#160;&amp;#160;The Company&amp;#146;s current finished&#13;product and finished product candidates include therapeutic nutraceutical products, cosmeceutical products, functional foods and&#13;functional beverages. The Company also possesses intellectual property covering a number of proprietary compounds and formulations&#13;that may be out-licensed to biotech and pharmaceutical companies as drug candidates.&amp;#160;&amp;#160;The Company&amp;#146;s primary focus&#13;currently is on products that incorporate the unique amino acid naturally occurring compound, L-Ergothioneine (&amp;#147;ERGO&amp;#148;),&#13;as a key component. Ergothioneine is produced only by microorganisms in soil and is not synthesized by humans, animals or plants.&amp;#160;&amp;#160;The&#13;Company has spent approximately $75 million in researching and developing ERGO, and now owns a patented process to synthesize&#13;commercial quantities of ERGO in a highly stable form that is highly soluble and tasteless, making it suitable for use in combination&#13;with other nutraceuticals and botanicals in a wide variety of dietary supplements, functional foods and beverages, and topical&#13;anti-aging products including lotions and creams.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In 1965, the&#13;corporate predecessor of OXIS, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic Data changed its&#13;incorporation to the State of Delaware in 1972; and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals&#13;merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Going Concern&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As shown in&#13;the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $88,205,000 through September&#13;30, 2012.&amp;#160;&amp;#160;On a consolidated basis, the Company had cash and cash equivalents of $61,000 at September 30, 2012. The&#13;Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash&#13;flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are&#13;many factors that may prevent the Company from reaching its goal of profitability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The current&#13;rate of cash usage raises substantial doubt about the Company&amp;#146;s ability to continue as a going concern, absent any sources&#13;of significant cash flows.&amp;#160;&amp;#160;In an effort to mitigate this near-term concern the Company intends to seek additional equity&#13;or debt financing to obtain sufficient funds to sustain operations.&amp;#160;&amp;#160;The Company plans to increase revenues by introducing&#13;new nutraceutical products primarily based on its ergothioneine assets.&amp;#160;&amp;#160;However, the Company cannot provide assurance&#13;that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company&#13;will generate future product related revenues.&amp;#160;&amp;#160;The Company&amp;#146;s financial statements do not include any adjustments&#13;relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might&#13;be necessary in the event that the Company cannot continue in existence.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Use of Estimates&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The financial&#13;statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.&#13;These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently&#13;applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates&#13;and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets&#13;and liabilities at the date of the financial statements. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Revenue Recognition&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Product&#13;Revenue&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products&#13;to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the&#13;products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales&#13;order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net&#13;of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor&#13;may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based&#13;upon historical data, current economic conditions and the underlying contractual terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;License&#13;Revenue&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;License arrangements&#13;may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various&#13;performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-refundable,&#13;up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on&#13;our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&amp;#160;&amp;#160;We&#13;defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right,&#13;product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent&#13;of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research&#13;and development services that are required because our know-how and expertise related to the technology is proprietary to us,&#13;or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Payments related&#13;to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement&#13;of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Segment Reporting&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;operates in one reportable segment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stock Based&#13;Compensation to Employees&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&amp;#147;ASC&amp;#148;)&#13;718.&amp;#160;&amp;#160;The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based&#13;compensation issued to employees and non-employees over the related vesting period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;granted stock options to purchase 26,384,193 and 2,066,491 shares of the Company&amp;#146;s common stock to employees and directors&#13;during the nine months ended September 30, 2012 and 2011, respectively.&amp;#160;&amp;#160;The fair values of employee stock options are&#13;estimated for the calculation of the pro forma adjustments at the date of grant using the Black-Scholes option-pricing model with&#13;the following weighted-average assumptions during 2012: expected volatility of 116%; average risk-free interest rate of 1.04%&#13;to 2.04%; initial expected life of 5 to 10 years; no expected dividend yield; and amortized over the vesting period of typically&#13;one to four years.&amp;#160;&amp;#160;The Company reported an expense for share-based compensation for its employees and directors of&#13;$699,000 and $307,000 for the nine months ended September 30, 2012 and 2011, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stock Based&#13;Compensation to Other than Employees&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance&#13;with ASC 718. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value&#13;of the equity instruments issued, whichever is more reliably determinable. The value of equity instruments issued for consideration&#13;other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider&#13;of goods or services. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized&#13;over the term of the consulting agreement. The Company recognized no expense in share-based compensation for non-employees for&#13;the nine months ended September 30, 2012 and 2011, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Earnings Per&#13;Share&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic earnings&#13;per share is computed by dividing the net income or loss for the period by the weighted average number of common shares outstanding&#13;during the period.&amp;#160;&amp;#160;Diluted earnings per share is computed by dividing the earnings for the period by the weighted average&#13;number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise&#13;or conversion of outstanding stock options and warrants during the period.&amp;#160;&amp;#160;Since the Company incurred a net loss for&#13;the six months ended June 30, 2012 and 2011, all instruments convertible into shares of common stock are excluded from net diluted&#13;loss per share because of their anti-dilutive effect.&amp;#160;&amp;#160;Total potentially dilutive shares excluded from the calculation&#13;of earnings per share at September 30, 2012 totaled 538,285,943.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Recent Accounting&#13;Pronouncements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Management&#13;does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material&#13;effect on the Company&amp;#146;s financial position or results of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Fair Value&#13;Measurements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The carrying&#13;amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a&#13;reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected&#13;realization and their current market rate of interest.&amp;#160; The three levels are defined as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 1 inputs to&#13;    the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&amp;#146;s&#13;    Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair&#13;    value because of their short-term maturities of the investments held by these funds.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 2 inputs to&#13;    the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are&#13;    observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&#13;    The Company&amp;#146;s Level 2 liabilities consist of two liabilities arising from the issuance of convertible securities and&#13;    in accordance with EITF 00-19: a warrant liability for detachable warrants, as well as an accrued derivative liability for&#13;    the beneficial conversion feature. These liabilities are remeasured on a quarterly basis. Fair value is determined using the&#13;    Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with&#13;    that of a government-issued security of a similar maturity.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 3 inputs to&#13;    the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The following&#13;table represents the Company&amp;#146;s assets and liabilities by level measured at fair value on a recurring basis at September&#13;30, 2012.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 64%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;514,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options&#13;    Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of December 31, 2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;16,078,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;26,384,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,679,027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of September 30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;38,784,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    as of September 30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;23,415,441&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants&#13;    Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of December 31, 2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;105,001,252&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;462,300,546&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;52,500,000&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Adjustments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(15,300,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of September 30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;499,501,798&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;September&#13;    30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Capitalized&#13;    patent costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accumulated&#13;    amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(625,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(615,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 84%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 64%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;514,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:LiquidityDisclosureTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As shown in&#13;the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $88,205,000 through September&#13;30, 2012.&amp;#160;&amp;#160;On a consolidated basis, the Company had cash and cash equivalents of $61,000 at September 30, 2012. The&#13;Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash&#13;flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are&#13;many factors that may prevent the Company from reaching its goal of profitability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The current&#13;rate of cash usage raises substantial doubt about the Company&amp;#146;s ability to continue as a going concern, absent any sources&#13;of significant cash flows.&amp;#160;&amp;#160;In an effort to mitigate this near-term concern the Company intends to seek additional equity&#13;or debt financing to obtain sufficient funds to sustain operations.&amp;#160;&amp;#160;The Company plans to increase revenues by introducing&#13;new nutraceutical products primarily based on its ergothioneine assets.&amp;#160;&amp;#160;However, the Company cannot provide assurance&#13;that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company&#13;will generate future product related revenues.&amp;#160;&amp;#160;The Company&amp;#146;s financial statements do not include any adjustments&#13;relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might&#13;be necessary in the event that the Company cannot continue in existence.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The financial&#13;statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.&#13;These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently&#13;applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates&#13;and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets&#13;and liabilities at the date of the financial statements. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Product&#13;Revenue&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products&#13;to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the&#13;products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales&#13;order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net&#13;of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor&#13;may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based&#13;upon historical data, current economic conditions and the underlying contractual terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;License&#13;Revenue&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;License arrangements&#13;may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various&#13;performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-refundable,&#13;up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on&#13;our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&amp;#160;&amp;#160;We&#13;defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right,&#13;product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent&#13;of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research&#13;and development services that are required because our know-how and expertise related to the technology is proprietary to us,&#13;or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Payments related&#13;to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement&#13;of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;operates in one reportable segment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&amp;#147;ASC&amp;#148;)&#13;718.&amp;#160;&amp;#160;The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based&#13;compensation issued to employees and non-employees over the related vesting period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;granted stock options to purchase 26,384,193 and 2,066,491 shares of the Company&amp;#146;s common stock to employees and directors&#13;during the nine months ended September 30, 2012 and 2011, respectively.&amp;#160;&amp;#160;The fair values of employee stock options are&#13;estimated for the calculation of the pro forma adjustments at the date of grant using the Black-Scholes option-pricing model with&#13;the following weighted-average assumptions during 2012: expected volatility of 116%; average risk-free interest rate of 1.04%&#13;to 2.04%; initial expected life of 5 to 10 years; no expected dividend yield; and amortized over the vesting period of typically&#13;one to four years.&amp;#160;&amp;#160;The Company reported an expense for share-based compensation for its employees and directors of&#13;$699,000 and $307,000 for the nine months ended September 30, 2012 and 2011, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance&#13;with ASC 718. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value&#13;of the equity instruments issued, whichever is more reliably determinable. The value of equity instruments issued for consideration&#13;other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider&#13;of goods or services. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized&#13;over the term of the consulting agreement. The Company recognized no expense in share-based compensation for non-employees for&#13;the nine months ended September 30, 2012 and 2011, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic earnings&#13;per share is computed by dividing the net income or loss for the period by the weighted average number of common shares outstanding&#13;during the period.&amp;#160;&amp;#160;Diluted earnings per share is computed by dividing the earnings for the period by the weighted average&#13;number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise&#13;or conversion of outstanding stock options and warrants during the period.&amp;#160;&amp;#160;Since the Company incurred a net loss for&#13;the six months ended June 30, 2012 and 2011, all instruments convertible into shares of common stock are excluded from net diluted&#13;loss per share because of their anti-dilutive effect.&amp;#160;&amp;#160;Total potentially dilutive shares excluded from the calculation&#13;of earnings per share at September 30, 2012 totaled 538,285,943.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Management&#13;does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material&#13;effect on the Company&amp;#146;s financial position or results of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The carrying&#13;amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a&#13;reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected&#13;realization and their current market rate of interest.&amp;#160; The three levels are defined as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 1 inputs to&#13;    the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&amp;#146;s&#13;    Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair&#13;    value because of their short-term maturities of the investments held by these funds.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 2 inputs to&#13;    the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are&#13;    observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&#13;    The Company&amp;#146;s Level 2 liabilities consist of two liabilities arising from the issuance of convertible securities and&#13;    in accordance with EITF 00-19: a warrant liability for detachable warrants, as well as an accrued derivative liability for&#13;    the beneficial conversion feature. These liabilities are remeasured on a quarterly basis. Fair value is determined using the&#13;    Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with&#13;    that of a government-issued security of a similar maturity.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 3 inputs to&#13;    the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The following&#13;table represents the Company&amp;#146;s assets and liabilities by level measured at fair value on a recurring basis at September&#13;30, 2012.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Description&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 64%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;514,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <OXIS:AdvisoryAndConsultingAgreementsObligationsTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Advisory Agreements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;entered into a two-year Scientific Advisory Board Services Agreement with L. Stephen Coles on March 4, 2010.&amp;#160;&amp;#160;Mr. Coles&#13;receives an advisory fee for $9,000 per quarter.&amp;#160;&amp;#160;Upon entering into the agreement, the Company granted Mr. Coles an&#13;initial option to purchase 250,000 shares of the Company&amp;#146;s common stock under its 2003 Stock Incentive Plan.&amp;#160;&amp;#160;The&#13;options vest and become exercisable in four equal quarterly installments beginning June 4, 2010.&amp;#160;&amp;#160;Pursuant to the terms&#13;of the agreement, a second option to purchase 500,000 shares of the Company&amp;#146;s common stock under our 2003 Stock Incentive&#13;Plan was granted on March 4, 2011.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;entered into a two-year Scientific Advisory Board Services Agreement with Rajan Shah on July 15, 2010.&amp;#160;&amp;#160;Mr. Shah receives&#13;an advisory fee for $9,000 per quarter.&amp;#160;&amp;#160;Upon entering into the agreement, the Company granted Mr. Shah an initial option&#13;to purchase 250,000 shares of the Company&amp;#146;s common stock under its 2003 Stock Incentive Plan.&amp;#160;&amp;#160;The options vested&#13;and become exercisable in four equal quarterly installments beginning October 15, 2010.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;entered into a two-year Advisory Board Services Agreement with Sandep Rahi on July 15, 2010.&amp;#160;&amp;#160;Mr. Rahi receives an advisory&#13;fee for $9,000 per quarter.&amp;#160;&amp;#160;Upon entering into the agreement, the Company granted Mr. Rahi an initial option to purchase&#13;250,000 shares of the Company&amp;#146;s common stock under its 2003 Stock Incentive Plan.&amp;#160;&amp;#160;The options vested and become&#13;exercisable in four equal quarterly installments beginning October 15, 2010.&amp;#160;&amp;#160;Pursuant to the terms of the agreement,&#13;a second option to purchase 500,000 shares of the Company&amp;#146;s common stock under its 2003 Stock Incentive Plan was granted&#13;on July 15, 2011.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consulting&#13;Agreements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On January&#13;1, 2011, we entered into a consulting agreement with Bristol Capital, LLC whereby Bristol will assist us in general corporate&#13;activities including but not limited to strategic and financial planning, management and business operations, final projections&#13;and investor relation materials. As compensation for these services, we issued 5,000,000 shares of our common stock. The term&#13;of the agreement is for six months unless terminated or extended in accordance with subsequent agreements between the parties.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On January&#13;1, 2011, the Company entered into a consulting agreement with Piter Korompis, whereby Mr. Korompis will assist the company in&#13;general corporate activities including but not limited to strategic and financial planning, management and business operations,&#13;final projections and investor relation materials. As compensation for these services, the Company will issue 5,000,000 shares&#13;of common stock of the Company. The term of the agreement is for six months unless terminated or extended in accordance with subsequent&#13;agreements between the parties.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In connection&#13;with a joint venture agreement, the Company entered into a consulting agreement with John E. Repine, M.D. on June 28, 2011, whereby&#13;Dr. Repine will provide advisory services to OXIS and Ergo ARDS and serve as Ergo ARDS&amp;#146; Chief Executive Officer.&amp;#160;&amp;#160;OXIS&amp;#146;&#13;payments to Dr. Repine under the consulting agreement will be made in shares of OXIS common stock. OXIS agreed to issue shares&#13;of Common Stock to Dr. Repine as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On July 6, 2011&#13;    OXIS issued to Dr. Repine 2,777,778 shares of common stock (valued at $250,000) for various services relating to the terms&#13;    of the consulting agreement;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;OXIS agreed to issue&#13;    to Dr. Repine additional shares of common stock valued at $50,000 upon completion of the first animal study and Dr. Repine&amp;#146;s&#13;    delivery to Ergo ARDS of a summary presentation of the findings of the study; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;OXIS agreed to issue&#13;    Dr. Repine additional shares of common stock valued at $100,000 upon the completion of such second animal study and Dr. Repine&amp;#146;s&#13;    delivery to Ergo ARDS of a summary presentation of the findings of the study.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;If the value&#13;of these shares decreases at the end of the 6-month period following the date of issuance of such shares, OXIS will be obligated&#13;to issue additional shares of common stock to Dr. Repine so that the market value of the shares previously issued to Dr. Repine&#13;on that date will equal to $250,000, $50,000 or $100,000, as the case may be.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</OXIS:AdvisoryAndConsultingAgreementsObligationsTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Under the&#13;Company's Second Amended and Restated Certificate of Incorporation, the Company was authorized to issue a total of 150,000,000&amp;#160;shares&#13;of Common Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On January&#13;5, 2011, the Company's Board of Directors approved an amendment to its Second Amended and Restated Certificate of Incorporation&#13;to increase the shares of Common Stock that are authorized for issuance by 450,000,000 shares, bringing the total number of common&#13;shares authorized for issuance to 600,000,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The approval&#13;of the Amendment required the consent of no less than at least a majority of the voting power of the Company.&amp;#160;&amp;#160;Theorem&#13;Group, LLC owns, in addition to other of our securities, 25,000 shares of Series H Convertible Preferred Stock.&amp;#160;&amp;#160;The&#13;Certificate of Designation of Preferences, Rights and Limitations of the Series H Convertible Preferred Stock provides that each&#13;outstanding share of Series H Convertible Preferred Stock entitles the holder thereof to a number of votes equal to (A) the number&#13;of shares of Common Stock that such share of preferred stock could, at such time, be converted into (B) multiplied by 100.&amp;#160;&amp;#160;The&#13;Series H Convertible Preferred Stock is currently convertible into 2,500,000 shares of Common Stock.&amp;#160;&amp;#160;Accordingly, Theorem&#13;Group, LLC has the voting power of 250,000,000 shares, which represents more than a majority of voting power of all of the Company's&#13;outstanding voting shares.&amp;#160;&amp;#160;Theorem Group, LLC approved the Amendment on January 5, 2011 by an action taken by written&#13;consent.&amp;#160;&amp;#160;The amendment was filed with the Delaware Secretary of State in February 2011.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Each share&#13;of common stock is entitled to one vote at the Company's annual meeting of stockholders.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During the&#13;nine months ended September 30, 2012 and 2011, the Company issued a total of 160,107,475 and 61,831,683 shares of common stock,&#13;respectively for retirement of debt valued at $2,382,281 and $1,144,000, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Preferred&#13;Stock&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The 96,230&#13;shares of Series C preferred stock are convertible into 27,800 shares of the Company's common stock at the option of the holders&#13;at any time. The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading&#13;days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than .20 or more than&#13;.2889 common shares for each Series C preferred share. The conversion ratio may be adjusted under certain circumstances such as&#13;stock splits or stock dividends. The Company has the right to automatically convert the Series C preferred stock into common stock&#13;if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company's&#13;common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $13.00. Each share of Series C preferred stock&#13;is entitled to the number of votes equal to .26 divided by the average closing bid price of the Company's common stock during&#13;the fifteen consecutive trading days immediately prior to the date such shares of Series C preferred stock were purchased. In&#13;the event of liquidation, the holders of the Series C preferred stock shall participate on an equal basis with the holders of&#13;the common stock (as if the Series C preferred stock had converted into common stock) in any distribution of any of the assets&#13;or surplus funds of the Company. The holders of Series C preferred stock are entitled to noncumulative dividends if and when declared&#13;by the Company's board of directors. No dividends to Series C preferred stockholders were issued or unpaid through September 30,&#13;2012.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On December&#13;4, 2008, the Company entered into and closed an Agreement (the &amp;#147;Bristol Agreement&amp;#148;) with Bristol Investment Fund,&#13;Ltd. pursuant to which Bristol agreed to cancel the debt payable by the Company to Bristol in the amount of approximately $20,000&#13;in consideration of the Company issuing Bristol 25,000 shares of Series&amp;#160;G Convertible Preferred Stock, which such shares&#13;carry a stated value equal to $1.00 per share (the &amp;#147;Series&amp;#160;G Stock&amp;#148;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Series&amp;#160;G&#13;Stock is convertible, at any time at the option of the holder, into common shares of the Company based on a conversion price equal&#13;to the lesser of $.01 or 60% of the average of the three lowest trading prices occurring at any time during the 20 trading days&#13;preceding the conversion.&amp;#160;&amp;#160;&amp;#160;The Series&amp;#160;G Stock, as amended,&amp;#160;shall have voting rights on an as converted&#13;basis multiplied by 100.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In the event&#13;of any liquidation or winding up of the Company, the holders of Series&amp;#160;G Stock will be entitled to receive, in preference&#13;to holders of common stock, an amount equal to the stated value plus interest of 15% per year.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Series&#13;G Stock restricts the ability of the holder to convert the Series&amp;#160;G Stock and receive shares of the Company&amp;#146;s common&#13;stock such that the number of shares of the Company common stock held by Bristol and its affiliates after such conversion does&#13;not exceed 4.9% of the Company&amp;#146;s then issued and outstanding shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Series&#13;G Stock was previously referred to in an 8-K filed by the Company on December 10, 2008 in error as the &amp;#147;Series E Stock&amp;#148;.&#13;Further, the Series G Stock initially incorrectly provided that it voted on an as converted basis multiplied by 10.&amp;#160;&amp;#160;This&#13;incorrectly reflected the intent of the Company and the holder.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On October&#13;13, 2009, the Company was informed by Theorem Group, LLC that it had purchased all of the outstanding Series G Preferred Stock&#13;and Theorem gave notice to the Company that it intended to exercise its ability to vote on all shareholder matters utilizing the&#13;super voting privileges provided by the Series G Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Effective&#13;February 10, 2010, the Company issued 25,000 shares of its new Series H Convertible Preferred Stock (the &amp;#147;Series H Preferred&amp;#148;)&#13;to Theorem Group, LLC, a California limited liability company (the &amp;#147;Stockholder&amp;#148;), in exchange for the 25,000 shares&#13;of Series G Stock then owned by the Stockholder.&amp;#160;&amp;#160;The foregoing exchange was effected pursuant to that certain Exchange&#13;Agreement, dated February 10, 2010, between the Company and the Stockholder (the &amp;#147;Exchange Agreement&amp;#148;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Certificate&#13;of Designation of the Series H Preferred is based on, and substantially similar to the form and substance of the Certificate of&#13;Designation of the Series G Preferred.&amp;#160;&amp;#160;Some of the corrections, changes and differences between the Certificate of&#13;Designation of the Series G Preferred and the Certificate of Designation of the Series H Preferred include the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As previously disclosed,&#13;    the holder of the Series H Preferred is entitled to vote with the common stock, and is entitled to a number of votes equal&#13;    to (i) the number of shares of common stock it can convert into (without any restrictions or limitations on such conversion),&#13;    (ii) multiplied by 100.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The holder of the&#13;    Series H Preferred cannot convert such preferred stock into shares of common stock if the holder and its affiliates after&#13;    such conversion would own more than&amp;#160;9.9% of the Company&amp;#146;s then issued and outstanding shares of common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Series G Preferred&#13;    contained a limitation that the holder of the Series G Preferred could not convert such preferred shares into more than 19.999%&#13;    of the issued and outstanding shares of common stock without the approval of the stockholders if the rules of the principal&#13;    market on which the common stock is traded would prohibit such a conversion.&amp;#160;&amp;#160;Since the rules of the Company&amp;#146;s&#13;    principal market did not require such a limitation, that provision has been deleted.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On November&#13;8, 2010, Gemini Pharmaceuticals purchased 1,666,667 shares of the Company&amp;#146;s Series I Preferred Stock, $.001 par value, at&#13;a price of $0.15 per share ($250,000).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As the holder&#13;of the Series I Preferred Stock, Gemini Pharmaceuticals will be entitled to receive, out of funds legally available, dividends&#13;in cash at the annual rate of 8.0% of the Preference Amount ($0.15), when, as, and if declared by the Board.&amp;#160;&amp;#160;No dividends&#13;or other distributions shall be made with respect to any shares of junior stock until dividends in the same amount per share on&#13;the Series I Preferred Stock shall have been declared and paid or set apart during that fiscal year. Dividends on the Series I&#13;Preferred Stock shall not be cumulative and no right shall accrue to the Series I Preferred Stock by reason of the fact that the&#13;Company may fail to declare or pay dividends on the Series I Preferred Stock in the amount of the Dividend Rate per share or in&#13;any amount in any previous fiscal year of the Company, whether or not the earnings of the Company in that previous fiscal year&#13;were sufficient to pay such dividends in whole or in part.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Each share&#13;of Series I Preferred Stock shall entitle the holder thereof to such number of votes per share as shall equal the number of shares&#13;of Common Stock (rounded to the nearest whole number) into which such share of Series I Preferred Stock is then convertible.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Upon any liquidation&#13;of the Company, subject to the rights of any series of Preferred Stock that may from time to time come into existence, before&#13;any distribution or payment shall be made to the holders of any Junior Stock, the holders of the shares of Series I Preferred&#13;Stock then outstanding shall be entitled to receive and be paid out of the assets of the Company legally available for distribution&#13;to its stockholders liquidating distributions in cash or property at its fair market value as determined by the Board in the amount&#13;of $0.15 per share (as adjusted for any stock dividends, combinations or splits with respect to such shares).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Shares of&#13;Series I Preferred Stock may, at the option of the holder thereof, be converted at any time or from time to time into fully paid&#13;and non-assessable shares of Common Stock.&amp;#160;&amp;#160;The number of shares of Common Stock which a holder of shares of Series&#13;I Preferred Stock shall be entitled to receive upon conversion of such shares shall be the product obtained by multiplying the&#13;Conversion Rate by the number of shares of Series I Preferred Stock being converted.&amp;#160;&amp;#160;Initially, the Series I Preferred&#13;Stock is convertible into 1,666,667 shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In the event&#13;that the per-share Market Price of the Common Stock over a period of 20 consecutive trading days is equal to at least 130% of&#13;the initial conversion price (130% of $0.15), all outstanding shares of Series I Preferred Stock shall&amp;#160;&amp;#160;be converted&#13;automatically into the number of shares of Common Stock into which such shares of Series I Preferred Stock are then convertible&#13;without any further action by the holders of such shares and whether or not the certificates representing such shares of Series&#13;I Preferred Stock are surrendered to the Company or its transfer agent.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Convertible&#13;debentures&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On October&#13;25, 2006, the Company entered into a securities purchase agreement (&amp;#147;2006 Purchase Agreement&amp;#148;) with four accredited&#13;investors (the &amp;#147;2006 Purchasers&amp;#148;). In conjunction with the signing of the 2006 Purchase Agreement, the Company issued&#13;secured convertible debentures (&amp;#147;2006 Debentures&amp;#148;) and Series A, B, C, D, and E common stock warrants (&amp;#147;2006&#13;Warrants&amp;#148;) to the 2006 Purchasers, and the parties also entered into a security agreement (the &amp;#147;2006 Security Agreement&amp;#148;)&#13;pursuant to which the Company agreed to grant the 2006 Purchasers, pari passu, a security interest in substantially all of the&#13;Company&amp;#146;s assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Pursuant to&#13;the terms of the 2006 Purchase Agreement, the Company issued the 2006 Debentures in an aggregate principal amount of $1,694,250&#13;to the 2006 Purchasers. The 2006 Debentures are subject to an original issue discount of 20.318% resulting in proceeds to the&#13;Company of $1,350,000 from the transaction. The 2006 Debentures were due on October 25, 2008. The 2006 Debentures are convertible,&#13;at the option of the 2006 Purchasers, at any time prior to payment in full, into shares of common stock of the Company. As a result&#13;of the full ratchet anti-dilution provision the current conversion price is $0.01 per share (the &amp;#147;2006 Conversion Price&amp;#148;).&#13;Beginning on the first of the month beginning February 1, 2007, the Company was required to amortize the 2006 Debentures in equal&#13;installments on a monthly basis resulting in a complete repayment by the maturity date (the &amp;#147;Monthly Redemption Amounts&amp;#148;).&#13;The Monthly Redemption Amounts could have been paid in cash or in shares, subject to certain restrictions. If the Company chose&#13;to make any Monthly Redemption Amount payment in shares of common stock, the price per share would have been the lesser of the&#13;Conversion Price then in effect and 85% of the weighted average price for the 10-trading days prior to the due date of the Monthly&#13;Redemption Amount. The Company did not make any of the required monthly redemption payments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Pursuant to&#13;the provisions of the 2006 Debentures, such non-payment was an event of default and penalty interest has accrued on the unpaid&#13;redemption balance at an interest rate equal to the lower of 18% per annum and the maximum rate permitted by applicable law. In&#13;addition, each of the 2006 Purchasers has the right to accelerate the cash repayment of at least 130% of the outstanding principal&#13;amount of the 2006 Debenture (plus accrued but unpaid liquidated damages and interest) and to sell substantially all of the Company&amp;#146;s&#13;assets pursuant to the provisions of the 2006 Security Agreement to satisfy any such unpaid balance. On June 6, 2008, the Company&#13;received notification from Bristol Investment Fund, Ltd (&amp;#147;Bristol&amp;#148;), that the collateral held under the 2006 Security&#13;Agreement would be sold to the highest qualified bidder on Thursday, June 19, 2008. On June 19, 2008, the Company received a Notice&#13;of Disposition of Collateral from Bristol in which Bristol notified the Company that Bristol, acting as the agent for itself and&#13;the three other 2006 Purchasers, purchased certain assets held as collateral under the 2006 Security Agreement. Bristol purchased&#13;111,025 shares of common stock of BioCheck, Inc., the Company&amp;#146;s majority owned subsidiary, on a credit bid of $50,000, and&#13;Bristol also purchased 1,000 shares of the capital stock of OXIS Therapeutics, Inc., a wholly owned subsidiary of OXIS, for a&#13;credit bid of $10,000. In December 2005, OXIS purchased the 111,025 shares of common stock of BioCheck, Inc. for $3,060,000. After&#13;crediting the aggregate amount of $60,000 to the aggregate amount due under the 2006 Debentures, plus fees and charges due through&#13;June 19, 2008, Bristol notified the Company that the Company remains obligated to the 2006 Purchasers in a deficiency in an aggregate&#13;amount of $2,688,000 as of June 19, 2008. As a result of the disposition of the collateral, the Company recorded a net loss aggregating&#13;$2,978,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Under the&#13;2006 Purchase Agreement, the 2006 Purchasers also have a right of first refusal to participate in up to 100% of any future financing&#13;undertaken by the Company until the 2006 Debentures are no longer outstanding. In addition, the Company is also prohibited from&#13;effecting any subsequent financing involving a variable rate transaction until such time as no 2006 Purchaser holds any of the&#13;2006 Debentures. Furthermore, so long as any 2006 Purchaser holds any of the securities issued under the 2006 Purchase Agreement,&#13;if the Company issues or sells any common stock or instruments convertible into common stock which a 2006 Purchaser reasonably&#13;believes is on terms more favorable to such investors than the terms pursuant to the 2006 Debentures or 2006 Warrants, the Company&#13;is obligated to permit such 2006 Purchaser the benefits of such better terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Of the 2006&#13;Warrants issued by the Company to the 2006 Purchasers, only the Series A Warrants remain outstanding. The Series A Warrants, which&#13;now expire in October 2014, permit the holders to purchase 2,420,357 shares of common stock at an original exercise price of $0.35&#13;per share. Such exercise price is adjustable pursuant to a full ratchet anti-dilution provision and upon the occurrence of a stock&#13;split or a related event.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During 2009,&#13;Bristol converted $177,900 of the principal amount of 2006 Debentures for 17,790,000 shares of the Company&amp;#146;s common stock.&#13;During 2010, Bristol converted an additional $401,000 of the principal amount of 2006 Debentures for 40,100,000 shares of the&#13;Company&amp;#146;s common stock. During 2011, an additional $605,000 of the principal amount of 2006 Debentures was converted into&#13;60,500,000 shares of the Company&amp;#146;s common stock. Of the $605,000 converted in 2011, $53,125 was converted into 5,312,500&#13;shares of the Company&amp;#146;s common stock during the first quarter of 2011. During the nine months ended September 30, 2012,&#13;an additional $372,000 of the principal amount of 2006 Debentures was converted into 37,200,000 shares of the Company&amp;#146;s&#13;common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The 2006 Debentures&#13;do not meet the definition of a &amp;#147;conventional convertible debt instrument&amp;#148; since they are not convertible into a fixed&#13;number of shares. The Monthly Redemption Amounts can be paid with common stock at a conversion price that is a percentage of the&#13;market price; therefore the number of shares that could be required to be delivered upon &amp;#147;net-share settlement&amp;#148; is&#13;essentially indeterminate. Therefore, the 2006 Debentures are considered &amp;#147;non-conventional,&amp;#148; which means that the&#13;conversion feature must be bifurcated from the debt and shown as a separate derivative liability. This beneficial conversion liability&#13;has been calculated to be $690,000 on October 25, 2006. In addition, since the 2006 Debentures are convertible into an indeterminate&#13;number of shares of common stock, it is assumed that the Company could never have enough authorized and unissued shares to settle&#13;the conversion of the 2006 Warrants issues in this transaction into common stock. Therefore, the 2006 Warrants have a fair value&#13;of $2,334,000 at October 25, 2006. The value of the 2006 Warrant was calculated using the Black-Scholes model using the following&#13;assumptions: Discount rate of 4.5%, volatility of 158% and expected term of 1 to 6 years. The fair value of the beneficial conversion&#13;feature and the 2006 Warrant liability will be adjusted to fair value on each balance sheet date with the change being shown as&#13;a component of net loss. The fair value of the beneficial conversion feature and the 2006 Warrants at the inception of the 2006&#13;Debentures were $690,000 and $2,334,000, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The first&#13;$1,350,000 of these discounts has been shown as a discount to the 2006 Debentures which will be amortized over the term of the&#13;2006 Debenture and the excess of $1,674,000 has been shown as financing costs in the accompanying statement of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;At September&#13;30, 2012 and December 31, 2011, the Company determined the fair value of the 2006 Warrants was $79,000 and $39,000, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On October&#13;1, 2009, the Company entered into a financing arrangement with several accredited investors (the &amp;#147;2009 Investors&amp;#148;),&#13;pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $2,000,000 (the &amp;#147;2009&#13;Financing&amp;#148;). In connection with the 2009 Financing, the Company issued the following securities to the 2009 Investors:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0% Convertible Debentures&#13;    in the principal amount of $2,000,000 due 24 months from the date of issuance (the &amp;#147; 2009 Debentures&amp;#148;), convertible&#13;    into shares of the Company&amp;#146;s common stock at a per share conversion price equal to $0.05 per share;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series A warrant&#13;    to purchase such number of shares of the Company&amp;#146;s common stock equal to 50% of the principal amount invested by each&#13;    2009 Investor (the &amp;#147;2009 Class A Warrants&amp;#148; ) resulting in the issuance of Class A Warrants to purchase 20,000,000&#13;    shares of common stock of the Company.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Series B warrant&#13;    to purchase such number of shares of the Company&amp;#146;s common stock equal to 50% of the principal amount invested by each&#13;    2009 Investor (the &amp;#147;2009 Class B Warrants&amp;#148;) resulting in the issuance of Class B Warrants to purchase 20,000,000&#13;    shares of common stock of the Company.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Class&#13;A Warrants and Class B Warrants (collectively, the &amp;#147; 2009 Warrants&amp;#148;) are exercisable for up to five years from the&#13;date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively,&#13;on a cash or cashless basis. The 2009 Debentures and the 2009 Warrants are collectively referred to herein as the &amp;#147;2009&#13;Securities&amp;#148;.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In connection&#13;with the sale of the 2009 Securities by the Company, the Company and Bristol entered a Standstill and Forbearance Agreement, pursuant&#13;to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect to (i) the 2006 Debentures&#13;and (ii) certain demand notes (the &amp;#147;Bridge Notes&amp;#148;) issued by the Company on October 8, 2008, March 19, 2009, April&#13;7, 2009, April 28, 2009, May 21, 2009 and June 25, 2009 and discussed under the caption &amp;#147;Demand Notes&amp;#148; below. In connection&#13;with the sale of the 2009 Securities by the Company, the Company and Bristol have also entered into a waiver agreement (the &amp;#147;Waiver&#13;Agreement&amp;#148;) pursuant to which Bristol waived certain rights with respect to the 2006 Debentures and Bridge Notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The conversion&#13;price of the 2009 Debentures and the exercise price of the 2009 Warrants are subject to full ratchet anti-dilution adjustment&#13;in the event that the Company thereafter issues common stock or common stock equivalents at a price per share less than the conversion&#13;price or the exercise price, respectively, and to other normal and customary anti-dilution adjustment upon certain other events.&#13;So long as the 2009 Debentures are outstanding, if the Company effects a subsequent financing, the October 2009 Investors may&#13;elect, in their sole discretion, to exchange all or some of the October 2009 Debentures (but not the 2009 Warrants) for any securities&#13;or units issued in a subsequent financing on a $1.00 for $1.00 basis or to have any particular provisions of the subsequent financing&#13;legal documents apply to the documents utilized for the October 2009 Financing.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The Company&#13;also agreed that if it determines to prepare and file with the Commission a registration statement relating to an offering for&#13;its own account or the account of others, then it shall include the shares of common stock underlying the 2009 Securities on such&#13;registration statement. The 2009 Investors have contractually agreed to restrict their ability to convert the 2009 Debentures&#13;and exercise the 2009 Warrants and receive shares of our common stock such that the number of shares of the Company common stock&#13;held by a 2009 Investor and its affiliates after such conversion or exercise does not exceed 4.9% of the Company&amp;#146;s then&#13;issued and outstanding shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During 2010,&#13;2009 Investors converted $1,335,000 of the principal amount of 2009 Debentures for 26,700,000 shares of the Company&amp;#146;s common&#13;stock. During 2011, 2009 Investors converted $610,000 of the principal amount of 2009 Debentures for 12,200,000 shares of the&#13;Company&amp;#146;s common stock. Accordingly, at September 30, 2012, $55,000 in aggregate principal amount of 2009 Debentures remained&#13;outstanding. In addition, as of September 30, 2012, 14,900,000 of the 2009 Class A Warrants and 16,750,000 of the 2009 Class B&#13;Warrants remained outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On June 1,&#13;2011, the Company entered into a financing arrangement with several accredited investors (the &amp;#147;June 2011 Investors&amp;#148;),&#13;pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $500,000 (the &amp;#147;June&#13;2011 Financing&amp;#148;). In connection with the June 2011 Financing, the Company issued the following securities to the June 2011&#13;Investors:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12% Convertible&#13;    Debentures in the principal amount of $500,000 due April 15, 2012, convertible into shares of the Company&amp;#146;s common stock&#13;    at a per share conversion price equal to $0.10 per share; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants to purchase&#13;    5,000,000 of shares of the Company&amp;#146;s common stock. The warrants are exercisable, on a cash or cashless basis, for up&#13;    to two years from the date of issue at a per share exercise price equal to $0.15.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In November,&#13;2011, the Company entered into a financing arrangement with several accredited investors (the &amp;#147;November 2011 Investors&amp;#148;),&#13;pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the &amp;#147;November&#13;2011 Financing&amp;#148;). In connection with the November 2011 Financing, the Company issued the following securities to the November&#13;2011 Investors:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8% Convertible Debentures&#13;    in the principal amount of $275,000 due in two years, convertible into shares of the Company&amp;#146;s common stock at a per&#13;    share conversion price equal to $0.05 per share; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants to purchase&#13;    5,500,000 of shares of the Company&amp;#146;s common stock. The Class A Warrants and Class B Warrants (collectively, the &amp;#147;Warrants&amp;#148;)&#13;    are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for&#13;    the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In March,&#13;2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities&#13;in consideration of a maximum aggregate purchase price of $617,500 (the &amp;#147;March 2012 Financing&amp;#148;). In connection with&#13;the March 2012 Financing, the Company issued the following securities to the investors:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8% Convertible Debentures&#13;    in the principal amount of $617,500&amp;#160;&amp;#160;due in two years, convertible into shares of the Company&amp;#146;s common stock&#13;    at a per share conversion price equal to $0.05 per share; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants to purchase&#13;    12,350,000 of shares of the Company&amp;#146;s common stock. The Class A Warrants and Class B Warrants (collectively, the &amp;#147;&#13;    March 2012 Warrants&amp;#148;) are exercisable for up to five years from the date of issue at a per share exercise price equal&#13;    to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In April 2012,&#13;the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company.&amp;#160;&amp;#160;Pursuant&#13;to the anti-dilution provisions in the convertible instruments, the conversion price of certain convertible instruments is now&#13;$0.01 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $0.01&#13;and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In May, 2012,&#13;the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities&#13;in consideration of a maximum aggregate purchase price of $275,000 (the &amp;#147;May 2012 Financing&amp;#148;). In connection with&#13;the May 2012 Financing, the Company issued the following securities to the investors:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8% Convertible Debentures&#13;    in the principal amount of $275,000 due May 2014, convertible into shares of the Company&amp;#146;s common stock at a per share&#13;    conversion price equal to $0.05 per share; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants to purchase&#13;    5,500,000 of shares of the Company&amp;#146;s common stock. The Class A Warrants and Class B Warrants (collectively, the &amp;#147;&#13;    May&amp;#160;&amp;#160;2012 Warrants&amp;#148;) are exercisable for up to five years from the date of issue at a per share exercise price&#13;    equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On August&#13;8, 2012, a Settlement Agreement and Mutual General Release (&amp;#34;Agreement&amp;#34;) was made by and between OXIS and Bristol Investment&#13;Fund, Ltd., in order to settle certain claims regarding certain convertible debentures held by Bristol.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Pursuant to&#13;the Agreement, OXIS shall pay Bristol (half of which payment would redound to Merit Capital Limited (&amp;#147;Merit&amp;#148;)) a total&#13;of $1,119,778 as payment in full for the losses suffered and all costs incurred by Bristol in connection with the Transaction.&#13;Payment of such $1,119,778 shall be made as follows: OXIS shall issue restricted common stock to each of Bristol and Merit, in&#13;an amount such that each Bristol and Merit shall hold no more than 9.99% of the outstanding shares of OXIS (including any shares&#13;that each may hold as of the date of issuance). The shares so issued represent $417,475.65 of the $1,119,778 payment (27,831,710&#13;shares at $0.015 per share, of which 9,168,750 will be retained by Bristol and 18,662,960 will be issued to Merit). The remaining&#13;balance of the payment shall be made in the form of two convertible promissory notes in the respective amounts of $422,357.75&#13;for Bristol and $279,944.60 for Merit (collectively, the &amp;#147;Notes&amp;#148;) with a maturity of December 1, 2017 having an 8%&#13;annual interest rate, with interest only accruing until January 1, 2013, and then level payments of $3,750 each beginning January&#13;1, 2013 until paid in full on December 1, 2017. In the event a default in the monthly payments on the Notes has occurred and is&#13;continuing each holder of the Notes shall be permitted to convert the unpaid principal and interest of the Notes into shares of&#13;OXIS at $.01 cents per share.&amp;#160;&amp;#160;In the absence of such continuing default no conversion of the Notes will be permitted.&#13;OXIS will have the right to repay the Notes in full at any time without penalty.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Demand Notes&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On May 15,&#13;2009, the Company entered into a convertible demand promissory note with Bristol Capital, LLC for certain consulting services&#13;totaling $100,000. The note does not provide for any interest and is due upon demand by the holder. The note has been converted&#13;into common stock of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On June 22,&#13;2009, the Company entered into a convertible demand promissory note with Theorem Group (&amp;#147;Theorem&amp;#148;) pursuant to which&#13;Theorem purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price&#13;of $25,000 (the &amp;#147; 2009 Theorem Note&amp;#148;). The 2009 Theorem Note was subsequently sold as described below.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Simultaneously&#13;with the issuance of the 2009 Theorem Note, the Company issued Theorem a seven-year warrant (the &amp;#147;2009 Theorem Warrant&amp;#148;)&#13;to purchase 3,137,500 shares of common stock of the Company at a price equal to the lower of (i) $0.01 and (ii) 60% of the average&#13;of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Theorem&#13;Note (the &amp;#147;Exercise Price&amp;#148;). The 2009 Theorem Warrant may be exercised on a cashless basis if the shares of common&#13;stock underlying the 2009 Theorem Warrant are not then registered pursuant to an effective registration statement. In the event&#13;the 2009 Theorem Warrant is exercised on a cashless basis, we will not receive any proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On December&#13;1, 2009, Theorem sold the 2009 Theorem Note to Net Capital Partners, Inc. (&amp;#147;Net Capital&amp;#148;). In December 2009, Net Capital&#13;converted $24,000 of the principal for 2,400,000 shares of the Company&amp;#146;s common stock. In January 2010, Net Capital converted&#13;the remaining $7,375 of principal amount for an additional 737,500 shares of the Company&amp;#146;s common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On February&#13;7, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate&#13;principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &amp;#147;February&#13;2011 Bristol Note&amp;#148;). The February 2011 Bristol Note is convertible into shares of common stock of the Company at a price&#13;equal to $0.05 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Simultaneously&#13;with the issuance of the February 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the &amp;#147;February 2011 Bristol&#13;Series A Warrants&amp;#148;) to purchase 313,750 shares of the Company&amp;#146;s common stock at a per share exercise price of $0.0625,&#13;and a Series B Warrant (the &amp;#147;February 2011 Bristol Series B Warrants&amp;#148; and, together with the February 2011 Bristol&#13;Series A Warrants, the &amp;#147;February 2011 Bristol Warrants&amp;#148;) to purchase 313,750 shares of the Company&amp;#146;s common&#13;stock at a per share exercise price of $0.075. The February 2011 Warrants are exercisable for up to seven years from the date&#13;of issue. The February 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the February&#13;2011 Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Bristol&#13;Warrants are exercised on a cashless basis, the Company will not receive any proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On February&#13;7, 2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased&#13;an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the&#13;&amp;#147;February 2011 Net Capital Note&amp;#148;). The February 2011 Net Capital Note is convertible into shares of common stock of&#13;the Company at a price equal to $0.05 per share. As of September, 2012, the February 2011 Net Capital Note had been converted&#13;into shares of the Company&amp;#146;s common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Simultaneously&#13;with the issuance of the February 2011 Net Capital Note, the Company issued Net Capital a Series A Warrant (the &amp;#147;February&#13;2011 Net Capital Series A Warrants&amp;#148;) to purchase 313,750 shares of the Company&amp;#146;s common stock at a per share exercise&#13;price of $0.0625, and a Series B Warrant (the &amp;#147;February 2011 Net Capital Series B Warrants&amp;#148; and, together with the&#13;February 2011 Net Capital Series A Warrants, the &amp;#147;February 2011 Net Capital Warrants&amp;#148;) to purchase 313,750 shares&#13;of the Company&amp;#146;s common stock at a per share exercise price of $0.075. The February 2011 Net Capital Warrants are exercisable&#13;for up to seven years from the date of issue. The February 2011 Net Capital Warrants may be exercised on a cashless basis if the&#13;shares of common stock underlying the February 2011 Net Capital Warrants are not then registered pursuant to an effective registration&#13;statement. In the event the February 2011 Net Capital Warrants are exercised on a cashless basis, the Company will not receive&#13;any proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On March 4,&#13;2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate&#13;principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &amp;#147;March&#13;2011 Bristol Note&amp;#148;). The March 2011 Bristol Note is convertible at the option of the holder at any time into shares of common&#13;stock, at a price equal to $0.05.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Simultaneously&#13;with the issuance of the March 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the &amp;#147;March 2011 Bristol&#13;Series A Warrants&amp;#148;) to purchase 313,750 shares of the Company&amp;#146;s common stock at a per share exercise price of $0.0625,&#13;and a Series B Warrant (the &amp;#147;March 2011 Bristol Series B Warrants&amp;#148; and, together with the March 2011 Bristol Series&#13;A Warrants, the &amp;#147;March 2011 Bristol Warrants&amp;#148;) to purchase 313,750 shares of the Company&amp;#146;s common stock at a&#13;per share exercise price of $0.075. The March 2011 Warrants are exercisable for up to seven years from the date of issue. The&#13;March 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the March 2011 Warrants are&#13;not then registered pursuant to an effective registration statement. In the event the March 2011 Warrants are exercised on a cashless&#13;basis, the Company will not receive any proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On April 4,&#13;2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased an&#13;aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &amp;#147;April&#13;2011 Net Capital Note&amp;#148;). The April 2011 Net Capital Note is convertible into shares of common stock of the Company, at a&#13;price equal to $0.05 per share.&amp;#160;&amp;#160;As of September, 2012, April&amp;#160;&amp;#160;2011 Net Capital Note had been converted into&#13;shares of the Company&amp;#146;s common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Simultaneously&#13;with the issuance of the Net Capital Note, the Company issued Net Capital a Series A Warrant (the &amp;#147;April 2011 Net Capital&#13;Series A Warrants&amp;#148;) to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.0625,&#13;and a Series B Warrant (the &amp;#147;April 2011 Net Capital Series B Warrants&amp;#148; and, together with the April 2011 Net Capital&#13;Series A Warrants, the &amp;#147;April 2011 Net Capital Warrants&amp;#148;) to purchase 313,750 shares of common stock of the Company&#13;at a per share exercise price of $0.075. The April 2011 Net Capital Warrants are exercisable for up to seven years from the date&#13;of issue. The April 2011 Net Capital Warrants may be exercised on a cashless basis if the shares of common stock underlying the&#13;April 2011 Net Capital Warrants are not then registered pursuant to an effective registration statement. In the event the April&#13;2011 Net Capital Warrants are exercised on a cashless basis, we will not receive any proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On October&#13;26, 2011 the Company entered into a convertible demand promissory note with Theorem pursuant to which Theorem purchased an aggregate&#13;principal amount of $200,000 of convertible demand promissory notes for an aggregate purchase price of $157,217 (the &amp;#147;October&#13;2011 Theorem Note&amp;#148;). The October 2011 Theorem Note is convertible into shares of common stock of the Company, at a price&#13;equal to $0.05 per share. As of September, 2012, the October&amp;#160;&amp;#160;2011 Theorem&amp;#160;&amp;#160;Capital Note had been converted&#13;into shares of the Company&amp;#146;s common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Simultaneously&#13;with the issuance of the October 2011 Theorem Note, the Company issued Theorem a Series A Warrant (the &amp;#147;October 2011 Series&#13;A Warrant&amp;#148;) to purchase 10,000,000 shares of common stock of the Company at a per share exercise price of $0.0625, and a&#13;Series B Warrant (the &amp;#147;October 2011 Series B Warrants&amp;#148; and, together with the October 2011 Series A Warrants, the&#13;&amp;#147;October 2011 Warrants&amp;#148;) to purchase 10,000,000 shares of common stock of the Company at a per share exercise price&#13;of $0.075. The October 2011 Warrants are exercisable for up to seven years from the date of issue. The October 2011 Warrants may&#13;be exercised on a cashless basis if the shares of common stock underlying the October 2011 Warrants are not then registered pursuant&#13;to an effective registration statement. In the event the October 2011 Warrants are exercised on a cashless basis, we will not&#13;receive any proceeds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;All of the&#13;foregoing securities were issued in reliance upon an exemption from the registration requirements pursuant to Section 4(2) of&#13;the Securities Act of 1933, as amended.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Financing&#13;Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On November&#13;8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing&#13;partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in the Company and&#13;agreed to make a $750,000 purchase order line of credit facility available to the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The aggregate&#13;amount of outstanding Advances available to the Company under the Line of Credit may not exceed $750,000.00 at any time. The credit&#13;amounts available to the Company will be tiered, starting at $250,000 and will ramp up to $500,000 and then $750,000 upon achievement&#13;of determined milestones. The Advances requested under the Line of Credit may only be used for purchases of products and inventory&#13;from Gemini Pharmaceuticals.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The outstanding&#13;principal of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In partial&#13;consideration of the commitment made by Gemini Pharmaceuticals under the Line of Credit, the Company has issued to Gemini, non-callable&#13;5-year warrants to purchase 300,000 additional shares of Common&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stock at a&#13;share price of $0.12. The warrants contain a cashless exercise provision. The warrants vest as follows: 50% immediately, 25% when&#13;the credit line is increased to $500,000, and the remaining 25% when the credit line is increased to $750,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Joint Ventures&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In March 2011,&#13;the Company agreed to form a joint venture with engage:BDR, Inc., an on-line marketing company that offers both premium and placement-specific&#13;display marketing solutions and the ability to distribute campaigns through its own display platforms and channels.&amp;#160;&amp;#160;engage:BDR&#13;partners with most of comScore's top 1000 websites (globally) for the most advanced display marketing capabilities.&amp;#160;&amp;#160;Under&#13;the joint venture agreement, engage:BDR will provide a full range of online marketing services to the joint venture, including&#13;developing brand strategy, the design of all digital media and interfaces, online media planning and buying, leveraging and integrating&#13;social media, and customer analysis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In March 2012&#13;the Company signed a term sheet with engage:BDR that further evidences its arrangement and that permits both parties to commence&#13;operations under the arrangement.&amp;#160;&amp;#160;The parties contemplate that the existing binding arrangement will be evidenced by&#13;a formal limited liability company agreement that the parties are preparing. The following is a summary of the principal provisions&#13;of our joint venture arrangement (the &amp;#147;Joint Venture&amp;#148;) with engage:BDR, Inc.:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;A.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The&#13;Company has agreed to grant the Joint Venture an exclusive license for the on-line marketing of products containing EGT&amp;#153;.&amp;#160;&amp;#160;The&#13;first product to be marketed and sold through the Joint Venture shall be Oxis&amp;#146; ErgoFlex&amp;#153; product, which product was&#13;successfully test marketed in mail offering in late 2010 and early 2011.&amp;#160;&amp;#160;Additional Oxis products designated by the&#13;Company will be offered by the Joint Venture.&amp;#160;&amp;#160;If both parties agree, third party products may also be offered through&#13;the Joint Venture.&amp;#160;&amp;#160;However, nothing in the Joint Venture is intended to prohibit the Company from marketing, distributing&#13;and selling ErgoFlex&amp;#153; or any of its other current or future products by means other than through online sales.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;B.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Oxis&#13;and engage:BDR have agreed to make the following&amp;#160;&amp;#160;contributions to the Joint Venture:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(a)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Oxis&#13;will contribute up to $240,000 during the first year following the formation of the Joint Venture.&amp;#160;&amp;#160;These funds will&#13;be provided if, when and as needed by the Joint Venture.&amp;#160;&amp;#160;OXIS&amp;#146; cash capital contribution will be used (i) to&#13;purchase ErgoFlex and other products from Oxis, at OXIS&amp;#146; cost, without any markup, (ii) to purchase website media inventory&#13;from engage:BDR, at engage:BDR&amp;#146;s cost, plus a 15% administrative mark-up, and (iii) to fund the Joint Venture&amp;#146;s other&#13;operating costs.&amp;#160;&amp;#160;engage:BDR has agreed to waive the 15% administrative mark-up through December 31, 2012.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(b)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In&#13;addition to the cash, OXIS&amp;#146; contribution to the Joint Venture includes the exclusive license for the on-line marketing of&#13;any products created by Oxis which utilize its proprietary EGT&amp;#153;.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(c)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;engage:BDR&#13;, at its own cost and expense, is designing, developing and providing to the Joint Venture, on a turnkey basis, all online product&#13;offering systems and technologies, including website layouts, landing pages, graphic designs, display advertising, rich media,&#13;in-banner and in-stream video development.&amp;#160;&amp;#160;During the initial start-up phase of the Joint Venture, engage:BDR will,&#13;at its own cost and expense, also manage all day-to-day online activities of the Joint Venture.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Cash&#13;from operations in excess of the amounts needed for its operations and for reasonable reserves, shall be distributed by the Joint&#13;Venture in the following order:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(a)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;First,&#13;to Oxis on a cumulative basis, an amount equal to the cash that OXIS contributed to the Joint Venture, and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(b)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Thereafter,&#13;all excess net operating cash will be distributed 50.1% to Oxis and 49.9% to engage:BDR.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;C.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The&#13;administrative affairs of the Joint Venture shall be managed by a committee consisting of one representative of each Joint Venture&#13;member.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As additional&#13;consideration for engage:BDR entering into the Joint Venture and for contributing its services in designing, developing and implementing&#13;the advertising platform, at the time that the Joint Venture operating agreement is signed, OXIS will grant engage:BDR a two-year&#13;option to purchase Oxis securities.&amp;#160;&amp;#160;The option shall entitle engage:BDR to purchase the type of securities sold by&#13;us in a future $6,000,000 or more financing, on the same terms and conditions, and at the same price, as such securities are sold&#13;to third party investors in such financing.&amp;#160;&amp;#160;The number of such securities that engage:BDR may purchase upon the exercise&#13;of the option (determined by assuming all convertible securities are converted and all exercisable securities are exercised) shall&#13;be equal to 4.99% of the Company&amp;#146;s common stock issued and outstanding on the date the Joint Venture agreement is signed.&amp;#160;&amp;#160;If&#13;the Company has not raised $6,000,000 by December 31, 2012, commencing on that date, engage:BDR will have a two-year right to&#13;purchase Oxis&amp;#146; common stock at a price equal to $.03.&amp;#160;&amp;#160;OXIS has also agreed to issue to engage:BDR a warrant to&#13;purchase up to 5,000,000 shares of its common stock if the Joint Venture, through engage:BDR efforts, attains certain revenue&#13;and profits targets.&amp;#160;&amp;#160;The warrant will have an exercise price of $.03 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On June 29,&#13;2011 the Company entered into a Joint Venture Agreement (&amp;#147;&lt;u&gt;Joint Venture Agreement&lt;/u&gt;&amp;#148;) with John E. Repine, M.D.&#13;(&amp;#147;&lt;u&gt;Dr. Repine&lt;/u&gt;&amp;#148;), a member of the Company&amp;#146;s advisory board.&amp;#160;&amp;#160;Under the terms of the Joint Venture&#13;Agreement, the Company formed a Delaware limited liability company, Ergo ARDS, LLC (the &amp;#147;&lt;u&gt;ARDS Venture&lt;/u&gt;&amp;#148;), in&#13;which the Company holds a 60% membership interest and Dr. Repine holds a 40% membership interest.&amp;#160;&amp;#160;The ARDS Venture&#13;was formed to develop, acquire and market dietary supplements, cosmeceutical products, nutraceutical products, medical foods and&#13;pharmaceuticals using EGT&amp;#153; for treating, diagnosing and preventing acute respiratory distress syndrome and other lung disorders&#13;(collectively &amp;#147;&lt;u&gt;ARDS&lt;/u&gt;&amp;#148;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Concurrently&#13;with the execution of the Joint Venture Agreement, Dr. Repine assigned his interest in the patent applications relating to the&#13;use of ERGO in treating ARDS (the &amp;#147;&lt;u&gt;Assigned IP&lt;/u&gt;&amp;#148;) to the ARDS Venture.&amp;#160;&amp;#160;In consideration for the Assigned&#13;Interest, Dr. Repine was issued a 40% membership interest in the ARDS Venture.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Oxis will&#13;be responsible for supplying EGT&amp;#153; to the ARDS Venture at no cost in connection with the ARDS Venture&amp;#146;s animal studies.&#13;Oxis will also pay all patent prosecution and maintenance costs relating to the Assigned IP.&amp;#160;&amp;#160;The ARDS Venture is required&#13;to make payments to Dr. Repine upon the achievement of certain milestones by the ARDS Venture.&amp;#160;&amp;#160;Any future payments&#13;to Dr. Repine shall be made based on the achievement of following milestones with respect to products to be commercialized using&#13;the Assigned IP:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The ARDS Venture&#13;    shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(i)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Licensing&#13;the Assigned IP to a pharmaceutical company -- $1,000,000;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(ii)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Completion&#13;of Phase I Clinical Trial -- $250,000;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 20pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(iii)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Completion of Phase II Clinical&#13;Trial -- $1,000,000;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(iv)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Completion&#13;of pivotal Phase III Clinical Trial -- $1,500,000; and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(v)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Receipt&#13;of FDA Marketing approval -- $3,000,000&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The ARDS Venture&#13;    shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(i)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Licensing&#13;the Assigned IP to, or entering into a distribution agreement with, a nutraceutical or similar company -- $100,000; and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(ii)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Gross&#13;sales of products utilizing EGT&amp;#153; in the field &amp;#150; 5% of annual gross sales by the ARDS Venture or any licensee or distributor&#13;(including Oxis).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Following&#13;the successful completion of the animal studies, Oxis and Dr. Repine will make a joint decision to commence human clinical trials.&#13;If the parties do not agree to proceed, the Joint Venture Agreement will terminate and the intellectual property belonging to&#13;the ARDS Venture will be assigned to the party that elected to proceed.&amp;#160;&amp;#160;In the event both parties agree to not proceed,&#13;the ARDS Venture will continue to hold the intellectual property.&amp;#160;&amp;#160;If the parties agree to proceed, Oxis will use its&#13;best efforts to raise $3 million for the ARDS Venture.&amp;#160;&amp;#160;Once the $3 million in funds have been successfully raised by&#13;Oxis, Oxis will no longer be responsible for paying the ARDS Venture&amp;#146;s operating costs, including costs related to the ARDS&#13;Venture&amp;#146;s intellectual property.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The ARDS Venture&#13;will be managed by Dr. Repine as Manager, who will also serve as the ARDS Venture&amp;#146;s Chief Executive Officer and Treasurer.&#13;The ARDS Venture will also have a board of five members, consisting of Dr. Repine and a designee of Dr. Repine, and three designees&#13;of Oxis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;September&#13;    30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Capitalized&#13;    patent costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accumulated&#13;    amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(625,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(615,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Periodically,&#13;the Company reviews its patent portfolio and has determined that certain patent applications no longer possessed commercial viability&#13;or were abandoned since they were inconsistent with the Company's business development strategy.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The following&#13;table presents expected future amortization of patent costs as of December 31, 2011 that may change according to the Company's&#13;amortization policy upon additional patents being issued or allowed:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 84%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;12,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">457207313</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">92000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">61000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-09-30" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">54000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">15000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:GrossProfit contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">90000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-25000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">88000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">-6000</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">33000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">48000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">32000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">8000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">123000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">23000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">120000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">2000</us-gaap:SalesRevenueNet>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:LicenseAndServicesRevenue>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">123000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">23000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">120000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">2000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-1663000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">318000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-65000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">564000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">1305000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">465000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">65000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">117000</us-gaap:InterestExpense>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-358000</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">783000</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">681000</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-2775000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-2880000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-1350000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">-541000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">2865000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">2855000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">1438000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">535000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">2865000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">2806000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">1438000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">535000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">49000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">336824712</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2011-01-01to2011-09-30" unitRef="Shares" decimals="INF">183038141</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-07-01to2012-09-30" unitRef="Shares" decimals="INF">397553268</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2011-07-01to2011-09-30" unitRef="Shares" decimals="INF">213511550</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-09-30" unitRef="USDPShares" decimals="INF">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2011-01-01to2011-09-30" unitRef="USDPShares" decimals="INF">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-07-01to2012-09-30" unitRef="USDPShares" decimals="INF">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2011-07-01to2011-09-30" unitRef="USDPShares" decimals="INF">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-4410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-09-30_RetainedEarningsMember" unitRef="USD" decimals="0">-4410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-2562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-1400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">23000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-4410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-2562000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-1400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">23000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">28000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">15000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-4438000</OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes>
    <OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">0</OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes>
    <OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-1415000</OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes>
    <OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">23000</OXIS:LossBeforeMinorityInterestAndProvisionForIncomeTaxes>
    <OXIS:ChangeInValueOfWarrantAndDerivativeLiabilities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">356000</OXIS:ChangeInValueOfWarrantAndDerivativeLiabilities>
    <OXIS:ChangeInValueOfWarrantAndDerivativeLiabilities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-783000</OXIS:ChangeInValueOfWarrantAndDerivativeLiabilities>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">40000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">306000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">782000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">1597000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">699000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">126000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">10000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">20000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-773000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-639000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">1750000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">667000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-12000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-10000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">12000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">615000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">585000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">50000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">615000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">621000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-31000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-54000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">127000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:SharesIssued contextRef="AsOf2010-12-31_PreferredStockMember" unitRef="Shares" decimals="INF">1787897</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2011-12-31_PreferredStockMember" unitRef="Shares" decimals="INF">1787897</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2012-09-30_PreferredStockMember" unitRef="Shares" decimals="INF">1787897</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2010-12-31_CommonStockMember" unitRef="Shares" decimals="INF">149571976</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">269299838</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2012-09-30_CommonStockMember" unitRef="Shares" decimals="INF">457207313</us-gaap:SharesIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">307000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2012-01-01to2012-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">699000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">18000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-01-01to2012-09-30_CommonStockMember" unitRef="USD" decimals="0">28000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2355000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-01-01to2012-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">754000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">18210498</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2012-01-01to2012-09-30_CommonStockMember" unitRef="Shares" decimals="INF">27800000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">78000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2012-01-01to2012-09-30_CommonStockMember" unitRef="USD" decimals="0">160000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1286000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2012-01-01to2012-09-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2438000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">77734000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2012-01-01to2012-09-30_CommonStockMember" unitRef="Shares" decimals="INF">160107475</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <OXIS:ExerciseOfWarrantsAmount contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">24000</OXIS:ExerciseOfWarrantsAmount>
    <OXIS:ExerciseOfWarrantsShares contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">23783364</OXIS:ExerciseOfWarrantsShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Stock&#13;Options&lt;/font&gt; &lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Following&#13;is a summary of the stock option activity:&lt;/font&gt; &lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options&#13;    Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of December 31, 2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;16,078,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;26,384,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,679,027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of September 30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;38,784,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    as of September 30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;23,415,441&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt; &lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Following&#13;is a summary of the warrant activity:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants&#13;    Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of December 31, 2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;105,001,252&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;462,300,546&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;52,500,000&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Adjustments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(15,300,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    as of September 30, 2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;499,501,798&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In April 2012,&#13;the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company.&amp;#160;&amp;#160;Pursuant&#13;to the anti-dilution provisions in the warrants, the exercise price of certain warrants is now $0.01, and the number of shares&#13;underlying the warrants has increased such that the number of shares underlying each warrant is equal to the aggregate exercise&#13;price in effect prior to the adjustment divided by the new exercise price of $0.01.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure contextRef="AsOf2012-09-30_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure contextRef="AsOf2012-09-30_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure contextRef="AsOf2012-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2012-09-30_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2012-09-30_FairValueInputsLevel2Member" unitRef="USD" decimals="0">514000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2012-09-30_FairValueInputsLevel3Member" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">26384193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2011-01-01to2011-09-30" unitRef="Shares" decimals="INF">2066491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-09-30" unitRef="Percent" decimals="INF">1.16</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-09-30_MinimumMember" unitRef="Percent" decimals="INF">0.0104</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-09-30_MaximumMember" unitRef="Percent" decimals="INF">0.0204</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-01-01to2012-09-30_MinimumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-01-01to2012-09-30_MaximumMember">P10Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsWeightedAverageExpectedDividend contextRef="From2012-01-01to2012-09-30" unitRef="USDPShares" decimals="INF">0.00</us-gaap:FairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2012-01-01to2012-09-30_MinimumMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2012-01-01to2012-09-30_MaximumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">699000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">307000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">538285943</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">640000</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">640000</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-615000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">-625000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">12000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">16078979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">38784145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2011-12-31_WarrantMember" unitRef="Shares" decimals="INF">105001252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-09-30_WarrantMember" unitRef="Shares" decimals="INF">499501798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <OXIS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">26384193</OXIS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">3679027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="Shares" decimals="INF">52500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">23415441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-09-30" unitRef="USDPShares" decimals="INF">0.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2011-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">0.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-09-30_WarrantMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-09-30" unitRef="USDPShares" decimals="INF">0.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-09-30" unitRef="USDPShares" decimals="INF">0.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-09-30" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2012-09-30" unitRef="USDPShares" decimals="INF">0.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <OXIS:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="Shares" decimals="INF">462300546</OXIS:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross>
    <OXIS:AdjustmentsOfWarrantsWeightedAverageExercisePrice contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="USDPShares" decimals="INF">0.01</OXIS:AdjustmentsOfWarrantsWeightedAverageExercisePrice>
    <OXIS:AdjustmentsOfWarrants contextRef="From2012-01-01to2012-09-30_WarrantMember" unitRef="Shares" decimals="INF">-15300000</OXIS:AdjustmentsOfWarrants>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">2382281</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">1144000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">160107475</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2011-01-01to2011-09-30" unitRef="Shares" decimals="INF">61831683</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>oxis-20120930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- QXInteractive -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:OXIS="http://oxis.com/20120930" elementFormDefault="qualified" targetNamespace="http://oxis.com/20120930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://oxis.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>0001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>0002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>0004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit" id="ConsolidatedStatementOfStockholdersDeficit">
	  <link:definition>0005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>0006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies" id="Note1-CompanyAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>0007 - Disclosure - Note 1 - The Company and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/Note2-Patents" id="Note2-Patents">
	  <link:definition>0008 - Disclosure - Note 2 - Patents</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/Note3-Debt" id="Note3-Debt">
	  <link:definition>0009 - Disclosure - Note 3 - Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/Note4-StockholdersEquity" id="Note4-StockholdersEquity">
	  <link:definition>0010 - Disclosure - Note 4 - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/Note5-StockOptionsAndWarrants" id="Note5-StockOptionsAndWarrants">
	  <link:definition>0011 - Disclosure - Note 5 - Stock Options and Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations" id="Note6-AdvisoryAndConsultingAgreementsObligations">
	  <link:definition>0012 - Disclosure - Note 6 - Advisory and Consulting Agreements Obligations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/Note7-SubsequentEvents" id="Note7-SubsequentEvents">
	  <link:definition>0013 - Disclosure - Note 7 - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="CompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>0014 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" id="CompanyAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>0015 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/PatentsTables" id="PatentsTables">
	  <link:definition>0016 - Disclosure - Patents (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/StockOptionsAndWarrantsTables" id="StockOptionsAndWarrantsTables">
	  <link:definition>0017 - Disclosure - Stock Options and Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" id="CompanyAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>0018 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>0019 - Disclosure - The Company and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/PatentsDetails" id="PatentsDetails">
	  <link:definition>0020 - Disclosure - Patents (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/PatentsDetails1" id="PatentsDetails1">
	  <link:definition>0021 - Disclosure - Patents (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>0022 - Disclosure - Stockholders' Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails" id="StockOptionsAndWarrantsDetails">
	  <link:definition>0023 - Disclosure - Stock Options and Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails1" id="StockOptionsAndWarrantsDetails1">
	  <link:definition>0024 - Disclosure - Stock Options and Warrants (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="oxis-20120930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="oxis-20120930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="oxis-20120930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="oxis-20120930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="OXIS_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_DemandNotesPayableNetOfDiscountOf54000And0" name="DemandNotesPayableNetOfDiscountOf54000And0" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" name="ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ConvertiblePreferredStockSeriesC" name="ConvertiblePreferredStockSeriesC" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ConvertiblePreferredStockSeriesH" name="ConvertiblePreferredStockSeriesH" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ConvertiblePreferredStockSeriesI" name="ConvertiblePreferredStockSeriesI" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_DemandNotesPayableNetOfDiscount" name="DemandNotesPayableNetOfDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ConvertibleDebenturesNetOfDiscount" name="ConvertibleDebenturesNetOfDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_SeriesCPreferredStockIssuedShares" name="SeriesCPreferredStockIssuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_SeriesCPreferredStockOutstandingShares" name="SeriesCPreferredStockOutstandingShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_SeriesHPreferredStockIssuedShares" name="SeriesHPreferredStockIssuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_SeriesHPreferredStockOutstandingShares" name="SeriesHPreferredStockOutstandingShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_SeriesIPreferredStockIssuedShares" name="SeriesIPreferredStockIssuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_SeriesIPreferredStockOutstandingShares" name="SeriesIPreferredStockOutstandingShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes" name="LossBeforeMinorityInterestAndProvisionForIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ExerciseOfWarrantsAmount" name="ExerciseOfWarrantsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ExerciseOfWarrantsShares" name="ExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" name="ChangeInValueOfWarrantAndDerivativeLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock" name="AdvisoryAndConsultingAgreementsObligationsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" name="CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" name="CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_PatentsTablesAbstract" name="PatentsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_StockOptionsAndWarrantsTablesAbstract" name="StockOptionsAndWarrantsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" name="CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" name="CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_PatentsDetailsAbstract" name="PatentsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_PatentsDetails1Abstract" name="PatentsDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_StockholdersEquityDetailsNarrativeAbstract" name="StockholdersEquityDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_StockOptionsAndWarrantsDetailsAbstract" name="StockOptionsAndWarrantsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_StockOptionsAndWarrantsDetails1Abstract" name="StockOptionsAndWarrantsDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_AdjustmentsOfWarrants" name="AdjustmentsOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice" name="AdjustmentsOfWarrantsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>oxis-20120930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- QXInteractive -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oxis.com/role/DocumentAndEntityInformation" xlink:href="oxis-20120930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedBalanceSheets" xlink:href="oxis-20120930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="oxis-20120930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementsOfOperations" xlink:href="oxis-20120930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit" xlink:href="oxis-20120930.xsd#ConsolidatedStatementOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oxis-20120930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="oxis-20120930.xsd#Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note2-Patents" xlink:href="oxis-20120930.xsd#Note2-Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note3-Debt" xlink:href="oxis-20120930.xsd#Note3-Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note4-StockholdersEquity" xlink:href="oxis-20120930.xsd#Note4-StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note5-StockOptionsAndWarrants" xlink:href="oxis-20120930.xsd#Note5-StockOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations" xlink:href="oxis-20120930.xsd#Note6-AdvisoryAndConsultingAgreementsObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note7-SubsequentEvents" xlink:href="oxis-20120930.xsd#Note7-SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsTables" xlink:href="oxis-20120930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsTables" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsDetails" xlink:href="oxis-20120930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsDetails1" xlink:href="oxis-20120930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockholdersEquityDetailsNarrative" xlink:href="oxis-20120930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails1" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsDetails1" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedBalanceSheets" xlink:title="0002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_OXISAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_OXISCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISAssetsCurrent" xlink:to="loc_OXISCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_OXISPrepaidExpenseCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISAssetsCurrent" xlink:to="loc_OXISPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_OXISInventoryNet" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISAssetsCurrent" xlink:to="loc_OXISInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_OXISAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_OXISFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISAssetsNoncurrent" xlink:to="loc_OXISFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_OXISAssets" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISAssets" xlink:to="loc_OXISAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISAssets" xlink:to="loc_OXISAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_OXISLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_OXISAccountsPayableCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_OXISInterestPayableCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_OXISAccruedLiabilitiesCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_OXISLineOfCredit" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISLineOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="loc_OXISProductWarrantyAccrualClassifiedCurrent" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_DemandNotesPayableNetOfDiscountOf54000And0" xlink:label="loc_OXISDemandNotesPayableNetOfDiscountOf54000And0" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISDemandNotesPayableNetOfDiscountOf54000And0" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" xlink:label="loc_OXISConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_OXISConvertibleDebtCurrent" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesCurrent" xlink:to="loc_OXISConvertibleDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_OXISStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_OXISCommonStockValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISStockholdersEquity" xlink:to="loc_OXISCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_OXISAdditionalPaidInCapital" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISStockholdersEquity" xlink:to="loc_OXISAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_OXISRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISStockholdersEquity" xlink:to="loc_OXISRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesC" xlink:label="loc_OXISConvertiblePreferredStockSeriesC" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISStockholdersEquity" xlink:to="loc_OXISConvertiblePreferredStockSeriesC" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesH" xlink:label="loc_OXISConvertiblePreferredStockSeriesH" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISStockholdersEquity" xlink:to="loc_OXISConvertiblePreferredStockSeriesH" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesI" xlink:label="loc_OXISConvertiblePreferredStockSeriesI" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISStockholdersEquity" xlink:to="loc_OXISConvertiblePreferredStockSeriesI" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_OXISMinorityInterest" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISStockholdersEquity" xlink:to="loc_OXISMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_OXISLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesAndStockholdersEquity" xlink:to="loc_OXISLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISLiabilitiesAndStockholdersEquity" xlink:to="loc_OXISStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="0003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementsOfOperations" xlink:title="0004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_OXISSalesRevenueNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_OXISSalesRevenueGoodsNet" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISSalesRevenueNet" xlink:to="loc_OXISSalesRevenueGoodsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_OXISLicenseAndServicesRevenue" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISSalesRevenueNet" xlink:to="loc_OXISLicenseAndServicesRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_OXISGrossProfit" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISGrossProfit" xlink:to="loc_OXISSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_OXISCostOfGoodsAndServicesSold" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISGrossProfit" xlink:to="loc_OXISCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OXISOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_OXISResearchAndDevelopmentExpense" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISOperatingExpenses" xlink:to="loc_OXISResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_OXISSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISOperatingExpenses" xlink:to="loc_OXISSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OXISOperatingIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISOperatingIncomeLoss" xlink:to="loc_OXISGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISOperatingIncomeLoss" xlink:to="loc_OXISOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_OXISNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_OXISInterestExpense" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNonoperatingIncomeExpense" xlink:to="loc_OXISInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="loc_OXISIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNonoperatingIncomeExpense" xlink:to="loc_OXISIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_OXISNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_OXISIncomeTaxExpenseBenefit" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetIncomeLoss" xlink:to="loc_OXISIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_OXISIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetIncomeLoss" xlink:to="loc_OXISIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit" xlink:title="0005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="0006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_OXISNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_OXISNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_OXISAmortizationOfIntangibleAssets" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_OXISShareBasedCompensation" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_OXISIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_OXISAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_OXISIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_OXISIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" xlink:label="loc_OXISChangeInValueOfWarrantAndDerivativeLiabilities" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISChangeInValueOfWarrantAndDerivativeLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_OXISIncreaseDecreaseInInventories" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OXISIncreaseDecreaseInInventories" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_OXISNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_OXISProceedsFromStockOptionsExercised" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OXISProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_OXISProceedsFromNotesPayable" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OXISProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_OXISRepaymentsOfNotesPayable" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OXISRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_OXISCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_OXISNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_OXISProceedsFromMinorityShareholders" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OXISCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_OXISProceedsFromMinorityShareholders" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="0007 - Disclosure - Note 1 - The Company and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note2-Patents" xlink:title="0008 - Disclosure - Note 2 - Patents" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note3-Debt" xlink:title="0009 - Disclosure - Note 3 - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note4-StockholdersEquity" xlink:title="0010 - Disclosure - Note 4 - Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note5-StockOptionsAndWarrants" xlink:title="0011 - Disclosure - Note 5 - Stock Options and Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations" xlink:title="0012 - Disclosure - Note 6 - Advisory and Consulting Agreements Obligations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note7-SubsequentEvents" xlink:title="0013 - Disclosure - Note 7 - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0014 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="0015 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsTables" xlink:title="0016 - Disclosure - Patents (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsTables" xlink:title="0017 - Disclosure - Stock Options and Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="0018 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="0019 - Disclosure - The Company and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsDetails" xlink:title="0020 - Disclosure - Patents (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsDetails1" xlink:title="0021 - Disclosure - Patents (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockholdersEquityDetailsNarrative" xlink:title="0022 - Disclosure - Stockholders' Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsDetails" xlink:title="0023 - Disclosure - Stock Options and Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsDetails1" xlink:title="0024 - Disclosure - Stock Options and Warrants (Details 1)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>oxis-20120930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- QXInteractive -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oxis.com/role/DocumentAndEntityInformation" xlink:href="oxis-20120930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedBalanceSheets" xlink:href="oxis-20120930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="oxis-20120930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementsOfOperations" xlink:href="oxis-20120930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit" xlink:href="oxis-20120930.xsd#ConsolidatedStatementOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oxis-20120930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="oxis-20120930.xsd#Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note2-Patents" xlink:href="oxis-20120930.xsd#Note2-Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note3-Debt" xlink:href="oxis-20120930.xsd#Note3-Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note4-StockholdersEquity" xlink:href="oxis-20120930.xsd#Note4-StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note5-StockOptionsAndWarrants" xlink:href="oxis-20120930.xsd#Note5-StockOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations" xlink:href="oxis-20120930.xsd#Note6-AdvisoryAndConsultingAgreementsObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note7-SubsequentEvents" xlink:href="oxis-20120930.xsd#Note7-SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsTables" xlink:href="oxis-20120930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsTables" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsDetails" xlink:href="oxis-20120930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsDetails1" xlink:href="oxis-20120930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockholdersEquityDetailsNarrative" xlink:href="oxis-20120930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails1" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsDetails1" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedBalanceSheets" xlink:title="0002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="0003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementsOfOperations" xlink:title="0004 - Statement - Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit" xlink:title="0005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_OXISStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_OXISStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_OXISStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISStatementEquityComponentsAxis" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_OXISEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_OXISEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_OXISPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISEquityComponentDomain" xlink:to="loc_OXISPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_OXISCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISEquityComponentDomain" xlink:to="loc_OXISCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_OXISAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISEquityComponentDomain" xlink:to="loc_OXISAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_OXISRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISEquityComponentDomain" xlink:to="loc_OXISRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_OXISStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_OXISSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISSharesIssued_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_OXISAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_OXISStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_OXISStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_OXISStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_OXISStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ExerciseOfWarrantsAmount" xlink:label="loc_OXISExerciseOfWarrantsAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISExerciseOfWarrantsAmount_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ExerciseOfWarrantsShares" xlink:label="loc_OXISExerciseOfWarrantsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISExerciseOfWarrantsShares_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_OXISNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISNetIncomeLoss_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="0006 - Statement - Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="0007 - Disclosure - Note 1 - The Company and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/Note2-Patents" xlink:title="0008 - Disclosure - Note 2 - Patents" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/Note3-Debt" xlink:title="0009 - Disclosure - Note 3 - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/Note4-StockholdersEquity" xlink:title="0010 - Disclosure - Note 4 - Stockholders' Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/Note5-StockOptionsAndWarrants" xlink:title="0011 - Disclosure - Note 5 - Stock Options and Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations" xlink:title="0012 - Disclosure - Note 6 - Advisory and Consulting Agreements Obligations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/Note7-SubsequentEvents" xlink:title="0013 - Disclosure - Note 7 - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0014 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="0015 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsTables" xlink:title="0016 - Disclosure - Patents (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsTables" xlink:title="0017 - Disclosure - Stock Options and Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="0018 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_OXISDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_OXISScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OXISDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_OXISScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_OXISFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OXISScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_OXISFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_OXISFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_OXISFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_OXISFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_OXISFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_OXISFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_OXISFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_OXISFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_OXISFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_OXISFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_OXISFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_OXISFinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_OXISFinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_OXISInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISFinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_40" xlink:to="loc_OXISInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:label="loc_OXISFinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_OXISFinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_OXISLiabilitiesFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISFinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_40" xlink:to="loc_OXISLiabilitiesFairValueDisclosure_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="0019 - Disclosure - The Company and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_OXISStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_OXISStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_OXISRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISRangeAxis" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_OXISRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_OXISRangeAxis" xlink:to="loc_OXISRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_OXISRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_OXISRangeAxis" xlink:to="loc_OXISRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_OXISMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISRangeMember" xlink:to="loc_OXISMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_OXISMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISRangeMember" xlink:to="loc_OXISMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_OXISRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_OXISCashAndCashEquivalentsAtCarryingValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISCashAndCashEquivalentsAtCarryingValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_OXISFairValueAssumptionsExpectedVolatilityRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsExpectedVolatilityRate_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_OXISFairValueAssumptionsRiskFreeInterestRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsRiskFreeInterestRate_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_OXISFairValueAssumptionsExpectedTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsExpectedTerm_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_OXISFairValueAssumptionsWeightedAverageExpectedDividend_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsWeightedAverageExpectedDividend_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_OXISAllocatedShareBasedCompensationExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISAllocatedShareBasedCompensationExpense_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_OXISAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsDetails" xlink:title="0020 - Disclosure - Patents (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsDetails1" xlink:title="0021 - Disclosure - Patents (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/StockholdersEquityDetailsNarrative" xlink:title="0022 - Disclosure - Stockholders' Equity (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsDetails" xlink:title="0023 - Disclosure - Stock Options and Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsDetails1" xlink:title="0024 - Disclosure - Stock Options and Warrants (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_OXISStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_OXISStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_OXISStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISStatementEquityComponentsAxis" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_OXISEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_OXISEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_OXISWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISEquityComponentDomain" xlink:to="loc_OXISWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdjustmentsOfWarrants" xlink:label="loc_OXISAdjustmentsOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" xlink:to="loc_OXISAdjustmentsOfWarrants_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_OXISStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" xlink:to="loc_OXISStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice" xlink:label="loc_OXISAdjustmentsOfWarrantsWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:to="loc_OXISAdjustmentsOfWarrantsWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>oxis-20120930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- QXInteractive -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">FairValueInputsLevel1Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">FairValueByFairValueHierarchyLevel [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">FairValueInputsLevel2Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">FairValueInputsLevel3Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">MinimumMember</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">MaximumMember</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">WarrantMember</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_DocumentAndEntityInformationAbstract" xlink:label="OXIS_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_DocumentAndEntityInformationAbstract" xlink:to="OXIS_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_DemandNotesPayableNetOfDiscountOf54000And0" xlink:label="OXIS_DemandNotesPayableNetOfDiscountOf54000And0" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_DemandNotesPayableNetOfDiscountOf54000And0" xlink:to="OXIS_DemandNotesPayableNetOfDiscountOf54000And0_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_DemandNotesPayableNetOfDiscountOf54000And0_lbl" xml:lang="en-US">Demand notes payable, net of discount of $0 and $54,000</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" xlink:label="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" xlink:to="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion_lbl" xml:lang="en-US">Convertible debentures, net of discount of $0 and $0, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible debentures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Deficit:</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesC" xlink:label="OXIS_ConvertiblePreferredStockSeriesC" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertiblePreferredStockSeriesC" xlink:to="OXIS_ConvertiblePreferredStockSeriesC_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ConvertiblePreferredStockSeriesC_lbl" xml:lang="en-US">Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized: Series C - 96,230 and 96,230 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesH" xlink:label="OXIS_ConvertiblePreferredStockSeriesH" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertiblePreferredStockSeriesH" xlink:to="OXIS_ConvertiblePreferredStockSeriesH_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ConvertiblePreferredStockSeriesH_lbl" xml:lang="en-US">Series H - 25,000 and 25,000 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesI" xlink:label="OXIS_ConvertiblePreferredStockSeriesI" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertiblePreferredStockSeriesI" xlink:to="OXIS_ConvertiblePreferredStockSeriesI_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ConvertiblePreferredStockSeriesI_lbl" xml:lang="en-US">Series I - 1,666,667 and 1,666,667 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.001 par value; 600,000,000 shares authorized; 457,207,313 and 269,299,838 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Minority interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_DemandNotesPayableNetOfDiscount" xlink:label="OXIS_DemandNotesPayableNetOfDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_DemandNotesPayableNetOfDiscount" xlink:to="OXIS_DemandNotesPayableNetOfDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_DemandNotesPayableNetOfDiscount_lbl" xml:lang="en-US">Demand notes payable, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertibleDebenturesNetOfDiscount" xlink:label="OXIS_ConvertibleDebenturesNetOfDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertibleDebenturesNetOfDiscount" xlink:to="OXIS_ConvertibleDebenturesNetOfDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ConvertibleDebenturesNetOfDiscount_lbl" xml:lang="en-US">Convertible debentures, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesCPreferredStockIssuedShares" xlink:label="OXIS_SeriesCPreferredStockIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesCPreferredStockIssuedShares" xlink:to="OXIS_SeriesCPreferredStockIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_SeriesCPreferredStockIssuedShares_lbl" xml:lang="en-US">Series C - Preferred stock, issued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesCPreferredStockOutstandingShares" xlink:label="OXIS_SeriesCPreferredStockOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesCPreferredStockOutstandingShares" xlink:to="OXIS_SeriesCPreferredStockOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_SeriesCPreferredStockOutstandingShares_lbl" xml:lang="en-US">Series C - Preferred stock, outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesHPreferredStockIssuedShares" xlink:label="OXIS_SeriesHPreferredStockIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesHPreferredStockIssuedShares" xlink:to="OXIS_SeriesHPreferredStockIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_SeriesHPreferredStockIssuedShares_lbl" xml:lang="en-US">Series H - Preferred stock, issued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesHPreferredStockOutstandingShares" xlink:label="OXIS_SeriesHPreferredStockOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesHPreferredStockOutstandingShares" xlink:to="OXIS_SeriesHPreferredStockOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_SeriesHPreferredStockOutstandingShares_lbl" xml:lang="en-US">Series H - Preferred stock, outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesIPreferredStockIssuedShares" xlink:label="OXIS_SeriesIPreferredStockIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesIPreferredStockIssuedShares" xlink:to="OXIS_SeriesIPreferredStockIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_SeriesIPreferredStockIssuedShares_lbl" xml:lang="en-US">Series I - Preferred stock, issued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesIPreferredStockOutstandingShares" xlink:label="OXIS_SeriesIPreferredStockOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesIPreferredStockOutstandingShares" xlink:to="OXIS_SeriesIPreferredStockOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_SeriesIPreferredStockOutstandingShares_lbl" xml:lang="en-US">Series I - Preferred stock, outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US">Revenue:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Product revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US">License revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of Product Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_lbl" xml:lang="en-US">Change in value of warrant and derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense/income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes" xlink:label="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes" xlink:to="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes_lbl" xml:lang="en-US">Loss before minority interest and provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Minority interest in subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (loss) before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Loss Per Share - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Shares Outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Beginning balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Issuance of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of debt, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of debt, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ExerciseOfWarrantsAmount" xlink:label="OXIS_ExerciseOfWarrantsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ExerciseOfWarrantsAmount" xlink:to="OXIS_ExerciseOfWarrantsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ExerciseOfWarrantsAmount_lbl" xml:lang="en-US">Exercise of warrants, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ExerciseOfWarrantsShares" xlink:label="OXIS_ExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ExerciseOfWarrantsShares" xlink:to="OXIS_ExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ExerciseOfWarrantsShares_lbl" xml:lang="en-US">Exercise of warrants, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Ending balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock compensation expense for options and warrants issued to employees and non-employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of shares for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" xlink:label="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" xlink:to="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities_lbl" xml:lang="en-US">Change in value of warrant and derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMinorityShareholders" xlink:to="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xml:lang="en-US">Minority Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Note 1 - The Company and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_NotesToFinancialStatementsAbstract" xlink:label="OXIS_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_NotesToFinancialStatementsAbstract" xlink:to="OXIS_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Note 2 - Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Note 3 - Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Note 4 - Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="us-gaap_GuaranteesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesAbstract" xlink:to="us-gaap_GuaranteesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteesAbstract_lbl" xml:lang="en-US">Guarantees [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Note 5 - Stock Options and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock" xlink:label="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock" xlink:to="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock_lbl" xml:lang="en-US">Note 6 - Advisory and Consulting Agreements Obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Note 7 - Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xml:lang="en-US">Company And Summary Of Significant Accounting Policies Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock Based Compensation to Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US">Stock Based Compensation to Other than Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" xlink:label="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" xlink:to="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract_lbl" xml:lang="en-US">Company And Summary Of Significant Accounting Policies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Company assets and liabilities by level measured at fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_PatentsTablesAbstract" xlink:label="OXIS_PatentsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_PatentsTablesAbstract" xlink:to="OXIS_PatentsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_PatentsTablesAbstract_lbl" xml:lang="en-US">Patents Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Expected future amortization of patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_StockOptionsAndWarrantsTablesAbstract" xlink:label="OXIS_StockOptionsAndWarrantsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_StockOptionsAndWarrantsTablesAbstract" xlink:to="OXIS_StockOptionsAndWarrantsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_StockOptionsAndWarrantsTablesAbstract_lbl" xml:lang="en-US">Stock Options And Warrants Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of the stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of the warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_lbl" xml:lang="en-US">Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xml:lang="en-US">Cash and cash equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Amortized over vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Diluted shares excluded from calcuation of EPS</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_PatentsDetailsAbstract" xlink:label="OXIS_PatentsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_PatentsDetailsAbstract" xlink:to="OXIS_PatentsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_PatentsDetailsAbstract_lbl" xml:lang="en-US">Patents Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Capitalized patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Net</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_PatentsDetails1Abstract" xlink:label="OXIS_PatentsDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_PatentsDetails1Abstract" xlink:to="OXIS_PatentsDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_PatentsDetails1Abstract_lbl" xml:lang="en-US">Patents Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2012</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2013</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2014</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_StockholdersEquityDetailsNarrativeAbstract" xlink:label="OXIS_StockholdersEquityDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_StockholdersEquityDetailsNarrativeAbstract" xlink:to="OXIS_StockholdersEquityDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_StockholdersEquityDetailsNarrativeAbstract_lbl" xml:lang="en-US">Stockholders Equity Details Narrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Retirement of debt, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Retirement of debt, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_StockOptionsAndWarrantsDetailsAbstract" xlink:label="OXIS_StockOptionsAndWarrantsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_StockOptionsAndWarrantsDetailsAbstract" xlink:to="OXIS_StockOptionsAndWarrantsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_StockOptionsAndWarrantsDetailsAbstract_lbl" xml:lang="en-US">Stock Options And Warrants Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of December 31, 2011</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding as of September 30, 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable as of September 30, 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding as of December 31, 2011</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding as of September 30, 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable as of September 30, 2012</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2_lbl" xml:lang="en-US">Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:label="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:to="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdjustmentsOfWarrants" xlink:label="OXIS_AdjustmentsOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_AdjustmentsOfWarrants" xlink:to="OXIS_AdjustmentsOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_AdjustmentsOfWarrants_lbl" xml:lang="en-US">Adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice" xlink:label="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice" xlink:to="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenue, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_3_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" xlink:to="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities_2_lbl" xml:lang="en-US">ChangeInValueOfWarrantAndDerivativeLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:to="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice" xlink:to="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">AdjustmentsOfWarrantsWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_DemandNotesPayableNetOfDiscountOf54000And0" xlink:to="OXIS_DemandNotesPayableNetOfDiscountOf54000And0_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_DemandNotesPayableNetOfDiscountOf54000And0_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" xlink:to="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertiblePreferredStockSeriesC" xlink:to="OXIS_ConvertiblePreferredStockSeriesC_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ConvertiblePreferredStockSeriesC_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertiblePreferredStockSeriesH" xlink:to="OXIS_ConvertiblePreferredStockSeriesH_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ConvertiblePreferredStockSeriesH_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertiblePreferredStockSeriesI" xlink:to="OXIS_ConvertiblePreferredStockSeriesI_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ConvertiblePreferredStockSeriesI_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" xlink:to="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesCPreferredStockIssuedShares" xlink:to="OXIS_SeriesCPreferredStockIssuedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_SeriesCPreferredStockIssuedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesCPreferredStockOutstandingShares" xlink:to="OXIS_SeriesCPreferredStockOutstandingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_SeriesCPreferredStockOutstandingShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesHPreferredStockIssuedShares" xlink:to="OXIS_SeriesHPreferredStockIssuedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_SeriesHPreferredStockIssuedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesHPreferredStockOutstandingShares" xlink:to="OXIS_SeriesHPreferredStockOutstandingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_SeriesHPreferredStockOutstandingShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesIPreferredStockIssuedShares" xlink:to="OXIS_SeriesIPreferredStockIssuedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_SeriesIPreferredStockIssuedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_SeriesIPreferredStockOutstandingShares" xlink:to="OXIS_SeriesIPreferredStockOutstandingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_SeriesIPreferredStockOutstandingShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_DemandNotesPayableNetOfDiscount" xlink:to="OXIS_DemandNotesPayableNetOfDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_DemandNotesPayableNetOfDiscount_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ConvertibleDebenturesNetOfDiscount" xlink:to="OXIS_ConvertibleDebenturesNetOfDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ConvertibleDebenturesNetOfDiscount_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes" xlink:to="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock" xlink:to="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ExerciseOfWarrantsAmount" xlink:to="OXIS_ExerciseOfWarrantsAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ExerciseOfWarrantsAmount_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OXIS_ExerciseOfWarrantsShares" xlink:to="OXIS_ExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OXIS_ExerciseOfWarrantsShares_doc" xml:lang="en-US">Custom Element.</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>oxis-20120930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- QXInteractive -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oxis.com/role/DocumentAndEntityInformation" xlink:href="oxis-20120930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedBalanceSheets" xlink:href="oxis-20120930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="oxis-20120930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementsOfOperations" xlink:href="oxis-20120930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit" xlink:href="oxis-20120930.xsd#ConsolidatedStatementOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oxis-20120930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="oxis-20120930.xsd#Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note2-Patents" xlink:href="oxis-20120930.xsd#Note2-Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note3-Debt" xlink:href="oxis-20120930.xsd#Note3-Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note4-StockholdersEquity" xlink:href="oxis-20120930.xsd#Note4-StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note5-StockOptionsAndWarrants" xlink:href="oxis-20120930.xsd#Note5-StockOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations" xlink:href="oxis-20120930.xsd#Note6-AdvisoryAndConsultingAgreementsObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/Note7-SubsequentEvents" xlink:href="oxis-20120930.xsd#Note7-SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsTables" xlink:href="oxis-20120930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsTables" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="oxis-20120930.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsDetails" xlink:href="oxis-20120930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/PatentsDetails1" xlink:href="oxis-20120930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockholdersEquityDetailsNarrative" xlink:href="oxis-20120930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oxis.com/role/StockOptionsAndWarrantsDetails1" xlink:href="oxis-20120930.xsd#StockOptionsAndWarrantsDetails1" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_DocumentAndEntityInformationAbstract" xlink:label="loc_OXISDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_OXISEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_OXISEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="loc_OXISDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_OXISDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_OXISAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_OXISCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_OXISEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_OXISEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_OXISEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_OXISEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_OXISEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_OXISEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_OXISDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_OXISDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDocumentAndEntityInformationAbstract" xlink:to="loc_OXISDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedBalanceSheets" xlink:title="0002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_OXISStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_OXISAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfFinancialPositionAbstract" xlink:to="loc_OXISAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_OXISAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_OXISCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_OXISInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_OXISPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_OXISAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_OXISFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_OXISAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_OXISAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAssetsAbstract" xlink:to="loc_OXISAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_OXISLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfFinancialPositionAbstract" xlink:to="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_OXISLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_OXISAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_OXISInterestPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_OXISAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_OXISLineOfCredit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="loc_OXISProductWarrantyAccrualClassifiedCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_DemandNotesPayableNetOfDiscountOf54000And0" xlink:label="loc_OXISDemandNotesPayableNetOfDiscountOf54000And0" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISDemandNotesPayableNetOfDiscountOf54000And0" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" xlink:label="loc_OXISConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_OXISConvertibleDebtCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISConvertibleDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_OXISLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OXISLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_OXISStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfFinancialPositionAbstract" xlink:to="loc_OXISStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesC" xlink:label="loc_OXISConvertiblePreferredStockSeriesC" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISConvertiblePreferredStockSeriesC" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesH" xlink:label="loc_OXISConvertiblePreferredStockSeriesH" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISConvertiblePreferredStockSeriesH" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertiblePreferredStockSeriesI" xlink:label="loc_OXISConvertiblePreferredStockSeriesI" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISConvertiblePreferredStockSeriesI" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_OXISCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_OXISAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_OXISRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_OXISMinorityInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_OXISStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_OXISLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="0003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_OXISStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_OXISLiabilitiesCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfFinancialPositionAbstract" xlink:to="loc_OXISLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_DemandNotesPayableNetOfDiscount" xlink:label="loc_OXISDemandNotesPayableNetOfDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesCurrentAbstract" xlink:to="loc_OXISDemandNotesPayableNetOfDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ConvertibleDebenturesNetOfDiscount" xlink:label="loc_OXISConvertibleDebenturesNetOfDiscount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISLiabilitiesCurrentAbstract" xlink:to="loc_OXISConvertibleDebenturesNetOfDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_OXISStockholdersEquityAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfFinancialPositionAbstract" xlink:to="loc_OXISStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_OXISPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_OXISPreferredStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesCPreferredStockIssuedShares" xlink:label="loc_OXISSeriesCPreferredStockIssuedShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISSeriesCPreferredStockIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesCPreferredStockOutstandingShares" xlink:label="loc_OXISSeriesCPreferredStockOutstandingShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISSeriesCPreferredStockOutstandingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesHPreferredStockIssuedShares" xlink:label="loc_OXISSeriesHPreferredStockIssuedShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISSeriesHPreferredStockIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesHPreferredStockOutstandingShares" xlink:label="loc_OXISSeriesHPreferredStockOutstandingShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISSeriesHPreferredStockOutstandingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesIPreferredStockIssuedShares" xlink:label="loc_OXISSeriesIPreferredStockIssuedShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISSeriesIPreferredStockIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_SeriesIPreferredStockOutstandingShares" xlink:label="loc_OXISSeriesIPreferredStockOutstandingShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISSeriesIPreferredStockOutstandingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_OXISCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_OXISCommonStockSharesAuthorized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_OXISCommonStockSharesIssued" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_OXISCommonStockSharesOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityAbstract" xlink:to="loc_OXISCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementsOfOperations" xlink:title="0004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_OXISIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="loc_OXISSalesRevenueNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISIncomeStatementAbstract" xlink:to="loc_OXISSalesRevenueNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_OXISSalesRevenueGoodsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISSalesRevenueNetAbstract" xlink:to="loc_OXISSalesRevenueGoodsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_OXISLicenseAndServicesRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISSalesRevenueNetAbstract" xlink:to="loc_OXISLicenseAndServicesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_OXISSalesRevenueNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISSalesRevenueNetAbstract" xlink:to="loc_OXISSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_OXISCostOfGoodsAndServicesSold" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISSalesRevenueNetAbstract" xlink:to="loc_OXISCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_OXISGrossProfit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISSalesRevenueNetAbstract" xlink:to="loc_OXISGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_OXISOperatingExpensesAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISIncomeStatementAbstract" xlink:to="loc_OXISOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_OXISResearchAndDevelopmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_OXISSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OXISOperatingExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OXISOperatingIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="loc_OXISIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_OXISInterestExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_OXISNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes" xlink:label="loc_OXISLossBeforeMinorityInterestAndProvisionForIncomeTaxes" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISLossBeforeMinorityInterestAndProvisionForIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_OXISNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_OXISIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_OXISIncomeTaxExpenseBenefit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_OXISNetIncomeLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_OXISEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_OXISWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOperatingExpensesAbstract" xlink:to="loc_OXISWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit" xlink:title="0005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_OXISStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_OXISStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfStockholdersEquityAbstract" xlink:to="loc_OXISStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_OXISStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISStatementLineItems" order="300" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_OXISStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISStatementEquityComponentsAxis" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_OXISPreferredStockMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISPreferredStockMember" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_OXISCommonStockMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISCommonStockMember" order="110" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_OXISAdditionalPaidInCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISAdditionalPaidInCapitalMember" order="210" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_OXISRetainedEarningsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISRetainedEarningsMember" order="310" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_OXISStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_OXISSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_OXISAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_OXISStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_OXISStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_OXISStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_OXISStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ExerciseOfWarrantsAmount" xlink:label="loc_OXISExerciseOfWarrantsAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISExerciseOfWarrantsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ExerciseOfWarrantsShares" xlink:label="loc_OXISExerciseOfWarrantsShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_OXISNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_OXISStockholdersEquity_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_OXISSharesIssued_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISSharesIssued_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="0006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_OXISStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_OXISNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfCashFlowsAbstract" xlink:to="loc_OXISNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_OXISNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OXISNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_OXISAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfCashFlowsAbstract" xlink:to="loc_OXISAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_OXISAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OXISAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_OXISShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OXISShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_OXISIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OXISIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_OXISAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OXISAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities" xlink:label="loc_OXISChangeInValueOfWarrantAndDerivativeLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OXISChangeInValueOfWarrantAndDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_OXISIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfCashFlowsAbstract" xlink:to="loc_OXISIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_OXISIncreaseDecreaseInInventories" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_OXISIncreaseDecreaseInInventories" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_OXISIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_OXISIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_OXISIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_OXISIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_OXISNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_OXISNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementOfCashFlowsAbstract" xlink:to="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_OXISProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_OXISProceedsFromNotesPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_OXISRepaymentsOfNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_OXISNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_OXISProceedsFromMinorityShareholders" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISProceedsFromMinorityShareholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_OXISCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_OXISCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_OXISCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OXISCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="0007 - Disclosure - Note 1 - The Company and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OXISOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_OXISOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_OXISOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note2-Patents" xlink:title="0008 - Disclosure - Note 2 - Patents">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_NotesToFinancialStatementsAbstract" xlink:label="loc_OXISNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_OXISGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNotesToFinancialStatementsAbstract" xlink:to="loc_OXISGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note3-Debt" xlink:title="0009 - Disclosure - Note 3 - Debt">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_OXISDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_OXISDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDebtDisclosureAbstract" xlink:to="loc_OXISDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note4-StockholdersEquity" xlink:title="0010 - Disclosure - Note 4 - Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_OXISEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_OXISStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISEquityAbstract" xlink:to="loc_OXISStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note5-StockOptionsAndWarrants" xlink:title="0011 - Disclosure - Note 5 - Stock Options and Warrants">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_OXISGuaranteesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_OXISDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISGuaranteesAbstract" xlink:to="loc_OXISDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations" xlink:title="0012 - Disclosure - Note 6 - Advisory and Consulting Agreements Obligations">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_NotesToFinancialStatementsAbstract" xlink:label="loc_OXISNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock" xlink:label="loc_OXISAdvisoryAndConsultingAgreementsObligationsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISNotesToFinancialStatementsAbstract" xlink:to="loc_OXISAdvisoryAndConsultingAgreementsObligationsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/Note7-SubsequentEvents" xlink:title="0013 - Disclosure - Note 7 - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_OXISSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_OXISSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISSubsequentEventsAbstract" xlink:to="loc_OXISSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0014 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_OXISLiquidityDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISLiquidityDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_OXISUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_OXISRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_OXISSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_OXISShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="loc_OXISShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_OXISEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_OXISNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_OXISFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_OXISFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="0015 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" xlink:label="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_OXISScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract" xlink:to="loc_OXISScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsTables" xlink:title="0016 - Disclosure - Patents (Tables)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_PatentsTablesAbstract" xlink:label="loc_OXISPatentsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_OXISScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsTablesAbstract" xlink:to="loc_OXISScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_OXISScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsTablesAbstract" xlink:to="loc_OXISScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsTables" xlink:title="0017 - Disclosure - Stock Options and Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_StockOptionsAndWarrantsTablesAbstract" xlink:label="loc_OXISStockOptionsAndWarrantsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_OXISScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockOptionsAndWarrantsTablesAbstract" xlink:to="loc_OXISScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_OXISScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockOptionsAndWarrantsTablesAbstract" xlink:to="loc_OXISScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="0018 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_OXISScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="loc_OXISScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_OXISDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_OXISDefinedBenefitPlanDisclosureLineItems" order="300" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_OXISFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_OXISFairValueByFairValueHierarchyLevelAxis" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_OXISFairValueInputsLevel1Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_OXISFairValueInputsLevel1Member" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_OXISFairValueInputsLevel2Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_OXISFairValueInputsLevel2Member" order="110" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_OXISFairValueInputsLevel3Member" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_OXISFairValueInputsLevel3Member" order="210" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_OXISFinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_OXISFinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_OXISInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISFinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="loc_OXISInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:label="loc_OXISFinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_OXISFinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_OXISLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISFinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="loc_OXISLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="0019 - Disclosure - The Company and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:label="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_OXISStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISCompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:to="loc_OXISStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_OXISStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISStatementLineItems" order="300" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_OXISRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISRangeAxis" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_OXISRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISRangeAxis" xlink:to="loc_OXISRangeMember" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_OXISMinimumMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISRangeMember" xlink:to="loc_OXISMinimumMember" order="110" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_OXISMaximumMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISRangeMember" xlink:to="loc_OXISMaximumMember" order="210" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_OXISRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_OXISCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_OXISFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_OXISFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_OXISFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_OXISFairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_OXISAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_OXISAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsDetails" xlink:title="0020 - Disclosure - Patents (Details)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_PatentsDetailsAbstract" xlink:label="loc_OXISPatentsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_OXISFiniteLivedPatentsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetailsAbstract" xlink:to="loc_OXISFiniteLivedPatentsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_OXISFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetailsAbstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_OXISFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetailsAbstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/PatentsDetails1" xlink:title="0021 - Disclosure - Patents (Details 1)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_PatentsDetails1Abstract" xlink:label="loc_OXISPatentsDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetails1Abstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetails1Abstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetails1Abstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetails1Abstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISPatentsDetails1Abstract" xlink:to="loc_OXISFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockholdersEquityDetailsNarrative" xlink:title="0022 - Disclosure - Stockholders' Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_StockholdersEquityDetailsNarrativeAbstract" xlink:label="loc_OXISStockholdersEquityDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_OXISCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityDetailsNarrativeAbstract" xlink:to="loc_OXISCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_OXISDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityDetailsNarrativeAbstract" xlink:to="loc_OXISDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_OXISDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockholdersEquityDetailsNarrativeAbstract" xlink:to="loc_OXISDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsDetails" xlink:title="0023 - Disclosure - Stock Options and Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_StockOptionsAndWarrantsDetailsAbstract" xlink:label="loc_OXISStockOptionsAndWarrantsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_OXISStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oxis.com/role/StockOptionsAndWarrantsDetails1" xlink:title="0024 - Disclosure - Stock Options and Warrants (Details 1)">
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_StockOptionsAndWarrantsDetails1Abstract" xlink:label="loc_OXISStockOptionsAndWarrantsDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_OXISStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStockOptionsAndWarrantsDetails1Abstract" xlink:to="loc_OXISStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_OXISStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISStatementLineItems" order="300" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_OXISStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementTable" xlink:to="loc_OXISStatementEquityComponentsAxis" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_OXISEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementEquityComponentsAxis" xlink:to="loc_OXISEquityComponentDomain" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_OXISWarrantMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISEquityComponentDomain" xlink:to="loc_OXISWarrantMember" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdjustmentsOfWarrants" xlink:label="loc_OXISAdjustmentsOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISAdjustmentsOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_OXISStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISStatementLineItems" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="oxis-20120930.xsd#OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice" xlink:label="loc_OXISAdjustmentsOfWarrantsWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISAdjustmentsOfWarrantsWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_OXISShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note 3 - Debt</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Convertible
debentures</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On October
25, 2006, the Company entered into a securities purchase agreement (&#147;2006 Purchase Agreement&#148;) with four accredited
investors (the &#147;2006 Purchasers&#148;). In conjunction with the signing of the 2006 Purchase Agreement, the Company issued
secured convertible debentures (&#147;2006 Debentures&#148;) and Series A, B, C, D, and E common stock warrants (&#147;2006
Warrants&#148;) to the 2006 Purchasers, and the parties also entered into a security agreement (the &#147;2006 Security Agreement&#148;)
pursuant to which the Company agreed to grant the 2006 Purchasers, pari passu, a security interest in substantially all of the
Company&#146;s assets.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Pursuant to
the terms of the 2006 Purchase Agreement, the Company issued the 2006 Debentures in an aggregate principal amount of $1,694,250
to the 2006 Purchasers. The 2006 Debentures are subject to an original issue discount of 20.318% resulting in proceeds to the
Company of $1,350,000 from the transaction. The 2006 Debentures were due on October 25, 2008. The 2006 Debentures are convertible,
at the option of the 2006 Purchasers, at any time prior to payment in full, into shares of common stock of the Company. As a result
of the full ratchet anti-dilution provision the current conversion price is $0.01 per share (the &#147;2006 Conversion Price&#148;).
Beginning on the first of the month beginning February 1, 2007, the Company was required to amortize the 2006 Debentures in equal
installments on a monthly basis resulting in a complete repayment by the maturity date (the &#147;Monthly Redemption Amounts&#148;).
The Monthly Redemption Amounts could have been paid in cash or in shares, subject to certain restrictions. If the Company chose
to make any Monthly Redemption Amount payment in shares of common stock, the price per share would have been the lesser of the
Conversion Price then in effect and 85% of the weighted average price for the 10-trading days prior to the due date of the Monthly
Redemption Amount. The Company did not make any of the required monthly redemption payments.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Pursuant to
the provisions of the 2006 Debentures, such non-payment was an event of default and penalty interest has accrued on the unpaid
redemption balance at an interest rate equal to the lower of 18% per annum and the maximum rate permitted by applicable law. In
addition, each of the 2006 Purchasers has the right to accelerate the cash repayment of at least 130% of the outstanding principal
amount of the 2006 Debenture (plus accrued but unpaid liquidated damages and interest) and to sell substantially all of the Company&#146;s
assets pursuant to the provisions of the 2006 Security Agreement to satisfy any such unpaid balance. On June 6, 2008, the Company
received notification from Bristol Investment Fund, Ltd (&#147;Bristol&#148;), that the collateral held under the 2006 Security
Agreement would be sold to the highest qualified bidder on Thursday, June 19, 2008. On June 19, 2008, the Company received a Notice
of Disposition of Collateral from Bristol in which Bristol notified the Company that Bristol, acting as the agent for itself and
the three other 2006 Purchasers, purchased certain assets held as collateral under the 2006 Security Agreement. Bristol purchased
111,025 shares of common stock of BioCheck, Inc., the Company&#146;s majority owned subsidiary, on a credit bid of $50,000, and
Bristol also purchased 1,000 shares of the capital stock of OXIS Therapeutics, Inc., a wholly owned subsidiary of OXIS, for a
credit bid of $10,000. In December 2005, OXIS purchased the 111,025 shares of common stock of BioCheck, Inc. for $3,060,000. After
crediting the aggregate amount of $60,000 to the aggregate amount due under the 2006 Debentures, plus fees and charges due through
June 19, 2008, Bristol notified the Company that the Company remains obligated to the 2006 Purchasers in a deficiency in an aggregate
amount of $2,688,000 as of June 19, 2008. As a result of the disposition of the collateral, the Company recorded a net loss aggregating
$2,978,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Under the
2006 Purchase Agreement, the 2006 Purchasers also have a right of first refusal to participate in up to 100% of any future financing
undertaken by the Company until the 2006 Debentures are no longer outstanding. In addition, the Company is also prohibited from
effecting any subsequent financing involving a variable rate transaction until such time as no 2006 Purchaser holds any of the
2006 Debentures. Furthermore, so long as any 2006 Purchaser holds any of the securities issued under the 2006 Purchase Agreement,
if the Company issues or sells any common stock or instruments convertible into common stock which a 2006 Purchaser reasonably
believes is on terms more favorable to such investors than the terms pursuant to the 2006 Debentures or 2006 Warrants, the Company
is obligated to permit such 2006 Purchaser the benefits of such better terms.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Of the 2006
Warrants issued by the Company to the 2006 Purchasers, only the Series A Warrants remain outstanding. The Series A Warrants, which
now expire in October 2014, permit the holders to purchase 2,420,357 shares of common stock at an original exercise price of $0.35
per share. Such exercise price is adjustable pursuant to a full ratchet anti-dilution provision and upon the occurrence of a stock
split or a related event.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">During 2009,
Bristol converted $177,900 of the principal amount of 2006 Debentures for 17,790,000 shares of the Company&#146;s common stock.
During 2010, Bristol converted an additional $401,000 of the principal amount of 2006 Debentures for 40,100,000 shares of the
Company&#146;s common stock. During 2011, an additional $605,000 of the principal amount of 2006 Debentures was converted into
60,500,000 shares of the Company&#146;s common stock. Of the $605,000 converted in 2011, $53,125 was converted into 5,312,500
shares of the Company&#146;s common stock during the first quarter of 2011. During the nine months ended September 30, 2012,
an additional $372,000 of the principal amount of 2006 Debentures was converted into 37,200,000 shares of the Company&#146;s
common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The 2006 Debentures
do not meet the definition of a &#147;conventional convertible debt instrument&#148; since they are not convertible into a fixed
number of shares. The Monthly Redemption Amounts can be paid with common stock at a conversion price that is a percentage of the
market price; therefore the number of shares that could be required to be delivered upon &#147;net-share settlement&#148; is
essentially indeterminate. Therefore, the 2006 Debentures are considered &#147;non-conventional,&#148; which means that the
conversion feature must be bifurcated from the debt and shown as a separate derivative liability. This beneficial conversion liability
has been calculated to be $690,000 on October 25, 2006. In addition, since the 2006 Debentures are convertible into an indeterminate
number of shares of common stock, it is assumed that the Company could never have enough authorized and unissued shares to settle
the conversion of the 2006 Warrants issues in this transaction into common stock. Therefore, the 2006 Warrants have a fair value
of $2,334,000 at October 25, 2006. The value of the 2006 Warrant was calculated using the Black-Scholes model using the following
assumptions: Discount rate of 4.5%, volatility of 158% and expected term of 1 to 6 years. The fair value of the beneficial conversion
feature and the 2006 Warrant liability will be adjusted to fair value on each balance sheet date with the change being shown as
a component of net loss. The fair value of the beneficial conversion feature and the 2006 Warrants at the inception of the 2006
Debentures were $690,000 and $2,334,000, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The first
$1,350,000 of these discounts has been shown as a discount to the 2006 Debentures which will be amortized over the term of the
2006 Debenture and the excess of $1,674,000 has been shown as financing costs in the accompanying statement of operations.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">At September
30, 2012 and December 31, 2011, the Company determined the fair value of the 2006 Warrants was $79,000 and $39,000, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On October
1, 2009, the Company entered into a financing arrangement with several accredited investors (the &#147;2009 Investors&#148;),
pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $2,000,000 (the &#147;2009
Financing&#148;). In connection with the 2009 Financing, the Company issued the following securities to the 2009 Investors:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0% Convertible Debentures
    in the principal amount of $2,000,000 due 24 months from the date of issuance (the &#147; 2009 Debentures&#148;), convertible
    into shares of the Company&#146;s common stock at a per share conversion price equal to $0.05 per share;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Series A warrant
    to purchase such number of shares of the Company&#146;s common stock equal to 50% of the principal amount invested by each
    2009 Investor (the &#147;2009 Class A Warrants&#148; ) resulting in the issuance of Class A Warrants to purchase 20,000,000
    shares of common stock of the Company.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Series B warrant
    to purchase such number of shares of the Company&#146;s common stock equal to 50% of the principal amount invested by each
    2009 Investor (the &#147;2009 Class B Warrants&#148;) resulting in the issuance of Class B Warrants to purchase 20,000,000
    shares of common stock of the Company.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Class
A Warrants and Class B Warrants (collectively, the &#147; 2009 Warrants&#148;) are exercisable for up to five years from the
date of issue at a per share exercise price equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively,
on a cash or cashless basis. The 2009 Debentures and the 2009 Warrants are collectively referred to herein as the &#147;2009
Securities&#148;.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In connection
with the sale of the 2009 Securities by the Company, the Company and Bristol entered a Standstill and Forbearance Agreement, pursuant
to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect to (i) the 2006 Debentures
and (ii) certain demand notes (the &#147;Bridge Notes&#148;) issued by the Company on October 8, 2008, March 19, 2009, April
7, 2009, April 28, 2009, May 21, 2009 and June 25, 2009 and discussed under the caption &#147;Demand Notes&#148; below. In connection
with the sale of the 2009 Securities by the Company, the Company and Bristol have also entered into a waiver agreement (the &#147;Waiver
Agreement&#148;) pursuant to which Bristol waived certain rights with respect to the 2006 Debentures and Bridge Notes.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The conversion
price of the 2009 Debentures and the exercise price of the 2009 Warrants are subject to full ratchet anti-dilution adjustment
in the event that the Company thereafter issues common stock or common stock equivalents at a price per share less than the conversion
price or the exercise price, respectively, and to other normal and customary anti-dilution adjustment upon certain other events.
So long as the 2009 Debentures are outstanding, if the Company effects a subsequent financing, the October 2009 Investors may
elect, in their sole discretion, to exchange all or some of the October 2009 Debentures (but not the 2009 Warrants) for any securities
or units issued in a subsequent financing on a $1.00 for $1.00 basis or to have any particular provisions of the subsequent financing
legal documents apply to the documents utilized for the October 2009 Financing.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
also agreed that if it determines to prepare and file with the Commission a registration statement relating to an offering for
its own account or the account of others, then it shall include the shares of common stock underlying the 2009 Securities on such
registration statement. The 2009 Investors have contractually agreed to restrict their ability to convert the 2009 Debentures
and exercise the 2009 Warrants and receive shares of our common stock such that the number of shares of the Company common stock
held by a 2009 Investor and its affiliates after such conversion or exercise does not exceed 4.9% of the Company&#146;s then
issued and outstanding shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">During 2010,
2009 Investors converted $1,335,000 of the principal amount of 2009 Debentures for 26,700,000 shares of the Company&#146;s common
stock. During 2011, 2009 Investors converted $610,000 of the principal amount of 2009 Debentures for 12,200,000 shares of the
Company&#146;s common stock. Accordingly, at September 30, 2012, $55,000 in aggregate principal amount of 2009 Debentures remained
outstanding. In addition, as of September 30, 2012, 14,900,000 of the 2009 Class A Warrants and 16,750,000 of the 2009 Class B
Warrants remained outstanding.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On June 1,
2011, the Company entered into a financing arrangement with several accredited investors (the &#147;June 2011 Investors&#148;),
pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $500,000 (the &#147;June
2011 Financing&#148;). In connection with the June 2011 Financing, the Company issued the following securities to the June 2011
Investors:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">12% Convertible
    Debentures in the principal amount of $500,000 due April 15, 2012, convertible into shares of the Company&#146;s common stock
    at a per share conversion price equal to $0.10 per share; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Warrants to purchase
    5,000,000 of shares of the Company&#146;s common stock. The warrants are exercisable, on a cash or cashless basis, for up
    to two years from the date of issue at a per share exercise price equal to $0.15.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In November,
2011, the Company entered into a financing arrangement with several accredited investors (the &#147;November 2011 Investors&#148;),
pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the &#147;November
2011 Financing&#148;). In connection with the November 2011 Financing, the Company issued the following securities to the November
2011 Investors:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">8% Convertible Debentures
    in the principal amount of $275,000 due in two years, convertible into shares of the Company&#146;s common stock at a per
    share conversion price equal to $0.05 per share; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Warrants to purchase
    5,500,000 of shares of the Company&#146;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#147;Warrants&#148;)
    are exercisable for up to five years from the date of issue at a per share exercise price equal to $0.0625 and $0.075 for
    the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In March,
2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities
in consideration of a maximum aggregate purchase price of $617,500 (the &#147;March 2012 Financing&#148;). In connection with
the March 2012 Financing, the Company issued the following securities to the investors:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">8% Convertible Debentures
    in the principal amount of $617,500&#160;&#160;due in two years, convertible into shares of the Company&#146;s common stock
    at a per share conversion price equal to $0.05 per share; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Warrants to purchase
    12,350,000 of shares of the Company&#146;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#147;
    March 2012 Warrants&#148;) are exercisable for up to five years from the date of issue at a per share exercise price equal
    to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In April 2012,
the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company.&#160;&#160;Pursuant
to the anti-dilution provisions in the convertible instruments, the conversion price of certain convertible instruments is now
$0.01 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $0.01
and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In May, 2012,
the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities
in consideration of a maximum aggregate purchase price of $275,000 (the &#147;May 2012 Financing&#148;). In connection with
the May 2012 Financing, the Company issued the following securities to the investors:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">8% Convertible Debentures
    in the principal amount of $275,000 due May 2014, convertible into shares of the Company&#146;s common stock at a per share
    conversion price equal to $0.05 per share; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 72px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#149;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Warrants to purchase
    5,500,000 of shares of the Company&#146;s common stock. The Class A Warrants and Class B Warrants (collectively, the &#147;
    May&#160;&#160;2012 Warrants&#148;) are exercisable for up to five years from the date of issue at a per share exercise price
    equal to $0.0625 and $0.075 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On August
8, 2012, a Settlement Agreement and Mutual General Release (&#34;Agreement&#34;) was made by and between OXIS and Bristol Investment
Fund, Ltd., in order to settle certain claims regarding certain convertible debentures held by Bristol.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Pursuant to
the Agreement, OXIS shall pay Bristol (half of which payment would redound to Merit Capital Limited (&#147;Merit&#148;)) a total
of $1,119,778 as payment in full for the losses suffered and all costs incurred by Bristol in connection with the Transaction.
Payment of such $1,119,778 shall be made as follows: OXIS shall issue restricted common stock to each of Bristol and Merit, in
an amount such that each Bristol and Merit shall hold no more than 9.99% of the outstanding shares of OXIS (including any shares
that each may hold as of the date of issuance). The shares so issued represent $417,475.65 of the $1,119,778 payment (27,831,710
shares at $0.015 per share, of which 9,168,750 will be retained by Bristol and 18,662,960 will be issued to Merit). The remaining
balance of the payment shall be made in the form of two convertible promissory notes in the respective amounts of $422,357.75
for Bristol and $279,944.60 for Merit (collectively, the &#147;Notes&#148;) with a maturity of December 1, 2017 having an 8%
annual interest rate, with interest only accruing until January 1, 2013, and then level payments of $3,750 each beginning January
1, 2013 until paid in full on December 1, 2017. In the event a default in the monthly payments on the Notes has occurred and is
continuing each holder of the Notes shall be permitted to convert the unpaid principal and interest of the Notes into shares of
OXIS at $.01 cents per share.&#160;&#160;In the absence of such continuing default no conversion of the Notes will be permitted.
OXIS will have the right to repay the Notes in full at any time without penalty.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Demand Notes</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On May 15,
2009, the Company entered into a convertible demand promissory note with Bristol Capital, LLC for certain consulting services
totaling $100,000. The note does not provide for any interest and is due upon demand by the holder. The note has been converted
into common stock of the Company.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On June 22,
2009, the Company entered into a convertible demand promissory note with Theorem Group (&#147;Theorem&#148;) pursuant to which
Theorem purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price
of $25,000 (the &#147; 2009 Theorem Note&#148;). The 2009 Theorem Note was subsequently sold as described below.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Simultaneously
with the issuance of the 2009 Theorem Note, the Company issued Theorem a seven-year warrant (the &#147;2009 Theorem Warrant&#148;)
to purchase 3,137,500 shares of common stock of the Company at a price equal to the lower of (i) $0.01 and (ii) 60% of the average
of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Theorem
Note (the &#147;Exercise Price&#148;). The 2009 Theorem Warrant may be exercised on a cashless basis if the shares of common
stock underlying the 2009 Theorem Warrant are not then registered pursuant to an effective registration statement. In the event
the 2009 Theorem Warrant is exercised on a cashless basis, we will not receive any proceeds.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On December
1, 2009, Theorem sold the 2009 Theorem Note to Net Capital Partners, Inc. (&#147;Net Capital&#148;). In December 2009, Net Capital
converted $24,000 of the principal for 2,400,000 shares of the Company&#146;s common stock. In January 2010, Net Capital converted
the remaining $7,375 of principal amount for an additional 737,500 shares of the Company&#146;s common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On February
7, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate
principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#147;February
2011 Bristol Note&#148;). The February 2011 Bristol Note is convertible into shares of common stock of the Company at a price
equal to $0.05 per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Simultaneously
with the issuance of the February 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the &#147;February 2011 Bristol
Series A Warrants&#148;) to purchase 313,750 shares of the Company&#146;s common stock at a per share exercise price of $0.0625,
and a Series B Warrant (the &#147;February 2011 Bristol Series B Warrants&#148; and, together with the February 2011 Bristol
Series A Warrants, the &#147;February 2011 Bristol Warrants&#148;) to purchase 313,750 shares of the Company&#146;s common
stock at a per share exercise price of $0.075. The February 2011 Warrants are exercisable for up to seven years from the date
of issue. The February 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the February
2011 Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Bristol
Warrants are exercised on a cashless basis, the Company will not receive any proceeds.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On February
7, 2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased
an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the
&#147;February 2011 Net Capital Note&#148;). The February 2011 Net Capital Note is convertible into shares of common stock of
the Company at a price equal to $0.05 per share. As of September, 2012, the February 2011 Net Capital Note had been converted
into shares of the Company&#146;s common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Simultaneously
with the issuance of the February 2011 Net Capital Note, the Company issued Net Capital a Series A Warrant (the &#147;February
2011 Net Capital Series A Warrants&#148;) to purchase 313,750 shares of the Company&#146;s common stock at a per share exercise
price of $0.0625, and a Series B Warrant (the &#147;February 2011 Net Capital Series B Warrants&#148; and, together with the
February 2011 Net Capital Series A Warrants, the &#147;February 2011 Net Capital Warrants&#148;) to purchase 313,750 shares
of the Company&#146;s common stock at a per share exercise price of $0.075. The February 2011 Net Capital Warrants are exercisable
for up to seven years from the date of issue. The February 2011 Net Capital Warrants may be exercised on a cashless basis if the
shares of common stock underlying the February 2011 Net Capital Warrants are not then registered pursuant to an effective registration
statement. In the event the February 2011 Net Capital Warrants are exercised on a cashless basis, the Company will not receive
any proceeds.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On March 4,
2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate
principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#147;March
2011 Bristol Note&#148;). The March 2011 Bristol Note is convertible at the option of the holder at any time into shares of common
stock, at a price equal to $0.05.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Simultaneously
with the issuance of the March 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the &#147;March 2011 Bristol
Series A Warrants&#148;) to purchase 313,750 shares of the Company&#146;s common stock at a per share exercise price of $0.0625,
and a Series B Warrant (the &#147;March 2011 Bristol Series B Warrants&#148; and, together with the March 2011 Bristol Series
A Warrants, the &#147;March 2011 Bristol Warrants&#148;) to purchase 313,750 shares of the Company&#146;s common stock at a
per share exercise price of $0.075. The March 2011 Warrants are exercisable for up to seven years from the date of issue. The
March 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the March 2011 Warrants are
not then registered pursuant to an effective registration statement. In the event the March 2011 Warrants are exercised on a cashless
basis, the Company will not receive any proceeds.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On April 4,
2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased an
aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the &#147;April
2011 Net Capital Note&#148;). The April 2011 Net Capital Note is convertible into shares of common stock of the Company, at a
price equal to $0.05 per share.&#160;&#160;As of September, 2012, April&#160;&#160;2011 Net Capital Note had been converted into
shares of the Company&#146;s common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Simultaneously
with the issuance of the Net Capital Note, the Company issued Net Capital a Series A Warrant (the &#147;April 2011 Net Capital
Series A Warrants&#148;) to purchase 313,750 shares of common stock of the Company at a per share exercise price of $0.0625,
and a Series B Warrant (the &#147;April 2011 Net Capital Series B Warrants&#148; and, together with the April 2011 Net Capital
Series A Warrants, the &#147;April 2011 Net Capital Warrants&#148;) to purchase 313,750 shares of common stock of the Company
at a per share exercise price of $0.075. The April 2011 Net Capital Warrants are exercisable for up to seven years from the date
of issue. The April 2011 Net Capital Warrants may be exercised on a cashless basis if the shares of common stock underlying the
April 2011 Net Capital Warrants are not then registered pursuant to an effective registration statement. In the event the April
2011 Net Capital Warrants are exercised on a cashless basis, we will not receive any proceeds.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On October
26, 2011 the Company entered into a convertible demand promissory note with Theorem pursuant to which Theorem purchased an aggregate
principal amount of $200,000 of convertible demand promissory notes for an aggregate purchase price of $157,217 (the &#147;October
2011 Theorem Note&#148;). The October 2011 Theorem Note is convertible into shares of common stock of the Company, at a price
equal to $0.05 per share. As of September, 2012, the October&#160;&#160;2011 Theorem&#160;&#160;Capital Note had been converted
into shares of the Company&#146;s common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Simultaneously
with the issuance of the October 2011 Theorem Note, the Company issued Theorem a Series A Warrant (the &#147;October 2011 Series
A Warrant&#148;) to purchase 10,000,000 shares of common stock of the Company at a per share exercise price of $0.0625, and a
Series B Warrant (the &#147;October 2011 Series B Warrants&#148; and, together with the October 2011 Series A Warrants, the
&#147;October 2011 Warrants&#148;) to purchase 10,000,000 shares of common stock of the Company at a per share exercise price
of $0.075. The October 2011 Warrants are exercisable for up to seven years from the date of issue. The October 2011 Warrants may
be exercised on a cashless basis if the shares of common stock underlying the October 2011 Warrants are not then registered pursuant
to an effective registration statement. In the event the October 2011 Warrants are exercised on a cashless basis, we will not
receive any proceeds.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">All of the
foregoing securities were issued in reliance upon an exemption from the registration requirements pursuant to Section 4(2) of
the Securities Act of 1933, as amended.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Financing
Agreement</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On November
8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing
partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in the Company and
agreed to make a $750,000 purchase order line of credit facility available to the Company.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The aggregate
amount of outstanding Advances available to the Company under the Line of Credit may not exceed $750,000.00 at any time. The credit
amounts available to the Company will be tiered, starting at $250,000 and will ramp up to $500,000 and then $750,000 upon achievement
of determined milestones. The Advances requested under the Line of Credit may only be used for purchases of products and inventory
from Gemini Pharmaceuticals.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The outstanding
principal of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In partial
consideration of the commitment made by Gemini Pharmaceuticals under the Line of Credit, the Company has issued to Gemini, non-callable
5-year warrants to purchase 300,000 additional shares of Common</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Stock at a
share price of $0.12. The warrants contain a cashless exercise provision. The warrants vest as follows: 50% immediately, 25% when
the credit line is increased to $500,000, and the remaining 25% when the credit line is increased to $750,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Joint Ventures</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In March 2011,
the Company agreed to form a joint venture with engage:BDR, Inc., an on-line marketing company that offers both premium and placement-specific
display marketing solutions and the ability to distribute campaigns through its own display platforms and channels.&#160;&#160;engage:BDR
partners with most of comScore's top 1000 websites (globally) for the most advanced display marketing capabilities.&#160;&#160;Under
the joint venture agreement, engage:BDR will provide a full range of online marketing services to the joint venture, including
developing brand strategy, the design of all digital media and interfaces, online media planning and buying, leveraging and integrating
social media, and customer analysis.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In March 2012
the Company signed a term sheet with engage:BDR that further evidences its arrangement and that permits both parties to commence
operations under the arrangement.&#160;&#160;The parties contemplate that the existing binding arrangement will be evidenced by
a formal limited liability company agreement that the parties are preparing. The following is a summary of the principal provisions
of our joint venture arrangement (the &#147;Joint Venture&#148;) with engage:BDR, Inc.:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
Company has agreed to grant the Joint Venture an exclusive license for the on-line marketing of products containing EGT&#153;.&#160;&#160;The
first product to be marketed and sold through the Joint Venture shall be Oxis&#146; ErgoFlex&#153; product, which product was
successfully test marketed in mail offering in late 2010 and early 2011.&#160;&#160;Additional Oxis products designated by the
Company will be offered by the Joint Venture.&#160;&#160;If both parties agree, third party products may also be offered through
the Joint Venture.&#160;&#160;However, nothing in the Joint Venture is intended to prohibit the Company from marketing, distributing
and selling ErgoFlex&#153; or any of its other current or future products by means other than through online sales.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Oxis
and engage:BDR have agreed to make the following&#160;&#160;contributions to the Joint Venture:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Oxis
will contribute up to $240,000 during the first year following the formation of the Joint Venture.&#160;&#160;These funds will
be provided if, when and as needed by the Joint Venture.&#160;&#160;OXIS&#146; cash capital contribution will be used (i) to
purchase ErgoFlex and other products from Oxis, at OXIS&#146; cost, without any markup, (ii) to purchase website media inventory
from engage:BDR, at engage:BDR&#146;s cost, plus a 15% administrative mark-up, and (iii) to fund the Joint Venture&#146;s other
operating costs.&#160;&#160;engage:BDR has agreed to waive the 15% administrative mark-up through December 31, 2012.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
addition to the cash, OXIS&#146; contribution to the Joint Venture includes the exclusive license for the on-line marketing of
any products created by Oxis which utilize its proprietary EGT&#153;.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;engage:BDR
, at its own cost and expense, is designing, developing and providing to the Joint Venture, on a turnkey basis, all online product
offering systems and technologies, including website layouts, landing pages, graphic designs, display advertising, rich media,
in-banner and in-stream video development.&#160;&#160;During the initial start-up phase of the Joint Venture, engage:BDR will,
at its own cost and expense, also manage all day-to-day online activities of the Joint Venture.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">Cash
from operations in excess of the amounts needed for its operations and for reasonable reserves, shall be distributed by the Joint
Venture in the following order:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;First,
to Oxis on a cumulative basis, an amount equal to the cash that OXIS contributed to the Joint Venture, and</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Thereafter,
all excess net operating cash will be distributed 50.1% to Oxis and 49.9% to engage:BDR.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
administrative affairs of the Joint Venture shall be managed by a committee consisting of one representative of each Joint Venture
member.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">As additional
consideration for engage:BDR entering into the Joint Venture and for contributing its services in designing, developing and implementing
the advertising platform, at the time that the Joint Venture operating agreement is signed, OXIS will grant engage:BDR a two-year
option to purchase Oxis securities.&#160;&#160;The option shall entitle engage:BDR to purchase the type of securities sold by
us in a future $6,000,000 or more financing, on the same terms and conditions, and at the same price, as such securities are sold
to third party investors in such financing.&#160;&#160;The number of such securities that engage:BDR may purchase upon the exercise
of the option (determined by assuming all convertible securities are converted and all exercisable securities are exercised) shall
be equal to 4.99% of the Company&#146;s common stock issued and outstanding on the date the Joint Venture agreement is signed.&#160;&#160;If
the Company has not raised $6,000,000 by December 31, 2012, commencing on that date, engage:BDR will have a two-year right to
purchase Oxis&#146; common stock at a price equal to $.03.&#160;&#160;OXIS has also agreed to issue to engage:BDR a warrant to
purchase up to 5,000,000 shares of its common stock if the Joint Venture, through engage:BDR efforts, attains certain revenue
and profits targets.&#160;&#160;The warrant will have an exercise price of $.03 per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On June 29,
2011 the Company entered into a Joint Venture Agreement (&#147;<u>Joint Venture Agreement</u>&#148;) with John E. Repine, M.D.
(&#147;<u>Dr. Repine</u>&#148;), a member of the Company&#146;s advisory board.&#160;&#160;Under the terms of the Joint Venture
Agreement, the Company formed a Delaware limited liability company, Ergo ARDS, LLC (the &#147;<u>ARDS Venture</u>&#148;), in
which the Company holds a 60% membership interest and Dr. Repine holds a 40% membership interest.&#160;&#160;The ARDS Venture
was formed to develop, acquire and market dietary supplements, cosmeceutical products, nutraceutical products, medical foods and
pharmaceuticals using EGT&#153; for treating, diagnosing and preventing acute respiratory distress syndrome and other lung disorders
(collectively &#147;<u>ARDS</u>&#148;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Concurrently
with the execution of the Joint Venture Agreement, Dr. Repine assigned his interest in the patent applications relating to the
use of ERGO in treating ARDS (the &#147;<u>Assigned IP</u>&#148;) to the ARDS Venture.&#160;&#160;In consideration for the Assigned
Interest, Dr. Repine was issued a 40% membership interest in the ARDS Venture.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Oxis will
be responsible for supplying EGT&#153; to the ARDS Venture at no cost in connection with the ARDS Venture&#146;s animal studies.
Oxis will also pay all patent prosecution and maintenance costs relating to the Assigned IP.&#160;&#160;The ARDS Venture is required
to make payments to Dr. Repine upon the achievement of certain milestones by the ARDS Venture.&#160;&#160;Any future payments
to Dr. Repine shall be made based on the achievement of following milestones with respect to products to be commercialized using
the Assigned IP:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The ARDS Venture
    shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Licensing
the Assigned IP to a pharmaceutical company -- $1,000,000;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Completion
of Phase I Clinical Trial -- $250,000;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 20pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
&#160;&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Completion of Phase II Clinical
Trial -- $1,000,000;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Completion
of pivotal Phase III Clinical Trial -- $1,500,000; and</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Receipt
of FDA Marketing approval -- $3,000,000</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The ARDS Venture
    shall pay the following cash amounts to Dr. Repine upon the attainment of the following milestones:</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Licensing
the Assigned IP to, or entering into a distribution agreement with, a nutraceutical or similar company -- $100,000; and</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gross
sales of products utilizing EGT&#153; in the field &#150; 5% of annual gross sales by the ARDS Venture or any licensee or distributor
(including Oxis).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Following
the successful completion of the animal studies, Oxis and Dr. Repine will make a joint decision to commence human clinical trials.
If the parties do not agree to proceed, the Joint Venture Agreement will terminate and the intellectual property belonging to
the ARDS Venture will be assigned to the party that elected to proceed.&#160;&#160;In the event both parties agree to not proceed,
the ARDS Venture will continue to hold the intellectual property.&#160;&#160;If the parties agree to proceed, Oxis will use its
best efforts to raise $3 million for the ARDS Venture.&#160;&#160;Once the $3 million in funds have been successfully raised by
Oxis, Oxis will no longer be responsible for paying the ARDS Venture&#146;s operating costs, including costs related to the ARDS
Venture&#146;s intellectual property.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The ARDS Venture
will be managed by Dr. Repine as Manager, who will also serve as the ARDS Venture&#146;s Chief Executive Officer and Treasurer.
The ARDS Venture will also have a board of five members, consisting of Dr. Repine and a designee of Dr. Repine, and three designees
of Oxis.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X8C`X
M-S5F8C1A9#4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X
M8C`X-S5F8C1A9#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#5B
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N=%]O9E]3=&]C/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F]T95\Q7U1H95]#;VUP86YY7V%N9%]3=6UM87)Y
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\R
M7U!A=&5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.;W1E7S-?1&5B=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DYO=&5?-%]3=&]C:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\U7U-T;V-K7T]P=&EO
M;G-?86YD7U=A<G)A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3F]T95\V7T%D=FES;W)Y7V%N9%]#;VYS=6QT:6YG/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5&AE7T-O;7!A;GE?86YD
M7U-U;6UA<GE?;V9?4VEG/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^5&AE7T-O;7!A;GE?86YD7U-U;6UA<GE?;V9?4VEG,3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!A=&5N='-?5&%B
M;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O
M8VM?3W!T:6]N<U]A;F1?5V%R<F%N='-?5&%B/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^5&AE7T-O;7!A;GE?86YD7U-U;6UA<GE?
M;V9?4VEG,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E1H95]#;VUP86YY7V%N9%]3=6UM87)Y7V]F7U-I9S,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0871E;G1S7T1E=&%I;',\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0871E;G1S7T1E
M=&%I;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-T;V-K:&]L9&5R<U]%<75I='E?1&5T86EL<U].83PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K7T]P=&EO;G-?86YD7U=A
M<G)A;G1S7T1E=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-T;V-K7T]P=&EO;G-?86YD7U=A<G)A;G1S7T1E=#$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z
M17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R
M:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z
M06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z
M4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\
M+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM
M;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES
M('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!8
M4"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X8C`X-S5F8C1A
M9#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#5B9F-F-3A?93EF
M.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U+U=O<FMS:&5E=',O4VAE970P,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P135.04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C
M=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%
M;G1I='D@26YF;W)M871I;VX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3UA)4R!)3E1%4DY!5$E/3D%,($E.
M0SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XP,#`P,3`Y-C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I
M;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E
M<"`S,"P-"@D),C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N
M9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<R!%;G1I='D@82!796QL+6MN;W=N(%-E87-O;F5D($ES<W5E<C\\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<R!%;G1I='D@82!6
M;VQU;G1A<GD@1FEL97(_/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27,@16YT:71Y)W,@4F5P;W)T:6YG(%-T871U<R!#=7)R96YT/SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^665S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL
M97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-M
M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL
M(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#4W+#(P-RPS,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E$S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U
M,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5114%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED
M871E9"!"86QA;F-E(%-H965T<R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!4U-%
M5%,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#DR+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@
M97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!#=7)R96YT($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%T96YT<RP@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!/=&AE<B!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1/5$%,($%34T544SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,24%"24Q)
M5$E%4R!!3D0@4U1/0TM(3TQ$15)3)R!$149)0TE4/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U."PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#8L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-R=65D(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#(R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#4Y."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#0Y+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P-RPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQI;F4@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,30L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34X+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5M86YD(&YO
M=&5S('!A>6%B;&4L(&YE="!O9B!D:7-C;W5N="!O9B`D,"!A;F0@)#4T+#`P
M,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8V+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=F5R=&EB;&4@9&5B96YT=7)E<RP@;F5T(&]F(&1I<V-O=6YT(&]F
M("0P(&%N9"`D,"P@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#DV-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-S4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!D
M96)E;G1U<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,C4L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3DU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L($-U<G)E;G0@3&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S(V+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,C,P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=&]C:VAO;&1E<G,G($1E9FEC:70Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:R`M("0P+C`P,2!P87(@=F%L=64[(#$U+#`P,"PP,#`@<VAA
M<F5S(&%U=&AO<FEZ960Z(%-E<FEE<R!#("T@.38L,C,P(&%N9"`Y-BPR,S`@
M<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P
M+"`R,#$R(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@<F5S<&5C=&EV96QY/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I
M97,@2"`M(#(U+#`P,"!A;F0@,C4L,#`P('-H87)E<R!I<W-U960@86YD(&]U
M='-T86YD:6YG(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,B!A;F0@1&5C96UB97(@
M,S$L(#(P,3$L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-E<FEE<R!)("T@,2PV-C8L-C8W(&%N9"`Q+#8V-BPV
M-C<@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R
M(#,P+"`R,#$R(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@<F5S<&5C=&EV96QY
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VL@+2`D,"XP,#$@<&%R('9A;'5E.R`V,#`L,#`P+#`P,"!S
M:&%R97,@875T:&]R:7IE9#L@-#4W+#(P-RPS,3,@86YD(#(V.2PR.3DL.#,X
M('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%T(%-E<'1E;6)E<B`S
M,"P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$L(')E<W!E8W1I=F5L>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4W+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V.2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,2PV,S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@L-#(R+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T
M960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#@L
M,C`U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@X,RPW.34L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36EN;W)I='D@:6YT97)E<W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R-RPP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(%-T
M;V-K:&]L9&5R<R<@1&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-BPR,S@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#4L,3`Q+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y43U1!3"!,24%"24Q)5$E%
M4R!!3D0@4U1/0TM(3TQ$15)3)R!$149)0TE4/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#@X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(Y+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q
M7SDT-F1?.&(P.#<U9F(T860U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K
M<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$34%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H4&%R
M96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!,:6%B
M:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5M86YD(&YO=&5S('!A>6%B;&4L(&YE="!O9B!D:7-C;W5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE(&1E8F5N='5R97,L(&YE="!O9B!D:7-C;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@1&5F:6-I=#H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F5F97)R960@<W1O8VLL($%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0R`M
M(%!R969E<G)E9"!S=&]C:RP@:7-S=65D('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.38L,C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38L,C,P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0R`M(%!R
M969E<G)E9"!S=&]C:RP@;W5T<W1A;F1I;F<@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY-BPR,S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-BPR,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!(("T@
M4')E9F5R<F5D('-T;V-K+"!I<W-U960@<VAA<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!(("T@4')E
M9F5R<F5D('-T;V-K+"!O=71S=&%N9&EN9R!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($D@+2!0
M<F5F97)R960@<W1O8VLL(&ES<W5E9"!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C8V+#8V-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C8V+#8V-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($D@
M+2!0<F5F97)R960@<W1O8VLL(&]U='-T86YD:6YG('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-C8L-C8W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-C8L-C8W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@075T:&]R
M:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!)<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0U-RPR,#<L,S$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8Y+#(Y.2PX,S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0U-RPR,#<L,S$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8Y+#(Y.2PX,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0U8F9C9C4X7V4Y9CA?
M-&8U,5\Y-#9D7SAB,#@W-69B-&%D-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4O
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2%)!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/
M<&5R871I;VYS("A5;F%U9&ET960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E)E=F5N=64Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V1U8W0@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R,RPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(S+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&EC96YS92!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1/5$%,(%)%5D5.544\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,RPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@
M;V8@4')O9'5C="!2979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0X+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S('!R;V9I="`H
M;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L
M,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDP+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG($5X<&5N<V5S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V5L;&EN9RP@9V5N97)A;"!A;F0@861M
M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-#,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4S-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#@V-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@P-BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R
M871I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-#,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4S-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#@V-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@U-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O
M;2!/<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#,U,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-30Q+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R+#<W-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPX.#`L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E
M(&EN('9A;'5E(&]F('=A<G)A;G0@86YD(&1E<FEV871I=F4@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.#$L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4X
M+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW.#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E+VEN8V]M93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C4L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q-RPP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS,#4L
M,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0V-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@3W1H97(@26YC;VUE("A%>'!E;G-E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C4L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V-"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#8V,RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S$X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&]S<R!B969O<F4@;6EN;W)I='D@:6YT97)E
M<W0@86YD('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0Q-2PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PT,S@L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUI;F]R:71Y(&EN=&5R97-T(&EN('-U8G-I9&EA<GD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR."PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@
M*&QO<W,I(&)E9F]R92!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT,#`L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L
M-#$P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#4V,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!G
M86EN("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q
M+#0P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#0L-#$P+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(L-38R+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO
M<W,@4&5R(%-H87)E("T@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!!=F5R86=E(%-H87)E<R!/=71S=&%N9&EN9R`M(&)A<VEC(&%N9"!D
M:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3<L-34S
M+#(V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(Q,RPU,3$L-34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S,V+#@R-"PW,3(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#,L,#,X+#$T,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#5B9F-F-3A?93EF
M.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D
M-2]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)44)'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G0@;V8@
M4W1O8VMH;VQD97)S)R!$969I8VET("A5;F%U9&ET960I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4')E9F5R
M<F5D(%-T;V-K/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O
M;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!
M9&1I=&EO;F%L(%!A:60M26X@0V%P:71A;#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!8V-U;75L871E9"!$969I8VET/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC92P@
M06UO=6YT(&%T($1E8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$T.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<T+#0W-"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#@P+#`Y
M-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC92P@4VAA<F5S(&%T($1E8RX@,S$L
M(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S@W+#@Y
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$T.2PU-S$L.3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#<L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VL@9F]R('-E<G9I8V5S+"!!;6]U;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S4U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!S97)V:6-E<RP@4VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PR,3`L-#DX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S
M:6]N(&]F(&1E8G0L($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PR.#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(&1E8G0L(%-H
M87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<L-S,T+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V4@;V8@=V%R<F%N=',L($%M;W5N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!W87)R86YT
M<RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPW
M.#,L,S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPW,#`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N8V4L($%M;W5N="!A="!$96,N
M(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW."PT,C(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.#,L-SDU+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E
M+"!3:&%R97,@870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PW.#<L.#DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C8Y+#(Y.2PX,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8Y.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<V5R=FEC
M97,L($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S4T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!S97)V
M:6-E<RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-RPX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(&1E8G0L($%M;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#,X+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R<VEO;B!O9B!D96)T+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$V,"PQ,#<L-#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-"PT,3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N8V4L
M($%M;W5N="!A="!397`N(#,P+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T-3<L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,2PV,S0L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X."PR
M,#4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YD:6YG(&)A;&%N8V4L(%-H87)E<R!A="!397`N(#,P+"`R
M,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<X-RPX.3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-3<L,C`W+#,Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U
M,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$555T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED
M871E9"!3=&%T96UE;G1S(&]F($-A<V@@1FQO=W,@*%5N875D:71E9"D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($]015)!5$E.1R!!0U1)5DE42453
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T+#0Q
M,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@R+#4V,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E
M8V]N8VEL92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN
M9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@:6YT86YG:6)L92!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VL@8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&]P=&EO;G,@86YD('=A
M<G)A;G1S(&ES<W5E9"!T;R!E;7!L;WEE97,@86YD(&YO;BUE;7!L;WEE97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y.2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C8L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!S:&%R97,@9F]R('-E<G9I8V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW.#(L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU.3<L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ
M871I;VX@;V8@9&5B="!D:7-C;W5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!V86QU92!O9B!W
M87)R86YT(&%N9"!D97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-38L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S@S+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV
M96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<U
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-C<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T
M:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S<S+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V,SDL,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@1DE.04Y#24Y'
M($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&5X97)C:7-E(&]F(&]P=&EO
M;G,@86YD('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&YO=&5S('!A>6%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q-2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,C$L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!A
M>6UE;G0@;V8@;F]T92!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N
M8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3@U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36EN;W)I='D@26YT97)E<W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-RPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($1%0U)%05-%
M($E.($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,Q+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-"PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#05-(($%.1"!#05-(
M($5154E604Q%3E13("T@0F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#05-(($%.1"!#
M05-(($5154E604Q%3E13("T@16YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0U8F9C9C4X7V4Y9CA?-&8U,5\Y
M-#9D7SAB,#@W-69B-&%D-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4O5V]R:W-H
M965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^3F]T92`Q("T@5&AE($-O;7!A;GD@86YD(%-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO
M;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA
M;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92`Q("T@5&AE($-O;7!A;GD@86YD
M(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R
M9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
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M86QA;F-E(&ES(&QO<W0N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GDF(S$T-CMS
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M8V]M<&]U;F0L($PM17)G;W1H:6]N96EN92`H)B,Q-#<[15)'3R8C,30X.RDL
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M<RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY);B`Q.38U+"!T:&4-"F-O<G!O<F%T92!P<F5D96-E<W-O<B!O
M9B!/6$E3+"!$:6%G;F]S=&EC($1A=&$L($EN8RX@=V%S(&EN8V]R<&]R871E
M9"!I;B!T:&4@4W1A=&4@;V8@0V%L:69O<FYI82X@1&EA9VYO<W1I8R!$871A
M(&-H86YG960@:71S#0II;F-O<G!O<F%T:6]N('1O('1H92!3=&%T92!O9B!$
M96QA=V%R92!I;B`Q.3<R.R!A;F0@8VAA;F=E9"!I=',@;F%M92!T;R!$1$D@
M4&AA<FUA8V5U=&EC86QS+"!);F,N(&EN(#$Y.#4N($EN(#$Y.30L($1$22!0
M:&%R;6%C975T:6-A;',-"FUE<F=E9"!W:71H($EN=&5R;F%T:6]N86P@0FEO
M0VQI;FEC86PL($EN8RX@86YD($)I;WAY=&5C:"!3+D$N(&%N9"!C:&%N9V5D
M(&ET<R!N86UE('1O($]825,@26YT97)N871I;VYA;"P@26YC+CPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D=O
M:6YG($-O;F-E<FX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY!<R!S:&]W;B!I;@T*=&AE(&%C8V]M<&%N>6EN
M9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',L('1H92!#;VUP
M86YY(&AA<R!I;F-U<G)E9"!A;B!A8V-U;75L871E9"!D969I8VET(&]F("0X
M."PR,#4L,#`P('1H<F]U9V@@4V5P=&5M8F5R#0HS,"P@,C`Q,BXF(S$V,#LF
M(S$V,#M/;B!A(&-O;G-O;&ED871E9"!B87-I<RP@=&AE($-O;7!A;GD@:&%D
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@;V8@)#8Q+#`P,"!A="!397!T
M96UB97(@,S`L(#(P,3(N(%1H90T*0V]M<&%N>2=S('!L86X@:7,@=&\@<F%I
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M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^5&AE(&-U<G)E;G0-"G)A=&4@;V8@8V%S:"!U<V%G92!R86ES97,@
M<W5B<W1A;G1I86P@9&]U8G0@86)O=70@=&AE($-O;7!A;GDF(S$T-CMS(&%B
M:6QI='D@=&\@8V]N=&EN=64@87,@82!G;VEN9R!C;VYC97)N+"!A8G-E;G0@
M86YY('-O=7)C97,-"F]F('-I9VYI9FEC86YT(&-A<V@@9FQO=W,N)B,Q-C`[
M)B,Q-C`[26X@86X@969F;W)T('1O(&UI=&EG871E('1H:7,@;F5A<BUT97)M
M(&-O;F-E<FX@=&AE($-O;7!A;GD@:6YT96YD<R!T;R!S965K(&%D9&ET:6]N
M86P@97%U:71Y#0IO<B!D96)T(&9I;F%N8VEN9R!T;R!O8G1A:6X@<W5F9FEC
M:65N="!F=6YD<R!T;R!S=7-T86EN(&]P97)A=&EO;G,N)B,Q-C`[)B,Q-C`[
M5&AE($-O;7!A;GD@<&QA;G,@=&\@:6YC<F5A<V4@<F5V96YU97,@8GD@:6YT
M<F]D=6-I;F<-"FYE=R!N=71R86-E=71I8V%L('!R;V1U8W1S('!R:6UA<FEL
M>2!B87-E9"!O;B!I=',@97)G;W1H:6]N96EN92!A<W-E=',N)B,Q-C`[)B,Q
M-C`[2&]W979E<BP@=&AE($-O;7!A;GD@8V%N;F]T('!R;W9I9&4@87-S=7)A
M;F-E#0IT:&%T(&ET('=I;&P@<W5C8V5S<V9U;&QY(&]B=&%I;B!E<75I='D@
M;W(@9&5B="!O<B!O=&AE<B!F:6YA;F-I;F<L(&EF(&%N>2P@<W5F9FEC:65N
M="!T;R!F:6YA;F-E(&ET<R!G;V%L<R!O<B!T:&%T('1H92!#;VUP86YY#0IW
M:6QL(&=E;F5R871E(&9U='5R92!P<F]D=6-T(')E;&%T960@<F5V96YU97,N
M)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GDF(S$T-CMS(&9I;F%N8VEA;"!S=&%T
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M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY5<V4@;V8@17-T:6UA=&5S/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M5&AE(&9I;F%N8VEA;`T*<W1A=&5M96YT<R!A;F0@;F]T97,@87)E(')E<')E
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M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY2979E;G5E
M(%)E8V]G;FET:6]N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/'4^4')O9'5C=`T*4F5V96YU93PO=3X\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
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M<F]D=6-T<R!W:6QL(&)E(')E8V]G;FEZ960L(&YE=`T*;V8@86QL;W=A;F-E
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M;W=A;F-E<R!A<F4@8V%L8W5L871E9"!B87-E9`T*=7!O;B!H:7-T;W)I8V%L
M(&1A=&$L(&-U<G)E;G0@96-O;F]M:6,@8V]N9&ET:6]N<R!A;F0@=&AE('5N
M9&5R;'EI;F<@8V]N=')A8W1U86P@=&5R;7,N/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/'4^3&EC96YS90T*
M4F5V96YU93PO=3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
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M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
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M9WDL(')I9VAT+`T*<')O9'5C="!O<B!S97)V:6-E(&-O;G9E>65D(&EN(&-O
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M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
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M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY396=M96YT(%)E<&]R=&EN9SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H92!#;VUP86YY#0IO<&5R
M871E<R!I;B!O;F4@<F5P;W)T86)L92!S96=M96YT+CPO9F]N=#X\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-T;V-K($)A
M<V5D#0I#;VUP96YS871I;VX@=&\@16UP;&]Y965S/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE($-O;7!A
M;GD-"F%C8V]U;G1S(&9O<B!I=',@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M(&9O<B!E;7!L;WEE97,@:6X@86-C;W)D86YC92!W:71H($%C8V]U;G1I;F<@
M4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H)B,Q-#<[05-#)B,Q-#@[*0T*-S$X
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M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H
M92!#;VUP86YY#0IG<F%N=&5D('-T;V-K(&]P=&EO;G,@=&\@<'5R8VAA<V4@
M,C8L,S@T+#$Y,R!A;F0@,BPP-C8L-#DQ('-H87)E<R!O9B!T:&4@0V]M<&%N
M>28C,30V.W,@8V]M;6]N('-T;V-K('1O(&5M<&QO>65E<R!A;F0@9&ER96-T
M;W)S#0ID=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S
M,"P@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+B8C,38P.R8C,38P.U1H
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M:7-K+69R964@:6YT97)E<W0@<F%T92!O9B`Q+C`T)0T*=&\@,BXP-"4[(&EN
M:71I86P@97AP96-T960@;&EF92!O9B`U('1O(#$P('EE87)S.R!N;R!E>'!E
M8W1E9"!D:79I9&5N9"!Y:65L9#L@86YD(&%M;W)T:7IE9"!O=F5R('1H92!V
M97-T:6YG('!E<FEO9"!O9B!T>7!I8V%L;'D-"F]N92!T;R!F;W5R('EE87)S
M+B8C,38P.R8C,38P.U1H92!#;VUP86YY(')E<&]R=&5D(&%N(&5X<&5N<V4@
M9F]R('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!F;W(@:71S(&5M<&QO>65E
M<R!A;F0@9&ER96-T;W)S(&]F#0HD-CDY+#`P,"!A;F0@)#,P-RPP,#`@9F]R
M('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(@86YD
M(#(P,3$L(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-T;V-K($)A<V5D
M#0I#;VUP96YS871I;VX@=&\@3W1H97(@=&AA;B!%;7!L;WEE97,\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
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M(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV
M96QY+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D5A<FYI;F=S(%!E<@T*4VAA<F4\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
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M(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$R(&%N9"`R,#$Q+"!A;&P@:6YS
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M('-H87)E(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,B!T;W1A;&5D(#4S."PR.#4L
M.30S+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E)E8V5N="!!8V-O=6YT:6YG#0I0<F]N;W5N8V5M96YT<SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/DUA;F%G96UE;G0-"F1O97,@;F]T(&)E;&EE=F4@=&AA="!A;GD@<F5C
M96YT;'D@:7-S=65D+"!B=70@;F]T('EE="!E9F9E8W1I=F4@86-C;W5N=&EN
M9R!P<F]N;W5N8V5M96YT<RP@:68@861O<'1E9"P@=V]U;&0@:&%V92!A(&UA
M=&5R:6%L#0IE9F9E8W0@;VX@=&AE($-O;7!A;GDF(S$T-CMS(&9I;F%N8VEA
M;"!P;W-I=&EO;B!O<B!R97-U;'1S(&]F(&]P97)A=&EO;G,N/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F%I
M<B!686QU90T*365A<W5R96UE;G1S/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE(&-A<G)Y:6YG#0IA;6]U
M;G1S(')E<&]R=&5D(&EN('1H92!B86QA;F-E('-H965T<R!F;W(@<F5C96EV
M86)L97,@86YD(&-U<G)E;G0@;&EA8FEL:71I97,@96%C:"!Q=6%L:69Y(&%S
M(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!A;F0@87)E(&$-"G)E87-O;F%B;&4@
M97-T:6UA=&4@;V8@9F%I<B!V86QU92!B96-A=7-E(&]F('1H92!S:&]R="!P
M97)I;V0@;V8@=&EM92!B971W965N('1H92!O<FEG:6YA=&EO;B!O9B!S=6-H
M(&EN<W1R=6UE;G1S(&%N9"!T:&5I<B!E>'!E8W1E9`T*<F5A;&EZ871I;VX@
M86YD('1H96ER(&-U<G)E;G0@;6%R:V5T(')A=&4@;V8@:6YT97)E<W0N)B,Q
M-C`[(%1H92!T:')E92!L979E;',@87)E(&1E9FEN960@87,@9F]L;&]W<SH\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M-#AP>#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$X,SLF(S$V,#LF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQE
M=F5L(#$@:6YP=71S('1O#0H@("`@=&AE('9A;'5A=&EO;B!M971H;V1O;&]G
M>2!A<F4@<75O=&5D('!R:6-E<R`H=6YA9&IU<W1E9"D@9F]R(&ED96YT:6-A
M;"!A<W-E=',@;W(@;&EA8FEL:71I97,@:6X@86-T:79E(&UA<FME=',N(%1H
M92!#;VUP86YY)B,Q-#8[<PT*("`@($QE=F5L(#$@87-S971S(&EN8VQU9&4@
M8V%S:"!E<75I=F%L96YT<RP@<')I;6%R:6QY(&EN<W1I='5T:6]N86P@;6]N
M97D@;6%R:V5T(&9U;F1S+"!W:&]S92!C87)R>6EN9R!V86QU92!R97!R97-E
M;G1S(&9A:7(-"B`@("!V86QU92!B96-A=7-E(&]F('1H96ER('-H;W)T+71E
M<FT@;6%T=7)I=&EE<R!O9B!T:&4@:6YV97-T;65N=',@:&5L9"!B>2!T:&5S
M92!F=6YD<RX\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!X.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,3@S.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^3&5V96P@,B!I;G!U=',@=&\-"B`@("!T
M:&4@=F%L=6%T:6]N(&UE=&AO9&]L;V=Y(&EN8VQU9&4@<75O=&5D('!R:6-E
M<R!F;W(@<VEM:6QA<B!A<W-E=',@86YD(&QI86)I;&ET:65S(&EN(&%C=&EV
M92!M87)K971S+"!A;F0@:6YP=71S('1H870@87)E#0H@("`@;V)S97)V86)L
M92!F;W(@=&AE(&%S<V5T(&]R(&QI86)I;&ET>2P@96ET:&5R(&1I<F5C=&QY
M(&]R(&EN9&ER96-T;'DL(&9O<B!S=6)S=&%N=&EA;&QY('1H92!F=6QL('1E
M<FT@;V8@=&AE(&9I;F%N8VEA;"!I;G-T<G5M96YT+@T*("`@(%1H92!#;VUP
M86YY)B,Q-#8[<R!,979E;"`R(&QI86)I;&ET:65S(&-O;G-I<W0@;V8@='=O
M(&QI86)I;&ET:65S(&%R:7-I;F<@9G)O;2!T:&4@:7-S=6%N8V4@;V8@8V]N
M=F5R=&EB;&4@<V5C=7)I=&EE<R!A;F0-"B`@("!I;B!A8V-O<F1A;F-E('=I
M=&@@14E41B`P,"TQ.3H@82!W87)R86YT(&QI86)I;&ET>2!F;W(@9&5T86-H
M86)L92!W87)R86YT<RP@87,@=V5L;"!A<R!A;B!A8V-R=65D(&1E<FEV871I
M=F4@;&EA8FEL:71Y(&9O<@T*("`@('1H92!B96YE9FEC:6%L(&-O;G9E<G-I
M;VX@9F5A='5R92X@5&AE<V4@;&EA8FEL:71I97,@87)E(')E;65A<W5R960@
M;VX@82!Q=6%R=&5R;'D@8F%S:7,N($9A:7(@=F%L=64@:7,@9&5T97)M:6YE
M9"!U<VEN9R!T:&4-"B`@("!";&%C:RU38VAO;&5S('9A;'5A=&EO;B!M;V1E
M;"!B87-E9"!O;B!O8G-E<G9A8FQE(&UA<FME="!I;G!U=',L('-U8V@@87,@
M<VAA<F4@<')I8V4@9&%T82!A;F0@82!D:7-C;W5N="!R871E(&-O;G-I<W1E
M;G0@=VET:`T*("`@('1H870@;V8@82!G;W9E<FYM96YT+6ES<W5E9"!S96-U
M<FET>2!O9B!A('-I;6EL87(@;6%T=7)I='DN/"]F;VYT/CPO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-#AP
M>#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T
M97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$X,SLF(S$V,#LF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQE=F5L
M(#,@:6YP=71S('1O#0H@("`@=&AE('9A;'5A=&EO;B!M971H;V1O;&]G>2!A
M<F4@=6YO8G-E<G9A8FQE(&%N9"!S:6=N:69I8V%N="!T;R!T:&4@9F%I<B!V
M86QU92!M96%S=7)E;65N="X\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.R8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H
M92!F;VQL;W=I;F<-"G1A8FQE(')E<')E<V5N=',@=&AE($-O;7!A;GDF(S$T
M-CMS(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@8GD@;&5V96P@;65A<W5R960@
M870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!A="!397!T96UB
M97(-"C,P+"`R,#$R+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT86)L92!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4G
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^1&5S8W)I<'1I;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY,979E;`T*("`@(#$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3&5V96P-"B`@("`R
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/DQE=F5L#0H@("`@,SPO9F]N=#X\+W1D/@T*("`@(#QT
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M+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
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M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!<W-E=',\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C0E.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$U,3L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$U,3L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$U,3L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^3&EA8FEL:71I97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5V%R<F%N="!L:6%B:6QI='D\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-3$T+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H-"@T*/'`@<W1Y;&4],T0G;6%R9VEN
M.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U,5\Y
M-#9D7SAB,#@W-69B-&%D-2]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#(@+2!0871E
M;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3F]T97,@=&\@1FEN86YC:6%L(%-T871E;65N=',\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92`R("T@4&%T
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('=I9'1H.B`Q,#`E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY397!T96UB97(-"B`@("`S,"P@,C`Q,CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!C96YT
M97(G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^1&5C96UB97(-"B`@("`S,2P@,C`Q,3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M-S8E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^0V%P:71A;&EZ960-"B`@("!P871E;G0@8V]S=',\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXV-#`L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXV-#`L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!8V-U;75L871E9`T*
M("`@(&%M;W)T:7IA=&EO;CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B@V,C4L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X
M="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#8Q-2PP,#`\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`S<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ-2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`S<'0[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#-P=#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-2PP,#`\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`S<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/"]T
M86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E!E
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M=F5L;W!M96YT('-T<F%T96=Y+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H92!F;VQL;W=I;F<-"G1A8FQE
M('!R97-E;G1S(&5X<&5C=&5D(&9U='5R92!A;6]R=&EZ871I;VX@;V8@<&%T
M96YT(&-O<W1S(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q('1H870@;6%Y(&-H
M86YG92!A8V-O<F1I;F<@=&\@=&AE($-O;7!A;GDG<PT*86UO<G1I>F%T:6]N
M('!O;&EC>2!U<&]N(&%D9&ET:6]N86P@<&%T96YT<R!B96EN9R!I<W-U960@
M;W(@86QL;W=E9#H\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E)SX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@.#0E
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,C`Q,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q-"4[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,3(L,#`P/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3,\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-"PP,#`\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$T/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0L
M,#`P/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C(P,34\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-"PP,#`\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXR,#$V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L,#`P/"]F;VYT/CPO=&0^/"]T
M<CX-"CPO=&%B;&4^#0H-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]P/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#5B9F-F
M-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W
M-69B-&%D-2]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#,@+2!$96)T/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B="!$
M:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]T92`S("T@1&5B=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY#;VYV97)T:6)L90T*9&5B96YT=7)E<SPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]N($]C
M=&]B97(-"C(U+"`R,#`V+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!S
M96-U<FET:65S('!U<F-H87-E(&%G<F5E;65N="`H)B,Q-#<[,C`P-B!0=7)C
M:&%S92!!9W)E96UE;G0F(S$T.#LI('=I=&@@9F]U<B!A8V-R961I=&5D#0II
M;G9E<W1O<G,@*'1H92`F(S$T-SLR,#`V(%!U<F-H87-E<G,F(S$T.#LI+B!)
M;B!C;VYJ=6YC=&EO;B!W:71H('1H92!S:6=N:6YG(&]F('1H92`R,#`V(%!U
M<F-H87-E($%G<F5E;65N="P@=&AE($-O;7!A;GD@:7-S=65D#0IS96-U<F5D
M(&-O;G9E<G1I8FQE(&1E8F5N='5R97,@*"8C,30W.S(P,#8@1&5B96YT=7)E
M<R8C,30X.RD@86YD(%-E<FEE<R!!+"!"+"!#+"!$+"!A;F0@12!C;VUM;VX@
M<W1O8VL@=V%R<F%N=',@*"8C,30W.S(P,#8-"E=A<G)A;G1S)B,Q-#@[*2!T
M;R!T:&4@,C`P-B!0=7)C:&%S97)S+"!A;F0@=&AE('!A<G1I97,@86QS;R!E
M;G1E<F5D(&EN=&\@82!S96-U<FET>2!A9W)E96UE;G0@*'1H92`F(S$T-SLR
M,#`V(%-E8W5R:71Y($%G<F5E;65N="8C,30X.RD-"G!U<G-U86YT('1O('=H
M:6-H('1H92!#;VUP86YY(&%G<F5E9"!T;R!G<F%N="!T:&4@,C`P-B!0=7)C
M:&%S97)S+"!P87)I('!A<W-U+"!A('-E8W5R:71Y(&EN=&5R97-T(&EN('-U
M8G-T86YT:6%L;'D@86QL(&]F('1H90T*0V]M<&%N>28C,30V.W,@87-S971S
M+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E!U<G-U86YT('1O#0IT:&4@=&5R;7,@;V8@=&AE(#(P
M,#8@4'5R8VAA<V4@06=R965M96YT+"!T:&4@0V]M<&%N>2!I<W-U960@=&AE
M(#(P,#8@1&5B96YT=7)E<R!I;B!A;B!A9V=R96=A=&4@<')I;F-I<&%L(&%M
M;W5N="!O9B`D,2PV.30L,C4P#0IT;R!T:&4@,C`P-B!0=7)C:&%S97)S+B!4
M:&4@,C`P-B!$96)E;G1U<F5S(&%R92!S=6)J96-T('1O(&%N(&]R:6=I;F%L
M(&ES<W5E(&1I<V-O=6YT(&]F(#(P+C,Q."4@<F5S=6QT:6YG(&EN('!R;V-E
M961S('1O('1H90T*0V]M<&%N>2!O9B`D,2PS-3`L,#`P(&9R;VT@=&AE('1R
M86YS86-T:6]N+B!4:&4@,C`P-B!$96)E;G1U<F5S('=E<F4@9'5E(&]N($]C
M=&]B97(@,C4L(#(P,#@N(%1H92`R,#`V($1E8F5N='5R97,@87)E(&-O;G9E
M<G1I8FQE+`T*870@=&AE(&]P=&EO;B!O9B!T:&4@,C`P-B!0=7)C:&%S97)S
M+"!A="!A;GD@=&EM92!P<FEO<B!T;R!P87EM96YT(&EN(&9U;&PL(&EN=&\@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!T:&4@0V]M<&%N>2X@07,@82!R
M97-U;'0-"F]F('1H92!F=6QL(')A=&-H970@86YT:2UD:6QU=&EO;B!P<F]V
M:7-I;VX@=&AE(&-U<G)E;G0@8V]N=F5R<VEO;B!P<FEC92!I<R`D,"XP,2!P
M97(@<VAA<F4@*'1H92`F(S$T-SLR,#`V($-O;G9E<G-I;VX@4')I8V4F(S$T
M.#LI+@T*0F5G:6YN:6YG(&]N('1H92!F:7)S="!O9B!T:&4@;6]N=&@@8F5G
M:6YN:6YG($9E8G)U87)Y(#$L(#(P,#<L('1H92!#;VUP86YY('=A<R!R97%U
M:7)E9"!T;R!A;6]R=&EZ92!T:&4@,C`P-B!$96)E;G1U<F5S(&EN(&5Q=6%L
M#0II;G-T86QL;65N=',@;VX@82!M;VYT:&QY(&)A<VES(')E<W5L=&EN9R!I
M;B!A(&-O;7!L971E(')E<&%Y;65N="!B>2!T:&4@;6%T=7)I='D@9&%T92`H
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M=F5R86=E('!R:6-E(&9O<B!T:&4@,3`M=')A9&EN9R!D87ES('!R:6]R('1O
M('1H92!D=64@9&%T92!O9B!T:&4@36]N=&AL>0T*4F5D96UP=&EO;B!!;6]U
M;G0N(%1H92!#;VUP86YY(&1I9"!N;W0@;6%K92!A;GD@;V8@=&AE(')E<75I
M<F5D(&UO;G1H;'D@<F5D96UP=&EO;B!P87EM96YT<RX\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY0=7)S=6%N
M="!T;PT*=&AE('!R;W9I<VEO;G,@;V8@=&AE(#(P,#8@1&5B96YT=7)E<RP@
M<W5C:"!N;VXM<&%Y;65N="!W87,@86X@979E;G0@;V8@9&5F875L="!A;F0@
M<&5N86QT>2!I;G1E<F5S="!H87,@86-C<G5E9"!O;B!T:&4@=6YP86ED#0IR
M961E;7!T:6]N(&)A;&%N8V4@870@86X@:6YT97)E<W0@<F%T92!E<75A;"!T
M;R!T:&4@;&]W97(@;V8@,3@E('!E<B!A;FYU;2!A;F0@=&AE(&UA>&EM=6T@
M<F%T92!P97)M:71T960@8GD@87!P;&EC86)L92!L87<N($EN#0IA9&1I=&EO
M;BP@96%C:"!O9B!T:&4@,C`P-B!0=7)C:&%S97)S(&AA<R!T:&4@<FEG:'0@
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M<R!P=7)S=6%N="!T;R!T:&4@<')O=FES:6]N<R!O9B!T:&4@,C`P-B!396-U
M<FET>2!!9W)E96UE;G0@=&\@<V%T:7-F>2!A;GD@<W5C:"!U;G!A:60@8F%L
M86YC92X@3VX@2G5N92`V+"`R,#`X+"!T:&4@0V]M<&%N>0T*<F5C96EV960@
M;F]T:69I8V%T:6]N(&9R;VT@0G)I<W1O;"!);G9E<W1M96YT($9U;F0L($QT
M9"`H)B,Q-#<[0G)I<W1O;"8C,30X.RDL('1H870@=&AE(&-O;&QA=&5R86P@
M:&5L9"!U;F1E<B!T:&4@,C`P-B!396-U<FET>0T*06=R965M96YT('=O=6QD
M(&)E('-O;&0@=&\@=&AE(&AI9VAE<W0@<75A;&EF:65D(&)I9&1E<B!O;B!4
M:'5R<V1A>2P@2G5N92`Q.2P@,C`P."X@3VX@2G5N92`Q.2P@,C`P."P@=&AE
M($-O;7!A;GD@<F5C96EV960@82!.;W1I8V4-"F]F($1I<W!O<VET:6]N(&]F
M($-O;&QA=&5R86P@9G)O;2!"<FES=&]L(&EN('=H:6-H($)R:7-T;VP@;F]T
M:69I960@=&AE($-O;7!A;GD@=&AA="!"<FES=&]L+"!A8W1I;F<@87,@=&AE
M(&%G96YT(&9O<B!I='-E;&8@86YD#0IT:&4@=&AR964@;W1H97(@,C`P-B!0
M=7)C:&%S97)S+"!P=7)C:&%S960@8V5R=&%I;B!A<W-E=',@:&5L9"!A<R!C
M;VQL871E<F%L('5N9&5R('1H92`R,#`V(%-E8W5R:71Y($%G<F5E;65N="X@
M0G)I<W1O;"!P=7)C:&%S960-"C$Q,2PP,C4@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!O9B!":6]#:&5C:RP@26YC+BP@=&AE($-O;7!A;GDF(S$T-CMS(&UA
M:F]R:71Y(&]W;F5D('-U8G-I9&EA<GDL(&]N(&$@8W)E9&ET(&)I9"!O9B`D
M-3`L,#`P+"!A;F0-"D)R:7-T;VP@86QS;R!P=7)C:&%S960@,2PP,#`@<VAA
M<F5S(&]F('1H92!C87!I=&%L('-T;V-K(&]F($]825,@5&AE<F%P975T:6-S
M+"!);F,N+"!A('=H;VQL>2!O=VYE9"!S=6)S:61I87)Y(&]F($]825,L(&9O
M<B!A#0IC<F5D:70@8FED(&]F("0Q,"PP,#`N($EN($1E8V5M8F5R(#(P,#4L
M($]825,@<'5R8VAA<V5D('1H92`Q,3$L,#(U('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@;V8@0FEO0VAE8VLL($EN8RX@9F]R("0S+#`V,"PP,#`N($%F=&5R
M#0IC<F5D:71I;F<@=&AE(&%G9W)E9V%T92!A;6]U;G0@;V8@)#8P+#`P,"!T
M;R!T:&4@86=G<F5G871E(&%M;W5N="!D=64@=6YD97(@=&AE(#(P,#8@1&5B
M96YT=7)E<RP@<&QU<R!F965S(&%N9"!C:&%R9V5S(&1U92!T:')O=6=H#0I*
M=6YE(#$Y+"`R,#`X+"!"<FES=&]L(&YO=&EF:65D('1H92!#;VUP86YY('1H
M870@=&AE($-O;7!A;GD@<F5M86EN<R!O8FQI9V%T960@=&\@=&AE(#(P,#8@
M4'5R8VAA<V5R<R!I;B!A(&1E9FEC:65N8WD@:6X@86X@86=G<F5G871E#0IA
M;6]U;G0@;V8@)#(L-C@X+#`P,"!A<R!O9B!*=6YE(#$Y+"`R,#`X+B!!<R!A
M(')E<W5L="!O9B!T:&4@9&ES<&]S:71I;VX@;V8@=&AE(&-O;&QA=&5R86PL
M('1H92!#;VUP86YY(')E8V]R9&5D(&$@;F5T(&QO<W,@86=G<F5G871I;F<-
M"B0R+#DW."PP,#`N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^56YD97(@=&AE#0HR,#`V(%!U<F-H87-E($%G
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M=&EO;B!U;G1I;"!S=6-H('1I;64@87,@;F\@,C`P-B!0=7)C:&%S97(@:&]L
M9',@86YY(&]F('1H90T*,C`P-B!$96)E;G1U<F5S+B!&=7)T:&5R;6]R92P@
M<V\@;&]N9R!A<R!A;GD@,C`P-B!0=7)C:&%S97(@:&]L9',@86YY(&]F('1H
M92!S96-U<FET:65S(&ES<W5E9"!U;F1E<B!T:&4@,C`P-B!0=7)C:&%S92!!
M9W)E96UE;G0L#0II9B!T:&4@0V]M<&%N>2!I<W-U97,@;W(@<V5L;',@86YY
M(&-O;6UO;B!S=&]C:R!O<B!I;G-T<G5M96YT<R!C;VYV97)T:6)L92!I;G1O
M(&-O;6UO;B!S=&]C:R!W:&EC:"!A(#(P,#8@4'5R8VAA<V5R(')E87-O;F%B
M;'D-"F)E;&EE=F5S(&ES(&]N('1E<FUS(&UO<F4@9F%V;W)A8FQE('1O('-U
M8V@@:6YV97-T;W)S('1H86X@=&AE('1E<FUS('!U<G-U86YT('1O('1H92`R
M,#`V($1E8F5N='5R97,@;W(@,C`P-B!787)R86YT<RP@=&AE($-O;7!A;GD-
M"FES(&]B;&EG871E9"!T;R!P97)M:70@<W5C:"`R,#`V(%!U<F-H87-E<B!T
M:&4@8F5N969I=',@;V8@<W5C:"!B971T97(@=&5R;7,N/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3V8@=&AE
M(#(P,#8-"E=A<G)A;G1S(&ES<W5E9"!B>2!T:&4@0V]M<&%N>2!T;R!T:&4@
M,C`P-B!0=7)C:&%S97)S+"!O;FQY('1H92!397)I97,@02!787)R86YT<R!R
M96UA:6X@;W5T<W1A;F1I;F<N(%1H92!397)I97,@02!787)R86YT<RP@=VAI
M8V@-"FYO=R!E>'!I<F4@:6X@3V-T;V)E<B`R,#$T+"!P97)M:70@=&AE(&AO
M;&1E<G,@=&\@<'5R8VAA<V4@,BPT,C`L,S4W('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@870@86X@;W)I9VEN86P@97AE<F-I<V4@<')I8V4@;V8@)#`N,S4-
M"G!E<B!S:&%R92X@4W5C:"!E>&5R8VES92!P<FEC92!I<R!A9&IU<W1A8FQE
M('!U<G-U86YT('1O(&$@9G5L;"!R871C:&5T(&%N=&DM9&EL=71I;VX@<')O
M=FES:6]N(&%N9"!U<&]N('1H92!O8V-U<G)E;F-E(&]F(&$@<W1O8VL-"G-P
M;&ET(&]R(&$@<F5L871E9"!E=F5N="X\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$=7)I;F<@,C`P.2P-"D)R
M:7-T;VP@8V]N=F5R=&5D("0Q-S<L.3`P(&]F('1H92!P<FEN8VEP86P@86UO
M=6YT(&]F(#(P,#8@1&5B96YT=7)E<R!F;W(@,3<L-SDP+#`P,"!S:&%R97,@
M;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:RX-"D1U<FEN9R`R
M,#$P+"!"<FES=&]L(&-O;G9E<G1E9"!A;B!A9&1I=&EO;F%L("0T,#$L,#`P
M(&]F('1H92!P<FEN8VEP86P@86UO=6YT(&]F(#(P,#8@1&5B96YT=7)E<R!F
M;W(@-#`L,3`P+#`P,"!S:&%R97,@;V8@=&AE#0I#;VUP86YY)B,Q-#8[<R!C
M;VUM;VX@<W1O8VLN($1U<FEN9R`R,#$Q+"!A;B!A9&1I=&EO;F%L("0V,#4L
M,#`P(&]F('1H92!P<FEN8VEP86P@86UO=6YT(&]F(#(P,#8@1&5B96YT=7)E
M<R!W87,@8V]N=F5R=&5D(&EN=&\-"C8P+#4P,"PP,#`@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VLN($]F('1H92`D-C`U+#`P
M,"!C;VYV97)T960@:6X@,C`Q,2P@)#4S+#$R-2!W87,@8V]N=F5R=&5D(&EN
M=&\@-2PS,3(L-3`P#0IS:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O
M;6UO;B!S=&]C:R!D=7)I;F<@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,2X@
M1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P
M,3(L#0IA;B!A9&1I=&EO;F%L("0S-S(L,#`P(&]F('1H92!P<FEN8VEP86P@
M86UO=6YT(&]F(#(P,#8@1&5B96YT=7)E<R!W87,@8V]N=F5R=&5D(&EN=&\@
M,S<L,C`P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS#0IC;VUM
M;VX@<W1O8VLN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY4:&4@,C`P-B!$96)E;G1U<F5S#0ID;R!N;W0@
M;65E="!T:&4@9&5F:6YI=&EO;B!O9B!A("8C,30W.V-O;G9E;G1I;VYA;"!C
M;VYV97)T:6)L92!D96)T(&EN<W1R=6UE;G0F(S$T.#L@<VEN8V4@=&AE>2!A
M<F4@;F]T(&-O;G9E<G1I8FQE(&EN=&\@82!F:7AE9`T*;G5M8F5R(&]F('-H
M87)E<RX@5&AE($UO;G1H;'D@4F5D96UP=&EO;B!!;6]U;G1S(&-A;B!B92!P
M86ED('=I=&@@8V]M;6]N('-T;V-K(&%T(&$@8V]N=F5R<VEO;B!P<FEC92!T
M:&%T(&ES(&$@<&5R8V5N=&%G92!O9B!T:&4-"FUA<FME="!P<FEC93L@=&AE
M<F5F;W)E('1H92!N=6UB97(@;V8@<VAA<F5S('1H870@8V]U;&0@8F4@<F5Q
M=6ER960@=&\@8F4@9&5L:79E<F5D('5P;VX@)B,Q-#<[;F5T+7-H87)E('-E
M='1L96UE;G0F(S$T.#L@:7,-"F5S<V5N=&EA;&QY(&EN9&5T97)M:6YA=&4N
M(%1H97)E9F]R92P@=&AE(#(P,#8@1&5B96YT=7)E<R!A<F4@8V]N<VED97)E
M9"`F(S$T-SMN;VXM8V]N=F5N=&EO;F%L+"8C,30X.R!W:&EC:"!M96%N<R!T
M:&%T('1H90T*8V]N=F5R<VEO;B!F96%T=7)E(&UU<W0@8F4@8FEF=7)C871E
M9"!F<F]M('1H92!D96)T(&%N9"!S:&]W;B!A<R!A('-E<&%R871E(&1E<FEV
M871I=F4@;&EA8FEL:71Y+B!4:&ES(&)E;F5F:6-I86P@8V]N=F5R<VEO;B!L
M:6%B:6QI='D-"FAA<R!B965N(&-A;&-U;&%T960@=&\@8F4@)#8Y,"PP,#`@
M;VX@3V-T;V)E<B`R-2P@,C`P-BX@26X@861D:71I;VXL('-I;F-E('1H92`R
M,#`V($1E8F5N='5R97,@87)E(&-O;G9E<G1I8FQE(&EN=&\@86X@:6YD971E
M<FUI;F%T90T*;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL(&ET
M(&ES(&%S<W5M960@=&AA="!T:&4@0V]M<&%N>2!C;W5L9"!N979E<B!H879E
M(&5N;W5G:"!A=71H;W)I>F5D(&%N9"!U;FES<W5E9"!S:&%R97,@=&\@<V5T
M=&QE#0IT:&4@8V]N=F5R<VEO;B!O9B!T:&4@,C`P-B!787)R86YT<R!I<W-U
M97,@:6X@=&AI<R!T<F%N<V%C=&EO;B!I;G1O(&-O;6UO;B!S=&]C:RX@5&AE
M<F5F;W)E+"!T:&4@,C`P-B!787)R86YT<R!H879E(&$@9F%I<B!V86QU90T*
M;V8@)#(L,S,T+#`P,"!A="!/8W1O8F5R(#(U+"`R,#`V+B!4:&4@=F%L=64@
M;V8@=&AE(#(P,#8@5V%R<F%N="!W87,@8V%L8W5L871E9"!U<VEN9R!T:&4@
M0FQA8VLM4V-H;VQE<R!M;V1E;"!U<VEN9R!T:&4@9F]L;&]W:6YG#0IA<W-U
M;7!T:6]N<SH@1&ES8V]U;G0@<F%T92!O9B`T+C4E+"!V;VQA=&EL:71Y(&]F
M(#$U."4@86YD(&5X<&5C=&5D('1E<FT@;V8@,2!T;R`V('EE87)S+B!4:&4@
M9F%I<B!V86QU92!O9B!T:&4@8F5N969I8VEA;"!C;VYV97)S:6]N#0IF96%T
M=7)E(&%N9"!T:&4@,C`P-B!787)R86YT(&QI86)I;&ET>2!W:6QL(&)E(&%D
M:G5S=&5D('1O(&9A:7(@=F%L=64@;VX@96%C:"!B86QA;F-E('-H965T(&1A
M=&4@=VET:"!T:&4@8VAA;F=E(&)E:6YG('-H;W=N(&%S#0IA(&-O;7!O;F5N
M="!O9B!N970@;&]S<RX@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&)E;F5F:6-I
M86P@8V]N=F5R<VEO;B!F96%T=7)E(&%N9"!T:&4@,C`P-B!787)R86YT<R!A
M="!T:&4@:6YC97!T:6]N(&]F('1H92`R,#`V#0I$96)E;G1U<F5S('=E<F4@
M)#8Y,"PP,#`@86YD("0R+#,S-"PP,#`L(')E<W!E8W1I=F5L>2X\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4
M:&4@9FER<W0-"B0Q+#,U,"PP,#`@;V8@=&AE<V4@9&ES8V]U;G1S(&AA<R!B
M965N('-H;W=N(&%S(&$@9&ES8V]U;G0@=&\@=&AE(#(P,#8@1&5B96YT=7)E
M<R!W:&EC:"!W:6QL(&)E(&%M;W)T:7IE9"!O=F5R('1H92!T97)M(&]F('1H
M90T*,C`P-B!$96)E;G1U<F4@86YD('1H92!E>&-E<W,@;V8@)#$L-C<T+#`P
M,"!H87,@8F5E;B!S:&]W;B!A<R!F:6YA;F-I;F<@8V]S=',@:6X@=&AE(&%C
M8V]M<&%N>6EN9R!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<RX\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!="!3
M97!T96UB97(-"C,P+"`R,#$R(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE
M($-O;7!A;GD@9&5T97)M:6YE9"!T:&4@9F%I<B!V86QU92!O9B!T:&4@,C`P
M-B!787)R86YT<R!W87,@)#<Y+#`P,"!A;F0@)#,Y+#`P,"P@<F5S<&5C=&EV
M96QY+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D]N($]C=&]B97(-"C$L(#(P,#DL('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!A(&9I;F%N8VEN9R!A<G)A;F=E;65N="!W:71H('-E=F5R
M86P@86-C<F5D:71E9"!I;G9E<W1O<G,@*'1H92`F(S$T-SLR,#`Y($EN=F5S
M=&]R<R8C,30X.RDL#0IP=7)S=6%N="!T;R!W:&EC:"!I="!S;VQD('9A<FEO
M=7,@<V5C=7)I=&EE<R!I;B!C;VYS:61E<F%T:6]N(&]F(&$@;6%X:6UU;2!A
M9V=R96=A=&4@<'5R8VAA<V4@<')I8V4@;V8@)#(L,#`P+#`P,"`H=&AE("8C
M,30W.S(P,#D-"D9I;F%N8VEN9R8C,30X.RDN($EN(&-O;FYE8W1I;VX@=VET
M:"!T:&4@,C`P.2!&:6YA;F-I;F<L('1H92!#;VUP86YY(&ES<W5E9"!T:&4@
M9F]L;&]W:6YG('-E8W5R:71I97,@=&\@=&AE(#(P,#D@26YV97-T;W)S.CPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T
M.'!X.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,30Y.R8C,38P.R8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"4@
M0V]N=F5R=&EB;&4@1&5B96YT=7)E<PT*("`@(&EN('1H92!P<FEN8VEP86P@
M86UO=6YT(&]F("0R+#`P,"PP,#`@9'5E(#(T(&UO;G1H<R!F<F]M('1H92!D
M871E(&]F(&ES<W5A;F-E("AT:&4@)B,Q-#<[(#(P,#D@1&5B96YT=7)E<R8C
M,30X.RDL(&-O;G9E<G1I8FQE#0H@("`@:6YT;R!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:R!A="!A('!E<B!S:&%R92!C;VYV
M97)S:6]N('!R:6-E(&5Q=6%L('1O("0P+C`U('!E<B!S:&%R93L\+V9O;G0^
M/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`T.'!X.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,30Y
M.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^4V5R:65S($$@=V%R<F%N=`T*("`@('1O('!U<F-H87-E('-U8V@@
M;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N
M('-T;V-K(&5Q=6%L('1O(#4P)2!O9B!T:&4@<')I;F-I<&%L(&%M;W5N="!I
M;G9E<W1E9"!B>2!E86-H#0H@("`@,C`P.2!);G9E<W1O<B`H=&AE("8C,30W
M.S(P,#D@0VQA<W,@02!787)R86YT<R8C,30X.R`I(')E<W5L=&EN9R!I;B!T
M:&4@:7-S=6%N8V4@;V8@0VQA<W,@02!787)R86YT<R!T;R!P=7)C:&%S92`R
M,"PP,#`L,#`P#0H@("`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!T:&4@
M0V]M<&%N>2X\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!X.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,30Y.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^4V5R:65S($(@=V%R<F%N=`T*("`@('1O
M('!U<F-H87-E('-U8V@@;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N
M>28C,30V.W,@8V]M;6]N('-T;V-K(&5Q=6%L('1O(#4P)2!O9B!T:&4@<')I
M;F-I<&%L(&%M;W5N="!I;G9E<W1E9"!B>2!E86-H#0H@("`@,C`P.2!);G9E
M<W1O<B`H=&AE("8C,30W.S(P,#D@0VQA<W,@0B!787)R86YT<R8C,30X.RD@
M<F5S=6QT:6YG(&EN('1H92!I<W-U86YC92!O9B!#;&%S<R!"(%=A<G)A;G1S
M('1O('!U<F-H87-E(#(P+#`P,"PP,#`-"B`@("!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&]F('1H92!#;VUP86YY+CPO9F]N=#X\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE
M($-L87-S#0I!(%=A<G)A;G1S(&%N9"!#;&%S<R!"(%=A<G)A;G1S("AC;VQL
M96-T:79E;'DL('1H92`F(S$T-SL@,C`P.2!787)R86YT<R8C,30X.RD@87)E
M(&5X97)C:7-A8FQE(&9O<B!U<"!T;R!F:79E('EE87)S(&9R;VT@=&AE#0ID
M871E(&]F(&ES<W5E(&%T(&$@<&5R('-H87)E(&5X97)C:7-E('!R:6-E(&5Q
M=6%L('1O("0P+C`V,C4@86YD("0P+C`W-2!F;W(@=&AE($-L87-S($$@5V%R
M<F%N=',@86YD('1H92!#;&%S<R!"(%=A<G)A;G1S+"!R97-P96-T:79E;'DL
M#0IO;B!A(&-A<V@@;W(@8V%S:&QE<W,@8F%S:7,N(%1H92`R,#`Y($1E8F5N
M='5R97,@86YD('1H92`R,#`Y(%=A<G)A;G1S(&%R92!C;VQL96-T:79E;'D@
M<F5F97)R960@=&\@:&5R96EN(&%S('1H92`F(S$T-SLR,#`Y#0I396-U<FET
M:65S)B,Q-#@[+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
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M=&\@*&DI('1H92`R,#`V($1E8F5N='5R97,-"F%N9"`H:6DI(&-E<G1A:6X@
M9&5M86YD(&YO=&5S("AT:&4@)B,Q-#<[0G)I9&=E($YO=&5S)B,Q-#@[*2!I
M<W-U960@8GD@=&AE($-O;7!A;GD@;VX@3V-T;V)E<B`X+"`R,#`X+"!-87)C
M:"`Q.2P@,C`P.2P@07!R:6P-"C<L(#(P,#DL($%P<FEL(#(X+"`R,#`Y+"!-
M87D@,C$L(#(P,#D@86YD($IU;F4@,C4L(#(P,#D@86YD(&1I<V-U<W-E9"!U
M;F1E<B!T:&4@8V%P=&EO;B`F(S$T-SM$96UA;F0@3F]T97,F(S$T.#L@8F5L
M;W<N($EN(&-O;FYE8W1I;VX-"G=I=&@@=&AE('-A;&4@;V8@=&AE(#(P,#D@
M4V5C=7)I=&EE<R!B>2!T:&4@0V]M<&%N>2P@=&AE($-O;7!A;GD@86YD($)R
M:7-T;VP@:&%V92!A;'-O(&5N=&5R960@:6YT;R!A('=A:79E<B!A9W)E96UE
M;G0@*'1H92`F(S$T-SM786EV97(-"D%G<F5E;65N="8C,30X.RD@<'5R<W5A
M;G0@=&\@=VAI8V@@0G)I<W1O;"!W86EV960@8V5R=&%I;B!R:6=H=',@=VET
M:"!R97-P96-T('1O('1H92`R,#`V($1E8F5N='5R97,@86YD($)R:61G92!.
M;W1E<RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY4:&4@8V]N=F5R<VEO;@T*<')I8V4@;V8@=&AE
M(#(P,#D@1&5B96YT=7)E<R!A;F0@=&AE(&5X97)C:7-E('!R:6-E(&]F('1H
M92`R,#`Y(%=A<G)A;G1S(&%R92!S=6)J96-T('1O(&9U;&P@<F%T8VAE="!A
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M<G1A:6X@;W1H97(@979E;G1S+@T*4V\@;&]N9R!A<R!T:&4@,C`P.2!$96)E
M;G1U<F5S(&%R92!O=71S=&%N9&EN9RP@:68@=&AE($-O;7!A;GD@969F96-T
M<R!A('-U8G-E<75E;G0@9FEN86YC:6YG+"!T:&4@3V-T;V)E<B`R,#`Y($EN
M=F5S=&]R<R!M87D-"F5L96-T+"!I;B!T:&5I<B!S;VQE(&1I<V-R971I;VXL
M('1O(&5X8VAA;F=E(&%L;"!O<B!S;VUE(&]F('1H92!/8W1O8F5R(#(P,#D@
M1&5B96YT=7)E<R`H8G5T(&YO="!T:&4@,C`P.2!787)R86YT<RD@9F]R(&%N
M>2!S96-U<FET:65S#0IO<B!U;FET<R!I<W-U960@:6X@82!S=6)S97%U96YT
M(&9I;F%N8VEN9R!O;B!A("0Q+C`P(&9O<B`D,2XP,"!B87-I<R!O<B!T;R!H
M879E(&%N>2!P87)T:6-U;&%R('!R;W9I<VEO;G,@;V8@=&AE('-U8G-E<75E
M;G0@9FEN86YC:6YG#0IL96=A;"!D;V-U;65N=',@87!P;'D@=&\@=&AE(&1O
M8W5M96YT<R!U=&EL:7IE9"!F;W(@=&AE($]C=&]B97(@,C`P.2!&:6YA;F-I
M;F<N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF
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M<R!O;B!S=6-H#0IR96=I<W1R871I;VX@<W1A=&5M96YT+B!4:&4@,C`P.2!)
M;G9E<W1O<G,@:&%V92!C;VYT<F%C='5A;&QY(&%G<F5E9"!T;R!R97-T<FEC
M="!T:&5I<B!A8FEL:71Y('1O(&-O;G9E<G0@=&AE(#(P,#D@1&5B96YT=7)E
M<PT*86YD(&5X97)C:7-E('1H92`R,#`Y(%=A<G)A;G1S(&%N9"!R96-E:79E
M('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K('-U8V@@=&AA="!T:&4@;G5M
M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>2!C;VUM;VX@<W1O8VL-"FAE
M;&0@8GD@82`R,#`Y($EN=F5S=&]R(&%N9"!I=',@869F:6QI871E<R!A9G1E
M<B!S=6-H(&-O;G9E<G-I;VX@;W(@97AE<F-I<V4@9&]E<R!N;W0@97AC965D
M(#0N.24@;V8@=&AE($-O;7!A;GDF(S$T-CMS('1H96X-"FES<W5E9"!A;F0@
M;W5T<W1A;F1I;F<@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$=7)I
M;F<@,C`Q,"P-"C(P,#D@26YV97-T;W)S(&-O;G9E<G1E9"`D,2PS,S4L,#`P
M(&]F('1H92!P<FEN8VEP86P@86UO=6YT(&]F(#(P,#D@1&5B96YT=7)E<R!F
M;W(@,C8L-S`P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O
M;6UO;@T*<W1O8VLN($1U<FEN9R`R,#$Q+"`R,#`Y($EN=F5S=&]R<R!C;VYV
M97)T960@)#8Q,"PP,#`@;V8@=&AE('!R:6YC:7!A;"!A;6]U;G0@;V8@,C`P
M.2!$96)E;G1U<F5S(&9O<B`Q,BPR,#`L,#`P('-H87)E<R!O9B!T:&4-"D-O
M;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:RX@06-C;W)D:6YG;'DL(&%T(%-E
M<'1E;6)E<B`S,"P@,C`Q,BP@)#4U+#`P,"!I;B!A9V=R96=A=&4@<')I;F-I
M<&%L(&%M;W5N="!O9B`R,#`Y($1E8F5N='5R97,@<F5M86EN960-"F]U='-T
M86YD:6YG+B!);B!A9&1I=&EO;BP@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R
M+"`Q-"PY,#`L,#`P(&]F('1H92`R,#`Y($-L87-S($$@5V%R<F%N=',@86YD
M(#$V+#<U,"PP,#`@;V8@=&AE(#(P,#D@0VQA<W,@0@T*5V%R<F%N=',@<F5M
M86EN960@;W5T<W1A;F1I;F<N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^3VX@2G5N92`Q+`T*,C`Q,2P@=&AE
M($-O;7!A;GD@96YT97)E9"!I;G1O(&$@9FEN86YC:6YG(&%R<F%N9V5M96YT
M('=I=&@@<V5V97)A;"!A8V-R961I=&5D(&EN=F5S=&]R<R`H=&AE("8C,30W
M.TIU;F4@,C`Q,2!);G9E<W1O<G,F(S$T.#LI+`T*<'5R<W5A;G0@=&\@=VAI
M8V@@:70@<V]L9"!V87)I;W5S('-E8W5R:71I97,@:6X@8V]N<VED97)A=&EO
M;B!O9B!A(&UA>&EM=6T@86=G<F5G871E('!U<F-H87-E('!R:6-E(&]F("0U
M,#`L,#`P("AT:&4@)B,Q-#<[2G5N90T*,C`Q,2!&:6YA;F-I;F<F(S$T.#LI
M+B!);B!C;VYN96-T:6]N('=I=&@@=&AE($IU;F4@,C`Q,2!&:6YA;F-I;F<L
M('1H92!#;VUP86YY(&ES<W5E9"!T:&4@9F]L;&]W:6YG('-E8W5R:71I97,@
M=&\@=&AE($IU;F4@,C`Q,0T*26YV97-T;W)S.CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!X.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,30Y.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3(E($-O;G9E<G1I8FQE#0H@
M("`@1&5B96YT=7)E<R!I;B!T:&4@<')I;F-I<&%L(&%M;W5N="!O9B`D-3`P
M+#`P,"!D=64@07!R:6P@,34L(#(P,3(L(&-O;G9E<G1I8FQE(&EN=&\@<VAA
M<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL-"B`@("!A
M="!A('!E<B!S:&%R92!C;VYV97)S:6]N('!R:6-E(&5Q=6%L('1O("0P+C$P
M('!E<B!S:&%R93L@86YD/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-#AP>#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$T.3LF(S$V,#LF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G1S('1O('!U<F-H
M87-E#0H@("`@-2PP,#`L,#`P(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M,30V.W,@8V]M;6]N('-T;V-K+B!4:&4@=V%R<F%N=',@87)E(&5X97)C:7-A
M8FQE+"!O;B!A(&-A<V@@;W(@8V%S:&QE<W,@8F%S:7,L(&9O<B!U<`T*("`@
M('1O('1W;R!Y96%R<R!F<F]M('1H92!D871E(&]F(&ES<W5E(&%T(&$@<&5R
M('-H87)E(&5X97)C:7-E('!R:6-E(&5Q=6%L('1O("0P+C$U+CPO9F]N=#X\
M+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^26X@3F]V96UB97(L#0HR,#$Q+"!T:&4@0V]M<&%N>2!E
M;G1E<F5D(&EN=&\@82!F:6YA;F-I;F<@87)R86YG96UE;G0@=VET:"!S979E
M<F%L(&%C8W)E9&ET960@:6YV97-T;W)S("AT:&4@)B,Q-#<[3F]V96UB97(@
M,C`Q,2!);G9E<W1O<G,F(S$T.#LI+`T*<'5R<W5A;G0@=&\@=VAI8V@@:70@
M<V]L9"!V87)I;W5S('-E8W5R:71I97,@:6X@8V]N<VED97)A=&EO;B!O9B!A
M(&UA>&EM=6T@86=G<F5G871E('!U<F-H87-E('!R:6-E(&]F("0R-S4L,#`P
M("AT:&4@)B,Q-#<[3F]V96UB97(-"C(P,3$@1FEN86YC:6YG)B,Q-#@[*2X@
M26X@8V]N;F5C=&EO;B!W:71H('1H92!.;W9E;6)E<B`R,#$Q($9I;F%N8VEN
M9RP@=&AE($-O;7!A;GD@:7-S=65D('1H92!F;VQL;W=I;F<@<V5C=7)I=&EE
M<R!T;R!T:&4@3F]V96UB97(-"C(P,3$@26YV97-T;W)S.CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!X.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI
M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,30Y.R8C,38P.R8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^."4@0V]N=F5R=&EB
M;&4@1&5B96YT=7)E<PT*("`@(&EN('1H92!P<FEN8VEP86P@86UO=6YT(&]F
M("0R-S4L,#`P(&1U92!I;B!T=V\@>65A<G,L(&-O;G9E<G1I8FQE(&EN=&\@
M<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@870@
M82!P97(-"B`@("!S:&%R92!C;VYV97)S:6]N('!R:6-E(&5Q=6%L('1O("0P
M+C`U('!E<B!S:&%R93L@86YD/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-#AP>#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$T.3LF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G1S('1O('!U
M<F-H87-E#0H@("`@-2PU,#`L,#`P(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N
M>28C,30V.W,@8V]M;6]N('-T;V-K+B!4:&4@0VQA<W,@02!787)R86YT<R!A
M;F0@0VQA<W,@0B!787)R86YT<R`H8V]L;&5C=&EV96QY+"!T:&4@)B,Q-#<[
M5V%R<F%N=',F(S$T.#LI#0H@("`@87)E(&5X97)C:7-A8FQE(&9O<B!U<"!T
M;R!F:79E('EE87)S(&9R;VT@=&AE(&1A=&4@;V8@:7-S=64@870@82!P97(@
M<VAA<F4@97AE<F-I<V4@<')I8V4@97%U86P@=&\@)#`N,#8R-2!A;F0@)#`N
M,#<U(&9O<@T*("`@('1H92!#;&%S<R!!(%=A<G)A;G1S(&%N9"!T:&4@0VQA
M<W,@0B!787)R86YT<RP@<F5S<&5C=&EV96QY+"!O;B!A(&-A<V@@;W(@8V%S
M:&QE<W,@8F%S:7,N/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M92!P<FEC92!O9B`D-C$W+#4P,"`H=&AE("8C,30W.TUA<F-H(#(P,3(@1FEN
M86YC:6YG)B,Q-#@[*2X@26X@8V]N;F5C=&EO;B!W:71H#0IT:&4@36%R8V@@
M,C`Q,B!&:6YA;F-I;F<L('1H92!#;VUP86YY(&ES<W5E9"!T:&4@9F]L;&]W
M:6YG('-E8W5R:71I97,@=&\@=&AE(&EN=F5S=&]R<SH\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-S)P>#L@
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$T.3LF(S$V,#LF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@E($-O;G9E
M<G1I8FQE($1E8F5N='5R97,-"B`@("!I;B!T:&4@<')I;F-I<&%L(&%M;W5N
M="!O9B`D-C$W+#4P,"8C,38P.R8C,38P.V1U92!I;B!T=V\@>65A<G,L(&-O
M;G9E<G1I8FQE(&EN=&\@<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C
M;VUM;VX@<W1O8VL-"B`@("!A="!A('!E<B!S:&%R92!C;VYV97)S:6]N('!R
M:6-E(&5Q=6%L('1O("0P+C`U('!E<B!S:&%R93L@86YD/"]F;VYT/CPO=&0^
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@-S)P>#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$T.3LF(S$V
M,#LF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E=A<G)A;G1S('1O('!U<F-H87-E#0H@("`@,3(L,S4P+#`P,"!O9B!S:&%R
M97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:RX@5&AE($-L
M87-S($$@5V%R<F%N=',@86YD($-L87-S($(@5V%R<F%N=',@*&-O;&QE8W1I
M=F5L>2P@=&AE("8C,30W.PT*("`@($UA<F-H(#(P,3(@5V%R<F%N=',F(S$T
M.#LI(&%R92!E>&5R8VES86)L92!F;W(@=7`@=&\@9FEV92!Y96%R<R!F<F]M
M('1H92!D871E(&]F(&ES<W5E(&%T(&$@<&5R('-H87)E(&5X97)C:7-E('!R
M:6-E(&5Q=6%L#0H@("`@=&\@)#`N,#8R-2!A;F0@)#`N,#<U(&9O<B!T:&4@
M0VQA<W,@02!787)R86YT<R!A;F0@=&AE($-L87-S($(@5V%R<F%N=',L(')E
M<W!E8W1I=F5L>2P@;VX@82!C87-H(&]R(&-A<VAL97-S(&)A<VES+CPO9F]N
M=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^26X@07!R:6P@,C`Q,BP-"G1H92!#;VUP86YY(&%G
M<F5E9"!T;R!A;B!A9&IU<W1M96YT(&%S(&YE9V]T:6%T960@=&\@96YA8FQE
M(&EN9'5C96UE;G0@;V8@9G5R=&AE<B!F:6YA;F-I;F<@;V8@=&AE($-O;7!A
M;GDN)B,Q-C`[)B,Q-C`[4'5R<W5A;G0-"G1O('1H92!A;G1I+61I;'5T:6]N
M('!R;W9I<VEO;G,@:6X@=&AE(&-O;G9E<G1I8FQE(&EN<W1R=6UE;G1S+"!T
M:&4@8V]N=F5R<VEO;B!P<FEC92!O9B!C97)T86EN(&-O;G9E<G1I8FQE(&EN
M<W1R=6UE;G1S(&ES(&YO=PT*)#`N,#$@*'=I=&@@=&AE(&5X8V5P=&EO;B!O
M9B!T:&4@8V]N=F5R<VEO;B!P<FEC92!O9B!T:&4@3V-T;V)E<B`R,#`V($1E
M8F5N='5R92!W:&EC:"!I<R!A;')E861Y('!R:6-E9"!A="!T:&4@;&5S<V5R
M(&]F("0P+C`Q#0IA;F0@-C`E(&]F('1H92!A=F5R86=E(&]F('1H92!L;W=E
M<W0@=&AR964@=')A9&EN9R!P<FEC97,@;V-C=7)R:6YG(&%T(&%N>2!T:6UE
M(&1U<FEN9R!T:&4@,C`@=')A9&EN9R!D87ES('!R96-E9&EN9R!C;VYV97)S
M:6]N*2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY);B!-87DL(#(P,3(L#0IT:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!F:6YA;F-I;F<@87)R86YG96UE;G0@=VET:"!S979E<F%L(&%C
M8W)E9&ET960@:6YV97-T;W)S('!U<G-U86YT('1O('=H:6-H(&ET('-O;&0@
M=F%R:6]U<R!S96-U<FET:65S#0II;B!C;VYS:61E<F%T:6]N(&]F(&$@;6%X
M:6UU;2!A9V=R96=A=&4@<'5R8VAA<V4@<')I8V4@;V8@)#(W-2PP,#`@*'1H
M92`F(S$T-SM-87D@,C`Q,B!&:6YA;F-I;F<F(S$T.#LI+B!);B!C;VYN96-T
M:6]N('=I=&@-"G1H92!-87D@,C`Q,B!&:6YA;F-I;F<L('1H92!#;VUP86YY
M(&ES<W5E9"!T:&4@9F]L;&]W:6YG('-E8W5R:71I97,@=&\@=&AE(&EN=F5S
M=&]R<SH\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@-S)P>#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$T.3LF
M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C@E($-O;G9E<G1I8FQE($1E8F5N='5R97,-"B`@("!I;B!T:&4@<')I
M;F-I<&%L(&%M;W5N="!O9B`D,C<U+#`P,"!D=64@36%Y(#(P,30L(&-O;G9E
M<G1I8FQE(&EN=&\@<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM
M;VX@<W1O8VL@870@82!P97(@<VAA<F4-"B`@("!C;VYV97)S:6]N('!R:6-E
M(&5Q=6%L('1O("0P+C`U('!E<B!S:&%R93L@86YD/"]F;VYT/CPO=&0^/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M-S)P>#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$T.3LF(S$V,#LF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A
M<G)A;G1S('1O('!U<F-H87-E#0H@("`@-2PU,#`L,#`P(&]F('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K+B!4:&4@0VQA<W,@
M02!787)R86YT<R!A;F0@0VQA<W,@0B!787)R86YT<R`H8V]L;&5C=&EV96QY
M+"!T:&4@)B,Q-#<[#0H@("`@36%Y)B,Q-C`[)B,Q-C`[,C`Q,B!787)R86YT
M<R8C,30X.RD@87)E(&5X97)C:7-A8FQE(&9O<B!U<"!T;R!F:79E('EE87)S
M(&9R;VT@=&AE(&1A=&4@;V8@:7-S=64@870@82!P97(@<VAA<F4@97AE<F-I
M<V4@<')I8V4-"B`@("!E<75A;"!T;R`D,"XP-C(U(&%N9"`D,"XP-S4@9F]R
M('1H92!#;&%S<R!!(%=A<G)A;G1S(&%N9"!T:&4@0VQA<W,@0B!787)R86YT
M<RP@<F5S<&5C=&EV96QY+"!O;B!A(&-A<V@@;W(@8V%S:&QE<W,@8F%S:7,N
M/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!!=6=U<W0-"C@L(#(P,3(L(&$@4V5T
M=&QE;65N="!!9W)E96UE;G0@86YD($UU='5A;"!'96YE<F%L(%)E;&5A<V4@
M*"8C,S0[06=R965M96YT)B,S-#LI('=A<R!M861E(&)Y(&%N9"!B971W965N
M($]825,@86YD($)R:7-T;VP@26YV97-T;65N=`T*1G5N9"P@3'1D+BP@:6X@
M;W)D97(@=&\@<V5T=&QE(&-E<G1A:6X@8VQA:6US(')E9V%R9&EN9R!C97)T
M86EN(&-O;G9E<G1I8FQE(&1E8F5N='5R97,@:&5L9"!B>2!"<FES=&]L+CPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/E!U<G-U86YT('1O#0IT:&4@06=R965M96YT+"!/6$E3('-H86QL('!A
M>2!"<FES=&]L("AH86QF(&]F('=H:6-H('!A>6UE;G0@=V]U;&0@<F5D;W5N
M9"!T;R!-97)I="!#87!I=&%L($QI;6ET960@*"8C,30W.TUE<FET)B,Q-#@[
M*2D@82!T;W1A;`T*;V8@)#$L,3$Y+#<W."!A<R!P87EM96YT(&EN(&9U;&P@
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M;"!H;VQD(&YO(&UO<F4@=&AA;B`Y+CDY)2!O9B!T:&4@;W5T<W1A;F1I;F<@
M<VAA<F5S(&]F($]825,@*&EN8VQU9&EN9R!A;GD@<VAA<F5S#0IT:&%T(&5A
M8V@@;6%Y(&AO;&0@87,@;V8@=&AE(&1A=&4@;V8@:7-S=6%N8V4I+B!4:&4@
M<VAA<F5S('-O(&ES<W5E9"!R97!R97-E;G0@)#0Q-RPT-S4N-C4@;V8@=&AE
M("0Q+#$Q.2PW-S@@<&%Y;65N="`H,C<L.#,Q+#<Q,`T*<VAA<F5S(&%T("0P
M+C`Q-2!P97(@<VAA<F4L(&]F('=H:6-H(#DL,38X+#<U,"!W:6QL(&)E(')E
M=&%I;F5D(&)Y($)R:7-T;VP@86YD(#$X+#8V,BPY-C`@=VEL;"!B92!I<W-U
M960@=&\@365R:70I+B!4:&4@<F5M86EN:6YG#0IB86QA;F-E(&]F('1H92!P
M87EM96YT('-H86QL(&)E(&UA9&4@:6X@=&AE(&9O<FT@;V8@='=O(&-O;G9E
M<G1I8FQE('!R;VUI<W-O<GD@;F]T97,@:6X@=&AE(')E<W!E8W1I=F4@86UO
M=6YT<R!O9B`D-#(R+#,U-RXW-0T*9F]R($)R:7-T;VP@86YD("0R-SDL.30T
M+C8P(&9O<B!-97)I="`H8V]L;&5C=&EV96QY+"!T:&4@)B,Q-#<[3F]T97,F
M(S$T.#LI('=I=&@@82!M871U<FET>2!O9B!$96-E;6)E<B`Q+"`R,#$W(&AA
M=FEN9R!A;B`X)0T*86YN=6%L(&EN=&5R97-T(')A=&4L('=I=&@@:6YT97)E
M<W0@;VYL>2!A8V-R=6EN9R!U;G1I;"!*86YU87)Y(#$L(#(P,3,L(&%N9"!T
M:&5N(&QE=F5L('!A>6UE;G1S(&]F("0S+#<U,"!E86-H(&)E9VEN;FEN9R!*
M86YU87)Y#0HQ+"`R,#$S('5N=&EL('!A:60@:6X@9G5L;"!O;B!$96-E;6)E
M<B`Q+"`R,#$W+B!);B!T:&4@979E;G0@82!D969A=6QT(&EN('1H92!M;VYT
M:&QY('!A>6UE;G1S(&]N('1H92!.;W1E<R!H87,@;V-C=7)R960@86YD(&ES
M#0IC;VYT:6YU:6YG(&5A8V@@:&]L9&5R(&]F('1H92!.;W1E<R!S:&%L;"!B
M92!P97)M:71T960@=&\@8V]N=F5R="!T:&4@=6YP86ED('!R:6YC:7!A;"!A
M;F0@:6YT97)E<W0@;V8@=&AE($YO=&5S(&EN=&\@<VAA<F5S(&]F#0I/6$E3
M(&%T("0N,#$@8V5N=',@<&5R('-H87)E+B8C,38P.R8C,38P.TEN('1H92!A
M8G-E;F-E(&]F('-U8V@@8V]N=&EN=6EN9R!D969A=6QT(&YO(&-O;G9E<G-I
M;VX@;V8@=&AE($YO=&5S('=I;&P@8F4@<&5R;6ET=&5D+@T*3UA)4R!W:6QL
M(&AA=F4@=&AE(')I9VAT('1O(')E<&%Y('1H92!.;W1E<R!I;B!F=6QL(&%T
M(&%N>2!T:6UE('=I=&AO=70@<&5N86QT>2X\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96UA;F0@3F]T97,\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY/;B!-87D@,34L#0HR,#`Y+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN
M=&\@82!C;VYV97)T:6)L92!D96UA;F0@<')O;6ES<V]R>2!N;W1E('=I=&@@
M0G)I<W1O;"!#87!I=&%L+"!,3$,@9F]R(&-E<G1A:6X@8V]N<W5L=&EN9R!S
M97)V:6-E<PT*=&]T86QI;F<@)#$P,"PP,#`N(%1H92!N;W1E(&1O97,@;F]T
M('!R;W9I9&4@9F]R(&%N>2!I;G1E<F5S="!A;F0@:7,@9'5E('5P;VX@9&5M
M86YD(&)Y('1H92!H;VQD97(N(%1H92!N;W1E(&AA<R!B965N(&-O;G9E<G1E
M9`T*:6YT;R!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GDN/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^3VX@2G5N92`R,BP-"C(P,#DL('1H92!#;VUP86YY(&5N=&5R960@:6YT
M;R!A(&-O;G9E<G1I8FQE(&1E;6%N9"!P<F]M:7-S;W)Y(&YO=&4@=VET:"!4
M:&5O<F5M($=R;W5P("@F(S$T-SM4:&5O<F5M)B,Q-#@[*2!P=7)S=6%N="!T
M;R!W:&EC:`T*5&AE;W)E;2!P=7)C:&%S960@86X@86=G<F5G871E('!R:6YC
M:7!A;"!A;6]U;G0@;V8@)#,Q+#,W-2!O9B!C;VYV97)T:6)L92!D96UA;F0@
M<')O;6ES<V]R>2!N;W1E<R!F;W(@86X@86=G<F5G871E('!U<F-H87-E('!R
M:6-E#0IO9B`D,C4L,#`P("AT:&4@)B,Q-#<[(#(P,#D@5&AE;W)E;2!.;W1E
M)B,Q-#@[*2X@5&AE(#(P,#D@5&AE;W)E;2!.;W1E('=A<R!S=6)S97%U96YT
M;'D@<V]L9"!A<R!D97-C<FEB960@8F5L;W<N/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4VEM=6QT86YE;W5S
M;'D-"G=I=&@@=&AE(&ES<W5A;F-E(&]F('1H92`R,#`Y(%1H96]R96T@3F]T
M92P@=&AE($-O;7!A;GD@:7-S=65D(%1H96]R96T@82!S979E;BUY96%R('=A
M<G)A;G0@*'1H92`F(S$T-SLR,#`Y(%1H96]R96T@5V%R<F%N="8C,30X.RD-
M"G1O('!U<F-H87-E(#,L,3,W+#4P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&]F('1H92!#;VUP86YY(&%T(&$@<')I8V4@97%U86P@=&\@=&AE(&QO=V5R
M(&]F("AI*2`D,"XP,2!A;F0@*&EI*2`V,"4@;V8@=&AE(&%V97)A9V4-"F]F
M('1H92!T:')E92`H,RD@;&]W97-T('1R861I;F<@<')I8V5S(&]C8W5R<FEN
M9R!A="!A;GD@=&EM92!D=7)I;F<@=&AE(#(P('1R861I;F<@9&%Y<R!P<F5C
M961I;F<@=&AE(&ES<W5E(&1A=&4@;V8@=&AE(%1H96]R96T-"DYO=&4@*'1H
M92`F(S$T-SM%>&5R8VES92!0<FEC928C,30X.RDN(%1H92`R,#`Y(%1H96]R
M96T@5V%R<F%N="!M87D@8F4@97AE<F-I<V5D(&]N(&$@8V%S:&QE<W,@8F%S
M:7,@:68@=&AE('-H87)E<R!O9B!C;VUM;VX-"G-T;V-K('5N9&5R;'EI;F<@
M=&AE(#(P,#D@5&AE;W)E;2!787)R86YT(&%R92!N;W0@=&AE;B!R96=I<W1E
M<F5D('!U<G-U86YT('1O(&%N(&5F9F5C=&EV92!R96=I<W1R871I;VX@<W1A
M=&5M96YT+B!);B!T:&4@979E;G0-"G1H92`R,#`Y(%1H96]R96T@5V%R<F%N
M="!I<R!E>&5R8VES960@;VX@82!C87-H;&5S<R!B87-I<RP@=V4@=VEL;"!N
M;W0@<F5C96EV92!A;GD@<')O8V5E9',N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3VX@1&5C96UB97(-"C$L
M(#(P,#DL(%1H96]R96T@<V]L9"!T:&4@,C`P.2!4:&5O<F5M($YO=&4@=&\@
M3F5T($-A<&ET86P@4&%R=&YE<G,L($EN8RX@*"8C,30W.TYE="!#87!I=&%L
M)B,Q-#@[*2X@26X@1&5C96UB97(@,C`P.2P@3F5T($-A<&ET86P-"F-O;G9E
M<G1E9"`D,C0L,#`P(&]F('1H92!P<FEN8VEP86P@9F]R(#(L-#`P+#`P,"!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:RX@26X@
M2F%N=6%R>2`R,#$P+"!.970@0V%P:71A;"!C;VYV97)T960-"G1H92!R96UA
M:6YI;F<@)#<L,S<U(&]F('!R:6YC:7!A;"!A;6]U;G0@9F]R(&%N(&%D9&ET
M:6]N86P@-S,W+#4P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O
M;6UO;B!S=&]C:RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY/;B!&96)R=6%R>0T*-RP@,C`Q,2!T:&4@0V]M
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M,#`@*'1H92`F(S$T-SM&96)R=6%R>0T*,C`Q,2!"<FES=&]L($YO=&4F(S$T
M.#LI+B!4:&4@1F5B<G5A<GD@,C`Q,2!"<FES=&]L($YO=&4@:7,@8V]N=F5R
M=&EB;&4@:6YT;R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]F('1H92!#;VUP
M86YY(&%T(&$@<')I8V4-"F5Q=6%L('1O("0P+C`U('!E<B!S:&%R92X\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY3:6UU;'1A;F5O=7-L>0T*=VET:"!T:&4@:7-S=6%N8V4@;V8@=&AE($9E
M8G)U87)Y(#(P,3$@0G)I<W1O;"!.;W1E+"!T:&4@0V]M<&%N>2!I<W-U960@
M0G)I<W1O;"!A(%-E<FEE<R!!(%=A<G)A;G0@*'1H92`F(S$T-SM&96)R=6%R
M>2`R,#$Q($)R:7-T;VP-"E-E<FEE<R!!(%=A<G)A;G1S)B,Q-#@[*2!T;R!P
M=7)C:&%S92`S,3,L-S4P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C,30V.W,@
M8V]M;6]N('-T;V-K(&%T(&$@<&5R('-H87)E(&5X97)C:7-E('!R:6-E(&]F
M("0P+C`V,C4L#0IA;F0@82!397)I97,@0B!787)R86YT("AT:&4@)B,Q-#<[
M1F5B<G5A<GD@,C`Q,2!"<FES=&]L(%-E<FEE<R!"(%=A<G)A;G1S)B,Q-#@[
M(&%N9"P@=&]G971H97(@=VET:"!T:&4@1F5B<G5A<GD@,C`Q,2!"<FES=&]L
M#0I397)I97,@02!787)R86YT<RP@=&AE("8C,30W.T9E8G)U87)Y(#(P,3$@
M0G)I<W1O;"!787)R86YT<R8C,30X.RD@=&\@<'5R8VAA<V4@,S$S+#<U,"!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;@T*<W1O8VL@870@
M82!P97(@<VAA<F4@97AE<F-I<V4@<')I8V4@;V8@)#`N,#<U+B!4:&4@1F5B
M<G5A<GD@,C`Q,2!787)R86YT<R!A<F4@97AE<F-I<V%B;&4@9F]R('5P('1O
M('-E=F5N('EE87)S(&9R;VT@=&AE(&1A=&4-"F]F(&ES<W5E+B!4:&4@1F5B
M<G5A<GD@,C`Q,2!787)R86YT<R!M87D@8F4@97AE<F-I<V5D(&]N(&$@8V%S
M:&QE<W,@8F%S:7,@:68@=&AE('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=6YD
M97)L>6EN9R!T:&4@1F5B<G5A<GD-"C(P,3$@5V%R<F%N=',@87)E(&YO="!T
M:&5N(')E9VES=&5R960@<'5R<W5A;G0@=&\@86X@969F96-T:79E(')E9VES
M=')A=&EO;B!S=&%T96UE;G0N($EN('1H92!E=F5N="!T:&4@1F5B<G5A<GD@
M,C`Q,2!"<FES=&]L#0I787)R86YT<R!A<F4@97AE<F-I<V5D(&]N(&$@8V%S
M:&QE<W,@8F%S:7,L('1H92!#;VUP86YY('=I;&P@;F]T(')E8V5I=F4@86YY
M('!R;V-E961S+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D]N($9E8G)U87)Y#0HW+"`R,#$Q('1H92!#;VUP
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M9B`D,C4L,#`P("AT:&4-"B8C,30W.T9E8G)U87)Y(#(P,3$@3F5T($-A<&ET
M86P@3F]T928C,30X.RDN(%1H92!&96)R=6%R>2`R,#$Q($YE="!#87!I=&%L
M($YO=&4@:7,@8V]N=F5R=&EB;&4@:6YT;R!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K(&]F#0IT:&4@0V]M<&%N>2!A="!A('!R:6-E(&5Q=6%L('1O("0P+C`U
M('!E<B!S:&%R92X@07,@;V8@4V5P=&5M8F5R+"`R,#$R+"!T:&4@1F5B<G5A
M<GD@,C`Q,2!.970@0V%P:71A;"!.;W1E(&AA9"!B965N(&-O;G9E<G1E9`T*
M:6YT;R!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C
M:RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY3:6UU;'1A;F5O=7-L>0T*=VET:"!T:&4@:7-S=6%N8V4@;V8@
M=&AE($9E8G)U87)Y(#(P,3$@3F5T($-A<&ET86P@3F]T92P@=&AE($-O;7!A
M;GD@:7-S=65D($YE="!#87!I=&%L(&$@4V5R:65S($$@5V%R<F%N="`H=&AE
M("8C,30W.T9E8G)U87)Y#0HR,#$Q($YE="!#87!I=&%L(%-E<FEE<R!!(%=A
M<G)A;G1S)B,Q-#@[*2!T;R!P=7)C:&%S92`S,3,L-S4P('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K(&%T(&$@<&5R('-H87)E
M(&5X97)C:7-E#0IP<FEC92!O9B`D,"XP-C(U+"!A;F0@82!397)I97,@0B!7
M87)R86YT("AT:&4@)B,Q-#<[1F5B<G5A<GD@,C`Q,2!.970@0V%P:71A;"!3
M97)I97,@0B!787)R86YT<R8C,30X.R!A;F0L('1O9V5T:&5R('=I=&@@=&AE
M#0I&96)R=6%R>2`R,#$Q($YE="!#87!I=&%L(%-E<FEE<R!!(%=A<G)A;G1S
M+"!T:&4@)B,Q-#<[1F5B<G5A<GD@,C`Q,2!.970@0V%P:71A;"!787)R86YT
M<R8C,30X.RD@=&\@<'5R8VAA<V4@,S$S+#<U,"!S:&%R97,-"F]F('1H92!#
M;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@870@82!P97(@<VAA<F4@97AE
M<F-I<V4@<')I8V4@;V8@)#`N,#<U+B!4:&4@1F5B<G5A<GD@,C`Q,2!.970@
M0V%P:71A;"!787)R86YT<R!A<F4@97AE<F-I<V%B;&4-"F9O<B!U<"!T;R!S
M979E;B!Y96%R<R!F<F]M('1H92!D871E(&]F(&ES<W5E+B!4:&4@1F5B<G5A
M<GD@,C`Q,2!.970@0V%P:71A;"!787)R86YT<R!M87D@8F4@97AE<F-I<V5D
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
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M=7)C:&%S92!P<FEC92!O9B`D,C4L,#`P("AT:&4@)B,Q-#<[36%R8V@-"C(P
M,3$@0G)I<W1O;"!.;W1E)B,Q-#@[*2X@5&AE($UA<F-H(#(P,3$@0G)I<W1O
M;"!.;W1E(&ES(&-O;G9E<G1I8FQE(&%T('1H92!O<'1I;VX@;V8@=&AE(&AO
M;&1E<B!A="!A;GD@=&EM92!I;G1O('-H87)E<R!O9B!C;VUM;VX-"G-T;V-K
M+"!A="!A('!R:6-E(&5Q=6%L('1O("0P+C`U+CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.R8C,38P.SPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-I;75L
M=&%N96]U<VQY#0IW:71H('1H92!I<W-U86YC92!O9B!T:&4@36%R8V@@,C`Q
M,2!"<FES=&]L($YO=&4L('1H92!#;VUP86YY(&ES<W5E9"!"<FES=&]L(&$@
M4V5R:65S($$@5V%R<F%N="`H=&AE("8C,30W.TUA<F-H(#(P,3$@0G)I<W1O
M;`T*4V5R:65S($$@5V%R<F%N=',F(S$T.#LI('1O('!U<F-H87-E(#,Q,RPW
M-3`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@
M870@82!P97(@<VAA<F4@97AE<F-I<V4@<')I8V4@;V8@)#`N,#8R-2P-"F%N
M9"!A(%-E<FEE<R!"(%=A<G)A;G0@*'1H92`F(S$T-SM-87)C:"`R,#$Q($)R
M:7-T;VP@4V5R:65S($(@5V%R<F%N=',F(S$T.#L@86YD+"!T;V=E=&AE<B!W
M:71H('1H92!-87)C:"`R,#$Q($)R:7-T;VP@4V5R:65S#0I!(%=A<G)A;G1S
M+"!T:&4@)B,Q-#<[36%R8V@@,C`Q,2!"<FES=&]L(%=A<G)A;G1S)B,Q-#@[
M*2!T;R!P=7)C:&%S92`S,3,L-S4P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M,30V.W,@8V]M;6]N('-T;V-K(&%T(&$-"G!E<B!S:&%R92!E>&5R8VES92!P
M<FEC92!O9B`D,"XP-S4N(%1H92!-87)C:"`R,#$Q(%=A<G)A;G1S(&%R92!E
M>&5R8VES86)L92!F;W(@=7`@=&\@<V5V96X@>65A<G,@9G)O;2!T:&4@9&%T
M92!O9B!I<W-U92X@5&AE#0I-87)C:"`R,#$Q(%=A<G)A;G1S(&UA>2!B92!E
M>&5R8VES960@;VX@82!C87-H;&5S<R!B87-I<R!I9B!T:&4@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!U;F1E<FQY:6YG('1H92!-87)C:"`R,#$Q(%=A<G)A
M;G1S(&%R90T*;F]T('1H96X@<F5G:7-T97)E9"!P=7)S=6%N="!T;R!A;B!E
M9F9E8W1I=F4@<F5G:7-T<F%T:6]N('-T871E;65N="X@26X@=&AE(&5V96YT
M('1H92!-87)C:"`R,#$Q(%=A<G)A;G1S(&%R92!E>&5R8VES960@;VX@82!C
M87-H;&5S<PT*8F%S:7,L('1H92!#;VUP86YY('=I;&P@;F]T(')E8V5I=F4@
M86YY('!R;V-E961S+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D]N($%P<FEL(#0L#0HR,#$Q('1H92!#;VUP
M86YY(&5N=&5R960@:6YT;R!A(&-O;G9E<G1I8FQE(&1E;6%N9"!P<F]M:7-S
M;W)Y(&YO=&4@=VET:"!.970@0V%P:71A;"!P=7)S=6%N="!T;R!W:&EC:"!.
M970@0V%P:71A;"!P=7)C:&%S960@86X-"F%G9W)E9V%T92!P<FEN8VEP86P@
M86UO=6YT(&]F("0S,2PS-S4@;V8@8V]N=F5R=&EB;&4@9&5M86YD('!R;VUI
M<W-O<GD@;F]T97,@9F]R(&%N(&%G9W)E9V%T92!P=7)C:&%S92!P<FEC92!O
M9B`D,C4L,#`P("AT:&4@)B,Q-#<[07!R:6P-"C(P,3$@3F5T($-A<&ET86P@
M3F]T928C,30X.RDN(%1H92!!<')I;"`R,#$Q($YE="!#87!I=&%L($YO=&4@
M:7,@8V]N=F5R=&EB;&4@:6YT;R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]F
M('1H92!#;VUP86YY+"!A="!A#0IP<FEC92!E<75A;"!T;R`D,"XP-2!P97(@
M<VAA<F4N)B,Q-C`[)B,Q-C`[07,@;V8@4V5P=&5M8F5R+"`R,#$R+"!!<')I
M;"8C,38P.R8C,38P.S(P,3$@3F5T($-A<&ET86P@3F]T92!H860@8F5E;B!C
M;VYV97)T960@:6YT;PT*<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C
M;VUM;VX@<W1O8VLN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^4VEM=6QT86YE;W5S;'D-"G=I=&@@=&AE(&ES
M<W5A;F-E(&]F('1H92!.970@0V%P:71A;"!.;W1E+"!T:&4@0V]M<&%N>2!I
M<W-U960@3F5T($-A<&ET86P@82!397)I97,@02!787)R86YT("AT:&4@)B,Q
M-#<[07!R:6P@,C`Q,2!.970@0V%P:71A;`T*4V5R:65S($$@5V%R<F%N=',F
M(S$T.#LI('1O('!U<F-H87-E(#,Q,RPW-3`@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!O9B!T:&4@0V]M<&%N>2!A="!A('!E<B!S:&%R92!E>&5R8VES92!P
M<FEC92!O9B`D,"XP-C(U+`T*86YD(&$@4V5R:65S($(@5V%R<F%N="`H=&AE
M("8C,30W.T%P<FEL(#(P,3$@3F5T($-A<&ET86P@4V5R:65S($(@5V%R<F%N
M=',F(S$T.#L@86YD+"!T;V=E=&AE<B!W:71H('1H92!!<')I;"`R,#$Q($YE
M="!#87!I=&%L#0I397)I97,@02!787)R86YT<RP@=&AE("8C,30W.T%P<FEL
M(#(P,3$@3F5T($-A<&ET86P@5V%R<F%N=',F(S$T.#LI('1O('!U<F-H87-E
M(#,Q,RPW-3`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!T:&4@0V]M<&%N
M>0T*870@82!P97(@<VAA<F4@97AE<F-I<V4@<')I8V4@;V8@)#`N,#<U+B!4
M:&4@07!R:6P@,C`Q,2!.970@0V%P:71A;"!787)R86YT<R!A<F4@97AE<F-I
M<V%B;&4@9F]R('5P('1O('-E=F5N('EE87)S(&9R;VT@=&AE(&1A=&4-"F]F
M(&ES<W5E+B!4:&4@07!R:6P@,C`Q,2!.970@0V%P:71A;"!787)R86YT<R!M
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M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!/
M8W1O8F5R#0HR-BP@,C`Q,2!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C
M;VYV97)T:6)L92!D96UA;F0@<')O;6ES<V]R>2!N;W1E('=I=&@@5&AE;W)E
M;2!P=7)S=6%N="!T;R!W:&EC:"!4:&5O<F5M('!U<F-H87-E9"!A;B!A9V=R
M96=A=&4-"G!R:6YC:7!A;"!A;6]U;G0@;V8@)#(P,"PP,#`@;V8@8V]N=F5R
M=&EB;&4@9&5M86YD('!R;VUI<W-O<GD@;F]T97,@9F]R(&%N(&%G9W)E9V%T
M92!P=7)C:&%S92!P<FEC92!O9B`D,34W+#(Q-R`H=&AE("8C,30W.T]C=&]B
M97(-"C(P,3$@5&AE;W)E;2!.;W1E)B,Q-#@[*2X@5&AE($]C=&]B97(@,C`Q
M,2!4:&5O<F5M($YO=&4@:7,@8V]N=F5R=&EB;&4@:6YT;R!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&]F('1H92!#;VUP86YY+"!A="!A('!R:6-E#0IE<75A
M;"!T;R`D,"XP-2!P97(@<VAA<F4N($%S(&]F(%-E<'1E;6)E<BP@,C`Q,BP@
M=&AE($]C=&]B97(F(S$V,#LF(S$V,#LR,#$Q(%1H96]R96TF(S$V,#LF(S$V
M,#M#87!I=&%L($YO=&4@:&%D(&)E96X@8V]N=F5R=&5D#0II;G1O('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K+CPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-I
M;75L=&%N96]U<VQY#0IW:71H('1H92!I<W-U86YC92!O9B!T:&4@3V-T;V)E
M<B`R,#$Q(%1H96]R96T@3F]T92P@=&AE($-O;7!A;GD@:7-S=65D(%1H96]R
M96T@82!397)I97,@02!787)R86YT("AT:&4@)B,Q-#<[3V-T;V)E<B`R,#$Q
M(%-E<FEE<PT*02!787)R86YT)B,Q-#@[*2!T;R!P=7)C:&%S92`Q,"PP,#`L
M,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GD@870@
M82!P97(@<VAA<F4@97AE<F-I<V4@<')I8V4@;V8@)#`N,#8R-2P@86YD(&$-
M"E-E<FEE<R!"(%=A<G)A;G0@*'1H92`F(S$T-SM/8W1O8F5R(#(P,3$@4V5R
M:65S($(@5V%R<F%N=',F(S$T.#L@86YD+"!T;V=E=&AE<B!W:71H('1H92!/
M8W1O8F5R(#(P,3$@4V5R:65S($$@5V%R<F%N=',L('1H90T*)B,Q-#<[3V-T
M;V)E<B`R,#$Q(%=A<G)A;G1S)B,Q-#@[*2!T;R!P=7)C:&%S92`Q,"PP,#`L
M,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GD@870@
M82!P97(@<VAA<F4@97AE<F-I<V4@<')I8V4-"F]F("0P+C`W-2X@5&AE($]C
M=&]B97(@,C`Q,2!787)R86YT<R!A<F4@97AE<F-I<V%B;&4@9F]R('5P('1O
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M871I;VX@<W1A=&5M96YT+B!);B!T:&4@979E;G0@=&AE($]C=&]B97(@,C`Q
M,2!787)R86YT<R!A<F4@97AE<F-I<V5D(&]N(&$@8V%S:&QE<W,@8F%S:7,L
M('=E('=I;&P@;F]T#0IR96-E:79E(&%N>2!P<F]C965D<RX\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
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M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M1FEN86YC:6YG#0I!9W)E96UE;G0\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!.;W9E;6)E<@T*."P@,C`Q
M,"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@9FEN86YC:6YG(&%R<F%N
M9V5M96YT('=I=&@@1V5M:6YI(%!H87)M86-E=71I8V%L<RP@26YC+BP@82!P
M<F]D=6-T(&1E=F5L;W!M96YT(&%N9"!M86YU9F%C='5R:6YG#0IP87)T;F5R
M(&]F('1H92!#;VUP86YY+"!P=7)S=6%N="!T;R!W:&EC:"!'96UI;FD@4&AA
M<FUA8V5U=&EC86QS(&UA9&4@82`D,C4P+#`P,"!S=')A=&5G:6,@97%U:71Y
M(&EN=F5S=&UE;G0@:6X@=&AE($-O;7!A;GD@86YD#0IA9W)E960@=&\@;6%K
M92!A("0W-3`L,#`P('!U<F-H87-E(&]R9&5R(&QI;F4@;V8@8W)E9&ET(&9A
M8VEL:71Y(&%V86EL86)L92!T;R!T:&4@0V]M<&%N>2X\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4
M:&4@86=G<F5G871E#0IA;6]U;G0@;V8@;W5T<W1A;F1I;F<@061V86YC97,@
M879A:6QA8FQE('1O('1H92!#;VUP86YY('5N9&5R('1H92!,:6YE(&]F($-R
M961I="!M87D@;F]T(&5X8V5E9"`D-S4P+#`P,"XP,"!A="!A;GD@=&EM92X@
M5&AE(&-R961I=`T*86UO=6YT<R!A=F%I;&%B;&4@=&\@=&AE($-O;7!A;GD@
M=VEL;"!B92!T:65R960L('-T87)T:6YG(&%T("0R-3`L,#`P(&%N9"!W:6QL
M(')A;7`@=7`@=&\@)#4P,"PP,#`@86YD('1H96X@)#<U,"PP,#`@=7!O;B!A
M8VAI979E;65N=`T*;V8@9&5T97)M:6YE9"!M:6QE<W1O;F5S+B!4:&4@061V
M86YC97,@<F5Q=65S=&5D('5N9&5R('1H92!,:6YE(&]F($-R961I="!M87D@
M;VYL>2!B92!U<V5D(&9O<B!P=7)C:&%S97,@;V8@<')O9'5C=',@86YD(&EN
M=F5N=&]R>0T*9G)O;2!'96UI;FD@4&AA<FUA8V5U=&EC86QS+CPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H
M92!O=71S=&%N9&EN9PT*<')I;F-I<&%L(&]F(&%L;"!!9'9A;F-E<R!U;F1E
M<B!T:&4@3&EN92!O9B!#<F5D:70@=VEL;"!B96%R(&EN=&5R97-T(&%T('1H
M92!R871E(&]F(&EN=&5R97-T(&]F('!R:6UE('!L=7,@,B!P97)C96YT('!E
M<B!A;FYU;2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
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M;R!P=7)C:&%S92`S,#`L,#`P(&%D9&ET:6]N86P@<VAA<F5S(&]F($-O;6UO
M;CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/E-T;V-K(&%T(&$-"G-H87)E('!R:6-E(&]F("0P+C$R+B!4:&4@
M=V%R<F%N=',@8V]N=&%I;B!A(&-A<VAL97-S(&5X97)C:7-E('!R;W9I<VEO
M;BX@5&AE('=A<G)A;G1S('9E<W0@87,@9F]L;&]W<SH@-3`E(&EM;65D:6%T
M96QY+"`R-24@=VAE;@T*=&AE(&-R961I="!L:6YE(&ES(&EN8W)E87-E9"!T
M;R`D-3`P+#`P,"P@86YD('1H92!R96UA:6YI;F<@,C4E('=H96X@=&AE(&-R
M961I="!L:6YE(&ES(&EN8W)E87-E9"!T;R`D-S4P+#`P,"X\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY*;VEN
M="!696YT=7)E<SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
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M871F;W)M<R!A;F0@8VAA;FYE;',N)B,Q-C`[)B,Q-C`[96YG86=E.D)$4@T*
M<&%R=&YE<G,@=VET:"!M;W-T(&]F(&-O;5-C;W)E)W,@=&]P(#$P,#`@=V5B
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M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^26X@36%R8V@@
M,C`Q,@T*=&AE($-O;7!A;GD@<VEG;F5D(&$@=&5R;2!S:&5E="!W:71H(&5N
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M:F]I;G0@=F5N='5R92!A<G)A;F=E;65N="`H=&AE("8C,30W.TIO:6YT(%9E
M;G1U<F4F(S$T.#LI('=I=&@@96YG86=E.D)$4BP@26YC+CH\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D$N)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE#0I#
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M(&QA=&4@,C`Q,"!A;F0@96%R;'D@,C`Q,2XF(S$V,#LF(S$V,#M!9&1I=&EO
M;F%L($]X:7,@<')O9'5C=',@9&5S:6=N871E9"!B>2!T:&4-"D-O;7!A;GD@
M=VEL;"!B92!O9F9E<F5D(&)Y('1H92!*;VEN="!696YT=7)E+B8C,38P.R8C
M,38P.TEF(&)O=&@@<&%R=&EE<R!A9W)E92P@=&AI<F0@<&%R='D@<')O9'5C
M=',@;6%Y(&%L<V\@8F4@;V9F97)E9"!T:')O=6=H#0IT:&4@2F]I;G0@5F5N
M='5R92XF(S$V,#LF(S$V,#M(;W=E=F5R+"!N;W1H:6YG(&EN('1H92!*;VEN
M="!696YT=7)E(&ES(&EN=&5N9&5D('1O('!R;VAI8FET('1H92!#;VUP86YY
M(&9R;VT@;6%R:V5T:6YG+"!D:7-T<FEB=71I;F<-"F%N9"!S96QL:6YG($5R
M9V]&;&5X)B,Q-3,[(&]R(&%N>2!O9B!I=',@;W1H97(@8W5R<F5N="!O<B!F
M=71U<F4@<')O9'5C=',@8GD@;65A;G,@;W1H97(@=&AA;B!T:')O=6=H(&]N
M;&EN92!S86QE<RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D(N)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[3WAI<PT*86YD(&5N9V%G93I"1%(@:&%V92!A9W)E
M960@=&\@;6%K92!T:&4@9F]L;&]W:6YG)B,Q-C`[)B,Q-C`[8V]N=')I8G5T
M:6]N<R!T;R!T:&4@2F]I;G0@5F5N='5R93H\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/BAA*28C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T]X:7,-"G=I;&P@8V]N
M=')I8G5T92!U<"!T;R`D,C0P+#`P,"!D=7)I;F<@=&AE(&9I<G-T('EE87(@
M9F]L;&]W:6YG('1H92!F;W)M871I;VX@;V8@=&AE($IO:6YT(%9E;G1U<F4N
M)B,Q-C`[)B,Q-C`[5&AE<V4@9G5N9',@=VEL;`T*8F4@<')O=FED960@:68L
M('=H96X@86YD(&%S(&YE961E9"!B>2!T:&4@2F]I;G0@5F5N='5R92XF(S$V
M,#LF(S$V,#M/6$E3)B,Q-#8[(&-A<V@@8V%P:71A;"!C;VYT<FEB=71I;VX@
M=VEL;"!B92!U<V5D("AI*2!T;PT*<'5R8VAA<V4@17)G;T9L97@@86YD(&]T
M:&5R('!R;V1U8W1S(&9R;VT@3WAI<RP@870@3UA)4R8C,30V.R!C;W-T+"!W
M:71H;W5T(&%N>2!M87)K=7`L("AI:2D@=&\@<'5R8VAA<V4@=V5B<VET92!M
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
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M($5'5"8C,34S.RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BAC
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M=F5R=&ES:6YG+"!R:6-H(&UE9&EA+`T*:6XM8F%N;F5R(&%N9"!I;BUS=')E
M86T@=FED96\@9&5V96QO<&UE;G0N)B,Q-C`[)B,Q-C`[1'5R:6YG('1H92!I
M;FET:6%L('-T87)T+75P('!H87-E(&]F('1H92!*;VEN="!696YT=7)E+"!E
M;F=A9V4Z0D12('=I;&PL#0IA="!I=',@;W=N(&-O<W0@86YD(&5X<&5N<V4L
M(&%L<V\@;6%N86=E(&%L;"!D87DM=&\M9&%Y(&]N;&EN92!A8W1I=FET:65S
M(&]F('1H92!*;VEN="!696YT=7)E+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^0V%S:`T*9G)O;2!O<&5R871I;VYS(&EN(&5X8V5S<R!O9B!T:&4@86UO
M=6YT<R!N965D960@9F]R(&ET<R!O<&5R871I;VYS(&%N9"!F;W(@<F5A<V]N
M86)L92!R97-E<G9E<RP@<VAA;&P@8F4@9&ES=')I8G5T960@8GD@=&AE($IO
M:6YT#0I696YT=7)E(&EN('1H92!F;VQL;W=I;F<@;W)D97(Z/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P
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M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BAB*28C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.U1H97)E869T97(L#0IA;&P@97AC97-S(&YE
M="!O<&5R871I;F<@8V%S:"!W:6QL(&)E(&1I<W1R:6)U=&5D(#4P+C$E('1O
M($]X:7,@86YD(#0Y+CDE('1O(&5N9V%G93I"1%(N/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
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M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D%S(&%D9&ET:6]N86P-"F-O;G-I9&5R871I;VX@9F]R(&5N9V%G93I"
M1%(@96YT97)I;F<@:6YT;R!T:&4@2F]I;G0@5F5N='5R92!A;F0@9F]R(&-O
M;G1R:6)U=&EN9R!I=',@<V5R=FEC97,@:6X@9&5S:6=N:6YG+"!D979E;&]P
M:6YG(&%N9"!I;7!L96UE;G1I;F<-"G1H92!A9'9E<G1I<VEN9R!P;&%T9F]R
M;2P@870@=&AE('1I;64@=&AA="!T:&4@2F]I;G0@5F5N='5R92!O<&5R871I
M;F<@86=R965M96YT(&ES('-I9VYE9"P@3UA)4R!W:6QL(&=R86YT(&5N9V%G
M93I"1%(@82!T=V\M>65A<@T*;W!T:6]N('1O('!U<F-H87-E($]X:7,@<V5C
M=7)I=&EE<RXF(S$V,#LF(S$V,#M4:&4@;W!T:6]N('-H86QL(&5N=&ET;&4@
M96YG86=E.D)$4B!T;R!P=7)C:&%S92!T:&4@='EP92!O9B!S96-U<FET:65S
M('-O;&0@8GD-"G5S(&EN(&$@9G5T=7)E("0V+#`P,"PP,#`@;W(@;6]R92!F
M:6YA;F-I;F<L(&]N('1H92!S86UE('1E<FUS(&%N9"!C;VYD:71I;VYS+"!A
M;F0@870@=&AE('-A;64@<')I8V4L(&%S('-U8V@@<V5C=7)I=&EE<R!A<F4@
M<V]L9`T*=&\@=&AI<F0@<&%R='D@:6YV97-T;W)S(&EN('-U8V@@9FEN86YC
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M,38P.TEF#0IT:&4@0V]M<&%N>2!H87,@;F]T(')A:7-E9"`D-BPP,#`L,#`P
M(&)Y($1E8V5M8F5R(#,Q+"`R,#$R+"!C;VUM96YC:6YG(&]N('1H870@9&%T
M92P@96YG86=E.D)$4B!W:6QL(&AA=F4@82!T=V\M>65A<B!R:6=H="!T;PT*
M<'5R8VAA<V4@3WAI<R8C,30V.R!C;VUM;VX@<W1O8VL@870@82!P<FEC92!E
M<75A;"!T;R`D+C`S+B8C,38P.R8C,38P.T]825,@:&%S(&%L<V\@86=R965D
M('1O(&ES<W5E('1O(&5N9V%G93I"1%(@82!W87)R86YT('1O#0IP=7)C:&%S
M92!U<"!T;R`U+#`P,"PP,#`@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@
M:68@=&AE($IO:6YT(%9E;G1U<F4L('1H<F]U9V@@96YG86=E.D)$4B!E9F9O
M<G1S+"!A='1A:6YS(&-E<G1A:6X@<F5V96YU90T*86YD('!R;V9I=',@=&%R
M9V5T<RXF(S$V,#LF(S$V,#M4:&4@=V%R<F%N="!W:6QL(&AA=F4@86X@97AE
M<F-I<V4@<')I8V4@;V8@)"XP,R!P97(@<VAA<F4N/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3VX@2G5N92`R
M.2P-"C(P,3$@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@2F]I;G0@5F5N
M='5R92!!9W)E96UE;G0@*"8C,30W.SQU/DIO:6YT(%9E;G1U<F4@06=R965M
M96YT/"]U/B8C,30X.RD@=VET:"!*;VAN($4N(%)E<&EN92P@32Y$+@T**"8C
M,30W.SQU/D1R+B!297!I;F4\+W4^)B,Q-#@[*2P@82!M96UB97(@;V8@=&AE
M($-O;7!A;GDF(S$T-CMS(&%D=FES;W)Y(&)O87)D+B8C,38P.R8C,38P.U5N
M9&5R('1H92!T97)M<R!O9B!T:&4@2F]I;G0@5F5N='5R90T*06=R965M96YT
M+"!T:&4@0V]M<&%N>2!F;W)M960@82!$96QA=V%R92!L:6UI=&5D(&QI86)I
M;&ET>2!C;VUP86YY+"!%<F=O($%21%,L($Q,0R`H=&AE("8C,30W.SQU/D%2
M1%,@5F5N='5R93PO=3XF(S$T.#LI+"!I;@T*=VAI8V@@=&AE($-O;7!A;GD@
M:&]L9',@82`V,"4@;65M8F5R<VAI<"!I;G1E<F5S="!A;F0@1'(N(%)E<&EN
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M(S$T.#LI+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D-O;F-U<G)E;G1L>0T*=VET:"!T:&4@97AE8W5T:6]N
M(&]F('1H92!*;VEN="!696YT=7)E($%G<F5E;65N="P@1'(N(%)E<&EN92!A
M<W-I9VYE9"!H:7,@:6YT97)E<W0@:6X@=&AE('!A=&5N="!A<'!L:6-A=&EO
M;G,@<F5L871I;F<@=&\@=&AE#0IU<V4@;V8@15)'3R!I;B!T<F5A=&EN9R!!
M4D13("AT:&4@)B,Q-#<[/'4^07-S:6=N960@25`\+W4^)B,Q-#@[*2!T;R!T
M:&4@05)$4R!696YT=7)E+B8C,38P.R8C,38P.TEN(&-O;G-I9&5R871I;VX@
M9F]R('1H92!!<W-I9VYE9`T*26YT97)E<W0L($1R+B!297!I;F4@=V%S(&ES
M<W5E9"!A(#0P)2!M96UB97)S:&EP(&EN=&5R97-T(&EN('1H92!!4D13(%9E
M;G1U<F4N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
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M(&)Y('1H92!!4D13(%9E;G1U<F4N)B,Q-C`[)B,Q-C`[06YY(&9U='5R92!P
M87EM96YT<PT*=&\@1'(N(%)E<&EN92!S:&%L;"!B92!M861E(&)A<V5D(&]N
M('1H92!A8VAI979E;65N="!O9B!F;VQL;W=I;F<@;6EL97-T;VYE<R!W:71H
M(')E<W!E8W0@=&\@<')O9'5C=',@=&\@8F4@8V]M;65R8VEA;&EZ960@=7-I
M;F<-"G1H92!!<W-I9VYE9"!)4#H\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B
M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W
M:61T:#H@,3`P)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@.39P>#L@9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$X,SLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/E1H92!!4D13(%9E;G1U<F4-"B`@("!S:&%L
M;"!P87D@=&AE(&9O;&QO=VEN9R!C87-H(&%M;W5N=',@=&\@1'(N(%)E<&EN
M92!U<&]N('1H92!A='1A:6YM96YT(&]F('1H92!F;VQL;W=I;F<@;6EL97-T
M;VYE<SH\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*&DI)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[3&EC96YS:6YG#0IT:&4@07-S:6=N
M960@25`@=&\@82!P:&%R;6%C975T:6-A;"!C;VUP86YY("TM("0Q+#`P,"PP
M,#`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD
M96YT.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH:6DI)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[0V]M<&QE=&EO;@T*;V8@4&AA<V4@22!#;&EN:6-A;"!4<FEA;"`M+2`D
M,C4P+#`P,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
M,C!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L-"B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.RAI:6DI)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0V]M<&QE=&EO
M;B!O9B!0:&%S92!)22!#;&EN:6-A;`T*5')I86P@+2T@)#$L,#`P+#`P,#L\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BAI=BDF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M#
M;VUP;&5T:6]N#0IO9B!P:79O=&%L(%!H87-E($E)22!#;&EN:6-A;"!4<FEA
M;"`M+2`D,2PU,#`L,#`P.R!A;F0\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BAV*28C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.U)E8V5I<'0-"F]F($9$02!-87)K971I;F<@
M87!P<F]V86P@+2T@)#,L,#`P+#`P,#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y-G!X.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,3@S.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5&AE($%21%,@5F5N='5R90T*("`@('-H
M86QL('!A>2!T:&4@9F]L;&]W:6YG(&-A<V@@86UO=6YT<R!T;R!$<BX@4F5P
M:6YE('5P;VX@=&AE(&%T=&%I;FUE;G0@;V8@=&AE(&9O;&QO=VEN9R!M:6QE
M<W1O;F5S.CPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@<W1Y
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M<&%N>2`M+2`D,3`P+#`P,#L@86YD/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH:6DI
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[1W)O<W,-"G-A;&5S(&]F('!R;V1U8W1S
M('5T:6QI>FEN9R!%1U0F(S$U,SL@:6X@=&AE(&9I96QD("8C,34P.R`U)2!O
M9B!A;FYU86P@9W)O<W,@<V%L97,@8GD@=&AE($%21%,@5F5N='5R92!O<B!A
M;GD@;&EC96YS964@;W(@9&ES=')I8G5T;W(-"BAI;F-L=61I;F<@3WAI<RDN
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT
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M+`T*=&AE($%21%,@5F5N='5R92!W:6QL(&-O;G1I;G5E('1O(&AO;&0@=&AE
M(&EN=&5L;&5C='5A;"!P<F]P97)T>2XF(S$V,#LF(S$V,#M)9B!T:&4@<&%R
M=&EE<R!A9W)E92!T;R!P<F]C965D+"!/>&ES('=I;&P@=7-E(&ET<PT*8F5S
M="!E9F9O<G1S('1O(')A:7-E("0S(&UI;&QI;VX@9F]R('1H92!!4D13(%9E
M;G1U<F4N)B,Q-C`[)B,Q-C`[3VYC92!T:&4@)#,@;6EL;&EO;B!I;B!F=6YD
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M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4:&4@05)$4R!696YT=7)E
M#0IW:6QL(&)E(&UA;F%G960@8GD@1'(N(%)E<&EN92!A<R!-86YA9V5R+"!W
M:&\@=VEL;"!A;'-O('-E<G9E(&%S('1H92!!4D13(%9E;G1U<F4F(S$T-CMS
M($-H:65F($5X96-U=&EV92!/9F9I8V5R(&%N9"!4<F5A<W5R97(N#0I4:&4@
M05)$4R!696YT=7)E('=I;&P@86QS;R!H879E(&$@8F]A<F0@;V8@9FEV92!M
M96UB97)S+"!C;VYS:7-T:6YG(&]F($1R+B!297!I;F4@86YD(&$@9&5S:6=N
M964@;V8@1'(N(%)E<&EN92P@86YD('1H<F5E(&1E<VEG;F5E<PT*;V8@3WAI
M<RX\+V9O;G0^/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#5B
M9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB
M,#@W-69B-&%D-2]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#0@+2!3=&]C:VAO;&1E
M<G,G($5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D5Q=6ET>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&4@-"`M(%-T;V-K:&]L
M9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D-O;6UO;B!3
M=&]C:SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E5N9&5R('1H90T*0V]M<&%N>2=S(%-E8V]N9"!!;65N9&5D
M(&%N9"!297-T871E9"!#97)T:69I8V%T92!O9B!);F-O<G!O<F%T:6]N+"!T
M:&4@0V]M<&%N>2!W87,@875T:&]R:7IE9"!T;R!I<W-U92!A('1O=&%L(&]F
M(#$U,"PP,#`L,#`P)B,Q-C`[<VAA<F5S#0IO9B!#;VUM;VX@4W1O8VLN/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^3VX@2F%N=6%R>0T*-2P@,C`Q,2P@=&AE($-O;7!A;GDG<R!";V%R9"!O
M9B!$:7)E8W1O<G,@87!P<F]V960@86X@86UE;F1M96YT('1O(&ET<R!396-O
M;F0@06UE;F1E9"!A;F0@4F5S=&%T960@0V5R=&EF:6-A=&4@;V8@26YC;W)P
M;W)A=&EO;@T*=&\@:6YC<F5A<V4@=&AE('-H87)E<R!O9B!#;VUM;VX@4W1O
M8VL@=&AA="!A<F4@875T:&]R:7IE9"!F;W(@:7-S=6%N8V4@8GD@-#4P+#`P
M,"PP,#`@<VAA<F5S+"!B<FEN9VEN9R!T:&4@=&]T86P@;G5M8F5R(&]F(&-O
M;6UO;@T*<VAA<F5S(&%U=&AO<FEZ960@9F]R(&ES<W5A;F-E('1O(#8P,"PP
M,#`L,#`P+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E1H92!A<'!R;W9A;`T*;V8@=&AE($%M96YD;65N="!R
M97%U:7)E9"!T:&4@8V]N<V5N="!O9B!N;R!L97-S('1H86X@870@;&5A<W0@
M82!M86IO<FET>2!O9B!T:&4@=F]T:6YG('!O=V5R(&]F('1H92!#;VUP86YY
M+B8C,38P.R8C,38P.U1H96]R96T-"D=R;W5P+"!,3$,@;W=N<RP@:6X@861D
M:71I;VX@=&\@;W1H97(@;V8@;W5R('-E8W5R:71I97,L(#(U+#`P,"!S:&%R
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M92!C;VYV97)T960@:6YT;R`H0BD@;75L=&EP;&EE9"!B>2`Q,#`N)B,Q-C`[
M)B,Q-C`[5&AE#0I397)I97,@2"!#;VYV97)T:6)L92!0<F5F97)R960@4W1O
M8VL@:7,@8W5R<F5N=&QY(&-O;G9E<G1I8FQE(&EN=&\@,BPU,#`L,#`P('-H
M87)E<R!O9B!#;VUM;VX@4W1O8VLN)B,Q-C`[)B,Q-C`[06-C;W)D:6YG;'DL
M(%1H96]R96T-"D=R;W5P+"!,3$,@:&%S('1H92!V;W1I;F<@<&]W97(@;V8@
M,C4P+#`P,"PP,#`@<VAA<F5S+"!W:&EC:"!R97!R97-E;G1S(&UO<F4@=&AA
M;B!A(&UA:F]R:71Y(&]F('9O=&EN9R!P;W=E<B!O9B!A;&P@;V8@=&AE($-O
M;7!A;GDG<PT*;W5T<W1A;F1I;F<@=F]T:6YG('-H87)E<RXF(S$V,#LF(S$V
M,#M4:&5O<F5M($=R;W5P+"!,3$,@87!P<F]V960@=&AE($%M96YD;65N="!O
M;B!*86YU87)Y(#4L(#(P,3$@8GD@86X@86-T:6]N('1A:V5N(&)Y('=R:71T
M96X-"F-O;G-E;G0N)B,Q-C`[)B,Q-C`[5&AE(&%M96YD;65N="!W87,@9FEL
M960@=VET:"!T:&4@1&5L87=A<F4@4V5C<F5T87)Y(&]F(%-T871E(&EN($9E
M8G)U87)Y(#(P,3$N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^16%C:"!S:&%R90T*;V8@8V]M;6]N('-T;V-K
M(&ES(&5N=&ET;&5D('1O(&]N92!V;W1E(&%T('1H92!#;VUP86YY)W,@86YN
M=6%L(&UE971I;F<@;V8@<W1O8VMH;VQD97)S+CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1U<FEN9R!T:&4-
M"FYI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,B!A;F0@,C`Q
M,2P@=&AE($-O;7!A;GD@:7-S=65D(&$@=&]T86P@;V8@,38P+#$P-RPT-S4@
M86YD(#8Q+#@S,2PV.#,@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP-"G)E<W!E
M8W1I=F5L>2!F;W(@<F5T:7)E;65N="!O9B!D96)T('9A;'5E9"!A="`D,BPS
M.#(L,C@Q(&%N9"`D,2PQ-#0L,#`P+"!R97-P96-T:79E;'DN/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^4')E9F5R<F5D#0I3=&]C:SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H92`Y-BPR,S`-"G-H87)E<R!O
M9B!397)I97,@0R!P<F5F97)R960@<W1O8VL@87)E(&-O;G9E<G1I8FQE(&EN
M=&\@,C<L.#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S(&-O;6UO;B!S=&]C
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M=&AA;B`N,C`@;W(@;6]R92!T:&%N#0HN,C@X.2!C;VUM;VX@<VAA<F5S(&9O
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M36%R:V5T(&9O<B`Q-2!C;VYS96-U=&EV92!T<F%D:6YG(&1A>7,@97AC965D
M<R`D,3,N,#`N($5A8V@@<VAA<F4@;V8@4V5R:65S($,@<')E9F5R<F5D('-T
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M97!T96UB97(@,S`L#0HR,#$R+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]N($1E8V5M8F5R#0HT+"`R,#`X
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86YD(&-L;W-E9"!A;B!!9W)E
M96UE;G0@*'1H92`F(S$T-SM"<FES=&]L($%G<F5E;65N="8C,30X.RD@=VET
M:"!"<FES=&]L($EN=F5S=&UE;G0@1G5N9"P-"DQT9"X@<'5R<W5A;G0@=&\@
M=VAI8V@@0G)I<W1O;"!A9W)E960@=&\@8V%N8V5L('1H92!D96)T('!A>6%B
M;&4@8GD@=&AE($-O;7!A;GD@=&\@0G)I<W1O;"!I;B!T:&4@86UO=6YT(&]F
M(&%P<')O>&EM871E;'D@)#(P+#`P,`T*:6X@8V]N<VED97)A=&EO;B!O9B!T
M:&4@0V]M<&%N>2!I<W-U:6YG($)R:7-T;VP@,C4L,#`P('-H87)E<R!O9B!3
M97)I97,F(S$V,#M'($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:RP@=VAI
M8V@@<W5C:"!S:&%R97,-"F-A<G)Y(&$@<W1A=&5D('9A;'5E(&5Q=6%L('1O
M("0Q+C`P('!E<B!S:&%R92`H=&AE("8C,30W.U-E<FEE<R8C,38P.T<@4W1O
M8VLF(S$T.#LI+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E1H92!397)I97,F(S$V,#M'#0I3=&]C:R!I<R!C
M;VYV97)T:6)L92P@870@86YY('1I;64@870@=&AE(&]P=&EO;B!O9B!T:&4@
M:&]L9&5R+"!I;G1O(&-O;6UO;B!S:&%R97,@;V8@=&AE($-O;7!A;GD@8F%S
M960@;VX@82!C;VYV97)S:6]N('!R:6-E(&5Q=6%L#0IT;R!T:&4@;&5S<V5R
M(&]F("0N,#$@;W(@-C`E(&]F('1H92!A=F5R86=E(&]F('1H92!T:')E92!L
M;W=E<W0@=')A9&EN9R!P<FEC97,@;V-C=7)R:6YG(&%T(&%N>2!T:6UE(&1U
M<FEN9R!T:&4@,C`@=')A9&EN9R!D87ES#0IP<F5C961I;F<@=&AE(&-O;G9E
M<G-I;VXN)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE(%-E<FEE<R8C,38P.T<@4W1O
M8VLL(&%S(&%M96YD960L)B,Q-C`[<VAA;&P@:&%V92!V;W1I;F<@<FEG:'1S
M(&]N(&%N(&%S(&-O;G9E<G1E9`T*8F%S:7,@;75L=&EP;&EE9"!B>2`Q,#`N
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^26X@=&AE(&5V96YT#0IO9B!A;GD@;&EQ=6ED871I;VX@;W(@=VEN
M9&EN9R!U<"!O9B!T:&4@0V]M<&%N>2P@=&AE(&AO;&1E<G,@;V8@4V5R:65S
M)B,Q-C`[1R!3=&]C:R!W:6QL(&)E(&5N=&ET;&5D('1O(')E8V5I=F4L(&EN
M('!R969E<F5N8V4-"G1O(&AO;&1E<G,@;V8@8V]M;6]N('-T;V-K+"!A;B!A
M;6]U;G0@97%U86P@=&\@=&AE('-T871E9"!V86QU92!P;'5S(&EN=&5R97-T
M(&]F(#$U)2!P97(@>65A<BX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
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M=6-H(&-O;G9E<G-I;VX@9&]E<PT*;F]T(&5X8V5E9"`T+CDE(&]F('1H92!#
M;VUP86YY)B,Q-#8[<R!T:&5N(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4:&4@4V5R:65S#0I'(%-T;V-K
M('=A<R!P<F5V:6]U<VQY(')E9F5R<F5D('1O(&EN(&%N(#@M2R!F:6QE9"!B
M>2!T:&4@0V]M<&%N>2!O;B!$96-E;6)E<B`Q,"P@,C`P."!I;B!E<G)O<B!A
M<R!T:&4@)B,Q-#<[4V5R:65S($4@4W1O8VLF(S$T.#LN#0I&=7)T:&5R+"!T
M:&4@4V5R:65S($<@4W1O8VL@:6YI=&EA;&QY(&EN8V]R<F5C=&QY('!R;W9I
M9&5D('1H870@:70@=F]T960@;VX@86X@87,@8V]N=F5R=&5D(&)A<VES(&UU
M;'1I<&QI960@8GD@,3`N)B,Q-C`[)B,Q-C`[5&AI<PT*:6YC;W)R96-T;'D@
M<F5F;&5C=&5D('1H92!I;G1E;G0@;V8@=&AE($-O;7!A;GD@86YD('1H92!H
M;VQD97(N)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
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M97,@<')O=FED960@8GD@=&AE(%-E<FEE<R!'(%-T;V-K+CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5F9F5C
M=&EV90T*1F5B<G5A<GD@,3`L(#(P,3`L('1H92!#;VUP86YY(&ES<W5E9"`R
M-2PP,#`@<VAA<F5S(&]F(&ET<R!N97<@4V5R:65S($@@0V]N=F5R=&EB;&4@
M4')E9F5R<F5D(%-T;V-K("AT:&4@)B,Q-#<[4V5R:65S($@@4')E9F5R<F5D
M)B,Q-#@[*0T*=&\@5&AE;W)E;2!'<F]U<"P@3$Q#+"!A($-A;&EF;W)N:6$@
M;&EM:71E9"!L:6%B:6QI='D@8V]M<&%N>2`H=&AE("8C,30W.U-T;V-K:&]L
M9&5R)B,Q-#@[*2P@:6X@97AC:&%N9V4@9F]R('1H92`R-2PP,#`@<VAA<F5S
M#0IO9B!397)I97,@1R!3=&]C:R!T:&5N(&]W;F5D(&)Y('1H92!3=&]C:VAO
M;&1E<BXF(S$V,#LF(S$V,#M4:&4@9F]R96=O:6YG(&5X8VAA;F=E('=A<R!E
M9F9E8W1E9"!P=7)S=6%N="!T;R!T:&%T(&-E<G1A:6X@17AC:&%N9V4-"D%G
M<F5E;65N="P@9&%T960@1F5B<G5A<GD@,3`L(#(P,3`L(&)E='=E96X@=&AE
M($-O;7!A;GD@86YD('1H92!3=&]C:VAO;&1E<B`H=&AE("8C,30W.T5X8VAA
M;F=E($%G<F5E;65N="8C,30X.RDN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M;F%T:6]N(&]F('1H92!397)I97,@1R!0<F5F97)R960N)B,Q-C`[)B,Q-C`[
M4V]M92!O9B!T:&4@8V]R<F5C=&EO;G,L(&-H86YG97,@86YD(&1I9F9E<F5N
M8V5S(&)E='=E96X@=&AE($-E<G1I9FEC871E(&]F#0I$97-I9VYA=&EO;B!O
M9B!T:&4@4V5R:65S($<@4')E9F5R<F5D(&%N9"!T:&4@0V5R=&EF:6-A=&4@
M;V8@1&5S:6=N871I;VX@;V8@=&AE(%-E<FEE<R!((%!R969E<G)E9"!I;F-L
M=61E('1H92!F;VQL;W=I;F<Z/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#0X<'@[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q.#,[)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY!<R!P<F5V:6]U<VQY(&1I<V-L;W-E9"P-"B`@
M("!T:&4@:&]L9&5R(&]F('1H92!397)I97,@2"!0<F5F97)R960@:7,@96YT
M:71L960@=&\@=F]T92!W:71H('1H92!C;VUM;VX@<W1O8VLL(&%N9"!I<R!E
M;G1I=&QE9"!T;R!A(&YU;6)E<B!O9B!V;W1E<R!E<75A;`T*("`@('1O("AI
M*2!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:70@8V%N
M(&-O;G9E<G0@:6YT;R`H=VET:&]U="!A;GD@<F5S=')I8W1I;VYS(&]R(&QI
M;6ET871I;VYS(&]N('-U8V@@8V]N=F5R<VEO;BDL#0H@("`@*&EI*2!M=6QT
M:7!L:65D(&)Y(#$P,"X\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!X.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,3@S.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE(&AO;&1E<B!O9B!T:&4-
M"B`@("!397)I97,@2"!0<F5F97)R960@8V%N;F]T(&-O;G9E<G0@<W5C:"!P
M<F5F97)R960@<W1O8VL@:6YT;R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&EF
M('1H92!H;VQD97(@86YD(&ET<R!A9F9I;&EA=&5S(&%F=&5R#0H@("`@<W5C
M:"!C;VYV97)S:6]N('=O=6QD(&]W;B!M;W)E('1H86XF(S$V,#LY+CDE(&]F
M('1H92!#;VUP86YY)B,Q-#8[<R!T:&5N(&ES<W5E9"!A;F0@;W5T<W1A;F1I
M;F<@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\+V9O;G0^/"]T9#X\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T.'!X
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,3@S.R8C,38P.R8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE(%-E
M<FEE<R!'(%!R969E<G)E9`T*("`@(&-O;G1A:6YE9"!A(&QI;6ET871I;VX@
M=&AA="!T:&4@:&]L9&5R(&]F('1H92!397)I97,@1R!0<F5F97)R960@8V]U
M;&0@;F]T(&-O;G9E<G0@<W5C:"!P<F5F97)R960@<VAA<F5S(&EN=&\@;6]R
M92!T:&%N(#$Y+CDY.24-"B`@("!O9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N
M9&EN9R!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=I=&AO=70@=&AE(&%P<')O
M=F%L(&]F('1H92!S=&]C:VAO;&1E<G,@:68@=&AE(')U;&5S(&]F('1H92!P
M<FEN8VEP86P-"B`@("!M87)K970@;VX@=VAI8V@@=&AE(&-O;6UO;B!S=&]C
M:R!I<R!T<F%D960@=V]U;&0@<')O:&EB:70@<W5C:"!A(&-O;G9E<G-I;VXN
M)B,Q-C`[)B,Q-C`[4VEN8V4@=&AE(')U;&5S(&]F('1H92!#;VUP86YY)B,Q
M-#8[<PT*("`@('!R:6YC:7!A;"!M87)K970@9&ED(&YO="!R97%U:7)E('-U
M8V@@82!L:6UI=&%T:6]N+"!T:&%T('!R;W9I<VEO;B!H87,@8F5E;B!D96QE
M=&5D+CPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^3VX@3F]V96UB97(-"C@L(#(P,3`L
M($=E;6EN:2!0:&%R;6%C975T:6-A;',@<'5R8VAA<V5D(#$L-C8V+#8V-R!S
M:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(%-E<FEE<R!)(%!R969E<G)E
M9"!3=&]C:RP@)"XP,#$@<&%R('9A;'5E+"!A=`T*82!P<FEC92!O9B`D,"XQ
M-2!P97(@<VAA<F4@*"0R-3`L,#`P*2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M('=H;VQE(&]R(&EN('!A<G0N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
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M:R!I<R!T:&5N(&-O;G9E<G1I8FQE+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
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M9"!B>2!T:&4@0F]A<F0@:6X@=&AE(&%M;W5N=`T*;V8@)#`N,34@<&5R('-H
M87)E("AA<R!A9&IU<W1E9"!F;W(@86YY('-T;V-K(&1I=FED96YD<RP@8V]M
M8FEN871I;VYS(&]R('-P;&ET<R!W:71H(')E<W!E8W0@=&\@<W5C:"!S:&%R
M97,I+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M.R8C,38P.TEN:71I86QL>2P@=&AE(%-E<FEE<R!)(%!R969E<G)E9`T*4W1O
M8VL@:7,@8V]N=F5R=&EB;&4@:6YT;R`Q+#8V-BPV-C<@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY);B!T:&4@979E;G0-"G1H870@=&AE('!E<BUS
M:&%R92!-87)K970@4')I8V4@;V8@=&AE($-O;6UO;B!3=&]C:R!O=F5R(&$@
M<&5R:6]D(&]F(#(P(&-O;G-E8W5T:79E('1R861I;F<@9&%Y<R!I<R!E<75A
M;"!T;R!A="!L96%S="`Q,S`E(&]F#0IT:&4@:6YI=&EA;"!C;VYV97)S:6]N
M('!R:6-E("@Q,S`E(&]F("0P+C$U*2P@86QL(&]U='-T86YD:6YG('-H87)E
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M#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0U8F9C9C4X7V4Y9CA?-&8U,5\Y
M-#9D7SAB,#@W-69B-&%D-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4O5V]R:W-H
M965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^3F]T92`U("T@4W1O8VL@3W!T:6]N<R!A;F0@5V%R<F%N=',\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY'=6%R86YT965S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92`U("T@4W1O8VL@3W!T:6]N<R!A
M;F0@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP
M('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4W1O8VL-"D]P
M=&EO;G,\+V9O;G0^(#PO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^1F]L;&]W:6YG#0II<R!A('-U;6UA<GD@;V8@=&AE('-T
M;V-K(&]P=&EO;B!A8W1I=FET>3H\+V9O;G0^(#PO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'1A
M8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T
M:#H@,3`P)2<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M3W!T:6]N<PT*("`@($]U='-T86YD:6YG/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU
M<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E:6=H=&5D
M#0H@("`@079E<F%G92!%>&5R8VES92!0<FEC93PO9F]N=#X\+W1D/@T*("`@
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M(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`W-B4[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/=71S=&%N9&EN9PT*
M("`@(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
M)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$V+#`W."PY-SD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[('=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@
M,24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@
M.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XQ.3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N=#H@.7!T
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^1W)A;G1E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-BPS.#0L,3DS/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,"XP-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6EN9&5N=#H@.7!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F]R9F5I=&5D
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C,L-C<Y+#`R-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N,3<\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@=&5X="UI;F1E;G0Z(#EP=#L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5X97)C
M:7-E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]U='-T86YD:6YG#0H@("`@
M87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`S<'0[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,X+#<X-"PQ
M-#4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP.#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5X
M97)C:7-A8FQE#0H@("`@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`S<'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C(S+#0Q-2PT-#$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,"XP.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,W!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY7
M87)R86YT<SPO9F]N=#X@/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY&;VQL;W=I;F<-"FES(&$@<W5M;6%R>2!O9B!T:&4@
M=V%R<F%N="!A8W1I=FET>3H\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q
M,#`E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY787)R
M86YT<PT*("`@($]U='-T86YD:6YG/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@
M<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E:6=H=&5D#0H@
M("`@079E<F%G92!%>&5R8VES92!0<FEC93PO9F]N=#X\+W1D/@T*("`@(#QT
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M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`W-B4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/=71S=&%N9&EN9PT*("`@
M(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P-2PP,#$L,C4R)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP
M-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N=#H@.7!T.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1W)A
M;G1E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXT-C(L,S`P+#4T-B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N,#$\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#EP=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9O<F9E:71E9#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXU,BPU,#`L,#`P)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP,3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#EP=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D%D:G5S=&UE;G1S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q-2PS
M,#`L,#`P*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C`N,#$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CL@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R!T97AT+6EN9&5N=#H@.7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V5D/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$U,3L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$U,3L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D]U='-T86YD:6YG#0H@("`@87,@;V8@4V5P=&5M
M8F5R(#,P+"`R,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`S<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0Y.2PU,#$L-SDX)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`S
M<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N,#$\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G;6%R9VEN.B`P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^26X@07!R:6P@,C`Q,BP-"G1H92!#
M;VUP86YY(&%G<F5E9"!T;R!A;B!A9&IU<W1M96YT(&%S(&YE9V]T:6%T960@
M=&\@96YA8FQE(&EN9'5C96UE;G0@;V8@9G5R=&AE<B!F:6YA;F-I;F<@;V8@
M=&AE($-O;7!A;GDN)B,Q-C`[)B,Q-C`[4'5R<W5A;G0-"G1O('1H92!A;G1I
M+61I;'5T:6]N('!R;W9I<VEO;G,@:6X@=&AE('=A<G)A;G1S+"!T:&4@97AE
M<F-I<V4@<')I8V4@;V8@8V5R=&%I;B!W87)R86YT<R!I<R!N;W<@)#`N,#$L
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M<FEC92!O9B`D,"XP,2X\+V9O;G0^/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?
M-&8U,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K<VAE971S+U-H965T,3(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#8@
M+2!!9'9I<V]R>2!A;F0@0V]N<W5L=&EN9R!!9W)E96UE;G1S($]B;&EG871I
M;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3F]T97,@=&\@1FEN86YC:6%L(%-T871E;65N=',\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92`V("T@061V
M:7-O<GD@86YD($-O;G-U;'1I;F<@06=R965M96YT<R!/8FQI9V%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R
M9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!9'9I<V]R>2!!9W)E96UE;G1S/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^5&AE($-O;7!A;GD-"F5N=&5R960@:6YT;R!A('1W;RUY96%R(%-C:65N
M=&EF:6,@061V:7-O<GD@0F]A<F0@4V5R=FEC97,@06=R965M96YT('=I=&@@
M3"X@4W1E<&AE;B!#;VQE<R!O;B!-87)C:"`T+"`R,#$P+B8C,38P.R8C,38P
M.TUR+B!#;VQE<PT*<F5C96EV97,@86X@861V:7-O<GD@9F5E(&9O<B`D.2PP
M,#`@<&5R('%U87)T97(N)B,Q-C`[)B,Q-C`[57!O;B!E;G1E<FEN9R!I;G1O
M('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY(&=R86YT960@37(N($-O;&5S
M(&%N#0II;FET:6%L(&]P=&EO;B!T;R!P=7)C:&%S92`R-3`L,#`P('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K('5N9&5R(&ET
M<R`R,#`S(%-T;V-K($EN8V5N=&EV92!0;&%N+B8C,38P.R8C,38P.U1H90T*
M;W!T:6]N<R!V97-T(&%N9"!B96-O;64@97AE<F-I<V%B;&4@:6X@9F]U<B!E
M<75A;"!Q=6%R=&5R;'D@:6YS=&%L;&UE;G1S(&)E9VEN;FEN9R!*=6YE(#0L
M(#(P,3`N)B,Q-C`[)B,Q-C`[4'5R<W5A;G0@=&\@=&AE('1E<FUS#0IO9B!T
M:&4@86=R965M96YT+"!A('-E8V]N9"!O<'1I;VX@=&\@<'5R8VAA<V4@-3`P
M+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C
M:R!U;F1E<B!O=7(@,C`P,R!3=&]C:R!);F-E;G1I=F4-"E!L86X@=V%S(&=R
M86YT960@;VX@36%R8V@@-"P@,C`Q,2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4:&4@0V]M<&%N
M>0T*96YT97)E9"!I;G1O(&$@='=O+7EE87(@4V-I96YT:69I8R!!9'9I<V]R
M>2!";V%R9"!397)V:6-E<R!!9W)E96UE;G0@=VET:"!286IA;B!3:&%H(&]N
M($IU;'D@,34L(#(P,3`N)B,Q-C`[)B,Q-C`[37(N(%-H86@@<F5C96EV97,-
M"F%N(&%D=FES;W)Y(&9E92!F;W(@)#DL,#`P('!E<B!Q=6%R=&5R+B8C,38P
M.R8C,38P.U5P;VX@96YT97)I;F<@:6YT;R!T:&4@86=R965M96YT+"!T:&4@
M0V]M<&%N>2!G<F%N=&5D($UR+B!3:&%H(&%N(&EN:71I86P@;W!T:6]N#0IT
M;R!P=7)C:&%S92`R-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C,30V
M.W,@8V]M;6]N('-T;V-K('5N9&5R(&ET<R`R,#`S(%-T;V-K($EN8V5N=&EV
M92!0;&%N+B8C,38P.R8C,38P.U1H92!O<'1I;VYS('9E<W1E9`T*86YD(&)E
M8V]M92!E>&5R8VES86)L92!I;B!F;W5R(&5Q=6%L('%U87)T97)L>2!I;G-T
M86QL;65N=',@8F5G:6YN:6YG($]C=&]B97(@,34L(#(P,3`N/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE
M($-O;7!A;GD-"F5N=&5R960@:6YT;R!A('1W;RUY96%R($%D=FES;W)Y($)O
M87)D(%-E<G9I8V5S($%G<F5E;65N="!W:71H(%-A;F1E<"!286AI(&]N($IU
M;'D@,34L(#(P,3`N)B,Q-C`[)B,Q-C`[37(N(%)A:&D@<F5C96EV97,@86X@
M861V:7-O<GD-"F9E92!F;W(@)#DL,#`P('!E<B!Q=6%R=&5R+B8C,38P.R8C
M,38P.U5P;VX@96YT97)I;F<@:6YT;R!T:&4@86=R965M96YT+"!T:&4@0V]M
M<&%N>2!G<F%N=&5D($UR+B!286AI(&%N(&EN:71I86P@;W!T:6]N('1O('!U
M<F-H87-E#0HR-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C,30V.W,@
M8V]M;6]N('-T;V-K('5N9&5R(&ET<R`R,#`S(%-T;V-K($EN8V5N=&EV92!0
M;&%N+B8C,38P.R8C,38P.U1H92!O<'1I;VYS('9E<W1E9"!A;F0@8F5C;VUE
M#0IE>&5R8VES86)L92!I;B!F;W5R(&5Q=6%L('%U87)T97)L>2!I;G-T86QL
M;65N=',@8F5G:6YN:6YG($]C=&]B97(@,34L(#(P,3`N)B,Q-C`[)B,Q-C`[
M4'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F('1H92!A9W)E96UE;G0L#0IA('-E
M8V]N9"!O<'1I;VX@=&\@<'5R8VAA<V4@-3`P+#`P,"!S:&%R97,@;V8@=&AE
M($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:R!U;F1E<B!I=',@,C`P,R!3
M=&]C:R!);F-E;G1I=F4@4&QA;B!W87,@9W)A;G1E9`T*;VX@2G5L>2`Q-2P@
M,C`Q,2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY#;VYS=6QT:6YG#0I!9W)E96UE;G1S/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3VX@2F%N
M=6%R>0T*,2P@,C`Q,2P@=V4@96YT97)E9"!I;G1O(&$@8V]N<W5L=&EN9R!A
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M=&AE<V4@<V5R=FEC97,L('=E(&ES<W5E9"`U+#`P,"PP,#`@<VAA<F5S(&]F
M(&]U<B!C;VUM;VX@<W1O8VLN(%1H92!T97)M#0IO9B!T:&4@86=R965M96YT
M(&ES(&9O<B!S:7@@;6]N=&AS('5N;&5S<R!T97)M:6YA=&5D(&]R(&5X=&5N
M9&5D(&EN(&%C8V]R9&%N8V4@=VET:"!S=6)S97%U96YT(&%G<F5E;65N=',@
M8F5T=V5E;B!T:&4@<&%R=&EE<RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!*86YU87)Y#0HQ+"`R,#$Q
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M9"!B=7-I;F5S<R!O<&5R871I;VYS+`T*9FEN86P@<')O:F5C=&EO;G,@86YD
M(&EN=F5S=&]R(')E;&%T:6]N(&UA=&5R:6%L<RX@07,@8V]M<&5N<V%T:6]N
M(&9O<B!T:&5S92!S97)V:6-E<RP@=&AE($-O;7!A;GD@=VEL;"!I<W-U92`U
M+#`P,"PP,#`@<VAA<F5S#0IO9B!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A
M;GDN(%1H92!T97)M(&]F('1H92!A9W)E96UE;G0@:7,@9F]R('-I>"!M;VYT
M:',@=6YL97-S('1E<FUI;F%T960@;W(@97AT96YD960@:6X@86-C;W)D86YC
M92!W:71H('-U8G-E<75E;G0-"F%G<F5E;65N=',@8F5T=V5E;B!T:&4@<&%R
M=&EE<RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
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M2G5N92`R."P@,C`Q,2P@=VAE<F5B>0T*1'(N(%)E<&EN92!W:6QL('!R;W9I
M9&4@861V:7-O<GD@<V5R=FEC97,@=&\@3UA)4R!A;F0@17)G;R!!4D13(&%N
M9"!S97)V92!A<R!%<F=O($%21%,F(S$T-CL@0VAI968@17AE8W5T:79E($]F
M9FEC97(N)B,Q-C`[)B,Q-C`[3UA)4R8C,30V.PT*<&%Y;65N=',@=&\@1'(N
M(%)E<&EN92!U;F1E<B!T:&4@8V]N<W5L=&EN9R!A9W)E96UE;G0@=VEL;"!B
M92!M861E(&EN('-H87)E<R!O9B!/6$E3(&-O;6UO;B!S=&]C:RX@3UA)4R!A
M9W)E960@=&\@:7-S=64@<VAA<F5S#0IO9B!#;VUM;VX@4W1O8VL@=&\@1'(N
M(%)E<&EN92!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I
M9'1H.B`Q,#`E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Y-G!X.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,3@S.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^3VX@2G5L>2`V+"`R,#$Q#0H@("`@3UA)4R!I
M<W-U960@=&\@1'(N(%)E<&EN92`R+#<W-RPW-S@@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R`H=F%L=65D(&%T("0R-3`L,#`P*2!F;W(@=F%R:6]U<R!S97)V
M:6-E<R!R96QA=&EN9R!T;R!T:&4@=&5R;7,-"B`@("!O9B!T:&4@8V]N<W5L
M=&EN9R!A9W)E96UE;G0[/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.39P>#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$X,SLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]825,@86=R965D('1O(&ES
M<W5E#0H@("`@=&\@1'(N(%)E<&EN92!A9&1I=&EO;F%L('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@=F%L=65D(&%T("0U,"PP,#`@=7!O;B!C;VUP;&5T:6]N
M(&]F('1H92!F:7)S="!A;FEM86P@<W1U9'D@86YD($1R+B!297!I;F4F(S$T
M-CMS#0H@("`@9&5L:79E<GD@=&\@17)G;R!!4D13(&]F(&$@<W5M;6%R>2!P
M<F5S96YT871I;VX@;V8@=&AE(&9I;F1I;F=S(&]F('1H92!S='5D>3L@86YD
M/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@
M,3`P)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@.39P>#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$X,SLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D]825,@86=R965D('1O(&ES<W5E#0H@("`@1'(N(%)E
M<&EN92!A9&1I=&EO;F%L('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=F%L=65D
M(&%T("0Q,#`L,#`P('5P;VX@=&AE(&-O;7!L971I;VX@;V8@<W5C:"!S96-O
M;F0@86YI;6%L('-T=61Y(&%N9"!$<BX@4F5P:6YE)B,Q-#8[<PT*("`@(&1E
M;&EV97)Y('1O($5R9V\@05)$4R!O9B!A('-U;6UA<GD@<')E<V5N=&%T:6]N
M(&]F('1H92!F:6YD:6YG<R!O9B!T:&4@<W1U9'DN/"]F;VYT/CPO=&0^/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
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M4F5P:6YE#0IO;B!T:&%T(&1A=&4@=VEL;"!E<75A;"!T;R`D,C4P+#`P,"P@
M)#4P+#`P,"!O<B`D,3`P+#`P,"P@87,@=&AE(&-A<V4@;6%Y(&)E+CPO9F]N
M=#X\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-6)F8V8U.%]E
M.68X7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T
M860U+U=O<FMS:&5E=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13-(04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^5&AE($-O;7!A;GD@86YD(%-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M<&%N>2!!;F0@4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S(%!O;&EC:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=O:6YG($-O;F-E<FX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^07,@<VAO=VX@:6X-"G1H92!A8V-O;7!A;GEI;F<@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+"!T:&4@0V]M<&%N>2!H
M87,@:6YC=7)R960@86X@86-C=6UU;&%T960@9&5F:6-I="!O9B`D.#@L,C`U
M+#`P,"!T:')O=6=H(%-E<'1E;6)E<@T*,S`L(#(P,3(N)B,Q-C`[)B,Q-C`[
M3VX@82!C;VYS;VQI9&%T960@8F%S:7,L('1H92!#;VUP86YY(&AA9"!C87-H
M(&%N9"!C87-H(&5Q=6EV86QE;G1S(&]F("0V,2PP,#`@870@4V5P=&5M8F5R
M(#,P+"`R,#$R+B!4:&4-"D-O;7!A;GDG<R!P;&%N(&ES('1O(')A:7-E(&%D
M9&ET:6]N86P@8V%P:71A;"!U;G1I;"!S=6-H('1I;64@=&AA="!T:&4@0V]M
M<&%N>2!G96YE<F%T97,@<W5F9FEC:65N="!R979E;G5E<R!T;R!C;W9E<B!I
M=',@8V%S:`T*9FQO=R!N965D<R!A;F0O;W(@:70@86-H:65V97,@<')O9FET
M86)I;&ET>2X@2&]W979E<BP@=&AE($-O;7!A;GD@8V%N;F]T(&%S<W5R92!T
M:&%T(&ET('=I;&P@86-C;VUP;&ES:"!T:&ES('1A<VL@86YD('1H97)E(&%R
M90T*;6%N>2!F86-T;W)S('1H870@;6%Y('!R979E;G0@=&AE($-O;7!A;GD@
M9G)O;2!R96%C:&EN9R!I=',@9V]A;"!O9B!P<F]F:71A8FEL:71Y+CPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
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M;VX@;V8@;&EA8FEL:71I97,@=&AA="!M:6=H=`T*8F4@;F5C97-S87)Y(&EN
M('1H92!E=F5N="!T:&%T('1H92!#;VUP86YY(&-A;FYO="!C;VYT:6YU92!I
M;B!E>&ES=&5N8V4N/"]F;VYT/CPO<#X-"@T*#0H-"CQP('-T>6QE/3-$)VUA
M<F=I;CH@,'!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^5&AE(&9I;F%N8VEA;`T*<W1A=&5M96YT<R!A;F0@;F]T97,@
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M/@T*#0H-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!2
M96-O9VYI=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\=3Y0<F]D=6-T
M#0I2979E;G5E/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
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M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\=3Y,:6-E;G-E#0I2979E;G5E/"]U/CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
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M;G1S+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/DYO;BUR969U;F1A8FQE+`T*=7`M9G)O;G0@9F5E<R!T:&%T
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M9"!I<R!D96QI=F5R960N)B,Q-C`[)B,Q-C`[5V4-"F1E9F5R(')E8V]G;FET
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M(&ES('-E<&%R871E(&%N9"!I;F1E<&5N9&5N=`T*;V8@;W5R('!E<F9O<FUA
M;F-E('5N9&5R('1H92!O=&AE<B!E;&5M96YT<R!O9B!T:&4@87)R86YG96UE
M;G0N($EN(&%D9&ET:6]N+"!I9B!W92!H879E(&-O;G1I;G5I;F<@:6YV;VQV
M96UE;G0@=&AR;W5G:"!R97-E87)C:`T*86YD(&1E=F5L;W!M96YT('-E<G9I
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M=F5M96YT+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
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M87)N:6YG<R!P<F]C97-S+CPO9F]N=#X\+W`^#0H-"@T*#0H\<"!S='EL93TS
M1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y396=M96YT(%)E<&]R=&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY4:&4@0V]M<&%N>0T*;W!E<F%T97,@:6X@;VYE(')E
M<&]R=&%B;&4@<V5G;65N="X\+V9O;G0^/"]P/@T*#0H-"@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@0F%S960@0V]M<&5N<V%T:6]N('1O
M($5M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
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M(S$T-SM!4T,F(S$T.#LI#0HW,3@N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@
M<F5C;V=N:7IE<R!I;B!T:&4@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,@=&AE
M(&=R86YT+61A=&4@9F%I<B!V86QU92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!O
M=&AE<B!E<75I='DM8F%S960-"F-O;7!E;G-A=&EO;B!I<W-U960@=&\@96UP
M;&]Y965S(&%N9"!N;VXM96UP;&]Y965S(&]V97(@=&AE(')E;&%T960@=F5S
M=&EN9R!P97)I;V0N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^5&AE($-O;7!A;GD-"F=R86YT960@<W1O8VL@
M;W!T:6]N<R!T;R!P=7)C:&%S92`R-BPS.#0L,3DS(&%N9"`R+#`V-BPT.3$@
M<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@=&\@
M96UP;&]Y965S(&%N9"!D:7)E8W1O<G,-"F1U<FEN9R!T:&4@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T
M:79E;'DN)B,Q-C`[)B,Q-C`[5&AE(&9A:7(@=F%L=65S(&]F(&5M<&QO>65E
M('-T;V-K(&]P=&EO;G,@87)E#0IE<W1I;6%T960@9F]R('1H92!C86QC=6QA
M=&EO;B!O9B!T:&4@<')O(&9O<FUA(&%D:G5S=&UE;G1S(&%T('1H92!D871E
M(&]F(&=R86YT('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC
M:6YG(&UO9&5L('=I=&@-"G1H92!F;VQL;W=I;F<@=V5I9VAT960M879E<F%G
M92!A<W-U;7!T:6]N<R!D=7)I;F<@,C`Q,CH@97AP96-T960@=F]L871I;&ET
M>2!O9B`Q,38E.R!A=F5R86=E(')I<VLM9G)E92!I;G1E<F5S="!R871E(&]F
M(#$N,#0E#0IT;R`R+C`T)3L@:6YI=&EA;"!E>'!E8W1E9"!L:69E(&]F(#4@
M=&\@,3`@>65A<G,[(&YO(&5X<&5C=&5D(&1I=FED96YD('EI96QD.R!A;F0@
M86UO<G1I>F5D(&]V97(@=&AE('9E<W1I;F<@<&5R:6]D(&]F('1Y<&EC86QL
M>0T*;VYE('1O(&9O=7(@>65A<G,N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@
M<F5P;W)T960@86X@97AP96YS92!F;W(@<VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N(&9O<B!I=',@96UP;&]Y965S(&%N9"!D:7)E8W1O<G,@;V8-"B0V.3DL
M,#`P(&%N9"`D,S`W+#`P,"!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E
M<'1E;6)E<B`S,"P@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+CPO9F]N
M=#X\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!"87-E9"!#;VUP96YS871I;VX@
M=&\@3W1H97(@=&AA;B!%;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T
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M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(@86YD(#(P,3$L(')E<W!E
M8W1I=F5L>2X\+V9O;G0^/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G;6%R9VEN
M.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16%R;FEN9W,@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/D)A<VEC(&5A<FYI;F=S#0IP97(@<VAA<F4@:7,@8V]M<'5T960@
M8GD@9&EV:61I;F<@=&AE(&YE="!I;F-O;64@;W(@;&]S<R!F;W(@=&AE('!E
M<FEO9"!B>2!T:&4@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N
M('-H87)E<R!O=71S=&%N9&EN9PT*9'5R:6YG('1H92!P97)I;V0N)B,Q-C`[
M)B,Q-C`[1&EL=71E9"!E87)N:6YG<R!P97(@<VAA<F4@:7,@8V]M<'5T960@
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M)B,Q-C`[)B,Q-C`[4VEN8V4@=&AE($-O;7!A;GD@:6YC=7)R960@82!N970@
M;&]S<R!F;W(-"G1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3(@
M86YD(#(P,3$L(&%L;"!I;G-T<G5M96YT<R!C;VYV97)T:6)L92!I;G1O('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@87)E(&5X8VQU9&5D(&9R;VT@;F5T(&1I
M;'5T960-"FQO<W,@<&5R('-H87)E(&)E8V%U<V4@;V8@=&AE:7(@86YT:2UD
M:6QU=&EV92!E9F9E8W0N)B,Q-C`[)B,Q-C`[5&]T86P@<&]T96YT:6%L;'D@
M9&EL=71I=F4@<VAA<F5S(&5X8VQU9&5D(&9R;VT@=&AE(&-A;&-U;&%T:6]N
M#0IO9B!E87)N:6YG<R!P97(@<VAA<F4@870@4V5P=&5M8F5R(#,P+"`R,#$R
M('1O=&%L960@-3,X+#(X-2PY-#,N/"]F;VYT/CPO<#X-"@T*#0H-"CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO
M=6YC96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S
M='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
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M>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M
M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
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M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0X
M<'@[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q.#,[)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,979E
M;"`Q(&EN<'5T<R!T;PT*("`@('1H92!V86QU871I;VX@;65T:&]D;VQO9WD@
M87)E('%U;W1E9"!P<FEC97,@*'5N861J=7-T960I(&9O<B!I9&5N=&EC86P@
M87-S971S(&]R(&QI86)I;&ET:65S(&EN(&%C=&EV92!M87)K971S+B!4:&4@
M0V]M<&%N>28C,30V.W,-"B`@("!,979E;"`Q(&%S<V5T<R!I;F-L=61E(&-A
M<V@@97%U:79A;&5N=',L('!R:6UA<FEL>2!I;G-T:71U=&EO;F%L(&UO;F5Y
M(&UA<FME="!F=6YD<RP@=VAO<V4@8V%R<GEI;F<@=F%L=64@<F5P<F5S96YT
M<R!F86ER#0H@("`@=F%L=64@8F5C875S92!O9B!T:&5I<B!S:&]R="UT97)M
M(&UA='5R:71I97,@;V8@=&AE(&EN=F5S=&UE;G1S(&AE;&0@8GD@=&AE<V4@
M9G5N9',N/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B
M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W
M:61T:#H@,3`P)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@-#AP>#L@9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$X,SLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/DQE=F5L(#(@:6YP=71S('1O#0H@("`@=&AE
M('9A;'5A=&EO;B!M971H;V1O;&]G>2!I;F-L=61E('%U;W1E9"!P<FEC97,@
M9F]R('-I;6EL87(@87-S971S(&%N9"!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@
M;6%R:V5T<RP@86YD(&EN<'5T<R!T:&%T(&%R90T*("`@(&]B<V5R=F%B;&4@
M9F]R('1H92!A<W-E="!O<B!L:6%B:6QI='DL(&5I=&AE<B!D:7)E8W1L>2!O
M<B!I;F1I<F5C=&QY+"!F;W(@<W5B<W1A;G1I86QL>2!T:&4@9G5L;"!T97)M
M(&]F('1H92!F:6YA;F-I86P@:6YS=')U;65N="X-"B`@("!4:&4@0V]M<&%N
M>28C,30V.W,@3&5V96P@,B!L:6%B:6QI=&EE<R!C;VYS:7-T(&]F('1W;R!L
M:6%B:6QI=&EE<R!A<FES:6YG(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O;G9E
M<G1I8FQE('-E8W5R:71I97,@86YD#0H@("`@:6X@86-C;W)D86YC92!W:71H
M($5)5$8@,#`M,3DZ(&$@=V%R<F%N="!L:6%B:6QI='D@9F]R(&1E=&%C:&%B
M;&4@=V%R<F%N=',L(&%S('=E;&P@87,@86X@86-C<G5E9"!D97)I=F%T:79E
M(&QI86)I;&ET>2!F;W(-"B`@("!T:&4@8F5N969I8VEA;"!C;VYV97)S:6]N
M(&9E871U<F4N(%1H97-E(&QI86)I;&ET:65S(&%R92!R96UE87-U<F5D(&]N
M(&$@<75A<G1E<FQY(&)A<VES+B!&86ER('9A;'5E(&ES(&1E=&5R;6EN960@
M=7-I;F<@=&AE#0H@("`@0FQA8VLM4V-H;VQE<R!V86QU871I;VX@;6]D96P@
M8F%S960@;VX@;V)S97)V86)L92!M87)K970@:6YP=71S+"!S=6-H(&%S('-H
M87)E('!R:6-E(&1A=&$@86YD(&$@9&ES8V]U;G0@<F%T92!C;VYS:7-T96YT
M('=I=&@-"B`@("!T:&%T(&]F(&$@9V]V97)N;65N="UI<W-U960@<V5C=7)I
M='D@;V8@82!S:6UI;&%R(&UA='5R:71Y+CPO9F]N=#X\+W1D/CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0X<'@[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X
M="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q.#,[)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,979E;"`S
M(&EN<'5T<R!T;PT*("`@('1H92!V86QU871I;VX@;65T:&]D;VQO9WD@87)E
M('5N;V)S97)V86)L92!A;F0@<VEG;FEF:6-A;G0@=&\@=&AE(&9A:7(@=F%L
M=64@;65A<W5R96UE;G0N/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
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M#0HS,"P@,C`Q,BX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E)SX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D1E<V-R:7!T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3&5V96P-"B`@("`Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L
M:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQE=F5L#0H@("`@,CPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY,979E;`T*("`@(#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^07-S971S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#8T)3L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/DQI86)I;&ET:65S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G0@;&EA8FEL:71Y/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,34Q.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C4Q-"PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$U,3L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/CPO='(^#0H\+W1A8FQE/@T*#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@
M,'!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D-0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T-6)F8V8U.%]E.68X7S1F-3%?.30V
M9%\X8C`X-S5F8C1A9#4O5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^5&AE($-O;7!A;GD@86YD
M(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;7!A;GD@06YD(%-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<R!486)L97,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<&%N>2!A<W-E=',@86YD(&QI
M86)I;&ET:65S(&)Y(&QE=F5L(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@
M82!R96-U<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!W:61T:#H@,3`P)2<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$97-C<FEP=&EO;CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L
M:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQE=F5L#0H@("`@,3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY,979E;`T*("`@(#(\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3&5V96P-"B`@
M("`S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D%S<V5T<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`V-"4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE
M.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,34Q.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
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M97)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,:6%B:6QI=&EE<SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY7
M87)R86YT(&QI86)I;&ET>3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$U,3L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,30L
M,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-
M"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-6)F8V8U.%]E.68X7S1F-3%?
M.30V9%\X8C`X-S5F8C1A9#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U+U=O<FMS
M:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I&/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E!A=&5N=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0871E;G1S(%1A8FQE<SPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0871E
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS
M1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED
M=&@Z(#$P,"4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E-E<'1E;6)E<@T*("`@(#,P+"`R,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY$96-E;6)E<@T*("`@(#,Q+"`R,#$Q/"]F;VYT/CPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+6)O='1O
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M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`W-B4[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY#87!I=&%L:7IE9`T*("`@('!A=&5N="!C;W-T<SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C8T,"PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C8T,"PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%C8W5M=6QA=&5D#0H@("`@86UO
M<G1I>F%T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#8R-2PP
M,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXH-C$U+#`P,#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,W!T.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$U+#`P
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ
M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(U+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#-P
M=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*
M#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&9U='5R
M92!A;6]R=&EZ871I;VX@;V8@<&%T96YT(&-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4G/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`X-"4[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXR,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$T)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXQ,BPP,#`\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q,SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT
M+#`P,#PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-"PP,#`\+V9O
M;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,C`Q-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+#`P,#PO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL@
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C(P,38\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,2PP,#`\+V9O;G0^/"]T9#X\+W1R/@T*/"]T
M86)L93X-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T-6)F8V8U.%]E.68X
M7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U
M+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I&/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-T;V-K($]P=&EO;G,@86YD(%=A<G)A;G1S("A4
M86)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W1O8VL@3W!T:6]N<R!!;F0@5V%R<F%N=',@5&%B;&5S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@=&AE('-T;V-K(&]P=&EO;B!A8W1I=FET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E)SX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS#0H@("`@3W5T
M<W1A;F1I;F<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N
M.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5V5I9VAT960-"B`@("!!=F5R86=E($5X
M97)C:7-E(%!R:6-E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CL@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED
M=&@Z(#<V)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D]U='-T86YD:6YG#0H@("`@87,@;V8@1&5C96UB
M97(@,S$L(#(P,3$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T
M:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,38L,#<X+#DW.3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R!W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z(#$E
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXP+C$Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[(&9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY'<F%N=&5D
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(V+#,X-"PQ.3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`T/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`Y<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY&;W)F96ET960\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,RPV-SDL
M,#(W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,"XQ-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T
M97AT+6EN9&5N=#H@.7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V5D/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$U,3L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$U,3L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,W!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^3W5T<W1A;F1I;F<-"B`@("!A<R!O9B!397!T96UB97(@
M,S`L(#(P,3(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,S@L-S@T+#$T-3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`S<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXP+C`X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`S<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,W!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V%B;&4-"B`@("!A
M<R!O9B!397!T96UB97(@,S`L(#(P,3(\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C,L-#$U+#0T
M,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,W!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`S<'0[(&9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T
M97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`X/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`S<'0[(&9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*#0H\<"!S
M='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F('1H92!W87)R86YT
M(&%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S
M='EL93TS1"=M87)G:6XZ(#!P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@=VED=&@Z(#$P,"4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/E=A<G)A;G1S#0H@("`@3W5T<W1A;F1I;F<\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M5V5I9VAT960-"B`@("!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CL@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#<V)3L@9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]U='-T
M86YD:6YG#0H@("`@87,@;V8@1&5C96UB97(@,S$L(#(P,3$\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3`U+#`P,2PR-3(F
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXP+C`V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[
M(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY'<F%N=&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0V,BPS,#`L-30V)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,"XP,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N=#H@.7!T.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F]R
M9F5I=&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C4R+#4P,"PP,#`F(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`Q
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6EN9&5N=#H@.7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^061J=7-T;65N=',\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*#$U+#,P,"PP,#`I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP,3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[('1E>'0M:6YD96YT.B`Y<'0[(&9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%>&5R
M8VES960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,34Q.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,W!T.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3W5T<W1A;F1I;F<-"B`@("!A
M<R!O9B!397!T96UB97(@,S`L(#(P,3(\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#DY+#4P,2PW
M.3@F(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#-P=#L@9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T.R!F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[(&9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP,3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,W!T
M.R!F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H-
M"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0[(&9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT
M-F1?.&(P.#<U9F(T860U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K<VAE
M971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$552$%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/E1H92!#;VUP86YY(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1F%I<E9A;'5E26YP=71S3&5V96PQ365M8F5R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S971S/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EA8FEL:71I97,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7)686QU94EN<'5T<TQE=F5L,DUE;6)E<CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3$T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<E9A;'5E26YP=71S3&5V96PS365M8F5R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S971S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI
M86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D
M-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T-6)F8V8U.%]E.68X
M7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4O5V]R:W-H965T<R]3:&5E=#$X+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%1TE!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY4:&4@
M0V]M<&%N>2!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG
M(%!O;&EC:65S("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D
M969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#@X+#(P
M-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@X,RPW.34L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-30L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:R!O<'1I;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(V+#,X-"PQ.3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`V-BPT.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D
M('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q
M-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E(&)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8Y
M.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,P-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1I;'5T960@<VAA<F5S(&5X8VQU9&5D(&9R;VT@
M8V%L8W5A=&EO;B!O9B!%4%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4S."PR.#4L.30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M365M8F5R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C`T)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@
M;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UO<G1I>F5D(&]V97(@=F5S=&EN9R!P97)I;V0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/C$@>65A<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;4UE;6)E<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@
M<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP-"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M<&5C=&5D(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;6]R=&EZ960@;W9E<B!V97-T:6YG('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q
M7SDT-F1?.&(P.#<U9F(T860U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K
M<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T0T%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/E!A=&5N=',@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!A=&5N=',@1&5T86EL<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L:7IE9"!P871E;G0@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C0P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C0P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C=6UU;&%T960@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V,C4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8Q-2PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S0U8F9C9C4X
M7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D-0T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X8C`X-S5F
M8C1A9#4O5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T-!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY0871E;G1S("A$971A:6QS(#$I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY0871E;G1S($1E=&%I;',@,3PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,30\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?
M.&(P.#<U9F(T860U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0U
M8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K<VAE971S
M+U-H965T,C$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5(2$%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A$971A:6QS($YA<G)A=&EV
M92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,@17%U:71Y($1E=&%I;',@3F%R
M<F%T:79E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5T:7)E
M;65N="!O9B!D96)T+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V,"PQ,#<L-#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C$L.#,Q+#8X,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5T:7)E;65N="!O9B!D
M96)T+"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,BPS.#(L,C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+#$T-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S0U8F9C9C4X7V4Y9CA?-&8U,5\Y-#9D7SAB,#@W
M-69B-&%D-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T-6)F8V8U
M.%]E.68X7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4O5V]R:W-H965T<R]3:&5E
M=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%5D]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=&]C:R!/<'1I;VYS(&%N9"!787)R86YT<R`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D]P=&EO;G,@3W5T<W1A;F1I;F<\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@87,@;V8@1&5C96UB
M97(@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M+#`W."PY-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(V+#,X-"PQ.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9O<F9E:71E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPV-SDL,#(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG(&%S(&]F(%-E<'1E
M;6)E<B`S,"P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S@L-S@T+#$T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V%B;&4@87,@;V8@4V5P=&5M8F5R(#,P+"`R
M,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPT,34L-#0Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A
M;F1I;F<@87,@;V8@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XQ.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T
M86YD:6YG(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES86)L92!A<R!O9B!3
M97!T96UB97(@,S`L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S0U8F9C9C4X7V4Y9CA?-&8U
M,5\Y-#9D7SAB,#@W-69B-&%D-2]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5&5D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K($]P
M=&EO;G,@86YD(%=A<G)A;G1S("A$971A:6QS(#$I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY787)R
M86YT<R!/=71S=&%N9&EN9SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!A<R!O9B!$96-E;6)E<B`S,2P@
M,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#<X+#DW
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F]R9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#8W.2PP,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W5T<W1A;F1I;F<@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PW.#0L,30U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I
M;F<@87,@;V8@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XQ.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD
M:6YG(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT365M8F5R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V%R<F%N=',@3W5T
M<W1A;F1I;F<\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<@87,@;V8@1&5C96UB97(@,S$L(#(P,3$\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-2PP,#$L,C4R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C(L,S`P+#4T
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F]R9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,34L,S`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!A
M<R!O9B!397!T96UB97(@,S`L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0Y.2PU,#$L-SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V4@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@87,@;V8@1&5C96UB97(@,S$L
M(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&;W)F96ET960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^061J=7-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG(&%S(&]F(%-E<'1E
M;6)E<B`S,"P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\T-6)F8V8U.%]E.68X7S1F-3%?.30V9%\X8C`X-S5F8C1A9#4-"D-O;G1E
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M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R,RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X
M=%!A<G1?-#5B9F-F-3A?93EF.%\T9C4Q7SDT-F1?.&(P.#<U9F(T860U+2T-
!"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Patents<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Note 2 - Patents</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">September
    30, 2012</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2011</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Capitalized
    patent costs</font></td>
    <td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">640,000</font></td>
    <td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">640,000</font></td>
    <td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Accumulated
    amortization</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(625,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(615,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">15,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">25,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Periodically,
the Company reviews its patent portfolio and has determined that certain patent applications no longer possessed commercial viability
or were abandoned since they were inconsistent with the Company's business development strategy.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The following
table presents expected future amortization of patent costs as of December 31, 2011 that may change according to the Company's
amortization policy upon additional patents being issued or allowed:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; width: 84%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2012</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">12,000</font></td></tr>
<tr style="background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2013</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">4,000</font></td></tr>
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2014</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">4,000</font></td></tr>
<tr style="background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2015</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">4,000</font></td></tr>
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2016</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,000</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16373-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16265-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 42, 43, 44, 45, 46, 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13854-109267<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 61,000<span></span></td>
        <td class="nump">$ 92,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">12,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">12,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">73,000<span></span></td>
        <td class="nump">104,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
        <td class="nump">15,000<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Other Assets</a></td>
        <td class="nump">15,000<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump">88,000<span></span></td>
        <td class="nump">129,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' DEFICIT</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">858,000<span></span></td>
        <td class="nump">806,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
        <td class="nump">1,225,000<span></span></td>
        <td class="nump">1,598,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">1,049,000<span></span></td>
        <td class="nump">607,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="nump">26,000<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warrant liability</a></td>
        <td class="nump">514,000<span></span></td>
        <td class="nump">158,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_DemandNotesPayableNetOfDiscountOf54000And0', window );">Demand notes payable, net of discount of $0 and $54,000</a></td>
        <td class="nump">63,000<span></span></td>
        <td class="nump">266,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion', window );">Convertible debentures, net of discount of $0 and $0, current portion</a></td>
        <td class="nump">1,966,000<span></span></td>
        <td class="nump">775,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debentures</a></td>
        <td class="nump">625,000<span></span></td>
        <td class="nump">995,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">6,326,000<span></span></td>
        <td class="nump">5,230,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ConvertiblePreferredStockSeriesC', window );">Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized: Series C - 96,230 and 96,230 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</a></td>
        <td class="nump">1,000<span></span></td>
        <td class="nump">1,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ConvertiblePreferredStockSeriesH', window );">Series H - 25,000 and 25,000 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ConvertiblePreferredStockSeriesI', window );">Series I - 1,666,667 and 1,666,667 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</a></td>
        <td class="nump">2,000<span></span></td>
        <td class="nump">2,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 600,000,000 shares authorized; 457,207,313 and 269,299,838 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively</a></td>
        <td class="nump">457,000<span></span></td>
        <td class="nump">269,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">81,634,000<span></span></td>
        <td class="nump">78,422,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(88,205,000)<span></span></td>
        <td class="num">(83,795,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Minority interest</a></td>
        <td class="num">(127,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Deficit</a></td>
        <td class="num">(6,238,000)<span></span></td>
        <td class="num">(5,101,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</a></td>
        <td class="nump">$ 88,000<span></span></td>
        <td class="nump">$ 129,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ConvertibleDebenturesNetOfDiscountOf0And0CurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ConvertiblePreferredStockSeriesC">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ConvertiblePreferredStockSeriesC</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ConvertiblePreferredStockSeriesH">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ConvertiblePreferredStockSeriesH</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ConvertiblePreferredStockSeriesI">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ConvertiblePreferredStockSeriesI</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_DemandNotesPayableNetOfDiscountOf54000And0">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_DemandNotesPayableNetOfDiscountOf54000And0</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.10-17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20, 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6397716&amp;loc=d3e11281-110244<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12524-110249<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProductWarrantyAccrualClassifiedCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (4,410,000)<span></span></td>
        <td class="num">$ (2,562,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump">10,000<span></span></td>
        <td class="nump">20,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense for options and warrants issued to employees and non-employees</a></td>
        <td class="nump">699,000<span></span></td>
        <td class="nump">126,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of shares for services</a></td>
        <td class="nump">782,000<span></span></td>
        <td class="nump">1,597,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discounts</a></td>
        <td class="nump">40,000<span></span></td>
        <td class="nump">306,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities', window );">Change in value of warrant and derivative liabilities</a></td>
        <td class="nump">356,000<span></span></td>
        <td class="num">(783,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="nump">12,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num">(12,000)<span></span></td>
        <td class="num">(10,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">1,750,000<span></span></td>
        <td class="nump">667,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(773,000)<span></span></td>
        <td class="num">(639,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options and warrants</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">14,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
        <td class="nump">615,000<span></span></td>
        <td class="nump">621,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note payable</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(50,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">615,000<span></span></td>
        <td class="nump">585,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Minority Interest</a></td>
        <td class="nump">127,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(31,000)<span></span></td>
        <td class="num">(54,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS - Beginning of period</a></td>
        <td class="nump">92,000<span></span></td>
        <td class="nump">54,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS - End of period</a></td>
        <td class="nump">$ 61,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ChangeInValueOfWarrantAndDerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 21<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow contributed by noncontrolled interest that purchase additional shares or otherwise increase their ownership stake in a subsidiary of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromMinorityShareholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Options and Warrants (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2011</a></td>
        <td class="nump">16,078,979<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="nump">26,384,193<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
        <td class="nump">3,679,027<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of September 30, 2012</a></td>
        <td class="nump">38,784,145<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of September 30, 2012</a></td>
        <td class="nump">23,415,441<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2011</a></td>
        <td class="nump">$ 0.19<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 0.04<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
        <td class="nump">$ 0.17<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of September 30, 2012</a></td>
        <td class="nump">$ 0.08<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of September 30, 2012</a></td>
        <td class="nump">$ 0.08<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c), d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(f)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - The Company and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Note 1 - The Company and Summary of Significant Accounting Policies</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">OXIS International,
Inc. (collectively, &#147;OXIS&#148; or the &#147;Company&#148;) is engaged in the research, development and sale of products
that counteract the harmful effects of &#147;oxidative stress&#148; and inflammation.&#160;&#160;Oxidative stress refers to
the situations in which the body&#146;s antioxidant and other defensive abilities to combat free radicals (a.k.a. highly reactive
species of oxygen and nitrogen) are overwhelmed and normal healthy balance is lost.&#160;&#160;The Company&#146;s current finished
product and finished product candidates include therapeutic nutraceutical products, cosmeceutical products, functional foods and
functional beverages. The Company also possesses intellectual property covering a number of proprietary compounds and formulations
that may be out-licensed to biotech and pharmaceutical companies as drug candidates.&#160;&#160;The Company&#146;s primary focus
currently is on products that incorporate the unique amino acid naturally occurring compound, L-Ergothioneine (&#147;ERGO&#148;),
as a key component. Ergothioneine is produced only by microorganisms in soil and is not synthesized by humans, animals or plants.&#160;&#160;The
Company has spent approximately $75 million in researching and developing ERGO, and now owns a patented process to synthesize
commercial quantities of ERGO in a highly stable form that is highly soluble and tasteless, making it suitable for use in combination
with other nutraceuticals and botanicals in a wide variety of dietary supplements, functional foods and beverages, and topical
anti-aging products including lotions and creams.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In 1965, the
corporate predecessor of OXIS, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic Data changed its
incorporation to the State of Delaware in 1972; and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals
merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Going Concern</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">As shown in
the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $88,205,000 through September
30, 2012.&#160;&#160;On a consolidated basis, the Company had cash and cash equivalents of $61,000 at September 30, 2012. The
Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash
flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are
many factors that may prevent the Company from reaching its goal of profitability.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The current
rate of cash usage raises substantial doubt about the Company&#146;s ability to continue as a going concern, absent any sources
of significant cash flows.&#160;&#160;In an effort to mitigate this near-term concern the Company intends to seek additional equity
or debt financing to obtain sufficient funds to sustain operations.&#160;&#160;The Company plans to increase revenues by introducing
new nutraceutical products primarily based on its ergothioneine assets.&#160;&#160;However, the Company cannot provide assurance
that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company
will generate future product related revenues.&#160;&#160;The Company&#146;s financial statements do not include any adjustments
relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be necessary in the event that the Company cannot continue in existence.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Use of Estimates</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The financial
statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.
These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently
applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates
and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets
and liabilities at the date of the financial statements. Actual results could differ from those estimates.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Revenue Recognition</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>Product
Revenue</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products
to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the
products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales
order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net
of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor
may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based
upon historical data, current economic conditions and the underlying contractual terms.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>License
Revenue</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">License arrangements
may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various
performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Non-refundable,
up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on
our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&#160;&#160;We
defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right,
product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent
of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research
and development services that are required because our know-how and expertise related to the technology is proprietary to us,
or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Payments related
to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement
of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Segment Reporting</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
operates in one reportable segment.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Stock Based
Compensation to Employees</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&#147;ASC&#148;)
718.&#160;&#160;The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based
compensation issued to employees and non-employees over the related vesting period.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
granted stock options to purchase 26,384,193 and 2,066,491 shares of the Company&#146;s common stock to employees and directors
during the nine months ended September 30, 2012 and 2011, respectively.&#160;&#160;The fair values of employee stock options are
estimated for the calculation of the pro forma adjustments at the date of grant using the Black-Scholes option-pricing model with
the following weighted-average assumptions during 2012: expected volatility of 116%; average risk-free interest rate of 1.04%
to 2.04%; initial expected life of 5 to 10 years; no expected dividend yield; and amortized over the vesting period of typically
one to four years.&#160;&#160;The Company reported an expense for share-based compensation for its employees and directors of
$699,000 and $307,000 for the nine months ended September 30, 2012 and 2011, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Stock Based
Compensation to Other than Employees</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance
with ASC 718. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value
of the equity instruments issued, whichever is more reliably determinable. The value of equity instruments issued for consideration
other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider
of goods or services. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized
over the term of the consulting agreement. The Company recognized no expense in share-based compensation for non-employees for
the nine months ended September 30, 2012 and 2011, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Earnings Per
Share</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Basic earnings
per share is computed by dividing the net income or loss for the period by the weighted average number of common shares outstanding
during the period.&#160;&#160;Diluted earnings per share is computed by dividing the earnings for the period by the weighted average
number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise
or conversion of outstanding stock options and warrants during the period.&#160;&#160;Since the Company incurred a net loss for
the six months ended June 30, 2012 and 2011, all instruments convertible into shares of common stock are excluded from net diluted
loss per share because of their anti-dilutive effect.&#160;&#160;Total potentially dilutive shares excluded from the calculation
of earnings per share at September 30, 2012 totaled 538,285,943.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Recent Accounting
Pronouncements</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Management
does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material
effect on the Company&#146;s financial position or results of operations.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Fair Value
Measurements</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The carrying
amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a
reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected
realization and their current market rate of interest.&#160; The three levels are defined as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 1 inputs to
    the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&#146;s
    Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair
    value because of their short-term maturities of the investments held by these funds.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 2 inputs to
    the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
    observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
    The Company&#146;s Level 2 liabilities consist of two liabilities arising from the issuance of convertible securities and
    in accordance with EITF 00-19: a warrant liability for detachable warrants, as well as an accrued derivative liability for
    the beneficial conversion feature. These liabilities are remeasured on a quarterly basis. Fair value is determined using the
    Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with
    that of a government-issued security of a similar maturity.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 3 inputs to
    the valuation methodology are unobservable and significant to the fair value measurement.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The following
table represents the Company&#146;s assets and liabilities by level measured at fair value on a recurring basis at September
30, 2012.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Description</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    1</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    2</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    3</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Assets</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 64%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Liabilities</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Warrant liability</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">514,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDMAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_DemandNotesPayableNetOfDiscount', window );">Demand notes payable, net of discount</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 54,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ConvertibleDebenturesNetOfDiscount', window );">Convertible debentures, net of discount</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, Authorized</a></td>
        <td class="nump">15,000,000<span></span></td>
        <td class="nump">15,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_SeriesCPreferredStockIssuedShares', window );">Series C - Preferred stock, issued shares</a></td>
        <td class="nump">96,230<span></span></td>
        <td class="nump">96,230<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_SeriesCPreferredStockOutstandingShares', window );">Series C - Preferred stock, outstanding shares</a></td>
        <td class="nump">96,230<span></span></td>
        <td class="nump">96,230<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_SeriesHPreferredStockIssuedShares', window );">Series H - Preferred stock, issued shares</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_SeriesHPreferredStockOutstandingShares', window );">Series H - Preferred stock, outstanding shares</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_SeriesIPreferredStockIssuedShares', window );">Series I - Preferred stock, issued shares</a></td>
        <td class="nump">1,666,667<span></span></td>
        <td class="nump">1,666,667<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_SeriesIPreferredStockOutstandingShares', window );">Series I - Preferred stock, outstanding shares</a></td>
        <td class="nump">1,666,667<span></span></td>
        <td class="nump">1,666,667<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Authorized</a></td>
        <td class="nump">600,000,000<span></span></td>
        <td class="nump">600,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, Issued</a></td>
        <td class="nump">457,207,313<span></span></td>
        <td class="nump">269,299,838<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
        <td class="nump">457,207,313<span></span></td>
        <td class="nump">269,299,838<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ConvertibleDebenturesNetOfDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ConvertibleDebenturesNetOfDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_DemandNotesPayableNetOfDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_DemandNotesPayableNetOfDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_SeriesCPreferredStockIssuedShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_SeriesCPreferredStockIssuedShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_SeriesCPreferredStockOutstandingShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_SeriesCPreferredStockOutstandingShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_SeriesHPreferredStockIssuedShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_SeriesHPreferredStockIssuedShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_SeriesHPreferredStockOutstandingShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_SeriesHPreferredStockOutstandingShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_SeriesIPreferredStockIssuedShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_SeriesIPreferredStockIssuedShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_SeriesIPreferredStockOutstandingShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_SeriesIPreferredStockOutstandingShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">FairValueInputsLevel1Member</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure', window );">Asset</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">FairValueInputsLevel2Member</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure', window );">Asset</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
        <td class="nump">514,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">FairValueInputsLevel3Member</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure', window );">Asset</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total investments in (A) an entity in which the company has significant influence, but does not have control, (B) subsidiaries that are not required to be consolidated and are accounted for using the equity and or cost method. Investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, (C) an entity in which the reporting entity shares control of the entity with another party or group, and (D) an entity in which the company has significant influence, but does not have control.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 33<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the aggregate of the liabilities reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">OXIS INTERNATIONAL INC<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000109657<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
         2012<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
        <td class="text">No<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
        <td class="text">No<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
        <td class="text">Yes<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="nump">457,207,313<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EGIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">$ (88,205,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (83,795,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalent</a></td>
        <td class="nump">61,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">92,000<span></span></td>
        <td class="nump">54,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
        <td class="nump">26,384,193<span></span></td>
        <td class="nump">2,066,491<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">116.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividend yield</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
        <td class="nump">$ 699,000<span></span></td>
        <td class="nump">$ 307,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Diluted shares excluded from calcuation of EPS</a></td>
        <td class="nump">538,285,943<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">MinimumMember</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">1.04%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Amortized over vesting period</a></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">MaximumMember</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">2.04%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Amortized over vesting period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHRAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenue:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenues</a></td>
        <td class="nump">$ 120,000<span></span></td>
        <td class="nump">$ 2,000<span></span></td>
        <td class="nump">$ 123,000<span></span></td>
        <td class="nump">$ 23,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">License revenues</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">TOTAL REVENUE</a></td>
        <td class="nump">120,000<span></span></td>
        <td class="nump">2,000<span></span></td>
        <td class="nump">123,000<span></span></td>
        <td class="nump">23,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Product Revenue</a></td>
        <td class="nump">32,000<span></span></td>
        <td class="nump">8,000<span></span></td>
        <td class="nump">33,000<span></span></td>
        <td class="nump">48,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
        <td class="nump">88,000<span></span></td>
        <td class="num">(6,000)<span></span></td>
        <td class="nump">90,000<span></span></td>
        <td class="num">(25,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">49,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">1,438,000<span></span></td>
        <td class="nump">535,000<span></span></td>
        <td class="nump">2,865,000<span></span></td>
        <td class="nump">2,806,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">1,438,000<span></span></td>
        <td class="nump">535,000<span></span></td>
        <td class="nump">2,865,000<span></span></td>
        <td class="nump">2,855,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
        <td class="num">(1,350,000)<span></span></td>
        <td class="num">(541,000)<span></span></td>
        <td class="num">(2,775,000)<span></span></td>
        <td class="num">(2,880,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments', window );">Change in value of warrant and derivative liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">681,000<span></span></td>
        <td class="num">(358,000)<span></span></td>
        <td class="nump">783,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense/income</a></td>
        <td class="num">(65,000)<span></span></td>
        <td class="num">(117,000)<span></span></td>
        <td class="num">(1,305,000)<span></span></td>
        <td class="num">(465,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
        <td class="num">(65,000)<span></span></td>
        <td class="nump">564,000<span></span></td>
        <td class="num">(1,663,000)<span></span></td>
        <td class="nump">318,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes', window );">Loss before minority interest and provision for income taxes</a></td>
        <td class="num">(1,415,000)<span></span></td>
        <td class="nump">23,000<span></span></td>
        <td class="num">(4,438,000)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Minority interest in subsidiary</a></td>
        <td class="nump">15,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">28,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
        <td class="num">(1,400,000)<span></span></td>
        <td class="nump">23,000<span></span></td>
        <td class="num">(4,410,000)<span></span></td>
        <td class="num">(2,562,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net gain (loss)</a></td>
        <td class="num">$ (1,400,000)<span></span></td>
        <td class="nump">$ 23,000<span></span></td>
        <td class="num">$ (4,410,000)<span></span></td>
        <td class="num">$ (2,562,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss Per Share - basic and diluted</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="num">$ (0.01)<span></span></td>
        <td class="num">$ (0.01)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted Average Shares Outstanding - basic and diluted</a></td>
        <td class="nump">397,553,268<span></span></td>
        <td class="nump">213,511,550<span></span></td>
        <td class="nump">336,824,712<span></span></td>
        <td class="nump">183,038,141<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_LossBeforeMinorityInterestAndProvisionForIncomeTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsAndServicesSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period, which was recognized in earnings, in the unrealized gains or losses on derivative instruments that are not or are no longer designated as hedging instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 20<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6439004&amp;loc=d3e65527-113976<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 18<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Chapter V<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733213&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Paragraph 5A<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 6 - Advisory and Consulting Agreements Obligations<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock', window );">Note 6 - Advisory and Consulting Agreements Obligations</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Advisory Agreements</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
entered into a two-year Scientific Advisory Board Services Agreement with L. Stephen Coles on March 4, 2010.&#160;&#160;Mr. Coles
receives an advisory fee for $9,000 per quarter.&#160;&#160;Upon entering into the agreement, the Company granted Mr. Coles an
initial option to purchase 250,000 shares of the Company&#146;s common stock under its 2003 Stock Incentive Plan.&#160;&#160;The
options vest and become exercisable in four equal quarterly installments beginning June 4, 2010.&#160;&#160;Pursuant to the terms
of the agreement, a second option to purchase 500,000 shares of the Company&#146;s common stock under our 2003 Stock Incentive
Plan was granted on March 4, 2011.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
entered into a two-year Scientific Advisory Board Services Agreement with Rajan Shah on July 15, 2010.&#160;&#160;Mr. Shah receives
an advisory fee for $9,000 per quarter.&#160;&#160;Upon entering into the agreement, the Company granted Mr. Shah an initial option
to purchase 250,000 shares of the Company&#146;s common stock under its 2003 Stock Incentive Plan.&#160;&#160;The options vested
and become exercisable in four equal quarterly installments beginning October 15, 2010.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
entered into a two-year Advisory Board Services Agreement with Sandep Rahi on July 15, 2010.&#160;&#160;Mr. Rahi receives an advisory
fee for $9,000 per quarter.&#160;&#160;Upon entering into the agreement, the Company granted Mr. Rahi an initial option to purchase
250,000 shares of the Company&#146;s common stock under its 2003 Stock Incentive Plan.&#160;&#160;The options vested and become
exercisable in four equal quarterly installments beginning October 15, 2010.&#160;&#160;Pursuant to the terms of the agreement,
a second option to purchase 500,000 shares of the Company&#146;s common stock under its 2003 Stock Incentive Plan was granted
on July 15, 2011.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Consulting
Agreements</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On January
1, 2011, we entered into a consulting agreement with Bristol Capital, LLC whereby Bristol will assist us in general corporate
activities including but not limited to strategic and financial planning, management and business operations, final projections
and investor relation materials. As compensation for these services, we issued 5,000,000 shares of our common stock. The term
of the agreement is for six months unless terminated or extended in accordance with subsequent agreements between the parties.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On January
1, 2011, the Company entered into a consulting agreement with Piter Korompis, whereby Mr. Korompis will assist the company in
general corporate activities including but not limited to strategic and financial planning, management and business operations,
final projections and investor relation materials. As compensation for these services, the Company will issue 5,000,000 shares
of common stock of the Company. The term of the agreement is for six months unless terminated or extended in accordance with subsequent
agreements between the parties.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In connection
with a joint venture agreement, the Company entered into a consulting agreement with John E. Repine, M.D. on June 28, 2011, whereby
Dr. Repine will provide advisory services to OXIS and Ergo ARDS and serve as Ergo ARDS&#146; Chief Executive Officer.&#160;&#160;OXIS&#146;
payments to Dr. Repine under the consulting agreement will be made in shares of OXIS common stock. OXIS agreed to issue shares
of Common Stock to Dr. Repine as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">On July 6, 2011
    OXIS issued to Dr. Repine 2,777,778 shares of common stock (valued at $250,000) for various services relating to the terms
    of the consulting agreement;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">OXIS agreed to issue
    to Dr. Repine additional shares of common stock valued at $50,000 upon completion of the first animal study and Dr. Repine&#146;s
    delivery to Ergo ARDS of a summary presentation of the findings of the study; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 96px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">OXIS agreed to issue
    Dr. Repine additional shares of common stock valued at $100,000 upon the completion of such second animal study and Dr. Repine&#146;s
    delivery to Ergo ARDS of a summary presentation of the findings of the study.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">If the value
of these shares decreases at the end of the 6-month period following the date of issuance of such shares, OXIS will be obligated
to issue additional shares of common stock to Dr. Repine so that the market value of the shares previously issued to Dr. Repine
on that date will equal to $250,000, $50,000 or $100,000, as the case may be.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_AdvisoryAndConsultingAgreementsObligationsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stock Options and Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Note 5 - Stock Options and Warrants</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Stock
Options</font> </p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Following
is a summary of the stock option activity:</font> </p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Options
    Outstanding</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of December 31, 2011</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">16,078,979</font></td>
    <td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.19</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">26,384,193</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.04</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">3,679,027</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.17</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of September 30, 2012</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">38,784,145</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0.08</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    as of September 30, 2012</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">23,415,441</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0.08</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Warrants</font> </p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Following
is a summary of the warrant activity:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Warrants
    Outstanding</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of December 31, 2011</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">105,001,252&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.06</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">462,300,546&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">52,500,000&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Adjustments</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(15,300,000)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of September 30, 2012</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">499,501,798&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">In April 2012,
the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company.&#160;&#160;Pursuant
to the anti-dilution provisions in the warrants, the exercise price of certain warrants is now $0.01, and the number of shares
underlying the warrants has increased such that the number of shares underlying each warrant is equal to the aggregate exercise
price in effect prior to the adjustment divided by the new exercise price of $0.01.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GuaranteesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFVAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Options and Warrants (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Warrants Outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2011</a></td>
        <td class="nump">16,078,979<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
        <td class="nump">3,679,027<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of September 30, 2012</a></td>
        <td class="nump">38,784,145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2011</a></td>
        <td class="nump">$ 0.19<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 0.04<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
        <td class="nump">$ 0.17<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of September 30, 2012</a></td>
        <td class="nump">$ 0.08<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">WarrantMember</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Warrants Outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2011</a></td>
        <td class="nump">105,001,252<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="nump">462,300,546<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
        <td class="nump">52,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_AdjustmentsOfWarrants', window );">Adjustments</a></td>
        <td class="num">(15,300,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of September 30, 2012</a></td>
        <td class="nump">499,501,798<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2011</a></td>
        <td class="nump">$ 0.06<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice', window );">Adjustments</a></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of September 30, 2012</a></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_AdjustmentsOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_AdjustmentsOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_AdjustmentsOfWarrantsWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(f)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4CAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Patents (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_PatentsDetailsAbstract', window );"><strong>Patents Details</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Capitalized patent costs</a></td>
        <td class="nump">$ 640,000<span></span></td>
        <td class="nump">$ 640,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num">(625,000)<span></span></td>
        <td class="num">(615,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
        <td class="nump">$ 15,000<span></span></td>
        <td class="nump">$ 25,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_PatentsDetailsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_PatentsDetailsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedPatentsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Patents (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_PatentsTablesAbstract', window );"><strong>Patents Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Patents</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">September
    30, 2012</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2011</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Capitalized
    patent costs</font></td>
    <td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">640,000</font></td>
    <td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">640,000</font></td>
    <td nowrap="nowrap" style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Accumulated
    amortization</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(625,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(615,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">15,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">25,000</font></td>
    <td nowrap="nowrap" style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Expected future amortization of patent costs</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; width: 84%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2012</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">12,000</font></td></tr>
<tr style="background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2013</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">4,000</font></td></tr>
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2014</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">4,000</font></td></tr>
<tr style="background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2015</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">4,000</font></td></tr>
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2016</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,000</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_PatentsTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_PatentsTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E3HAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract', window );"><strong>Company And Summary Of Significant Accounting Policies Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Going Concern</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">As shown in
the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $88,205,000 through September
30, 2012.&#160;&#160;On a consolidated basis, the Company had cash and cash equivalents of $61,000 at September 30, 2012. The
Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash
flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are
many factors that may prevent the Company from reaching its goal of profitability.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The current
rate of cash usage raises substantial doubt about the Company&#146;s ability to continue as a going concern, absent any sources
of significant cash flows.&#160;&#160;In an effort to mitigate this near-term concern the Company intends to seek additional equity
or debt financing to obtain sufficient funds to sustain operations.&#160;&#160;The Company plans to increase revenues by introducing
new nutraceutical products primarily based on its ergothioneine assets.&#160;&#160;However, the Company cannot provide assurance
that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company
will generate future product related revenues.&#160;&#160;The Company&#146;s financial statements do not include any adjustments
relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be necessary in the event that the Company cannot continue in existence.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The financial
statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.
These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently
applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates
and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets
and liabilities at the date of the financial statements. Actual results could differ from those estimates.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>Product
Revenue</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products
to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the
products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales
order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net
of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor
may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based
upon historical data, current economic conditions and the underlying contractual terms.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>License
Revenue</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">License arrangements
may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various
performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Non-refundable,
up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on
our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&#160;&#160;We
defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right,
product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent
of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research
and development services that are required because our know-how and expertise related to the technology is proprietary to us,
or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Payments related
to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement
of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
operates in one reportable segment.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation to Employees</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&#147;ASC&#148;)
718.&#160;&#160;The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based
compensation issued to employees and non-employees over the related vesting period.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
granted stock options to purchase 26,384,193 and 2,066,491 shares of the Company&#146;s common stock to employees and directors
during the nine months ended September 30, 2012 and 2011, respectively.&#160;&#160;The fair values of employee stock options are
estimated for the calculation of the pro forma adjustments at the date of grant using the Black-Scholes option-pricing model with
the following weighted-average assumptions during 2012: expected volatility of 116%; average risk-free interest rate of 1.04%
to 2.04%; initial expected life of 5 to 10 years; no expected dividend yield; and amortized over the vesting period of typically
one to four years.&#160;&#160;The Company reported an expense for share-based compensation for its employees and directors of
$699,000 and $307,000 for the nine months ended September 30, 2012 and 2011, respectively.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Stock Based Compensation to Other than Employees</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company
accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance
with ASC 718. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value
of the equity instruments issued, whichever is more reliably determinable. The value of equity instruments issued for consideration
other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider
of goods or services. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized
over the term of the consulting agreement. The Company recognized no expense in share-based compensation for non-employees for
the nine months ended September 30, 2012 and 2011, respectively.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Basic earnings
per share is computed by dividing the net income or loss for the period by the weighted average number of common shares outstanding
during the period.&#160;&#160;Diluted earnings per share is computed by dividing the earnings for the period by the weighted average
number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise
or conversion of outstanding stock options and warrants during the period.&#160;&#160;Since the Company incurred a net loss for
the six months ended June 30, 2012 and 2011, all instruments convertible into shares of common stock are excluded from net diluted
loss per share because of their anti-dilutive effect.&#160;&#160;Total potentially dilutive shares excluded from the calculation
of earnings per share at September 30, 2012 totaled 538,285,943.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Management
does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material
effect on the Company&#146;s financial position or results of operations.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The carrying
amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a
reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected
realization and their current market rate of interest.&#160; The three levels are defined as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 1 inputs to
    the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&#146;s
    Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair
    value because of their short-term maturities of the investments held by these funds.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 2 inputs to
    the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are
    observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
    The Company&#146;s Level 2 liabilities consist of two liabilities arising from the issuance of convertible securities and
    in accordance with EITF 00-19: a warrant liability for detachable warrants, as well as an accrued derivative liability for
    the beneficial conversion feature. These liabilities are remeasured on a quarterly basis. Fair value is determined using the
    Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with
    that of a government-issued security of a similar maturity.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 3 inputs to
    the valuation methodology are unobservable and significant to the fair value measurement.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The following
table represents the Company&#146;s assets and liabilities by level measured at fair value on a recurring basis at September
30, 2012.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Description</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    1</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    2</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    3</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Assets</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 64%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Liabilities</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Warrant liability</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">514,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements, which may include, but is not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 18G<br><br> -URI http://asc.fasb.org/extlink&amp;oid=15229074&amp;loc=SL7494712-110257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for director stock option and stock incentive plans. This disclosure may include (1) the types of director stock option or incentive plans sponsored by the entity (2) significant plan provisions and (3) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 4, 9-15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 06-11<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 11, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract', window );"><strong>Company And Summary Of Significant Accounting Policies Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Company assets and liabilities by level measured at fair value on a recurring basis</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Description</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    1</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    2</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Level
    3</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Assets</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 64%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Liabilities</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Warrant liability</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">514,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_CompanyAndSummaryOfSignificantAccountingPoliciesTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Options and Warrants (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_StockOptionsAndWarrantsTablesAbstract', window );"><strong>Stock Options And Warrants Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the stock option activity</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Options
    Outstanding</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of December 31, 2011</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">16,078,979</font></td>
    <td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: top; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.19</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">26,384,193</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.04</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">3,679,027</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.17</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of September 30, 2012</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">38,784,145</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0.08</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    as of September 30, 2012</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">23,415,441</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0.08</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the warrant activity</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Warrants
    Outstanding</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of December 31, 2011</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">105,001,252&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.06</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">462,300,546&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">52,500,000&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Adjustments</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(15,300,000)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; text-indent: 9pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#151;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    as of September 30, 2012</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">499,501,798&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">0.01</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_StockOptionsAndWarrantsTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_StockOptionsAndWarrantsTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number D-98<br><br> -Paragraph 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_StockholdersEquityDetailsNarrativeAbstract', window );"><strong>Stockholders Equity Details Narrative</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized</a></td>
        <td class="nump">600,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Retirement of debt, Shares</a></td>
        <td class="nump">160,107,475<span></span></td>
        <td class="nump">61,831,683<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Retirement of debt, amount</a></td>
        <td class="nump">$ 2,382,281<span></span></td>
        <td class="nump">$ 1,144,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_StockholdersEquityDetailsNarrativeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_StockholdersEquityDetailsNarrativeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIQBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Deficit (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Preferred Stock</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, Amount at Dec. 31, 2010</a></td>
        <td class="nump">$ 3,000<span></span></td>
        <td class="nump">$ 149,000<span></span></td>
        <td class="nump">$ 74,474,000<span></span></td>
        <td class="num">$ (80,095,000)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, Shares at Dec. 31, 2010</a></td>
        <td class="nump">1,787,897<span></span></td>
        <td class="nump">149,571,976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Issuance of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">307,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services, Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,000<span></span></td>
        <td class="nump">2,355,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,210,498<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of debt, Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">78,000<span></span></td>
        <td class="nump">1,286,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of debt, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">77,734,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ExerciseOfWarrantsAmount', window );">Exercise of warrants, Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_ExerciseOfWarrantsShares', window );">Exercise of warrants, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,783,364<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,700,000)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, Amount at Dec. 31, 2011</a></td>
        <td class="nump">3,000<span></span></td>
        <td class="nump">269,000<span></span></td>
        <td class="nump">78,422,000<span></span></td>
        <td class="num">(83,795,000)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, Shares at Dec. 31, 2011</a></td>
        <td class="nump">1,787,897<span></span></td>
        <td class="nump">269,299,838<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Issuance of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">699,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services, Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">28,000<span></span></td>
        <td class="nump">754,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of debt, Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">160,000<span></span></td>
        <td class="nump">2,438,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of debt, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">160,107,475<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,410,000)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, Amount at Sep. 30, 2012</a></td>
        <td class="nump">$ 3,000<span></span></td>
        <td class="nump">$ 457,000<span></span></td>
        <td class="nump">$ 81,634,000<span></span></td>
        <td class="num">$ (88,205,000)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, Shares at Sep. 30, 2012</a></td>
        <td class="nump">1,787,897<span></span></td>
        <td class="nump">457,207,313<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ExerciseOfWarrantsAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ExerciseOfWarrantsAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_ExerciseOfWarrantsShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Custom Element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_ExerciseOfWarrantsShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Note 4 - Stockholders' Equity</a></td>
        <td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Common Stock</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Under the
Company's Second Amended and Restated Certificate of Incorporation, the Company was authorized to issue a total of 150,000,000&#160;shares
of Common Stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On January
5, 2011, the Company's Board of Directors approved an amendment to its Second Amended and Restated Certificate of Incorporation
to increase the shares of Common Stock that are authorized for issuance by 450,000,000 shares, bringing the total number of common
shares authorized for issuance to 600,000,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The approval
of the Amendment required the consent of no less than at least a majority of the voting power of the Company.&#160;&#160;Theorem
Group, LLC owns, in addition to other of our securities, 25,000 shares of Series H Convertible Preferred Stock.&#160;&#160;The
Certificate of Designation of Preferences, Rights and Limitations of the Series H Convertible Preferred Stock provides that each
outstanding share of Series H Convertible Preferred Stock entitles the holder thereof to a number of votes equal to (A) the number
of shares of Common Stock that such share of preferred stock could, at such time, be converted into (B) multiplied by 100.&#160;&#160;The
Series H Convertible Preferred Stock is currently convertible into 2,500,000 shares of Common Stock.&#160;&#160;Accordingly, Theorem
Group, LLC has the voting power of 250,000,000 shares, which represents more than a majority of voting power of all of the Company's
outstanding voting shares.&#160;&#160;Theorem Group, LLC approved the Amendment on January 5, 2011 by an action taken by written
consent.&#160;&#160;The amendment was filed with the Delaware Secretary of State in February 2011.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Each share
of common stock is entitled to one vote at the Company's annual meeting of stockholders.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">During the
nine months ended September 30, 2012 and 2011, the Company issued a total of 160,107,475 and 61,831,683 shares of common stock,
respectively for retirement of debt valued at $2,382,281 and $1,144,000, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Preferred
Stock</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The 96,230
shares of Series C preferred stock are convertible into 27,800 shares of the Company's common stock at the option of the holders
at any time. The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading
days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than .20 or more than
..2889 common shares for each Series C preferred share. The conversion ratio may be adjusted under certain circumstances such as
stock splits or stock dividends. The Company has the right to automatically convert the Series C preferred stock into common stock
if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company's
common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $13.00. Each share of Series C preferred stock
is entitled to the number of votes equal to .26 divided by the average closing bid price of the Company's common stock during
the fifteen consecutive trading days immediately prior to the date such shares of Series C preferred stock were purchased. In
the event of liquidation, the holders of the Series C preferred stock shall participate on an equal basis with the holders of
the common stock (as if the Series C preferred stock had converted into common stock) in any distribution of any of the assets
or surplus funds of the Company. The holders of Series C preferred stock are entitled to noncumulative dividends if and when declared
by the Company's board of directors. No dividends to Series C preferred stockholders were issued or unpaid through September 30,
2012.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On December
4, 2008, the Company entered into and closed an Agreement (the &#147;Bristol Agreement&#148;) with Bristol Investment Fund,
Ltd. pursuant to which Bristol agreed to cancel the debt payable by the Company to Bristol in the amount of approximately $20,000
in consideration of the Company issuing Bristol 25,000 shares of Series&#160;G Convertible Preferred Stock, which such shares
carry a stated value equal to $1.00 per share (the &#147;Series&#160;G Stock&#148;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Series&#160;G
Stock is convertible, at any time at the option of the holder, into common shares of the Company based on a conversion price equal
to the lesser of $.01 or 60% of the average of the three lowest trading prices occurring at any time during the 20 trading days
preceding the conversion.&#160;&#160;&#160;The Series&#160;G Stock, as amended,&#160;shall have voting rights on an as converted
basis multiplied by 100.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In the event
of any liquidation or winding up of the Company, the holders of Series&#160;G Stock will be entitled to receive, in preference
to holders of common stock, an amount equal to the stated value plus interest of 15% per year.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Series
G Stock restricts the ability of the holder to convert the Series&#160;G Stock and receive shares of the Company&#146;s common
stock such that the number of shares of the Company common stock held by Bristol and its affiliates after such conversion does
not exceed 4.9% of the Company&#146;s then issued and outstanding shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Series
G Stock was previously referred to in an 8-K filed by the Company on December 10, 2008 in error as the &#147;Series E Stock&#148;.
Further, the Series G Stock initially incorrectly provided that it voted on an as converted basis multiplied by 10.&#160;&#160;This
incorrectly reflected the intent of the Company and the holder.&#160;&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On October
13, 2009, the Company was informed by Theorem Group, LLC that it had purchased all of the outstanding Series G Preferred Stock
and Theorem gave notice to the Company that it intended to exercise its ability to vote on all shareholder matters utilizing the
super voting privileges provided by the Series G Stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Effective
February 10, 2010, the Company issued 25,000 shares of its new Series H Convertible Preferred Stock (the &#147;Series H Preferred&#148;)
to Theorem Group, LLC, a California limited liability company (the &#147;Stockholder&#148;), in exchange for the 25,000 shares
of Series G Stock then owned by the Stockholder.&#160;&#160;The foregoing exchange was effected pursuant to that certain Exchange
Agreement, dated February 10, 2010, between the Company and the Stockholder (the &#147;Exchange Agreement&#148;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Certificate
of Designation of the Series H Preferred is based on, and substantially similar to the form and substance of the Certificate of
Designation of the Series G Preferred.&#160;&#160;Some of the corrections, changes and differences between the Certificate of
Designation of the Series G Preferred and the Certificate of Designation of the Series H Preferred include the following:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">As previously disclosed,
    the holder of the Series H Preferred is entitled to vote with the common stock, and is entitled to a number of votes equal
    to (i) the number of shares of common stock it can convert into (without any restrictions or limitations on such conversion),
    (ii) multiplied by 100.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The holder of the
    Series H Preferred cannot convert such preferred stock into shares of common stock if the holder and its affiliates after
    such conversion would own more than&#160;9.9% of the Company&#146;s then issued and outstanding shares of common stock.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">&#183;&#160;&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The Series G Preferred
    contained a limitation that the holder of the Series G Preferred could not convert such preferred shares into more than 19.999%
    of the issued and outstanding shares of common stock without the approval of the stockholders if the rules of the principal
    market on which the common stock is traded would prohibit such a conversion.&#160;&#160;Since the rules of the Company&#146;s
    principal market did not require such a limitation, that provision has been deleted.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On November
8, 2010, Gemini Pharmaceuticals purchased 1,666,667 shares of the Company&#146;s Series I Preferred Stock, $.001 par value, at
a price of $0.15 per share ($250,000).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">As the holder
of the Series I Preferred Stock, Gemini Pharmaceuticals will be entitled to receive, out of funds legally available, dividends
in cash at the annual rate of 8.0% of the Preference Amount ($0.15), when, as, and if declared by the Board.&#160;&#160;No dividends
or other distributions shall be made with respect to any shares of junior stock until dividends in the same amount per share on
the Series I Preferred Stock shall have been declared and paid or set apart during that fiscal year. Dividends on the Series I
Preferred Stock shall not be cumulative and no right shall accrue to the Series I Preferred Stock by reason of the fact that the
Company may fail to declare or pay dividends on the Series I Preferred Stock in the amount of the Dividend Rate per share or in
any amount in any previous fiscal year of the Company, whether or not the earnings of the Company in that previous fiscal year
were sufficient to pay such dividends in whole or in part.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Each share
of Series I Preferred Stock shall entitle the holder thereof to such number of votes per share as shall equal the number of shares
of Common Stock (rounded to the nearest whole number) into which such share of Series I Preferred Stock is then convertible.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Upon any liquidation
of the Company, subject to the rights of any series of Preferred Stock that may from time to time come into existence, before
any distribution or payment shall be made to the holders of any Junior Stock, the holders of the shares of Series I Preferred
Stock then outstanding shall be entitled to receive and be paid out of the assets of the Company legally available for distribution
to its stockholders liquidating distributions in cash or property at its fair market value as determined by the Board in the amount
of $0.15 per share (as adjusted for any stock dividends, combinations or splits with respect to such shares).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Shares of
Series I Preferred Stock may, at the option of the holder thereof, be converted at any time or from time to time into fully paid
and non-assessable shares of Common Stock.&#160;&#160;The number of shares of Common Stock which a holder of shares of Series
I Preferred Stock shall be entitled to receive upon conversion of such shares shall be the product obtained by multiplying the
Conversion Rate by the number of shares of Series I Preferred Stock being converted.&#160;&#160;Initially, the Series I Preferred
Stock is convertible into 1,666,667 shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In the event
that the per-share Market Price of the Common Stock over a period of 20 consecutive trading days is equal to at least 130% of
the initial conversion price (130% of $0.15), all outstanding shares of Series I Preferred Stock shall&#160;&#160;be converted
automatically into the number of shares of Common Stock into which such shares of Series I Preferred Stock are then convertible
without any further action by the holders of such shares and whether or not the certificates representing such shares of Series
I Preferred Stock are surrendered to the Company or its transfer agent.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>34</ContextCount>
  <ElementCount>146</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>10</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/ConsolidatedStatementOfStockholdersDeficit</Role>
      <ShortName>Consolidated Statement of Stockholders' Deficit (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - Note 1 - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/Note1-CompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Note 1 - The Company and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Note 2 - Patents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/Note2-Patents</Role>
      <ShortName>Note 2 - Patents</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Note 3 - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/Note3-Debt</Role>
      <ShortName>Note 3 - Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Note 4 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/Note4-StockholdersEquity</Role>
      <ShortName>Note 4 - Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Note 5 - Stock Options and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/Note5-StockOptionsAndWarrants</Role>
      <ShortName>Note 5 - Stock Options and Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Note 6 - Advisory and Consulting Agreements Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/Note6-AdvisoryAndConsultingAgreementsObligations</Role>
      <ShortName>Note 6 - Advisory and Consulting Agreements Obligations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0014 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0015 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0016 - Disclosure - Patents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/PatentsTables</Role>
      <ShortName>Patents (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Stock Options and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/StockOptionsAndWarrantsTables</Role>
      <ShortName>Stock Options and Warrants (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0018 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0019 - Disclosure - The Company and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Patents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/PatentsDetails</Role>
      <ShortName>Patents (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Patents (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/PatentsDetails1</Role>
      <ShortName>Patents (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0022 - Disclosure - Stockholders' Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders' Equity (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/StockOptionsAndWarrantsDetails</Role>
      <ShortName>Stock Options and Warrants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Stock Options and Warrants (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oxis.com/role/StockOptionsAndWarrantsDetails1</Role>
      <ShortName>Stock Options and Warrants (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0002 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 0003 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0004 - Statement - Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>oxis-20120930.xml</File>
    <File>oxis-20120930.xsd</File>
    <File>oxis-20120930_cal.xml</File>
    <File>oxis-20120930_def.xml</File>
    <File>oxis-20120930_lab.xml</File>
    <File>oxis-20120930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>36
<FILENAME>0001513160-12-000090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001513160-12-000090-xbrl.zip
M4$L#!!0````(`'Q[=4&^U:`,'X4``#4G!0`1`!P`;WAI<RTR,#$R,#DS,"YX
M;6Q55`D``TLYK5!+.:U0=7@+``$$)0X```0Y`0``[%WK<^,VDO]^5?<_X+S9
MO6R59$M^R);GL>6Q9S:N3&QG/-ED/UU!)"0A0Q(,0=K6_O77W0#XD"F9EF2/
M/-%4*F6)!/J'?G<#I%[_XRX,V(U(M%31FZWN=F>+B<A3OHQ&;[9^N6Z?7)^>
MGV^Q?[S][_]B\._U_[3;[.??SJ-4)-Q+Y8U@[39<>WTW2`)YC/]G,&.DC^^T
M?+,U3M/X>&?G]O9V^W9O6R6CG=U.I[OSVT\?K[VQ"'E;1CKED2>VW*A`1E_J
MQG7[_?X.776WWKL3B3L:>SMX><!U,3,"G'/_/21PU4_S`>6;#W;,Q<JMLO;6
MGKE5NEM],76?%M[V2-WLP`6XO[O;[G3;>UUW>R*&,R'W=N"JNU%JM;_;/9RW
M/G.'&Y#I]HCS.!\PY'I`-]L+-6#@2J("H6O'T)6:09&*HBRLQ^6GR4XZB<4.
MW-2&NT0BO7S<PX.J`P`#?EV/CJ[4H+O\[?PZ'Z#NI-[V5$CW=?I[G2VG]*A+
MQYHT]I,8,E+#XS$)!P>UW8#M.^UOV<M(\LV6EF$<@$[MN*F,G7@*#.@N9=)_
ML_4A4:%#UNFFROS=;Q?T\V$B2F4ZR;_-OY<^7AE*D3!"*2JL<RIV>O[CUML.
M_.MV^KV#P]<[TX,+<CNU]"RU&-BN_/LHP'Z2](RGXFVQ'#=3<>W>,!'YI4&X
M[H*\7QGBOJ\`<%]:EL[F\XF^'`*-;AO(@`:\+-X:[Y2^+1:0D[!75LJDEZF`
M)29-:=*3,*EC!/%_5^`(1)((_SI5WI>?1#@0R5?C7&&-8A2*TI+S2SZ`N8L#
MZ<G48&6^A#M-`F"]__%U"H:'X]__D0'N4Q7&*H*/^@3\W=9;=UO=TE_OU%(I
M(]RIA[BTU#O/8!K=C=373.K/Z!`W4E\;J3^IA[<Y6;>4DSF[!_:$*OKSB?_>
MNI];]I7TLKM(>CGE*%:;7LY.XS<JLQ8JL[8526?C6;ZNFGRE#'(C[Z\O[^?,
M'3?R_OKR_EI9XXGORQ28QX,K+OWSZ)3',N7!GTH/YO)@DTTVS28WJK3.JK3V
M6>9&?=9,?;Y2]KG1@_75@^?,2C=ZL+YZ\+6RU4\BY3(2_GN>1#(:Z3^5,M0O
M?I.?-LU/-\JS7LJS]AGI1F&^NL)\I1QT(_EUDOQS9IT;R:^3Y)_CM)23_`<N
MDW_Q(!/G49RE^J.X$4'WVQ!_OK1WD_S/'X`.3[SQA!9:U8,YK/@3*\/N1AFF
M6/$G5H:]C3),L>);588Y%>5/,I)A%GX;JO")1R-1E79E?9M:L;%:\+MO6RW*
MZ]NHQ</-RY?XS,(J^GS/\=#,2^1MI;9]^CS&=35^Y4D"DW\;?JEA25M9\[?:
MPY@3BS8RW\2G.:7-1CV^T:JENI7Q<N/CDW;]"[]Y^&T]X7RX7DZG2(H/OZVD
M^/%\7GE2G$72,/F7Z[-[W`P%UUDBWMIW+!S#/6XR=ZE*`F>;,?_UF"="SR1A
MF4`W+4P#\%W-H./+&Q#C?=[BV`M\XP)/5=EM/YX'TQCK9BT1/1.1"F7T$-F'
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M;\.'3R)622JC$2:V67-J_T9/\]!L]ZD2FE-@]T@ES4WJ.N0!C&/Y]`SS;AY-
MRA`J4]<9@A&Y4>`/\%WSQ?Z\5S6">S/-)H<:]CAB^'<=N7PF1\S5&N?1#=P$
MB[X0:87*U$M?&#I8NH!AG/G"D\!7_68+W<DN>*W7.W53/I:<6\@\<@U)724B
MYM)_?Q=#&2:LCBVZQ!+-VGD7)MYDP5/\;03@1&N1ZB57W>WL5RA7)GTTQ29+
M/=Q[+,$+%7G+K7+WH(9F,>TB9!M)=1&RBYMHOX9:<QI-%G1TU(2$YRF(+?J*
M3_@@6-8LCSJ]*LW:V1?'T&C9!T<+8*#W``J=KH8/W8/^T90/KIM^<1#-W-24
M)34#`?Q*,N%_E'P@`YE*L:S7ZG4.IP523V`I)(TXTMGO+P;EHXS$Y?`T$;Y<
ME5\K3_E8<DT6N]MK3.XJ47[FI;;/.2&N\.`TX%IC$\1?VAJ.I@)F(W(K1-F$
M7P?=_6508HUZ?"9"'OD7*A7.W4`B=#D\@YP/?=#E\`!IG$1^9V$EZAFQ/I+<
M"E$VX65O;QF0]>]INN+)94(=>Y\.%$'&3IV?QIQTC:(2U/.+#Y!+;G>P*?<X
MJJO#6LO/9\1J*)UDZ5@E\C_";\;/&?@HB9K.CN<06Q[:??:M&!HI\364AQ`<
MJB.HZ/?-N*6XUN_M[CES>9#2\K@:LVS%N"ZS%#=C\(W,S\&T>^16A'!U[&N"
M\(<GTCF;C32CM#RNQDQ;,:[5ZMR#X!:0Z&IU;B4(SY](Y[H]_'=8@3>'UO+(
MF@>'52-;K=XU@+>`7%>K><M@K'G!TG.E>PU(K@CE,HG><BA7FN+U.IWI1&H.
MJ251-=:^%:,RQKY<K.CU=_O]H[VC.8@,F270-.;/_L'A;N=PK[NW/)J2%3\Y
M@TJTEL6U4E;-P;6ZQMG![EY5HYOTJ5;5*^OMW6L@/43\5$4W(DDEE/AG8I`N
MN?I^_V#*G.MF7QQ#(R;L/@8#!;[J+7`U`W69ZGA0M\,.OL)-4!4MRJ7#PU+"
MMR#MI\+?J"7;+S>TEES`K,>23SPO"[,`0^:9&.*AS479W3[:.YS2RX>)K09>
M$VZVCXYV.\O"F_$.H84U]&A_M[IA.H/`$C@:[0MU>WO[B^`H.7]*N!9OW?9G
MY2<T[R)TFRP<XEDCNM,6.-4>,PG]PHNO-?):$DOC:;0[\C1X?ECB0$.C^9<&
MT_!$Q\K!G"Y^Z*&II$Z7QM-L$_'1>(KG#>#:6`6^2+1YY&#A.'30[70K5GU_
M[L6H-PHSO=V]HR>A/O>7B.9!VGL2.'-_(N?YX<S][9;GAS/[=?]S[6=J#W[5
MLGH<FNF@O&I1/0[-=*A>M:3FOR)S;A:WOW^X_Z1R6P+;O0QSU5)<'-O]K'/5
M,IWQ`JKY94*G,U7%K%J:"Z&Z5UNM6HX+H;I74CV,JM0K@6IU=6%_^MC@0W16
M@6N!HX:/A?63C%0"W[L#:BLX%3P]Y2(D&Z5"W=VJRYY%N,E9F(4;A?N-C]LL
M"^<QY<-CH#S<^5EA936#P@H`+5A=/0#(Z=9E,N*1_`_'4`2CM0JD3Q_`RB`G
MU#`'?;P<?I`1CSS)@_P19XV3!@H?U4*;E*-(#J7'H]2>CP5W>*7P@6:A/\.B
MW@5@M(T?<_A;D+Z*F4XG@7BS%?)D)*-CUHG35VP(,QRSHSAEGV4H-+L0M^R3
M`KUHF2]:#&NEX=;?1NDKG`7O=Q,]:BP/XU=_Z?8Z-,L.#G53[L3TUU^Z>_9_
M9;`-:;QB^:J6AFJ>9D/W$'&35+0(UWGD;;/O/14$@GZ//)BTF%W6_B&-<I^.
M7C&5L'0L2M?M0S3%+7]G4C,1C?A(^$Q&=#OJ"+ZIJP4:"014C)K!P$B9YH%@
M:LAB<^I1$Z)TS%'+L\C\1CI-,>9).,P")H9#@*EQ3`%"W9%"W@C@"]#2)<!(
M1$;#@(<AK7J[)+'\K\NI\8P*'<U29?'`!9EF-('&1=V.I3<F7`/EYXOOO=)`
M#V["Z>P"%=R4P+*'^!(`()!'*)@<UA@.8*G#1`"/N`]V$6CV/=_^LLVWV5B.
MQL$$H)B?B2<D.A9H*;AZ=3<9B8AH@,TG"C[\G>$6L`+KOAV+(`3^TU65@`]@
M8\&#=#QA`Q[@K[2CE,`LTUI^?(:%30D6U^:>=!C*2.JQ\`F2E1R1<A><.)F'
M>U7`6H%<\X+,%\BTA,<B2Z7'HBP%`=/?@-#I0`OXHD-1\_TPBSRCNF#@RD=N
M&Q"E"P/0L`243V^STC(8<%:Q6&DM\#]`DPI2^,P0B,$C8AH"8W$?CP,T>GN#
M4<TXD0*?@T.!Q:"7AC)@2*BEC5I1*&[(@<D@ABQM@U_#9W-\E/5`0D`"I<&!
M,6ISL7"/,*)<N69^DHU*?'N,?`!FB"B'^(07`;(2`S4"<:LH9R4CI"`2E<0J
MP><@49<A>/R1@8J&D$LP[DG0'0[1@0<P7GDXE]GC-#QHL8_M]\D(%!S6+R"]
M9=\7%OG^TS\O2S[!>!I8'6=?A&4COO%BFU5GD-I"!)ZI",@.)BR47J(4A2`=
MDO5I)0-CV!JT&YSA)`+XFC;S8<`X`P<(V@(#,/BASXI!Y].9O"1P3E'&@!+,
M#,TW!BQW,`>HRH1]=W@`4((`-YT`@W-II"T`Q3HV_(AK;UG3NV7J-L)EQS`+
MZ!R9AH<N!E2BP&V$!36[2#!ZLC\R]".I-76<$&ERYQ-TBED-Z9^5I,XOJ2##
M:T@^Y1J@`[$6*.47A":!69`)N]$LTP(G1C\D350@)+<R'5O/53%1H_8#E0)K
MZ2.!NI5@UC<<;62"<'UK+#J+X\`D`?6F6]BJ85<*_(-IC:[`^MM\A*!SI34N
M!+\*E''%.,H##QF";-<]_KZ@5.$\8MU^[Z"%7L&JIO,3<2(@JP2=4N0<,3UH
ML3/)1Q$$$W#I9SSE+48YQ2W791>39P.4&^+@4QY(T,)(0K2;FH)Y8WR?'XRQ
M.4$Q$1H@&$]EIC,1\%L,?A*1'^Z:N%^:`SQ9*'#8V=DYNZJX7VWATM"C@VU&
MJ^_OM^KN)2Q@I3@M64DEH6+OI#H-)!F'G15QP+=W$W+^U]LGVS.AU21H-,?:
MJ\L+TNQ_*O/D-V1`2;3V:%\08T\@:HXAUH$9Y3DS]TQF,[%'HVSA*"A1-'4B
MAK+4Q8BTE*^-C?/`_`736)S+G1_`;)I.*X#A?W=TU-KM'+0ZG0X,3U0V`B,3
M<4H--@*RUVDQK!GK$W^,7Q5D`Z[E/2A@KUR;U(W^$']D\@8JE\@4(M_UN@0`
M`G%.F^5TV52&\;^:TA&,V6#T"9<0@WG>Z`4"YK@!UL;`G@SK#(D.`N-\&18D
M_/C:%Y"+SH;($,Q9$HBH4>:J"XBNY&$0M,F3`\A((B%,_-U1>!E8.Y8PC%*O
M(28'6*%,MMD/ZA;C<Y49D)EBRL4U5O0V^4C!%0:!%7<`%0!\CZOC^HN)ZY!(
M"*Q-C/?$:890U*C$YJ&8,<>$O+K"(93^5/^,3>ZBV4@!9TQ.7D*Z]L;Q@NP8
M2PM;-1">Q$98TOM,0[)F5!:U;D#O.$,K]E4V`*480-%3EF"E,#;",HJ)?1^L
M-#`S'BGK'M`E0R(XT*8Y@+ELED"J03@`@BZ:1P8.:G-]4G^.A3'V"E22(L40
MK&MDRARL&2!S;T.8#1W5BM9A:8@5'B;H0GPIVZ:@-K+!@T7]('6>#%8`]ZL!
M]OG+]CC,W%29IFM8:9J*\:'*CKP$C04_"%:@16'=`X))>3&0)D`1"+6^GK9U
MH<1RBFNJK,B81*7TXO2<?BVH>8X`B.";GHQ#P,9"40@[OP`^#!/&849UI&&1
MX21S7,1DDLJ-G)TM)H>H!*TR-X$7Y@:1>P-M6E)5WVB+&*#MG"0(`ON<>6,B
M$2:4.(X^ILRN"UY@`52*NBX'M1S\WT'H=-F8$M*TFF*Z8N2AG6%0=+&/^7HF
MS06EQYL2'V,@R:?E.G`\I+<+S!@5R%*?B5PL5(?&H`<"]!_E@26:S<B=ZYV*
M,%;$N;FBW.XDU)0@@(W372'47S3YV/=0_F"W0:\]X!?$6S3BW&)-$[6P6M.D
MP1P*B\=$Q*7=#$KM2N8`>1M0@`"(0UNV!2RQ5ZQCN%NZG@H,D0E%D5'B[%H-
M?J?F.F4KB`%0:9,@FST0%MM-$+0VT]=1E<L)>!89!W"#<6GH2^$ZIIMY8?U+
M)/$35<6$_@0J5?`*IKLRYC>"#82@,].:S#@-C*OD,:1MQ3PQOEDHR9U)6N9@
MR>>9!NO4S;7.,4%WCP]Z%0RDJ,R_@._)E=ZT?<C396%L1$`^B5//W_I,?'L7
MND/K_X"D\XQEIY='2IQ0F%<DF0]^OA]%@XUS&U'*0?/D,,K36<?HVV1H-D=.
M3$<9)L\">H5.%B!)6$!BTMETK'1IT2_*C;X<H_]DQ,\^0?2$I)$:F^N.^06Q
M%\=F^(=]60F!LCPGO%F.?*V7\7(X_GDJN86[,JRAT8U13HC]DM*7E.13:R.E
M+53;UAABIH^O)2ZZ^;/VX$Q\HYYJ6FPM5?=I%6YT:170!I<'R:Z"@`->T)F?
M]7@BW^8U4SD213]?CV5,>R=#@>NAU'U@,F0P7]S7N1U#X$IE&@B;/I<W'S4U
M4Z#\T.9\JLNP'22[F$QGQ5Z69AF$;:),\8A*D4!"0C[!;6J(&(2,;L*YL%[,
M4P)<CZU+(3E/B)&$T&ZCNYR>T@-\52<?8+RFIHD_Q1^:"Q'[^"I9.<BH,3+%
MK!J6M""/3UUM#.M2MU@8`?<(LEM+:7/=<:5,!R,6%ABELB1?J(SH+;X8STI#
M<IW"39OR!:N7N&,-&ICO-0(<RF5`.^G7>&SD)I9!<8SO0A4)U80PL:FTS0/A
M=&(.4Q)IWT6'1`%OOE)23E!:S[8%J;@E%,0!J/0!%6FU3YL2;OL:.(@O+O;*
M!&V;RB`*7,.22.+ZB2<O*E:O/5070CZ:/?)-"'EJJ);1C%XL9I)PG=NL+0G0
M[",5M1.!C2O:)LYB\%)`T9YEL!Y:W('KI@,M^1F'!%L,Y,CRO6[<>:>_F7.G
MN`L6J4"-)J8HP6UC90\KQ"+!RH?:.S#2^,50PO]3%=GL?;J-HR8\`#\;\XE-
MP*_!WULO/;56<A<AI.581C%A=J8K=VP,?(50+RIJU+)^N6V4"97(UG8@E*+)
M1'489B[8_;>B+FG%8`(QW"B.+2EA+.DN?!*F%6V[5;1C$-VHX,;(V9YL4!FJ
M9`+UNRGX\_R"YS6C337&N6HSVRH.0V'"CHT5N>:;\%*HMMM;<2=E,`VP\1BB
M?UU!]:OQ?WA,+'&H7$4]PQZ)A7+(;H6I[$OKKAC2(,#.-P4YW+#&#GUQ>JUL
MCF2_K<J9+K1"D=S`.G'Z&S$Q`1G^_MT>YS";X#C5%$R`1SDIR`=22]?Y+['-
M;1YI($$-!&'/ZIG<R^T_X$DWE%EI229KP*E,S]B:<IZ<E4R:-O-=`[\U@UUE
M-7%[B.YX3]X-*!]<M#PI:;#51CS1XG$\5(.8OT3JMCU6MWD/(DDE-?%-NI*G
M6[G:F--/^6$SN`&TW>TV>#RR1Z)RFS#'G3*S71F9O<*JB2$VWSZT9<TFUWC:
M':1V#[V#O&B&3#-EXQ97"/7*1BJG!JZ0RG?3;D2KK.UMLV53"H-TYLKI)YO6
MS9+RSW%Q>55C]W[#DKGAU^6H2\?A/'KWJ&L0EK)D/DJ$-3_G-R=%(]5684%H
M3Y<Y$Q7V01AW&FZC8BN$>FU^`*SXI8.U1_R"F#O=B#'[N<8LP5YL@YI"H/TA
MMHUNKU*W\:$N]BZO]%$4D$UP=RKP?1@':B(V6VA/J?-V7TK3=A=V9S1*Q48J
MKRP1O$$XD5#DHFX3I7&4.19/`>&V%>2.B:^!EE_L9I<.E9]<GY;.E!.4P^[1
M@^<H\A"H7?S*=VSH08K\1`9=&^%KM]NTTS/D,H$*%=^!@L=/2/547#2,;/I)
M1QG:1?>IP@%IWJ$&JEGPP>PZ1NWBFSP7<\GA#>X0F50><K.-"WE";2:!`\NK
M\L4V1@8)%AZ[V>VU]H[V6]W^'HENM]7I]5K[_2XSOY8VM4]<>6*&'L.W4]_3
M`1]*!CH&9XJ_C!ZOH%H*V_0P,!WCHU1X^N/^N4(#I=/MMF@'VCV[-=,:"F4F
MP`[)M%K;0WIN@])W6]IYH[64Q4'R1L\@\/)1E^F]4F(O%"EN;>\"#K[BVALK
M;.\8NFVH>>@,5:B@3B;/D!\B'2IL^.+%6X$5JO#;W#PU4-DHMMQ#SAQ3L>61
M&2E$3-4G0.EV>W]]Q=SH1.HO;7KT2KJ'<=UAM^YV9_^O+C/?Q0^OX"9)_85\
M[D`.Z>8#%&RWPR:0U.I76/#FMYA?P0,Y3:0(?',HG8>8E%4*L*JQ$W<G]"2$
MW9['O`*//F%1250:N#RW31ZYW6\2)"GL+$=-9\+J%10P$9+O>OV^.>H*5[_;
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M@`"#0[+RZ_<YNAN-BR(E4")H[)&Q)`#]=/=SG^4#RXZ4_,.\%$?NI8_$][@$
MU<GY/U&I\!(5M*:<>Z'$<L%;+J4T2J%('4?I1LE)RB(^OF=OG+R-N4V.KMC(
M:\F5A\UQ<.6(8D"4\"/GNG''&*`Q_4KY,E[#G24%;<`EC%LE6U[97LE8]?<D
MLHX=5-49Q_HL$97Z'1\]V"TZ81#,WE([7E7`E>D&Z1.))DTXI$!ZJS9&!%>*
MKRDJZX=QK.6$5%@EHU'ZN=:PLQIZ90=)>RGK8EVT?)2]6Z%LO?5\@B_S'>\$
MOGY\-Z"YEN)^P*T2T+:U\5/V(6S"1$8C700:P^3<MZ+\262L,JX7HB3&`G"9
M#<%R!,"*)7,WER][(VYY8EA<AJSR."\]E!'YPA=5;D=WKFY:\\K8^Y9GE7]/
M@7E6<$DP7'+"8YEUG$%;*S3LYIR!C%=)B07X<5(S$`Z7[YW`()BR>]?1MI7,
MNJ:J\<*95QM+(=;8Z7M"6:_>DL#E`2E8P$J65N!B91$@"$Y8#SXV'L[LP6QL
MST?#3GXTFO"+UI'A3B2H/D=A`#\O9;++L6^B1>?]JT[D9PX>"F[%L0#5&71I
M&1EGA4TU(&%U>Y$F].0=D#83*+7%,4L=S$OC.C`WQ#H'T-4IGYX"^)A0"+JC
M*NI0_#57RU==M;4)8YE<$>E$_9P?N*/,!D%]C^;!/[4]]BM;?AU!'J)N%S2`
M.\7[5(&,=@7*V(?J_Q1?"R&=`VQ,HQ8BZPEEHJQ9`8-5V-B6QO=6F,ALD),I
MZ<G!B4*00-"ISYE]3B5"F<&8%^#802!*3#<H[!*>26Z%S,@*(^_*2"6@C)?B
M^JP)*!^L`L27_>N,1]0VI;=!.7^5-]C0&\@$3:[15^QCKH5.K"%['4^#G-3Q
M3T>/)GMB-`>RE\+WXXV#'GKL)$@_;S"K2OXLX;CUW.3Z)ZO?Z_VX9P,^O5RD
MOD7Z(BA<RO>9A)L'?!.[&-)WW0*,H]GFV\[?RWMA*4VNJ7N8#7?T*R?NEDWM
MM?`C@/Z(N&_U@4+`U-+=\1">1+K&F,36(KD.79D*"83R[S3DSE?D['J9!APN
M$NXKCCM@LA_EZ3L\>![-3(/UD%N1M`2FU'QG-T/&:W`4H/)[JBB[V+O#-BKC
MD8MX22H+_<$F$7>*,5`-/_H)L7)/\5C)P'2F4TQL34-0Q=Z\B!D<MQY88VLU
MW>(+#]`+,!#$C.Q:^,I$Q=`-0E"AE4BLH']&.4KZ,U%N[E<=V^G83HO9SF`O
MMJ-(/L]Z*`3JK3W?B11O*%;ZEIB-+=.2>6V9\*LA"!?H17>,VF_^L,G#[FQ+
M>.3^YWBJ3WTOL+J*?[(9KJR=BL^N*6R8D7./5^E<YQJ4FFX5ZO3,31K5'LEM
MF*]TCCP*U6NO!SFH*)-\E7/DQ&*I^)?JPHE05.3XO/OP];W5ZYWUYS]AMT!V
M4V6G0[MW10(*)IVC\F/9J%C="FPL%,L.4%%*W9\B8.`)UYX8W\AAQ4($U"2*
M"P*4#VTED.ER*"<6A7TC,]=Q*:J>!'47-.>(^Z9X(';>9YIK/F2CTQLT$/DT
M!P-)*<-!]V$Q\$=*&\8TFW5;3+XEKQ(A,!4:L(Y-9>Q41T=J:U;1GR5/\%$X
M"0>0KC#@$B#&G,E8CKS`._Z[(@LIEJJB&YVTZ:3-]R)MAGLKN6E@T#*UMC;:
M5<E:#\/R76=^D!,AM7;Y2G1:&8<WZ-8,9;ZNB5FUT@"*.OD%<GD-9ER<2S94
M!V62)KE``0&1=2H\]@,\)(/=>3L&)]Z5P2[")`G7C?#8!17^G_$7X<LH[JW^
M^1B^2<TDGVX$P5L1+R-O4]WC9"M+E:>O-T'@'\?LA&JXER%B4/#7'P8_-'X/
M6W/M'B5,]"[ZIWX_;86[Y7@U./7[:2O<+<>KX<G=3X5"_23:PA$=0=L`K*"A
MXP6V`["[[@[`[KJ/6IXM0.6XBK`QS1D<?QC]9/V?-V_>O7O_OE6B[H*[M;;V
MZCI"^)X![*[[NP*PN^YC$'.WUUXBFHRP34;[!@&?XR*5H[R#M?+=%P\#<?YC
M1<CTR4]XW&_!";<)&]H$:X>Y'3:T$]8.<X\`&[YCY\''+'FCO5IQ!V`'8`=@
M!V`'8`?@B0-X=`Z@ISJ;?Q6K)=I[ART%L(WVQM$?:@=@B]%RW!]AV\]3.]$.
MP!;CY"FPR@HEIUCM4UT!H@L['I)MR04;?_ES&I]=.<[FIT_1E1/(9AEOPH"2
M4NF'B\#];(Q'_K1ZK\I1+_4`W+=ZN"X\?9D50&5]F3[+.<=?`5=>^^'RC[_]
M[_^%M_(7M?[E\EJXJ2\^K:@%(/63-5O)4IO93]SW[$+.5/Z*IZ2_2&-LX(<O
M8O77']Y'X1J+:LYZ??A_2<C_GI\->S_\K;E#/`16?">%-,>?-'PB<+<N&5T2
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M/.F^FB7,P?D`*=,-TX6_KS+5\DT<@K\,9_84O9"C\7>!4NV$^I@(8=\`VY'C
M?^^\-SLQ'#IZ:_5)#TQ:II1(W$G5(V,FQ[")0W"5P=`>]<?V:/38GN?M0*EV
M0GU,A-!)U6/'H0JI^@SE*8\O#]E2<(+O7H<^(%;\[M\IO/E;F`A9@AM_BKX@
M:L1=G4E79]+Y1>OA;E\-@"3PKM"D/7"W#\FZ0I-C\7&?5J')<68VGPRLSUTC
MTAO;O5[?'HP'W].I=[`V8R4?!Q*#,3PY_K-MHV.YJ]?H4AB?[,I'DX$][/7L
M\6ARNN?;`=AB#`5!LZ_Z?$3'>82F4E>ZT='O4W:6&]AC$##87.YDC[<#L,4(
MV@F8$S%?+MS?TSBAGG7MO<^6`OB,]/NR/R83!B3,JU,[U@[`%B-F)U@.7,C0
M%0@>0W)95Q?5U45]-SD*'2%TA'`4<O5$"AFZ\L`CSM\^ADT<@KN,YG-[W.O;
MT_GL.ZL.:"?4QT03IU?3<&K5/!4"]GEK&O:K0*@O97CO!2#S/WHWPOT0@-"\
M\F!3%W$LX.UN6$97Q-#9;MOA;EU^N5:!]4[V586#\#9R-G_]@?_[0VNOKJUP
MMP[E5.9ZAG%[9K"W%N..T-_]'$4-;YR-E\`N_V.4M6R<!+`+D#G>.[)Z'/WS
MNW3P0T,]&?7VF1]9PR6.,T.\P^P.LT\3LX_>%_W$:L+%<IFN4]\Q:SJ==0CG
MP+,SFU%7V\@NNH#78?UP+R>#<0-LYIGI9]_\JXY`3G(+AR&0_DD3R!&:G\?N
MZ-\#ZI/A*%W4JPEF<A!6TI%'1QZG01X'446/C3PJ!.ZSAHEWCN[6!8C#;9]X
MGR9I)"X,6_;=-^RO)[K(\8$CQ\\Z>'LV>D*'TP-R]([3+?:@HSZ)/8R>N3/2
M8*O@V6HC'=(MV4CVQ^,HZ^3FJ3[WF38.^'-V<6F2;)Y"/#TAX;1X[NMQGFE'
M.-^#O-EW<DYKL:^U@)\*V9R8O-FW*V)K\:^U@#^G@;,OX3RC2ZH)?]*68@;'
MB_[I^*G\WD7@?O2<A>=[B2?B7X43P^?=3\$7L4RCR`NN7CNQUY4YM+C,X7@"
MY&]%O(R\37,)/<>`12>2?_Y1W`A?[^*QI6E'?S]MA;OE>/784O*COY^VPMUR
MO-K727O\][/5ECN@MG!$1]`V`"MHZ'B![0#LKKL#L+ONHY9GA_59/M7IL*.E
MO5?7$<+W#&!WW=\5@-UU'X.8:RZB+7W/DZ?,1VQ3;72;8&UG'?>#6XIVV'`R
ML':8VV%#.V'M,/<(L.$[=AX8R1GMU8H[`#L`.P`[`#L`.P!/',"C<P`]U=G(
MOMJ6+Q66N_;>84L!;*.]<?2'V@'88K0<][<7S+3T1#L`6XR3I\`J*Y2<YVWA
M\OB:EF+!S$?OWZGG@AKSUHN7?HA?^`[J7S9[KO&SI7?50)J,%5^'MX'E!01/
M<BTL9[D,UQLGN(-+PU.GQ&/L$FNMO,`)EI[CPU+P"QH^;5OXSAM^P[IV8O@4
MWC@\[@3X+=5CUG+%REMZ"8X[>S&;V8,>-5Z"UT$)O[JV\O,?U.R'<^,P];\^
MP8?SD"T0N8J@N-;2B:\!#/D/`=AUX_@(-0$QH0(URTFL\OBU<^OKM2!(Y/?^
M%%L;'W;DQ5826I'CQ7!2+B"K%P9P($ON)&^E0>+!\:3+:RN!PP:(X/,F6%<B
M$!'`#`>?KO!`L-E\)&Y$D`KZ]#($B\7R`$8$FD!8^>&M%0CAQKB9/X?X9SC:
M:P]>`["B<`5KLP%P;OU7>`N_CO*'L72"((1W8J0I!@H^<>OYOKQNWX,#2JYQ
M=T[\!YT9O`_/.A$?PQH_LW*621C%_(&U<P=K(^3Y':Z`.&%'"!\@$&[D*H23
M@1//0WKTQ-$B.@9DM8CJ`$2$!S$,3YSP/HV=*\$HBUBWP!F$"5(Q=E\#I%B$
M:>X&Y;Y'DY\!W_BR&#'A+<!2'%GHP)U*]K`4$4#D+&+$`[S_.$RCI8@)#@`A
M!H'O`:*CG4K@(#;'E73](4">(5:K,$IPQ350UQ7NA!`S$$YTEHAHK5;-89T'
MTB%PB8)B(?XP:5/0'"J&)P(V!'N6G`QV`,^'B\3Q`I,>5ZGZ5!K3W\(-$BU\
MKAKPKP8@R"7H7>"#0`7`)C1U+PC,*'33I1H!&<"E!FD2.4N1DIL"B03^GB!=
M>X`@GG^'W`UX7!@0,8GH*H3S"`/A!7@7*'PK@=K&"&"1&\\5S!#@)(3D_@9?
M`!X&MQBO4A\@D$?$)VFI4X3_AL@ELN.T+6^%2&";IPEGP0\(S0UB?+?(&PD&
M6ELQ2;@(K+Q59P(GR:)$G>A]EV%B<I7P`@JP\#C@JOP4CP-.R'%_ATNG/S,I
MX9H24Q#82!"'5H1!TL6'<R0<1Q1!NL.'(A=E(-V/S=L5V%\]Q76KW_(S!4JR
M6%23"8J%`/S'^W`B1"+ZF&*]!0DCKUB3*][;-R\&\EB*'9CN$RB1V_2\HD[X
MCQATS7<Q"%,2FIT6>"#IH<F#(#)(!%$5\`D^`:H`(#:(?&3US`T1:PW<`R4)
M5@!I@Z_:Z%`%/0A8-[RR@:>QHA[.GTC!BXAE7T6*B,+%[V*9>#>D&B`,`%7,
MVB@J54"`&U#WEAXC`7QEC11I_AFLC*6W\>$!YA_(N.#OJ-NYBF;^@47^KG69
M$#8!]!=K.(:E8Q,,U\Z-L!9"!*1=$LTD/O,E9P,Z4O8=.(6-$VG*3<P3-!@,
MJ9'%ARLY482\%<[).$`2@<X?0.@*_1F2@-A*NM[P%1`#<%8K.#W)H#8@/Y'W
M2&8#2RHV9'(8+9;P@X(;&O`/KB9+>IDYR17)=TZK5V"8GY-<R)6:1_V)7"R3
M%'X%'T]]U'+#U,<E80,1ZX[)=1@;FSX.GI7G0T4N]87/$HS=$+0=O)?/B*QW
MG?EZ6`T=WDWQ'Y]902"@Y%T0O*F&_*BWT9X3_UI0U^"I%*U"Y!6DY:`'P/@E
MJ:UDK*..FRA#?86ZZ_):K%'EE3*F4@M60@1ECZ>5XCO]=]9;0V#:6"#MDIT"
MZEL(7!U8C40%Q5;@&3#_D3OQI]02K/ZA#(FOO<T&_[$2N!]21A>L\P%=_P>V
M<WL-TB'Q$O@.*X0$@5;:T8`&A3H&9H:;ESJC`DEN)HU3$D[A$FRVV$I!-M+*
MQ/1)N?8]4#%!BW8%L&6"C![";Z$%I.4N[D=:6E@X3@=)$"Y#WP>!H+14DL%.
M#.;0`H4BN0'<POG0MQ!B8/])Y"U2,O4+AU5Q)#9HIHFR]F!?X2VJ^G!Z!++:
MB[3_28V7IV*N@V(!569#T=8;]>`$P%I!H6&\HG$*5G+,/TB\O`,0`0,#O6JZ
M(84!L/.;MT[74CS2D8&Y!X<'-B59.?!AMAU9W81?L=PGGXQ<%.#5.R7D!*1=
M2D<7F6L$!9T`V*X`%6$U"$?0-*2A;L$)!B%0@+F@=+PP1+YRP=&2N'\ZD\YS
M<@@1\M%;H@;4B9!#@RH/VJ+<!=9T8TVS4N]&L@_"X"P2Z(JA!E'I!K@4Y3KP
MZ\RAQ3=@W3%P&/5[EV-+Q,AXE"?*H$B-]53L-!'+ZR#TPZL[UOQOG,@+4X9C
M(R(T+\AA`6\R7UQ[\+])&$@5N>B8".\<'_CLQKF36NXE\'O)I0M[)7:Q!MT7
M;15+^*SKFT]T!-X@J+_ET,B6?/F,D0F12!I0<"F9VX2,'=1<T)\MK]K`BL4=
MR'!&'&FWP;N$N_"38.>J]+^0#SRX"?T;ON>0`RUABB@9@9',5K76+QQMF$E5
MXUJCMB6=G^NU8+$C987&?!8O&6JK:`$Z^#'1"=4`*8]!^E?YSO[%_,\5:(Q%
MF36SA1[I"+V5=2O8?#;VG2.DA8^^7!)RMQZ8>&DBM2&6]1DY$OW:IEI%5"BB
M&]@G?OY&W+%`AG__G@9+`A"_29\J@`G@D4X*]P.JI?)E&\>FPB$Q+$%6NJ"#
M!:6#="_E48<#H#LSML1:`WZ*O:"2E+5R9I#TN86^;>F2MFN.RT03%15#9XL3
M+:^UR>UB#YZ0545Y)@8&2VP$'40LG110!F'^(PAOSZ[#6VWH1XE';FE65[2Z
MI='&(WT/5&V1H*X-#P"V*__YT@%L"-`KK6D"UV.*2!!E*?J5)S&$C9"*XX*N
MB?$4[R*?"M!LZ&8>A^*A=&RQ05`_2TFET$`94CH^="-L$]O/.`AAB$$/#3N%
MGU81-PWDW\+BM%4CHYEK@]SPUZ;4!0+=B*6W,KQPAI;L7$5"DI_BFW>9MU):
M8?[:"W(^.X`]@+<)W]&[?AR^IGN]2:5.H^(*M_Z%/'^P'WZ\<T$]@T.$(X5,
M'H"WTAM+HBCF6SH.'-L)94IX=@VD_!H9`6X9I"<1TR=R1%\$[H<`&\T!Y_B,
M,5#^UC-@W;&CB(Q9Q!0*0:<"<+CE'Y+!+HV#I0?$>N.'=T(R7'*2D/9!"L]%
M%OZX!*[M.I$;PUIN%E9\J6*@TY\O+M^H'V8_OR)0IOW9O0%MS;ECQ7:U-Q_9
M:!8:I[]=84+Z&44!5HX7@6'EIV0(T2;AZ<S/(;4FBBF?94Z3W`EX<9RRCI*=
M`T>D@K/L-UJ%4#K-#48/6`,%E:)3'`Z(S73APBW<+UK?*>@%F/\PF-C#V<CN
MSX=T=0.[-YG8HWG?BI&=%&.(9LP>;1WTC=*G2SC@@J9+^4ALLZ01&?9H`J!W
M&5Y,KF,+57BW(L&+0>GU^S9%)RGT*/R[6FK(D)D`5I`4T5IF2ZG@E:O"G=H_
M:"@?H'-8I%Z9.0?%.!H=+^C6:F^OL27HV>7R.D2O!*][!JHZ);.L0S#OB#/H
M;+Y5B'Y*_..M0,-*N&<.IB]<B5P049X>GLQ/9",LB8Q"A)B,)@"EWY_\^+.E
MWHZ\^`]0\86@."Z<86*IK*/^>6_THU(H!_C#SQ9V5T>S6'_;]U;T\!@OMM^S
M[D`7BW]&.TT_0FY?N$#KSA.^^S-=F9Q0;]H->6*GT[W;H+]5AFY1#&,."MI"
MM,H.+$^%4`,5&:6+)(2M8]24G%.-H``30?)B,I]SSB'\]<6P-Z4?%(H\"FV?
M0Z<X&+<SU)3]-8Y'*2UOY94]F_+R'4J0G#XD4\R\($ZBE#FBU`$HCPDD"EB5
MFF3@LH2W(3WD*@S=V/`4Q1S58B4CN49*KM:D9-H9:E.7;RS4B`"Z6/EI92*[
M8LL&8T>!`(?RAT@R)8<X/;JP7:D4,80W[(.N^`"]:5J\M?N7D5!!V<$Q\`DR
MJC$#P[\#RQM]@QZ&]P3GG&B0Z@]TQ4&T#%B&HWQ@V9&2`Y&7XM"N-*)]#][!
M\%_.08;BVTM45)/2C(42@`5WJI2'R.\C=1RE&R4O&@O3^)Z]<;XJ9I@X.DD]
MKX]6'C8'2I6G@@%18H:\K\8=HP??=#SPN9>T9E>)-!0BF&:Z38;DU=J5#&:V
M4C@\BI/GV7"1H[^37IO/(J*O=HZ.)^#:6+^SU`XS%2AC=$:R05Q.$W8%D^*F
MM7%!";84#XLL/XQCS;ZEQB;I7RFH6L4,4D)O<@BS(2`-AC1!'Z6KDJ@-U5\9
M?!4*WEO/)_@RG]].X.O'=P.:L[KO!]PJ`6U;&S]E(WH3)C**Y"+0&-X4G.!7
M^B3R.QF/"5%`BFCIR2@VLW<`*Y8\UUR^;([?<C%Y7(:L\C@O/63=^11\5?A#
M=ZYN6K.PV/N6YV!_3X&G53`OT-QS/)UWD5#Z*!@;H6$XYBQ$O$H*"./'2?HC
M'"[?.X%!,&7WKJ,D*YF2BH[OL\*95UL+(5;[Z'M"$:S>DL#E`2F8@$K$5>!B
M93D2R#-8#SXV'L[LP6QLST?#XV#K]_#B(NN&SV<^J\]1&,`_E^RW[YS63\;+
M?]4YQLP_0Q%3\'L!^B0HF#*>R%H,I4!K'721)O3D'1`6DP>B?"X+V[Q3K@=Q
M0TS!!@664GTI[(EI6*!0J7QSQ=UR-3W5U1N;,)8AZ4CG$.?<D,=!%_LB>I%0
M='FM+*7%-SL*>5(;=0D"\4[I&"J97KN&I"]\X?ADP\370D@3EDT^%,JRT$?F
M^YG9\E@>:?T[=7QOA?F8!GZ;@H\<7B@39"62S.#,K$@J)\C,FKP\P]+>*#'=
M8K!+>":Y%3*Q)(R\*R,B2H'[XOHL&)5/3@'BRT&(QB-JF](F5LY`Y1TTQ"@9
M2LDU^@Y]#!GK_`"R*O$TR&D9_W3T:'+(48?&!,,'-"6BY6J;("7AILE.UZ/9
MYML#1U-1MD]3]S`;_EREK)7OYBB:/M`X+:L/%`*6!X9,-#R)=.`PB:U%<AVZ
M,J,+".7?:8@,")W^L,++-.#P@7!?L1\:<Y8HW9BK=<CJ,E@/.;](;#.EQCG'
MA2%T-3@*4/D]52U9+*JWC9)5Y")>DLH*7%#1Q9UB#%1<B]XLK/)1/%8R,)VP
M$1-;TQ!4L3<O8@;'-<'`#<%LH0U*[N<%&!A@1G8M?&6QH2L?(:A0$W;OM-&Q
MG8[MM)OM#/9B.XKD\ZR'0F+>VO.=2/&&8E5@B=G8,KN2UY9YBQJ"<(&^7L>H
M$^4/FSSLSK:$1TYJCJ_Y5)".12+\D\UP97T.?/;48"5[SHE;I7.=:U!JRLC5
MZ9F;-)+6D]LP7Q49>12ZU4X`\M=00NPJY]>(L4^.?"=P-105.1_O/GQ];_5Z
M9_WY3V!&W19;`-+N79&`@DGGJ-PZ-BI6MP([?L2R-4N44EN6"!AXPBGTQC=R
M6+$0`75OX;QFY5):"62Z''"(16'?R,QU](2*P$#=!<TYXH8&'HB=]YGFF@\L
MZ'"W!B(?]C:0E"+>ND&"@3]2VC"FV:S;8@XA.5D(@2E?FG5L*GFE<B!26[/J
MWRR8SD?A)!SFN,*P0(`8<R8C#O("[_COBBRD6*KRP7?2II,VWXNT&>ZMY*:!
M0<M(HV8?&9FR;EB^Z\Q+<B*DUBY?B4XS8F\_W9JAS-=U%ZI6&D!1)[]`+OIN
M1F\Y\UPVEF-IDO.;$Q!9"[%C/\!#,MB=MV-PXET9;(,CD!L;?/WHRW@KXF7D
M45QL3Y9Z_`.N"W"W?`!Y_]3OIZUPMQRO!J=^/VV%N^5X-3RY^ZE0J)]$6SBB
M(V@;@-VLV>\*P.ZZORL`N^M^>GEV&C,/+[BS8VNOKB.$[QG`[KJ_*P"[ZSX&
M,=?<O#SI>YZ,CFL$\E9@CVQ<\]'`V@WO[K"AG;!VF-MA0SMA[3#W"+#A.W8>
M&)/_VJL5=P!V`'8`=@!V`'8`GCB`1^<`>JJS^5>Q6J*]=]A2`-MH;QS]H78`
MMA@MQ_T1MH$\M1/M`&PQ3IX"JZQ0<HK5/M45((WV@=FYCXMJ`//IOS]<_G3A
MWGAQ&-U=!.X;W6KP0H\X^)0-4^GZP)36:+(T1UV$E1W^T</<HN,MMH*EM&MJ
MKD.C^I+;\`P[-EN7-$D<R_\L?2.O0R?"+IBR-:F^(*Z2_GAN729B@Z-`WG"K
M[,#ZE2:5C*@LK%?9UNW7Z)P?)VAD[U8NEU;+XD`A++%^P9V<L7&;+&RN_.(_
MJ"T?;HNGV<C21=TU-#^>7353UW#`T@2*:I_-#?OR[=7'/8)DOV[J/+P(>U8/
M>KTAG!7^4C?AM+`+9UV;;`)(=0[$'AM4P+<0U.)1=B!TN%<?-]T6V.C(*/_&
M<GO'][DUQT(`+F$+.6X'N.UV/J<1%L\GN0F1#,VJ>*H.%F2'.&6@?&+CWL-/
M#/=3=6($!IZ:=>O$^AX+2-=O52UBQT:NK2_.[W"EE]?.-=[EWU/`WO[X'@9"
M3RO>0?`\"_\@,&#E/.O@^MSG9!^6R3ID1[%F&,BG91)BU\SLAHX=<4^0QG8D
MK$L'!^P!?5U[NU,6/5TEE0FB)Z,L`J-$6::((7B>F[(,L<PWUB1E[2J>K9)H
M9H(_D'C>>FZF:&:U(8]X[1+/QPYJ9K@2.)T!=0A0/P$&.P&0+[/`OBU;:-\*
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MX$4/<4P2&2H5ZK<Y2N-9(ZJ]/D%0(COK24F.-:TBV5F-D)QYIG0*1(`E^E,4
MEA/_>2TA(\>2_M$L*3*_Z<CQJ4#]0%._`T8[@H@NQ+%^#X'Z0/$-:%A[C1*_
M,Z'^/;P.K'>@Z8L-4(!M_7K^]IS-E``LYIF6LDR_!,?;2#W.N"NG&66&?ZRG
M=8<6.OF)9MY%5Z%U\>4M_X2/8,?+[->9NFN]N?;$RGKW32QYSL2GU0H^5VW;
MX/>S5PF^C1KX#,L;L&9#S&M.`[:RP&Z*;C:]B"0@;2$O`GE7^"[Q&Z;>/,V^
MX1<NU41'`Y*N[W<^N[D%+1'GDZXEXL-4"K0Z)\Q&-#1$/MG\,H,T!O9T.H7_
M/ZN;?/.2&N-1G[P7TNW`S<!OG,@+05_7S(=E,W97+?K0$80MX\T>%6CMR+4C
MU]:2:X54TR`51!A@AVQY7T.H!IU*[R#-[<K/1N3FU!$%UKPU?BQ)W3O2$++%
MJAKUN\('S0!T#0`KTRRX(7&Z!GJZLV1+3B>_%LT$TZXV6H[&[78TW]%\1_,%
MFG\HP?=[!L4KRSZC>NI0+KWBSTCW)](^^=@MB`\KW0#;G/\;Z_F!KECBP">A
M)\+C('1Y49,S\ERHT4[9C'=S<KPY:8!QBSYLLYZI#+N04\ED0$1;;?<C=E[R
MQ2$WQT<`JH8BRX\`%MZ@/JHGRN4_HX(R]"G:!X')02IX4NFVMI:>&.Z3=$4#
M#O1TX+5S!]M[WEEP#TWE*TTPQP._#GVPU.-W-++XMS`1;[UXZ8>84]CE`!XX
MD)7Y+(X>V!:=ZS^4ZXF@D3ZZ/\7P!,G`BS7[7U'\?1%Q0H[9-Z@MX10`YG$?
M`N4&!P(J.)!QS$F:7(<1#>'..!O/4L6W^Y*;8/:]/K9Z?U7GR#U<7&5<$5<!
M5.`<$K@'-1`<[G2#GE7""\M!%"$_)5YO\G#4T<(O8*%KRJR2UU(.+3*QB^:N
M*7F[N+-&&69IL;O`/!,EI!D'BW.B"0RY;-W7`<I)3W^]P\F&4YP8O>186JF\
M7&@TBW#<'480E)<,?PE/!:'%(:1KQ,H$?G#0>@?8?@_54"!2]T(>DAO>\K6;
M(:N:I)XP$AQ3_B4*TPT'Y\-;#'YC8$JJ:8@5(<W$DK'I;)P4$-:X$+S&'<._
M_@N6S@90?8[$2M#X;LGLMB3_%DCIK<#A+-JTX"^)@&)Z7]"(Y/C@1PQ%LJJC
M]KX+)"J2(L>%X>14OAQSFCE-==IQ:Q@&\A)?L+;(>A7^,Q((%0:&,KJ$"X/G
MM`+Z\N(5S[1/]9@1U*ZW,(I,\\:_;S0DK$0O<2*R;:GG$L!(&[5R.1E,A:I>
MOGYEK5%SW/@>CZCO]ZISL-0-[70../:>A[:"/EX:LCZPRXE8>7%8L?X%14KA
M2G`.6PWV7DL]O4@,@PJF>7OM+:_-23)K^*(DLQQU%3_F^'Z!P/X4E]!&OL2+
M;2-`RP!?"Z`\:PBU0+.D,,-[<GC^'5*H\X<(\%>W`'(BF-=+%E*;T)<)N%L:
M$HPCX"E`B6N_%;YSBXAUB:9B@BLC!:"T0][P7BPB`J?+;&L8U'>.HNG*5`0@
M*\EA2.T,`T)UH>SX3+MQ@@#YREH(0D/D)(:EUUU9@Z"^32-SI&"`/@N9_<&J
MHIX=9:FY422SRLD^TF]AFA&3GMWO3>W1=$SO3/KV;-BW)[-AC>^$DVC@#SA3
MV[L1_IV<&YYX7""(+[ABD9C>PX$]G`WLP:Q/:[SHV_W1B-T>YH=:A33M01\M
M.5FX=IZ`YA7O^<0>#'NF!92I<V]*BA.*O;+&,K5G=7GC?RJDBTMF+-//Y;.2
M\W)2%T;?[D@EXVPR8_`I&8W(Y_7@44HQ@S\[5_"@']+\TH4G)^5F874#`#7?
M=N6M$LP8(U5`IO8DD>.JO&G7N2,>11(BR#R\WGHM7`_^Y9-S?RG<G`,X`-7&
MG#)+<`/$5_!]N`),#UR"_`D35#<SV^5\0#Y5K641".>#V6RNH>?31?!1%:^\
M(GRDYM#8+VNID>4R_V@)]^B`SK+THF6Z1OT,<Q7DS%;&"3JT&!1@GFC./[L>
M6@8XS=N<UZLU3(I@D4J?)H!Z%&?+5%W3`BEC&&&4>6,$AI=#*LOW8AR(GL1U
M7G)Y8[\YL>O\&_XC?>J_LHL<.?E.F)-78?=8`:^I/ZY"+HL1Z]M2"#<&>3(\
M!Y/"RE2;;>3'1Y%7<S*SJ,)N.A],Y%VI,>Q[[#E_HBY)<G;8;"<?WF&>3CRD
MNC`C$R,PLI7?@%4A=(6*>VY]"#0$XD9*;-_[=^JYABM2LI."L5O^.*R/"8.8
M+KKT-F14!V@Y\/'Q>$NM]6<?U1#D4X$`][U[%KQVW**):7[C%;D6`+U=0._(
M`UXA>23^3N73\KP(TG]QVG:T\5/@"D#.1<[+I&F<Q5:F;J)4$`;`#5),6();
MU;2.VT/*N<7B;E<L?4<)9HE:&>8LE/_05?[#<^NWT/@4K%('CH*8KEYJ?;#5
M--@X'I(M6(17UWF]D8`XR9FCS^PJ?@OR37M<J):Z-]N6V@O8@7R%O<19Y>%+
M?$,%T*<_J]H6_8#ZT^SG5_G2F`^4VD[?>`\HSA?],0%&L#&*WMA9H=[)T@>6
M*,Y\9CJHU6^<.\HVR:,K/JG>]:1&L::9Y$AYZ'3XYJV9C[T8<-""V##S/L#G
M*!?<-^T59(;JTS7>P`P??MGF,U(>&8-OLDARHN@.TPW8U\ZQWRQNVS^7!9DL
M6@KW4(:`->SL-CIZ:EC;+AUY9MB06S##`/).*DUXF]ILYP5)E1*>Z<N.J1FR
MV"=L48$8?`FU4M8F7ISW^LA[)[T?M?R1ZH/\$=BQ@#?"6VQ'H>0_?1=@6*I)
MT>9.7.T1`&Z24QDX73ZG4F?`5KKJ\DZ[&G2F_`2'(U-V+MX(PO\:]J/<D1&[
MS%D'<.),4K.,(W6@PAM\[&C7(@KYP.R7-#OEXF-U7VMXB(ZWG#]EI9L"GI?4
MOQJ4T%DXIM8CZ]LIOK/1H11%&,9'<RXE#H>2N-!LEW.Z#(9,.II'DC)..`+^
M([%EK-SO,.@P/):B'_*^\=R!*25LGLH>I'DV2@I#R4`MHP[J.!)5=JV4-PUI
M"C>IC*W,;JMFVSD#XUKXQ'2TGH.E?QCB6ZU@.P[:?<X*ZQQI#8/-NZ$\#?0Z
ML.%IC<[G/VZ!.T$57WE<,?^M&/,K$4*'Q8?'8HQ%&9E\6D.D!`ID1+.S_RN#
M5045-\Q4>1!:K,?C._`^\%/IM2DJAM:[HCYX3N"\3R.,VMJFK:M`E*TYJ*/%
M,HS0^"/[/V0?!&&^EY";PJV0M%:UE*V)TWFQU,2SE>!,?/B7C!(BRV4]WCP,
MY?UANJ]6+(X=0UH$*IB1LHT)@=,?$OK-RUEC7K`*HS7?>47\5^$..E&T1\B,
M-YM,2J-EP8YB%S,@@%K@"A5`Z;25HEO;A7)!PB*7Z4SV<A',>:4<@=]3H!'Q
MV9>)NU*H@.&8H-J0)O#H?\Q06)RB`J#"YY%W`W1[1:FZ8<Y?ER>PCLTV&4]>
MK3A^QVQ-Q>V90>+_5L0?2V8\(D(`B^R4^5%I@,,[69PKL[V5YEDF!>RR]\;Q
M/2"7P'-TJP'=7%VW+B@NE[G7C'5(X06UX-H)KH0.C^3VJ73Q`K,G+2&\#0QD
MS5:HS:V`%<15B%BO%T7J%W09PLUY=H@$59#BG7R<H+G(*LU=TK0KKL]L"E!D
M_@:DQ6-2ZU3ZISH"S$#-ERTMR17XP[$>"\6ILOPYA=*%'+I<<EQ&O4;(T>:.
M`>D"98W4=6*@0-_1$0X48^931FPEE\!',-0#8`BO2F*ZQ+9].L1)&A!WYV'T
MY>0_UUNII,`\/3P0$DU`VW,1Z\Z1^J0(>4JR>J9K.]"2FL;1K*MIW/_=BYS1
MYG+UD)"Q#*IESGP06SF0Z:PB?5/')HL>J=+C-:FU&0BA]=(S4VSS/HE\FAUE
M,&A?"2?*(BB@?Y.W3CE;..$X8OU$Y1\'1??$J^P@7GI>9;YMW;WZIU88V3&.
MCG'D-98<7]#P5/`'F52DJ)*(K#*UIHZJ<[[0.M^BAJ#H8[S%A'JT!8P4)GV^
M\R=P-G8LH6,)WP=+*.OD&B@L0P9+F=*D,ZF;Q1LJM0Q3N:>Z&&L;(V%Z)$Z2
ME83T@<+G\Q\U''*!O6C:4BI$8E2#91T2C,0@R:JBU,\B)IL(3`MO8Z@TLAH>
M>1-E3I02MD!%PN@S5G;0KF'%:V_AR2T[]\6>+SVJ"BP"4N9O&B(-HX+-]?BL
M976;6CB[.9NOCER"Q&8QP7(A*/W*%PG:A=\-(WQF%_9OX4V6"353'J9?Q-H+
M/.LS8/3:68J4.&9LN*?[]F0R@?\_O3]6*,GQ0SGUY\5YK]?'/$4.)V-F"/NQ
ML\3-%[WS_MC,]-'MR#J'59-CB<S:1>5",GAIQ>75H,C6#`1D@_!ASNKTQ14Y
MF9P;Q_,=R@S2>90Z$\V)KU6.D*QNBJ1C9G:>)>]D%:+6!><LO"3$>44M-=&U
M%4OS<:43/)5KETK"*SFAF=BI$E.Y*-;,8XUENJUJ:DG&JRRA(1,5+,>,1GY/
M`T]GFP.@GF_FH;(+*W;6.E4OP_PPRQ"NNQ3+R/V1W%3N%?=.:::X-B:*8W)P
MEK($)[P"^QU.EQ(WK+<:))D-KE8D$*I7E:G_1H(M+AJ$,FF>'W*6RRC5`:G:
M?2S0V'9BH[.0@X<IQ3T!H?S>F/^_`@3";\KMXB8WSIUQL(5=E`M7B^F1^),Z
M!.L+8IQQ$9%JG4Q^=WY')C@KAXAYG*5<'D!)PB+X$!X:908Y46!V3M+!F4!)
MRO)W"01*)HY3;-WJR;X%N'62N#G$N@7:EK!39GC'/@]:P'D/B4KNF$O3R0K&
MZ?:*CJT,`1W%<F1B5H5S2X&1JQ]_2<.6C>H*X5#>%J,&?^(5J\#%I%QKVY8\
M:>H:29X==C79UV83!L5T05-&:\82IXO?I=1)5+52K.HL8KX^W4\ANS_B,,1'
MHW#-R:SX!?PO35`BC!#?0.:AA,7P(X8Z-0?,%W40ZZ7$]KQ8E#`9Z8;X[M]9
M'$J5HJ+&I51*\Z%@'IH1V[PM5JN'R#DV4B"FFN%S"4J1!9?4%`HEFYM6`6TJ
MVS(-.GU?F`B<4QF4:H/'%6$W_.3.HJ2,&(59E&]YYF#S-FXF7U!;\H)+X41)
M9\8\854?A\`3.N3KW6R\ZH47.-J[+4OCBNJ,D:C?J>!-@GJI,)W1NH[9`IW:
MV[+FE1PIM/TP,]7A<LN43D2^2A'3D2YT/E$0!F=(&#'/>=JC=<?7FJ!+3B:Q
MH'$,#TZID`0AJ9.C-00N>^!J+VZ8ZUB8O<L>EM!-`;?#A70Q`8')6,V=F=?T
M)OL<*822#JMV6*_7"ORBOI7*8_N@,@WM&IVUMK*"[[#*,N\26@\$:BFQ7[LD
M@?V>,?N5E;.?"[6H&0V$-QB94,TWL7%-;TOYJ5$%JQM#]8=D"VL#40V2*]7$
MO)1/6LH\IC3#2A_F=@VV"G--AL/\(U<EK2?BW<L4*E70[4`YY++-*Z%L(!D!
MW!4G^*H..I*"#8W#7$U6A!8MM666'A)G?83HZ*I`K>%>#EEMV"K)%5&FD>NT
M9AX\!Q<?Q"L$^(J:^MQ+#=5TT>C\\9U[AQ:;CKX5BZ1K,?I$?.E-@0I<L>!)
M-MVPO,-E@`^H3U=OLG5&4-9(+QM0F8W'>9EE:^*7K,_JD?J28AJ[B7XUX7J*
M\:K)67$Q!33WT2@V/H8M")`6?T\#YHXZ"0?SWV0[*4J@K8:K*JF8\\%QP\+-
M*2H9.I9V_#;#5&.GR(PE[[^PK=>V]<:VWK)+]UTAVN9$.)"S]&&"Y5_RC^:G
M)>LMG(RM\P'EU"V0E'%8<YEWY@U6'/BE>JSJ%@FP<M5W+K=75W[3L-%J>`%.
M#_X'#MXV(=/5>3AL*9?<F548F`Y5,W+#!G&K%,;V,`]CNJW6VW(3;O<@M.SY
MC'QDZ91S!2]>D0=;AVDS/_<+L!;F(WLP[BDG1@5N<<.-XN=9A=$.)P=]/]X5
M#?+CQLB8$:C6&?3.A_W9C^A(D'.`J!@UY&8QO&S.K<^P#657=C97KP5K1*R^
M54-%_G`WI9H5-618\N59_3[,\G367*L,[#*+,(QJW0I&N;]P(C*8T_;6[*1B
M9Y,+@$<>DNGAPP]AX&MY34U^$N_,]7QVN&4Q=-).N?UF6?$'LP%4?HRVUC5-
MH-T91B[9*[D"`03HM1[A+%?DN3(23IXBD(UYSFH7Z`:FY=JHK`%NB&@)=_`?
M48?-66IG;JHT5?_3ROZ=K+/+H9FCYF((U-?E[4C='ZP39I/4O*=P(K_*;WX1
MKE@S)G!T,2X="R)6_>,R_22+RY'GT?`!ZD%X.1^NJ@\Q\TY!3!=*::_#6!=S
MKYT_!*%D+2PF>M8T$U1Y)TLSZ'5;V`$^D_53J/"1L+G+*7"!+((AF3H;Z[#M
MK4`/-7JG9/,%7E65ZO1[9SG3-]]M*<TF4R39Z1,8I5WGNWFI]!1]6O(3&A<5
M,D79=]2TPU8)PV,'M4H$:GZ6EX,9)[!E>"P,SA0N4VO^(&N<Y8J5`_3/46\!
M$LG4@S#5B,/0NM$>MV`B$(PK7S@^E;@0E\_>I_R#7$L$7_4(1@FWH2S3(%UK
M!7+M?//6\',DP\AK;-=+;D9GL_&])?E5?>=6-P%33;AM;HA7+7TJ>M(ME\(7
MM`J)`N0M&</#@$O!7<0BSG#^Y)/-\M'P_"U8+ZGU@SI'[/XG^UBIF`?\UG76
MCBK74<?'JCP*1($5I34*:5VVF8S0Y"OI:G&FK';3PD[BQ:L[#H(@)DG`Y76?
M6Y_D6-9)15LHB2/D928FPJX@&D",.DI=?R?K8^*:%HE\+E>MJ%V'R]#W<=`Q
M8!CU1LA&JN:V1;!D6V,.O<#1.;YV*%T#<B#2(KH"J'A5GDN.]@!8(ARCB^$$
MVFY_KK0D=0#J-WFIK7?O6+]1>;&N.//B31A[2F-ZD^TB=S1>4.AKQ:<HE=A<
MC;)\PB:'';;;D6TNT!O&0PP20"-JWI:IT-2XA]-TRC:2SE]3LE5B%)TS%>QK
MH&M./4.F<[T#_5F"HM_OV[W!>(O*]]H+WUP+%+4?@N6Y78/Q1CMR*D5%8O%<
M#]0I6W8\(I.?&AVBNJQ&&:G3T/TTT'`U,_=ZI9ZF2V?C)30?3$)((YU`9D;.
MAC*[8@6J0]D"?ADF]9;-$4:"H`!@GR=,H*-!-VV`LQW+"5(9B"3\]SQ%6O;%
MT.Y-Y"H7.J^?P5"MES*#R#"#^"5%-:5'4-DHX(,ID+A5H9"L#C81(=O#EV17
M/P*C0%/WHW^>ZM:`KG$V7JO&;\$*+PA`R@=:WA6MP`)G?S&P)[,9[=VA0RZP
M`L,>4;CBYLD\S[!*K"*,:&Z*%8#AXH=QK"%1/3<!@OETUHT>.>@LI*VNA"(&
M$;\@3=^1R@6F;)*9%XE5&K/B8W87!1Q+-_A++-!0J1VKE!2%E1>`6%6W342D
M)Q>8N,*YD%66'YH?.`\E#*Y0<&7Z"G&23%G*NT4DVY.Y[YCX`$*(8&!;A.0)
MJ0"+&+0YDB@*5-C03>C?T",T\9A4--:L,@>$!%D/VD`*`CCSQTG1I=BP,K+[
MR+9X;LG6,UAY8./L.]PLM7<+[N[[H.E1EMZ@`JNJN'BVHLN-'06G?F!5CE5J
MU$2&*IBB*=O=I<ASW@\K`_L%Z#FM$\Z3U9>%\#U0VRFLB<HX^;^H_F+EW(01
MG;M*.LF<VE2;D?G+BNI@$8%"J0DH[V]9H_,*C)6U=%ZVL`%\%;X,##;)0H8+
M@=U0&)R.C3498<G4^9P#7V%ZN>-II:,N#/Q<TYD+C0M2L.;9RM>J)V6G4@(C
M"&\M\6V#M2V>X6?L]4>VPATSLIQD^I<UL$>#GCT<UZ5G2'-3^U)U8QZS)&(X
MYJB!<L^<6Y>(AH5G/97V161D4HFSFT<1M1D]7):[7@K9],&QLL;=E"F&5.;P
M-'BX%S+%.TIH?N`(=9C*J?=9CM>+_G1JSW&(::%VS-!TB[R1^KE/[>F\.)FI
MQB;)9Q(A'!HPK!LJ`^4$YNS7%Z,>VQ][@CC"B2@5(-9%KG)@6AF(?;L(T*0W
MWA>@VUQG-Q1]!`;8$.4!5[L<HR6YG(;%_+B$^L5X:/?!'"JO;8WM89]F:S$Q
M[K.TV;26-;Q_IZ#7R?%9..;)R@;=6+L,N9'AD_P9#Z>#QY^Q-9S:@QW/E\V^
M+NFM$M36=3<JY@500DO(+GPA6-2BQ1MHH]0QHCB$18%$Q4(20F(HM)DOSHI5
M">R=-#Z2LK(+(M3[)CT^Q80VUB"VQ8.`0%0".N59E#2`<@2/N_;%G"B(MY9U
MJR8@9,HX/?PS9P&ON)"Y(N..^X\ICZ$9A%L(-?U=2.&?'248\3*G,0:%UR]D
M,EBR;25&A0+=+%-EKH-:0,?"4-F5BKH,Q5+O>5C=6#@,SLQ[M(U5V=!8"[#+
MK%R%F'&"*^&0,;H&90AWN/!6H(\YRBR4&+3@B$%\C>T>T/B";8*9BV8?`.3=
M<%6;[D:'V\'^660,+`OIEOHI`D67-R\=?YGZRLQ8(,^7DK<<KYX4[%N-E?>%
ML-7,@OSI5V)J.?CG,9*!>KU6?4USX48NI!>8LDH^`A'0V`ICNBQIC8%4T!6^
MA1)EM)\VGYVM=Y57\&5)I!?G[.Z2L5F-6/I3TI=!A1544:$+)0;V<#AB[U=2
M<?Q(Q;FI\^9W641E]YG&2DZ^]IWE'V>72RRK0FL6Z,GXJVX/IB(:*3.'^"?T
MH'/&A*IQ'9V/?[2MFQ`+*E5GY_YX]B.=,1@@LB,L7#']A6;Y4FV@9$'9EM4.
M*K&5(%$THL)6N;UF+1A5?:\N*,&R`6.9@(-6*G@67R.'ID!MUM6)NQ!R,KRB
M-CX-"M6'@9J"*YV&>VW&VK:16)5.("V5DCM8GRTDDV@*I3%Y&F-:/";OV$']
MJK11=A!G:4!\57&66A1GC2,,KJT3CVK\02PQ-"++K!.7\_"56ZG>7:<1"UN.
MQ[%*HYHR(RD#E+D5ER%-]Y(U6TO9S92H`+OJJS@MUH-Q'5:'5DWV.$@R>X4`
MR@WFU!&I8;]B=+Q9@)=4\J(\ET'9\&(ZS_C&<-XQC2?MQEW5C+N0O9L1)EW;
ME8RCHYB*4<%Q?".OVMJ64SV7`?\PEU)MUZ3VHF<98_086<":?M.!7S%\R=$9
M)$8NIW(G9E[!@9YU70$?0?)>AV+*:=^!*&1]TZ[T&[5)IUJ;,7>1\5WC8+IN
MJ%T'L[WN831O4P>SWH^Y!ND%=P7")>5^91IV1KR8-3`8*3=;9IU*BP!)CQ3K
M`I$SL5463]BEFCB&)I>5O(NSD/P264IH]<`M&L_6.^\9!>CU5^:?6C.OCB=T
M/,$HZ5<Q1%F4I,$Q`X*%9B_[D:0FN7&6T5EB,*RY<+04C7,-1DY`5ZHU;WPG
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MT+F-#[P/HP40`#%3(^]7.:4X'%<_:1R0**(RB8`ZA^&GF)0DE9!76Y4I<KLY
MGB.Z%B["7^P>IH9Q5(7T\46:E*$^Z(HU=Z#"5BOE4>ONE<`*E'RC@.J\0".X
M.E/Y][\Z($-4JCO\[P70.Q<^37._L@8S]?.OSITUD)Y%VB=ER\MXX5R.)8J7
M:1SGDG"7#D>:,NC?\LX*T%L+X8>W!8]<\[C"X="*;@:WCD>=B.IZ&?R+_IXO
M.S+/OGYT/7W9+6)*$3DJ0]L,N+[K5C&E]K"GK[F(//NMS7Y5=3*HG)U:+9F,
MJN8MF:<<4UZK7EJ>T5RKG(E`&2X\&%CF"A23U8OZK7<#U"-CP$ZIPIG$KLXL
MKSZ,J&+3!9FNZANY`BT(H[7#G!C8`G;#BNYJ-RW;UDDBX0_0YF/.M+S,Z@(J
M[R3*57/:5B&_G^L>**VEHN:!^466RFRZ[K'I(*?VH'IA2RW=BS",P<'82,@:
MC#`;?DCEG/A,-LTM]WD#])=80*HZ;.6PYU76L#)344AMBC#)),L$I[JGRF(.
M4K!>],^QCP36B-&_N$\`EY,S0\3NS533DN+$NW)):=6W"1)J$&JYX5+616!5
MKTY%SW[-DU)E!\[28>A(2ZL8W+&#^K50YT%23VDWE$^'<TZSX"X;EU@T+</\
M.'0ZBXEADSI`-Z):H/HK;.G*8;HL?D\9\)3KPSU1<$HA_@BWSDP-RT8P,6`I
MFZ-$.AM`!@.(\+E():!8(76K-"<,UIBXI''HII4E_4".*",HJH$W[(V,]HDZ
ML$E;Y"R3E`NU#?V06U-(?F`,#C9'SA=C$TK;TXRT0FA43J/'5E>Y+3]\[#SG
MY<G1\T[!@;'S"'IX5F\"Q]%;^XVBE\5'W3CZ9ZZIZ/=LE>ACHKY96F$/A[L4
M"LR+E0N#B3W=KRJ`T_@K*A?JH9OT>P^!K3^HSJC?K:KB8HG5O0">SQV)*XH!
MK!=C/C3OOD941?"X+$OF5]?7?#JRU69YY?X(2V',4ZD,:!#9]>&.QG7/OLX7
MGBG`<A5C1X_I+2)*W7U"D60Q%>LP63QLRL-B1Y#*,ZY.Y$$0]9E8>V7S9+M[
M7$J/_@[!T>7V=-&W[R'ZUA_DDGLT-/GV=+7)/6,CM8==BOVQ$E.ELHV]HG8:
MDGU2<_H](S6'NL5\-[&PCJP[LL[>K8HH:Y#&.B-OWU`Z6]&WIOO3"$^JWDV5
M`3];!B_-\'YR&Q9BF-9#XY?]<1?W?JIHGYJK^;1:K%KU6#39P71<I<GFAH[N
MK\WF=_DXC;8,2J?5=N+O>Q!_L\=EK$O*1J46GU-2ZK$JK19G^82N/;+-.Y6V
MH^GOE:;O46G'CU)I*WVG^V7Q5>3O93;L/GE\#]:!*W+X,FW[$;E\V]3Z3NM^
M*JV;DKJTRCTXB,J]C^ZL\E@>JC]/^E,DVM)D`LI=H]KE715GSO2[%E;5NP_2
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MA0E<`H#)9ICCMEYUV4]-V[!W=@W!M=""K8D`42G5`^W7XIO?D?7:*;.=,OM<
M41Y)>*/&(CS\FH:C,TX[>N[HN>T1'L,VO:LZUJ<W5C5$AVSET!FKSP[J)S!6
MTZM4M@V>J0Q;!QY1S>J-2:!XK[^F6-!F_2("TI6_"!R/*M2<SN&H6.8.OWE%
MK5W7CBNH;BS`_OG)+?;[I1F&9IU]-@.4`-)S0,^I@!8'XT597_3,YO0=;XUE
M)E=.Y)KM%0JC"U3BL2IADZMVQMB!YQ,;333HQKDZ<^/H&[!>PF]6R)O8M-)#
MBJES/AACH%R14^176">QWLC1FQ^]-5EIQI!8>L!@D<`CX;U$.MZX[72_/[>G
MTQFZ7`J#YS5+PP[JL-$XQ5)466B(,*MNU#36R<0AF?!72KO[FO7@YX+TS]EL
M82J,-.#A8UD()A7L@DVV6/R3>6K,O%4-*3:(,-5$]!O)^<>Z,0D2+9X*DI!T
M?BAU-2L%I;=*K\@U<287CNE;\VP,>']^/L\*-:LK,`GFEUR"JP<'TE\E7JA5
MUX`'M(*C!6^Q<^<K%K7RXW&H#-9(;.`7>)PO1OVI/9J.SR=C]1'C9-4UOQQ,
M[=FP;T_[N<$_``FYA@Q]V<Z0<6[W)S,L=M/MSR.1<#V;<?]4$S>S)Y.!/9]D
MCRK+6J*NW`@7Q*EB>-7W7U4B2F#SZ"`M#D!0;K-^&^:XVP:$/*P51G>R]XM\
M/A.X\LZY]_IH@"[YZ?F4AZ(AVIL;`1MF;L]'H_,)U_\S,FS584I=98@$T.&1
M\`Q@6%;W"^=VX5.LDV;4L&8_2M0,4+KD!H?;_"G].QI,1U.T\5T>*/EW!]Z#
MO?.'A[9200++%P"M'D5/FQ_29?+(!0%L#R]"?8&@D%^1WZ:),XI!A$%I%^1Y
MR9IN.'J4NKP":DOKWQDP!#*+%N\)>]_+,7',9CPUB0D6#VB+!"G/Q5,XPN]J
M#,DFI!>JR.6<;L-.->:*YS^6-TH)!A;/0!SHKUT2[-GXO"I%51Z$LXC5S#M5
M_*WVHLXF"$W;-0>((AV]J?,,&/H;5=<3<JLQ[C2R/;<7OBW318M(!)Q*#;?O
MA'Z31>%F;Z9C![9%Y_J)/-M8^B;3L^[ISI_7=^E."H*!>:GB]5*1`A7[XQMB
M](;BK-I+QB*ZP<B'C![!X_C;%W*T(,LS^K+NY4#1)%?H+C2:WS![X\G@V+9'
M@BB;<#&',SZ838!25?O2L5Z<FWMOG\HCN]96MKM2->:#0</("/<->N7:^B4*
MTXVIR\L_;&V71J"H+RC?CIL;WU[MI04M<#@=<ZN0^^",)2K71FVT<3&H#-QP
M:P0%)7+)7.!&-Y`QGR";.>N?!/I#+'5D5\3+R%N@^DF][XX><UJ$Y)?>&MB>
M$X@PC>6X;6W*F0UVDZHKJXRIJ0<<"B\&9^B34X6.E4U_U0O2:5;,^C8[^0[M
M_I!S77=JX&OV<--^/17O)M426TUR=%XWEBQ'R16RXZ\X1/YR^$K'S!N+EJLC
MSZQ!LJ<E3T`8B$P*1_A.N3$_$UUN)3,UJ`T-T$7F`74SOV3FCU2-X8H'S69D
M;2NIXE)J-":9)MQ0BEAF;M!T(-O.H=%6UW3*-#FTGZ5R28!]Z\[`O!*L5R-@
MJG\4M7:+0FS*U*[^D<<.ZJ?,@,QL392DZMZ(S5?R%T2.WT3F_OKL1$E`;<\^
M!,MS4W(:3Q53!+3URJN:3TJS4S5(&HRJ^R-1AR9[]+"QS0"!LM5Y^K6YH;R>
MEYB.$NO%5,GKDCA7PCF;GCPML<5=@#MZW&D7FK\7BTB[5*8\(*Y)XZ6^=6ZU
M'DAP'%X7M.KUP-R)T'$HB"MU0O6X57H4F?J6A(+==`""HBY?H".&9](JZR^]
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M(\[`NN^#N^I'YJO[G:?I;VQ$UZS6D:H`+.I+.EGB'IW)VJ8O52ZTA^YD9J[L
MJ#_=L\,'ZU%2.]U5E[KOB!^B2TD9V^E3APM`8[WL*.O)]WW[<.@X=G3@Z%+C
M[=X;6:<8YFH@9;Z/&3:I5*\R`]&N5ZA:11/MH8Y]=)D:7'BD4Z?\U;9Z="K.
MYP'NG-JO$"3UNDK%>X<[.F9B.RHI!F2/\>+D-1*"H.K+S;MP:N`G"`[CO[GG
MQ(J;DBFXG=/F68M0J&-"PTK&`SPV<,G,LY[18V.PI6R^YF[N&MUXXK&^&O/X
M;8-I;7?65`GQ&O\-[ZRZUFTG7PYMH&`*=;Z<X]5_#N"]J<;VQRI`]P=/FU5\
M:FCV`<K//N=15(!JH&CT^/A0]O'0W`-50^&L^U9I7"EB972'O1U&0=HB5?;Q
MRG1I8T^K(\GN1WQQD^8"6U^S[.F"BO1U:UYUO2]FD!74-Z4?]<=3>]"?%IEG
M[DSP/+YN2[+.^D<5GGRL<K1+0LVV2);:1IT^]#67"9_[>Q?R.GI0]U&3:E'T
MGN3R^W2EW'>K7")U$IZG9!92/1O1D3BD9:HGM3I2!?1[:495[Q=TH4*<//?&
M?5I0LV>DBTD,1:@2G,?[@6J^JT:7-^L)JM_#-C5'%3T\3-6Y]]QV4&X(@D[!
M.3"H%UA<G<4W`97%55AH0W<+F&',KH^$[Q'OI&)"1)!O8LU!%(WS.4R)0#A[
MD>`J;%/=N91M&T8O!Z_,3!5C$OC%DG2;_GPXI!&Z#GS%Q=KD8S_8%N%`UM>0
M1)-N)'/L<+?HB#\%^>E=W/*G]]"A#[^(M1=XUF<0`&MG*5+J?28+4FS2BT,W
M!<IQL0M#N-%=A`"X=.4L$RH$8T."BUE*ZG79*JE>4S9-04^JE,1(]4#]2_17
M8@,*3_<64IT9M#@.9*J>[LV[=OZ@CZD1UUK4<PLBWPNXZ2WU";5@)YZ/2S@W
MCN>3*):5=5U)\B&!1@TF;XYF1JC9E.;"O4$Y$=?>#ZLJ])N/\FK?\-6B[P?5
M$^Q1C$51$B'.`2>,T#PK4XP-!AQ;%E1-+D"VP%LV*C%1(NLD-0HCI="#$=R)
MU.ST9%S=X40C*8O!Y;4'Q*9;:,%67)%@*PUL6+/V?.S@&HA8NK[4R:!HA+_`
M(UN/@GJO`-@I*DZH;BK"B+DRBZ@]EEU&4`L+97(=">1JRFT5<1P[J'BI!NH7
M?#38@AC02=]Z[5U+]'0BHWD#:]21,B*,)C*PP!J,%S^-K0&:-=@JALP;;.>S
M[NZWV5[7*"F]K%PSWV$:KPB-,(\%G6JZ5R,SZ^X_KPY@'XZLCQ5_R@:N&)S!
M1WR=%SG.U;;'^3B!8EI9C69F-+[A1*9C/_H68<EE/M>$O0RF`Z8_*$Q<QA9-
MV/C%L(0-KX2<#E!XYX;8@M&F;MS[T?+6:\`@8!+8(FPP_A&4-A%H@THJ3*0_
M>=1(+Q+D6#8DFV[>953_J@]9]WY$">BCOZ,6H=/?P1!/K'^J)MC'#FZ+3E:-
MWR,'U;9A(=3WS[%^IYNX48,OT`03P95S)7YZ_?:+-KM`$@1G1!X`Z1\BX>$3
M_$GJNQAB6\O86H3P_@:HS,.)!!B:\1V>-7*&70.]E;<DD%POAK_<&5^+0YX<
MDO7Z=19L`@&L+GI<O$4*BL(2KL+QKN"YY#H*TRN<F@`\_S:PU#?A?Q+<''\)
MI$40"-0)*^R1;*>FQ1CS,:Q#UD5@GY?+,!)_0@&TP:;>/>M6+&(/(TTOK_QP
M`3+K[I7N]$GO.:P0N59YITMGPUOS1#54_T`9JF\N?T%.UO@T`YZ5*]4DR^%.
M=617D]T2%"Y.]=]2%D1N!>SI*1ML\DVQG8WO+2(\4&D%RW:-KHCA,I0:Z'I7
M%#HBAIUU!@1K%I%4`4)_A$/A-HG4KRN]HPD2/LW+N%*_QI>O4!.1L,3ATE-?
M9YZ^3,'V6)->Z/AWU5V>CXQ`6\I+!B56@A>/`5P+;4%0OH1(BOR#>8,:,200
M/<E*\,AEGGE^F.2=1'9H5'P$U5)&4U1`\54V0#=2/3753>-SE42%>H;Z(*HF
M8HU\0O"RY.+_!DR&T-QC&S_OFF+C6FT!6\RQ64Y\%)#2EYV#?4_QK:7)<M<<
M/Y!K*4!8B1+P(RS(NE`V+07'#UEQNEYCM4NI9THV8$D9Y6$:%9F%L8-"_"LG
M@$M-5HL2X.2FLSP"5#D#`9!$X*N]\[$7/#Y648FSA_N7RM@V#;),-;BBB"DB
M3`Y-."`"PB'&N)4/(B2(A19[907!]-](:P!__>Z7KQ*0\?#G.EIE%X\7Q8GV
M^`)@"_5YV=E6=C9B/:`,K^YF^PEH.TM,L-Y%5^%[7WS+P%"+V*I=N%SSUF'R
MBM,E\*T8!2LH)&BE:#C`Q`&;PF<-B.@VL(BSH!><H`0;UN=ZM>I\ULR"13BS
M,V/92M/;N*%E[LH42PIE0W'9\S)W`M4M=5=Y]DKWCM+<BUSZY5T&`GKHP*P/
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ML!NHK+'0CES%I0D2YK.:_Q*[QZ.DI,CBFF!GV[H).[)U%`SIQN8VHZ:S6)KK
MTO2LB".9"B].D<C\`KET1ER0@A*.U1__"$8^.JXY&>2&59,S7%^V.F4@5JGT
M9U2JW/A=VK1IV9!S)4[N\UD4M+9;QY-=[.MAT])+-VT<\LR!P<%%V&'H>O'$
M=/U!5G-)G4UQ<\1_NXR@!AU4L7WI:D$3EPS0?51K*9T,70U]UE)7)#V2-5E8
MW??^(TC?@4?!@!0)&I0%+;Q%\J?EDFCYQ!A;\'$2?U,NTV4H>^B+;QO$.)N:
MZ9/9P>IUYOR3>?8@/4@L56"SG+X&_PS^$'<J[1$M,*DJ2TR5_@II+<5W<2*D
MKS81R^L@],,K#\\L&_2CV+?OW&$DVH9_L(MF`SN#'\%>W0"R2\AC6SM='9<2
M\&/:3(3DP+Y#F<-^MD#?<"1]C6?`+(6SME!`AF9^424;?IL);N"S&#[EC`MD
MLAM.[*D0UB6OK:U*F.JOA.PO0"8<)TU.5N?N+`G/7$Z>P(/%:5`WG%18K2&T
MB+K;2--O@/MGNH3AGO3(88*A3]7P7&;Q2'4+&3Q=?/8*7CW^&@.0(0]LQX%4
MT0TNJ1T:64`DK[,1%)ETR=LFG&K6V1JG9FN\1\/!5FGM)/LY`SU=ISZK?XH9
MZSEMN6[]I+V3<YI&(F76BEO#Z"LG_[;A:IY:700[#`AYE8A(,GH@7\D1`I%8
MAKZ/5Z!L)9.ZQ[WS_H^6NE?D#J/Y^9Q^DXF2CL,?FL,_DW^^8,4YJY4#Q%XI
MY<WI?J@KD&!P9.I6(@1-8)(A+HH*BVS8(7\=?DN#X?*&*H*Q)ENQP[(FJU-B
M(W6M(O,.=0!#5Z0$>G:=5UJ22FW(;$Y\%E0+'>SW@BV:O;?>\&Q>Y4<G9273
MGG52A:VR-C%).0MHYH')V%H6^P3FQ0%C.;&5>!T'FHQM.CB&DK+^I#]$V<[:
ME4-L,*O@J8WURE>9*'!C.-[7C$P;WZ3]W&UXO&!6H$/1)1GG3>D`'14A>#'1
M]7EPZ#3%5-<TV&H<8^S@$0F=B1(&?-^Q+%1,LJ<HDXZJ@&B\H0$$AH@1$"7>
MS3`-UQ^$$<%&+VH@:L\E2,GMHP8I&BOQ_-3LA##VHX^(,L'92V$T%95\2)[U
M2R,M''E/'*=K0@+?S]5"%W:7-6!1,W'-"L3"P[K([A5?K7)L:GUF9,Z1O:]W
MELQ!)<^CD=TOM^IR?D")U,HX71-G*Z5,H,..FALX5"=H8!&<5\DE9ZNT!PT3
M7)!+\TN+N3\<E]#$H^=8YEVMA3!H10>V0C>>\]ZPUOO+WD>T33,7)$]7RJDF
M\%4UFZH(#KO"QQ65KEY2O*A*6UHY,TT^N0(NE9"_&./-L9X_&&$)9ZJ:>Y(O
M8X7+@,U^)6I<K49NJGG,054),AQ5-^OB4`5F/"9POELSKSRU9K/FC6E&"$Y:
MRD.U\O6!J7%.66K,W\/KP'IW;GT1(#P!!W\]?\O39*L^_S92#U9^$>O96+7:
MPK!`"GO4VF(1.E$UI_F'SH)B:5.E'A*,QMCT7%0=!#ME<KT5OG.+;+8VF\FF
M>(UU\>7M)<_X+.05Z:WC$WKMZLW+X>'LI\ZQ29!W&&/!27%\/O&UM\E/_<R.
M5C\^JGZ\EK1S(!(DE'I.9Y%H#R!<TI**?&69(;K@P4)C+WJ<;J3B%".WCM="
ME4)HO[P-(A?T]XK?HR]R2>.O0C?6)8.;8D5%7$J:X<``NOME$H1S%81QYJ6E
M:G7Z<8DA1YS8[8%"ADA$IB6:G_%=X$;A6AAA-S_%F7F(;(!.'+W,#>BNN^;*
MZ^U88(.@O@D#F:52[/8!DFB9UL:&+8/@#8(!S8QS-Z]ES@U1E707;D#!P)1,
M0&Q`0'9*1L)G?9YM#ZD1D^![]^673_2J1$>FJEJNH%;^\+F:QTKCQB3-NKG@
M97N)WI0K$(P?Y-YRN[_-BH]J>88ZC#P<QXXF+<)HCE`:F0G(I/!"5=<1XJQW
M9=97@2"HN]+T=[XWP(M`=E_(&MF9K-X4KH&WILA-ZI(QB<!HT%B[W5`*G*_H
M`MAWK$B.!0(EK5'7"`K:%XG%,G!^)U&$9H7L*Z&M/DHT`DBXT03\PL!G;9H9
MA;I4MR`UWZQ"5X4*[J6N"U0*9"Z<7%1!8BQL.)Q<<C%SZY,*4+(0A`$,70Y>
MN^#D3AW(YD1/LGTB3/CW_H-%Q+'IFC#.].3B&0G9O4OA^_'&0=OOKS_T?J"?
M-^@QDC]+.&X]-[G^"8M2?D2U8`^@]'*1^A89Z*!SG,&17\'.DW#S@&]:\'_H
MNVX!QOED\VWG[TDOKH2$S-FF[F$VK':^ENXF<;=L:J^%'P%TI:**X##U(7?*
M!_DHDJ#BC'6<@HQC19WY]S,*K:`L>23TSRB'1G\FM,W]JD4T=VSQAI?>$P>J
M/E+*40V+I<:@5MXPT>4M9V?6B[[RX;3UM)_ZN-'2]84>>`-$^)E<8A^L-[X7
MT/E^C3"G!$]7-N\X^-G2_QWT-HUQ6MPRP;7W^5#VY'-=B95=1W8?M)'L3EJ/
M\3?/CO$;[R:DH>/RJ"MQOV_+&OZ?VYMT\-1'_04["VYTLY[W;R^PC%-FCH)=
M'X4W\G2'"HL[';K3H3L=NM.A.QWZ@#JT;5%.AYG(X1@5C.A0TL$J=(Y@>"@?
M.T"_F`?(Y41Y];OU(O+)M;U?HE`.:J("SERM,I=,E%V/*I_6$[ZKG-MC.)`Q
MY1M@9S('4UI"C*[01RO<;:H"599XT,\:!4+.>GF99;ZC+[(+I33:$597:BHB
MS6J[B:@R&X"X?,Y!;&=9F&9``7W%LK\G-V!PQ9)Z,YBM*ZSK%""REDK'35#'
ME2[G#ZM<6P@WI"P1X@;2,XJ](NUM`1Z&@O-O,&]%==%![S2%\%*./6X$9@XM
MA!\&5^RDSKB5B:<J%U7'BJ0WFS./.%<(/ZN+M1'"NE!-HEMHERO/\77<K=KD
M%G`PN<T+.,/DFDO_:S985_B>:[Y1.M[,\X_!+4\ZO1<8#Y)Y)?@X)>^`[HQ2
MWL^%GNYSJW]"-,`GC9>!J7"9)N66T*B%7+,!F2HDT]"X%C*#,P@MO$@1614A
M%-!K5(E*7?RC4'!H%MT8P8SL]BG<:]08F-^JN8AC9P@MXEW520M>*>LW%^H%
MVP__$&&];VC$M:BF!/^^#3_>7'MB9;WC(#,\_FFU`L'%%5-?L40%GH^8AY7"
M6-E2,CN-$E@H'$05J1QUM0MYR2;L-.V*DU:%R/]1M?1#$E9/Z$XX2!\[(%[U
MO>KKVB1[6FYZC;_\.8W/KAQG\]-;L4C>>O'2#_&DOH+F]-H/EW_\[7__+S0_
M_J(>^R4,73RNB\#]$"0.<&:@85`>11)7O,W]B[XE7\3JKS^\C\(U)@N>]?KP
M_Y*0_ST_&_9^^%MS^VJ`N`YHP.],BH:EOZL!#P(K"=>-V/`2\C/^)(!Q/GZF
MN]C/3&\=W,L0L2;XZP\#C2(+2FK26UCX#M`1;02SJSWW@4Z5)9ESC^^NJD8X
MZ9T,>YP#O.N6@_`V<C9__8'_^T-KKZZM<+<.Y52V>89QG'7>/WF,JW"\W<_^
M%W!Y8-J#IGX&5QU&/UG_Y\V;=^_>OV_2NSN=[.N`?L1)R3%OF%RCH9(Y3J3Z
M[TFQ2K3^6.%U/JKKOQ?\IX+UQ<-`G#_O"4]&-0&CO;C$,QQW$ZC187:'V:W$
M[(9DWNVUEXA3L(4NEK(Y@B'\G'4(Y_`?AW(4&E%7V\@N&M-:3V`+APB@O\1!
MI8]G,\],/Z\Z`ND(Y%`$TC]I`CE"\[-X5L,CL]CW@/ID.,K@?(#TZ(;IPM]7
MY7I"U;U!V`_!3`["2CKRZ,CC-,CC(*KHL9%'A<#];A,M'PWJ9_A72&T+_+OR
M=+%(W'CBEN?[J'I9,*I7H%2&%+#'GC%&ER!*(U)UJE6%YUE^RR:,8Q%C*DQ6
M&&K=J/84'/F/>)Z[LX"E0OQ^[,F,FSLYZ3V0R09ZW+0!_9]B:X%5IM@=P9PN
MK09>=:DL#:>RK/*I>!3QEPWI8FI_2]EEL@[9],Y0MJ81JL`L%LP.*310ZC-^
M81\KG`*'[7.72V#(1FVVOGH"(;?&!I!V>2='(&<C6GA=0!7!,YJHCP`F=>)>
MA/M]5R/OO)T=$C$.:_+4&5H2L-GH"?VW^\3YC]K+_*"C/HD]C)XW=-$?;-7C
MMKH<#NGE;R29ZG&4-=SSIEN+BJT%_!GI9M0DV3R%>'I"PAEUA'/D@)\*X9R4
MO!EW9'/D@)\*V9R8O)ETA'/D@#^G@;,OX10]O$]0Z[-?$8\J`7*%]],[;$]_
M]X8:7E]BO^M+ZH3]R6A);I;\7,2?5D:9CY4&'O^!7_N!RD_7CA__]8</O[W_
MX6^C\730FP[[P[_\>;?5BN5).-\(=H7_>??OU+MQ?'2!721OG"C"$L-_.GXJ
MJD#LGP&4P[X!XC\NWYKP]7[XVWP`5YN=XDYK-09@^0S+`$[ZSPA@?P<`GPVX
MW@[7.QX]_O3>XX0U\=&[$27*^DTD#T6\P3@'V?9%'@_2+JC6?PQ(U-+@,[6U
MW[5"<"M=]G*P&%_?<^&^L?`NZ'Q6N)B'KPS;G.ZSY=FLN2U/]]KR9->%WX1Q
M\FF%HB8&,KJ4PUTNL1B^@3L?#O/$6KO8X\#:%R-&LR<!:U]T&0Z>ZK3V0J:'
M'M8E]BSYPF,RBCSL@?C4'^01JK#$`R#8%W4:!V!?).D/>LT?P5[X,-AG?>YA
M)`Q4D<\V@0X&&+7K/`J@?;'CX`#MBRU/<4)[(<]#`#)1C!C/$W`3M<Y#86F0
MKSP6E"8Y3`/'TA"OJ8/DMS#036@^!,MP+=[QX.,F,.:L/YGD+ZIVN4?!M2_V
M#/NS)X!J7T0ZFXR?YJSV0JGQ9/0PJ-3PCP;QJ3_LY8^HL,8#0-A;%YXT#<&^
M:-(X`/MB1+\_W0^")78J$F\%__=#\-[Q(G(T?%K]([@6[I5PWXK(NW&PQ]&'
M($ZBE`=M-,&"AN-9`=J'@G/8C>V+B-/9L!7[>H0*=JQ;VI=@)K/^@:[J4YX3
M?\3>ETT0S6`ZS7.9BH4>",O^[BAR"QT$EKTE='\X/A0L>_NLQJ/^@T&1K+H1
M9!G,)C6XHE9Y$!A[6P2S\2'`V-L:&`UGASF-_;2VX9Z'<2E\'_[\BPC@08RA
M7>1&GS>HQ)7P9;>EFP-X?\SJ39X5X$?CX#.<\*.P]6'P?A&Q<*(EQK?>9O4C
M#6*N`>'6M1X-V-Y&R3QW?(<%[A$*W<%/[:&^M;T`^Y?`Y`OA7MP`=EZ)WVBB
M^Z<5A?&-*/YK)_:6^$'/3Q/Q@/A033K!<#B9#4;3_B`#_V$0'6Y?V_&W9E]]
M,&B&L_ZH?[S[VH[Z=?<UGX['P\%D=KS[VDXY-?L:@#+<[X/2U?2^WCE1`$_%
MGT5$;SZ:D(#T/]=LXJQWWC,0[IZE&X#T7M9^-)#>R^?K(`5`>T]\I-OY_D$`
M_4TD#1O=(S+H3%>KN<3>Z^<QC?)Q_N>+P%)?X:J]_DH%F_<XT-#;UQQ8%<?R
M(+`.>EH[9<E,!LT>RYZNB%&CU[)WI&FX^^+\EZ_.-ZE0O0:]OJ$LJ;Q7K6J5
M1P#SB'!V\\`\SH_:_,D\5-7>"QC$)ESR34B31X`W2$=&&,2OQ2J,A/Z<B-]]
M`_N0ZLN=Z.Y#(M;Q;R$V'$BBD,Q)%:<X#+,^(,#/?#:/9XVG>S:/9]NG>S:/
M%"E/>#`YZ761\#0P+&#X&AZ.A0QF]1)T%Q@.LHE'B+SCV,#>OM+Q<=["0\7K
M@S?PZ;\_7/Z$+S%5_>H%8>0E=^HQ,(0^1^$-C55['T8&T34D3J7+^L%@'&0?
M#R"'X]K``^23I(CCVL<#94DSFWA#W8L^!#)"_R\GBIP@(5^QBM%_E)VPO&;H
M83B>9/#OMWS#D.^M_*F\E$>`KGC9A=$/ZM-*S?+"J<"?(['VTG431SW*JV/W
MKMD(D'LG+!8BD'M#^2&.4R=8PAU0R2'<@+R+&/!>Y1-_BM[XCK=N!(.GLX()
ML`\`C4._[WGWQ_-I<^`K=Z)PL=\9&+UT;TV<\F2>C_Q5K_1P>/8^M\'D`?#D
ML;E8:M=(XN@V(B\N^'CP]LXP>`QXH/%A.2<),E>XK^_^$6.]HL[XN%@"FVU,
M,IU-IR7/WX[+-POXWH)I,IPW!'@Y?^]B2<PW_NS<H:Z-&0O+990*MV&]H#\=
ME[P'#P#E<!O:]U8FDV(N\6'V\RFY%E%VM8TQEK-^R=.UP\K-P;LW%92]EHW`
M^R'`\=*@7#>$Y_>=JK'>HX%[G)M_=\!J&,Y[+P#-HG%&/2E[-G9<O5FX]SW=
M\:PIN+^(C7-':=.?5K^%B5`LI/%4L.IE'@/.WH>6I^I=0?K,D]?)P=KT"17Q
MKVZMQ\"TM[09]!\-$^G_GS;D@'[W#1MAQP_,2:E'J7O7:P3`O97[4>WA[01D
M=>\1[FA>9*3-E/[LTCFF>OVF8=];3N_4MV4WV,V+4AXP,LRN0]\544,">UJ+
M'%5K-@'C(^3VON!Q`M$'[C9N@I+OQ/,_GR.Q$E$D7"*(4AI+7>;C=#:=S:<%
MLUDNMR\H_>,!1:7W'`$HZH*,MEL[PS&:CZ?]^732[/T\`)+!9#Z8SV?#6;/7
M\P!(C)9FNT!RX?Z>Q@DI)%_#"]W,_[/C`?.2@Y"K746F8/DB@//%7B*DOXVY
MWQ>Q#*\";S</%A]]#00[9)T->WDV]T0;.Z+SK$K?>_AY%OV7SW2>]#*C[MLT
M`J."WZ"H!?_:\/+NBF7;R*I"@!8J=O:!J/'M5%WR?ML9'--VFN4!@V&AT/#X
M[NKAFYL6],Y#[,V4%`W356UI"1A^H_GLWGW5@-;\QO:EL#J-8#HKI),=9&-T
MW6_"X`948XI)\+\3#$I<BB4\N9OWYR&,<;H[)[D7PH-O]_&,LS_9Z3Z/9+_-
M<M;^8#9IT>:;Y;R#4M'N$VR>V<*34'8-!YM.I\.=1,Z.H!Y^XPVQ;B#T?F\Z
MFHZ;WCDEWB@GG,ZYB2_6&$8[#(\>C+*4G[J5[P&/-WE`1!L,I[/A<#*J!9/?
M*^)/UCH<CSVS-[X(WTG0!(GEFV21?)9N]Z]"MAG?U;?VM^;ZHG\'TPOIX@D2
M:?'E(+:.$>06G>[[W%Q(+[8<*T[7\/T[G/*(8QMC/'\KI+.W'`[`W?UT<I?P
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MMB/'_]YY;W9B.'3TUNJ3'IBT3#%UM).JQ\9,CF$3A^`J@Z$]ZH_MT6C?O*EV
MHE0[H3XF0NBDZK'C4(54_3,5).1^U:)JBN<$5=5XY0`]A1*5XZX3NN5CKRD1
M.L8]=15"+7#DG0C<[:O>4%RT*Q%J#=SM0[*N1.A8HA.G52)TG#GI)P/K<U?W
M],9VK]>W!^/!]W3J':S-^#>.`XE[Y[W)\9]M&T,"7:5-EWSZ9%<^F@SL8:]G
MCT>3TSW?#L`68R@(FGW5YR,ZSB,TE;JBFXY^G_#2QP-[#`*FU^N=[O%V`+88
M03L!<R+FB]&1O[WWV5(`GY%^7_;'9,*`A'EU:L?:`=ABQ.P$RX%+4+K2SF-(
M"^PJVKJ*MN\F1Z$CA(X0CD*NGD@)2E?8><29]\>PB4-PE]%\;H][?7LZGWUG
M=1WMA/J8:.+TJE%.K0ZK0L">2#6*AN#ISOM#8%UL(L\G`6P32%@M@>.%G.#.
M<JXB(5PK"2TGL!SM?T41'HBK,/%P\!#^6014?@!6>KH4]`B(^%4:P<<B:^4%
M3H`E":H80W[^W#@H_:_/:12G#IP8P1+2\_"C=^9Z?DI37C91>./A]*D8UC.+
M.V!G^)-0V;D;S,[%-9>@=CGPK'K.\@#^\-9Z@>1AP^==>C%(21^!%V(:P$0@
M@$XF(O\.H3>7LJX=7)['G`/MI,MK^+N35'[(,CXB''A25:,`'.+?J>-;:J-7
M<.!7<*AZ$P0#;P0V(%8KL4QP8V&DW\FNQ?5N/!>@6=PQ&'#QY<.@39_?CYGW
MX.A#N`*OD4T9>^1$J^*`K`_!C9`!@@_!Q6KE^8B?\66ZB#W7<R)/Q!=Q'"[I
MMQ>!^_?0"Y)_PN,`0/S>\2(::)<!M6U2M7[\0[`!'?>CN!%^?X?Y9,9TN:;!
M/;;C&'3'81['\+B.XZ/G+.";.*[OZ5%_^^*'!747M!SW\X,@GQ/>/?%F/U"K
M)YA?H'2Z(CG^^J[$@"]`>KER1!.EE`*"\GC(7Z(PWG50Y0YC$B?#V:@_'QI3
M*9N']ID.)#])<M<#Z4TFHWG_2<]#XQ`PFW3-K[W[M@$M1+C_#$%,(Z[=?4&5
M9>][AV6Q4JL\C_2\/\DVN3L$N\#^Q8O_>`]*[0>L$`,&NP?D__.K%WCK=%VB
MQ[I]H*+5&VW?214\!]^'\VW??0P.M0]UDU]%M'[8/?SM\_C_[88MN,;!8,J=
MZ=\^]WL-`Z6*$64-HGK]+:G\@;L_]8$4^5S#:.#">]NAOP>:QK@J_<\_`9_T
M".+^0[&D__\:8)P5\!S%7@O8-WJBO5[X8(>AJ5:]"*)%$#]`,I0UG,E\GM/(
M=ENY.7BW"^PRO,/>M`EX@\1CO\>-,5[[W;>EGX*=CZ#A1]*$OO%I]<Z)`KBL
M&&Z+EJD?M/T@A6P\G`UFX_G(T,@:`;#$_H!R$_$1/@GXF*`%5-:CI.(LIW!O
M1QW4Y4U^5OWY1T"Q$P(_&@H0K4"R.&D=&+%(XHOE,EVGY"F!<XP2[S]TR@\]
MIK-)?UP'X8Y+'P;X74[W;#)X2N"-UR3E_@9`?[T5_HWX%79P_6!D[0]VWL;]
M0#QN2_]/.-'7V_"A.QD]8B-RZ0;@OP:=]-EV@(L_?@_OPS1ZKBW@V@WL`)Y]
M,$$\=@?P;--&OI'5\!N[^G?:7(U8[4]ZT]E\.F_.KB_!]RP'L+->,9Q-9Z/^
M:'QJ!R`QX']DLZ*2O5V'#ST09?W!>'!JYZ&LE3W/8S2?CWO]Z7SV!.?QZ;\_
M7-[_]?@HO*('@[5IY)!UH1B84.LT=AS#R73>&TR;0XT*8(_G//8EG3%IQ:8`
M?8KC2<+E'Q_B.!7N6S`(E?.`0:0_?E(N,)E>WQ@VF!O=&XHGV\>]M_@M]GX*
M//^O/R11*GZP_MPT`AJ-P1L0WX/AJ#\>C1J,2Y3@.Z"X*GDR^2ZIL]O..FN]
M([5_&+5N&]1'=%C[>IT/(^);<ECWJ8O;CV[R/1_=?8QU^]$UR+D.=73[:7$[
M'U\#@:+1'H?7W"Z._P"?`!>/^#@KU,0G1,K^/O9`PUMIR5$>`7H^]\&JKS\!
MACY:H7^.O>R$(D]HJK1(^=P1ZOV\3A5KQLUXG?;VR$T&PUYO/)KLZH1Z`.BY
MLS%:OWQ:J=[OS\H%'P;6_9LZT(V=]<=#Z0FJ7[M(NV_%(GD3!K`/K+;@?R48
M>(F!V`GE*7R_:Y;*UC#/8#@;#&:&>-EU\2:!WC?)H]\?Y0-L!P.:KY6=40\X
M[_K(4[\W'4W'>^P@!TGS^WA08NRD/QOV)[/A([;QES]_6T2^]Q/^+_SX_P%0
M2P,$%`````@`?'MU0<Q7T<GB"@``:'T``!4`'`!O>&ES+3(P,3(P.3,P7V-A
M;"YX;6Q55`D``TLYK5!+.:U0=7@+``$$)0X```0Y`0``U5U+<]LX$KYOU?X'
MKN:PF0,CR8Z3<2K>*46V$U5Y+&V4[.:6@DE(0@T%:`#*C_WUVZ!)BB^0D"@:
M2`Z.)7<WNOMK-(`&"'[X_7$=./>8"\+H16_X>M!S,/683^CRHO=M[H[FX\FD
MYX@041\%C.*+'F6]W__U][\Y\._#/US7^??W"0TQ1UY([K'CNO"W#P&A?[Z7
M/^Z0P`ZT0<7[1T$N>JLPW+SO]Q\>'EX_G+YF?-D_&0R&_>]_W,R]%5XCEU#9
MEH=["9>44L4W/#\_[T=_34A+E(]W/$C:..TGZJ22X:^DACZCB2#O1:3>#?-0
M&+FJL1E'22$_N0F9*[]RAR?NZ?#UH_![B6<C#W(6X"]XX<C_OWV9I*VR1R)>
M>VS=EW_H7S)ON\8T'%'_BH8D?)K0!>/K2%%0/I*TXGAQT9-\T.#P9'!^.I#-
M_:+#&SYM`'9!UIL`G-$_0,,QHX(%Q$<A]C^B0'IUOL(X%$WJ-3)VJ-L,<7#,
M"H?$0\'!BE9*.:[6\Q!^2A#%=#'=0$^4X.WEVGH)'6D[7<Q#YOVY8H$/^><2
M+XA'PH.TKI74G:_'2*RN`_9PL*M+`MKK>LM"/'3';+U!]`DZ]7R[7B/^!!XB
M2TK`,0CZNN>Q+71VNIR!5A[!C0:TDWH<JT[<&7B.-N>,2N+CZ'#J7N*[QA@M
M4QZG]3=N-LRO_MI"NM;1I8[O.)J=/;<PW41Y`P+DOXASI(E5(_-Q='SKCOQ[
M(AB7`2Q[Y#:0P3I:<ASWQ[N`+/5RYZ'RCF/).W>^O1/XKRVT<G6OVR747,?(
MD/ME!MV\TU;NRUOV%=T%Q[<K+[6]57%RU%.VDKB]#HI.KZ>3%O/+HW^)0T2"
MH\-?$&O,KEOI9KG*Z\C`DORC1;HF,-74Q]9BN)\:PR/WN=P\8%]D]25TEB$T
ML=3C[EK+1JPUV>OTA(6EMPVBF<8-?,YQX$<()1_[B1RI<HLR`GPM^0>#P=!Q
MG80C^RNBOO/,[N3X.U&YN3R0ZGL"2J9K+_@]R^K$O$[,'*N:*!LP+Z=@((M`
MC.>1C?6+*CT+).ZB<L]6N$N$-GV)>!\'H4B^B6+`'0SCJL\O\=<_1D*``N,M
MET6#I($`W>$@:O;']/MD7J#IF]-6KE_EY!?^D[G@'@4R;8W",03Q$Z3W_Z!@
MBQ56:/(6K<L$SHA[#N.0B"YZP\$@:09Q+Q<PY?);3-$7<FB2@EP"49'P+SA;
M*WT=^Y7M;486$&B_YSQ@LER%H+E1`&<<;Q#QKQXWF`I<'W8*6CV`3HP!5&NB
M=8!,J%R9P9KR%JMPR)/HN?_4F/NK#++.Z\]6W#+J:23>+)E!G:\)!5AN8,+E
M3VB(Z)+`TB?64!D[34Q69-LR#MF`TK/;TA"K#2Q+W%_E].INKN5C(^.!VH:*
MX+(M5&X(NB,!"6%=7#\B5Q&:#/'G9;V8H2=9AFF8Q"J(#7<!M>]SH51KJ74!
M%6W/8Q%J`:,B-MRO]8"IM]0Z8"".^!;[VAV^AM[P/%"[W]3;:QU"-X3BZ6+,
ML4_463A+HH?#&[,X5%EEG>MGG/E;+XP+8D]1[*!@'"`AR()@OVFUJLFM!]B9
M6<#V],41L2P7+*4^/R[Q&E%?;BLF@R!,OJ>+2R*BD7&Z.(,0'XRH/U#@LX\`
M/8C>FH5H?X]TC]*8P>J;AW*%=(GO0/$M#(X%M2*58KMFC&>+O<6*W:'2]/![
M9Q:_EKZR+GWF[0GKLZ6*6`^YWVQ"KFBI=<"HS^(40*DB-!I0ZS6CD5*U=?T2
MF>$E7<W9)U:GMJ7A,_)AT@86HV"&B#^A8[0AX>YD:7'%H*(VO)S3`Z7!5NNP
M^2(W;2GVKQ"GA"X%S-.V:^E5[!<.I19@TF$TO,+30TS?`R\Z^YD!'89AP8^L
MF&,N1Y3FL5#!9GB-IYO0]*PWCL/GPW#X;'SI=A0</EN#P^0P'";&UV='P6%B
M[:#R!Z&,1Z=QGFN;"IC*9(:777JPJ*RS#H;,6D0>:]2=Q#>SV;/C46M7OG[8
MKH!K;N]`V\2F)R94)G[H%RV\@<\O>O:M^HFS]"#<J?Y!..=53M:O+W"*K^%)
MM-2*-W56[(0X;.'LQ#BOOE&TA34%]G\U>,AOC@(LON![3+=8?5:C1&6R9I'1
MY1-C?LT1DVI2TS6`:H_G.GR-B18.1IX\S2:S&>;W\"'17#D**>E-%P*:D6DT
MUCIX/G$FQ(RSA7+!GZ,PW#DJM%5U#)O[Q)B)<+J(NFXF5.8PA"L7-FH&P[VB
M`9)F4RO0<<W"$X_"=!F?Q%6=A:N@,UK1$QB\*(]X7T(7"-A&3BMBU93%O%H>
MP[U=B4.^C*=AMG498(X#D+G\A"F8&(#N(W]-*!'A\X-)]:CI,AO.#%KP[><(
MZW!,;9Q06"/@&\B%3<DB2VE+!RMKG\6H*L7;N'C6-$<=E]:-1+>,LKQ1]9FA
MAMZ"0YWUNI>H#'>.1M]7G>9LSE>&(PHLX1@)?(F?_Y_0:T1XM(\\77RC*^PO
MY?X7)_=1_IU0R,31TY*JO-9&H.%\L2?";1UGW>`%2Z3&8:M`8S9R08VOZ#$&
MZ2-,&=2K5B6UZ:Q2Y?-"G-69:65&B<VY!DO'3-Z6L(4>M:ME?L0+QG%J&!97
MCS"]`T\3BOC3!'P5/>L"G.#&(.J,M?M'G;9H.B?IQ4>G[K9QVT#S`K6TZ'ZF
M5727-?>LN'\ZL<!<^?UEMQ+*-ZVE1KW5WTF04IQ(C"4["1#84B=81MP3<-#'
MIV]"/A:93L9'\D[.:.-+/1)I"_BY!]67'Y+V1":;CZH3EFU3G=%:GH'^7^2*
MZ:+X-*X"IB8F\T-%"]ST/&(=D/,5XO@CS+]]>7$33)!R=[X4"V4*8L/G$]L!
M5^\!ZP";"+&5^_3QN)VY-^B:\60_8,K'`2)KY1IS/QF&#SVV@_<@?UF'>CZ[
MR&<=DD=39AROR7:ME7(K^0P?I3QFUJWQBW6(ENL?TW"%^<[NNI%4E]GP\<R6
M/7<O#_T$`!?N#I";,Z6GHK4!UQ-F^"#HL0-@'P^^P*GJ%<SQ0*NX:!F/*]'&
M:5*V;$9V7R&&G\MKA^AA'OL)NG9RU]4^/3C'HP?KN9VP:OG#.A05-E\3"O/%
M%A642@%F;U/P,/:C^F;VRM&K1\P](K#JD)0&GYV5EAH$"S<KZ/G%NLC-:IZ]
M=D`#R#RYG167`_"K\H)UL'W!&_045Z4U8%.3VUEOT82MR0OV[<A57_0Z@RD+
M\XM#GVJ6MY<(PVGU$'L+)>Q])Q,V'G_JR`UUW<2VC)5-L<GC>E&]--[?TQAP
MJMD,9["VT.KZQ9:=WY8O<4HW3-_)Z]Z)\`(FMAS#!RG8D??!?UUA)Y8?W0,?
MMQ!M"._:<':-.+M6.MD.KGX55&K);Y66R)OB4Y;.U"J\("K5Z;Q2)_G0WC-]
M9PK5OB4J46\XJ%3O^6F\[)9_\>G6HZO;_-:H5.=AI<YGB<Y.+",*V9V4SC0_
MZ,51J3$GE<;(0PR)U,B.G5QG)]C)2>[,P)HW3:5FG%::(5/+CM=)F#LZ*M+R
MW5*I+6^*MAR>!YU7R6_=G9!I]>JIU.BS8QK]W$A7)E>_P"JUY&W1DIB^:[7T
MWF&5JED:=M7)JVO-V[Z_*K6I-`"W":*X%<N,+K\7*;6^--0?P7HG;:_CWJ3"
M]*0T0TB[4\<`J=Z:E6I6F@<4-7.&G?9UO==FI>J61OJJ&=8+`J_Y0JU4_](0
M7Y>P.HX-W;=LI<J7QG0-Y=/PB==T\H=\Q3=\\W]02P,$%`````@`?'MU0=D(
M;806#```8:$``!4`'`!O>&ES+3(P,3(P.3,P7V1E9BYX;6Q55`D``TLYK5!+
M.:U0=7@+``$$)0X```0Y`0``[5U+<]LX$KYOU?X'KN:PV0.MEYV,7?%.*7[,
M:,N)O7:2R<T%D9"$#0EH"-*/?[\`1%*4"/`E4H02S<&C2$#CZ_X:3;#1(-__
M]N(ZQA/T*"+XO-,_ZG4,B"UB(SP[[WQY,$</%^-QQZ`^P#9P"(;G'4PZO_W[
M[W\SV'_O_V&:QG^_C;$//6#YZ`D:ILE^>^\@_/V,_YD`"@TV!J9G+Q2==^:^
MOSCK=I^?GX^>AT?$FW4'O5Z_^^WCS8,UARXP$>9C6;`3]>)29/WZIZ>G7?%K
MU#35\F7B.=$8PVX$)Y;,?K7]N$.R\4EW^6.R*<H0G0!-T1D5FMP0"_C"JKF(
M#&4+_B\S:F;RK\S^P!SVCUZHW8E($,;VB`/OX=3@__]R/XY')2^('EG$[?(?
MNI?$"ER(_1&VK["/_-<QGA+/%4`9>"%I[L'I>8?W8P/V![W388\/]TN1OO[K
M@GD(1>["8<;H5D!X03`E#K*!#^T/P.%6?9A#Z-,\>+D=&\1V!SQFF#GTD06<
MRD"E4NI%_>"SOYQ$>CN]7;!)R\DK9=IL"0VAO9T^^,3Z/B>.S4+5)9PB"_F5
M4&=*:L[6%X#.KQWR7-G4*0';8_U$?-@W+XB[`/B53>J'P'6!]\HLA&88,<,`
M-M<MBP1LLN/9'4-E(9BKP'92Z]%J8-XQR^'\F"%M7`^&H7D))[D^FFY9S^C'
M9M+-K_X*6+@N@B6K7SW(3I8CW"Y$W&`.\B?P/%"0J]S.]6!\:X[L)T2)QQV8
MS\C`X<XZFGDPG(\3!\V*Q<ZJ\NK1Y)WY$$PH_"M@HUP]%9T2ZEYU1,ARD:%H
MW-E6[NXU^PPF3OUZK4O=7JLP.!8#*VV\/0;%I"^&J5#GW;-_"7V`G-KIWQ#;
MFEZ?N)GY#6%#"J;DU^;I!8F1MZX;1;\<C'[-<VYM'5"6V>(2&HL0!;DLUKMI
ME+E<%^R>A1-X5@15UC@YOB(G$:5&>#+B1,":,Q&>%4R@:2.VFJ$B'1`.E+1%
M+`5AO\N:=L,V7:F`YG''@YDV<0$J"3K=>P>(Q4BF"]T)]$K"7>_:/%;@..40
MB@[-X\+$'Y6%%O79J4_"*6"W"96=,NJ^CIE]C3#B$>2&_7,--WQA5Q(;VA%R
M+G"++"+[FO?O]7I]PS2B'LF/`-O&LKNQUK\)Q/G)P1CN@&&,,R_L<[*K$?8U
MHLX[Q2K/#\;`A\6!&V_69/VK>45RTH:Q$L=92JR$&&1JK,08;[Y@$-B(M=FE
M*MFYQ%BEDT(J<8V2XOYIA`+7E`M5BY1SB+6FD</W'(@G#3XB:$P!G8C($5!S
M!L"BRQ<87>CX-/I&+#G,7C_<9/@E_/HQ!LK,",?L8TR>`R;0$6,_WGX;/\@:
M=C7`+6[X\C"'C3;QKIQHY$7(PYA;\,*V#/1G%L$^<[LK1XS&+A9PQC]$L*8>
M<;,M&5J-J+$G[<H@=`SB,7\Z[_1[*Q0.H=`^[_A>(%&V#7*6]P?\7I!@/K]'
M;/;E<27O4RMUTI5I)E7K),AHRE(US=J@URI!&V`OPZ6NE!A%VUH)2:^Z,]G(
MM#7)A?ZCDO+8ERA0%R_1PG.KB+<5<4(]%7?#=KF[8[*@Y_%5!+O6?PQOQZ34
MR9H^UD[<^GVAC)3LR4'R`2NO2*TRP11R"<ZG(=6N@=E3(PERN$H*VN5@9-O"
M9L"Y`\@>XPNP0#YP,OG([/,H"\W:<),/77G%:9>G>YYBQ-"^`AY&>$8S"9(W
M?I0%7FV8R<"LO)"T2XEZGSZU7MYL^'C2`A5%;V:D8)73HET*YL"#=$QIL,HA
M;!H_T41GLV_"5#I]RY>+_P74%PF@ST013(4J'P"[O^73GBU*18HHN75R#YEC
M4>3#!^@](0O>00\1^QY:9+9D0GGAV<GH&KO)+BV@\L"W[4?=Y3RY##R^+2W`
M?P5.`)=?7Q,OU$N=P"@A0V-O**^'BM-W.G*:C(F5254(V3]6LQ11T?JKCK0*
M][P@.#SS<#M=?O;1Q&$!R6(M?51IZN;*W#_22^BE\H%3'7U@Z<PU.T%!H?OG
M!644R]I\J.0'Z2H8CO3QZ@5Z%J+P=AI5P8Q<7BBFRH(JFFM,1B;DVM,YA<V\
M=(;"9EXVWRLS)R`KS=SN?><GZ(^Q15QX0ZB*BK4V&ML_C5-I],2]Y_ONA@IL
MC.\[K&!(G\:)=_O?%B]@X%(,(:;Y`H8MC^7$ZKWC%3R(\AWDP(/L'URPP4M\
M/L^A$<H7I3WA"**N836&L1K$6(W2E,;ILSVQ(K]*%>'%/W&7IE!M'/B)(9U*
M(?&RGF7[IO!D'OJ)T/5[4G3+>IUDV4K4ORFT^6>`8LA]*>23"+(1RA#NNI+2
M%/!*IX!B709277BTB:0*-59RC95@8TUR4_IEG!J*M1A*M>!!9=77B#HW4\BU
MY3&A6)7C356J!T#C3?2IL?*UK0X1Q3J?U*GS<I"&-):?1(H5>;NI2-B^853%
MSB+%*%,76W78:ACXML>08I52E]UM/"@<I<VR2%ZDB:']`6+VP;]S`%YIEUKX
M;JS1"_9M,W]BS:$=..SN*(V5KL#2S-K*<C+T*+TL1>M:#J6*Q?:C6/,:($]D
M!#^\QA__0-!CN.>O-_`).AE5FT4[MU2^68DU4EX]Y49VNU5I,>:/$'!%Q:HQ
MK4AFI6%)&2V4A98D249O&?L<6-:VSG1'GJ!S(6J,>8P7@4^%TOW,NJZ,'FV4
MI5:;DS(JY?HH+\W:T38H3=N@Q4K61G@;Z%_K*H,]+,W<L,4ZUT:8&^I?_7J-
M,,`6`LX84[8*7ZH=?3>B%/HT>4[S=X\$"UY$.IJPYL!2;4IN*_;QN`4?J'QC
M5(NV>L;D,7Z"85G<&(^F4^0@X$/*,YK(1L!#D#(%B26^'6'[/X09_BMKSF\I
MXCFQLJ/"7^H>IA7_J=,-2,.V488C?:/1#0(3ICNOQZ@])!65_0/%I5(J*Q?Z
MK;I+0H7BH2:[DWZ!HPI/I)2Z*G*/VRA*J.F)67%2/K7Q7$-2WHC'.SRUX/#4
M@G2>?(^?6G`/\`QFY+H3O^OZ-(*4"MHE*P7"['.&R18MI)/3-MPT\#K\_3:Q
MMKG<HC3HG(S]R*SH!FXF%VMM6LG<R7R:9`'4-!/W$;SD6SO9II5L6YZU4P`U
MS9YM'JUFB\;`#1Q>#[OQR*R<<^3ICH]OM:UK+@A>SX06+TSF-8KL?[R:\PDX
MXADL_@5;TK\R;<0-DH*U0GTU)JXX?CW30_+SMR->)383VG]X736Y`Z_B.8[/
MP+/#JK+?13G9&"_/_K`[:.41@P9&TM@OFM)6SZQ1G`8941JX2PVN7A;08O'K
M*V%AC*=+7N^9X?+VKG(%:,QY224*Y(@TH?(>T>_7'H3BQ5V0^B6)E'7?,QJ5
M*JA(/-&.Q,@3/T//K3`+>;<](RT%7456NP^)D$'_$Z+9G$$?/4$/S&"DR25Z
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M1=N2@Q__-07A53USBWRMC=8O)D@AU7/;==LMIMO`ISY;D[%;IWOB.-?$XS\V
MM'LG'ZR5TN#=;.!E**QRIW;G<(T*?PHRXD#MX[3C1(V[1S.^F#!9W5%-\5#(
M*N#I[DH,\H8Z>%=EJRD7FGL=YY@QIQ")DV"1R@U%.LE(!V^L:C3ERKG>:)=X
MY\'J&;&J-+ZL[8_/L%IM%4?M5L1D/N<ZF2.-'@ZLC`>E!?WXSE#1)BI/:;?L
MID;+I0H=EMK?><B"W*K37=VM%03R<]S)E3&&GE4%.S)&NWZY[V&S@IOMWM\S
MG;SE]WCD68"6JKYNPM'K0W!P]ET:NDA!R3YZO.2VJ0VW+PGCX/L[M[9R`M2<
M-I3>)59PR=)R?FZ?JF8NI5-HGNK+FR"1IJW&Q%(@?F[O;<'62M<O\/ZA\'O^
M9\(`L6_^#U!+`P04````"`!\>W5!AF\;Y4XI``!K;P(`%0`<`&]X:7,M,C`Q
M,C`Y,S!?;&%B+GAM;%54"0`#2SFM4$LYK5!U>`L``00E#@``!#D!``#M7?MO
MY,:1_OV`^Q_Z-@'L`))76MGK6U^<8%:/W;EH-3J-UDY@!`9%]DB,.:1"<K2:
M^^NO'R2'CWZ1P^FN42Y`;%FJ*G[5_77UN_J/?WY>1N@)IUF8Q#^^.O[FZ!7"
ML9\$87S_XZO/\\/)_'0Z?86RW(L#+TIB_..K.'GUYS_]^[\A\K\__L?A(?J?
MOT[C'*>>GX=/&!T>DK_],0KCWWZ@_[CS,HS(-^+LA^<L_/'50YX__O#Z]9<O
M7[[Y<O)-DMZ_?G-T=/SZKY\NY_X#7GJ'84R_Y>-7I1:U(M([?O?NW6OVUU*T
M(_E\ET;E-TY>EW`JR^2OH4*^AB0+?\@8O,O$]W)65-K/(*D$_:_#4NR0_NKP
M^,WAR?$WSUGPJBQ95H)I$N$;O$#,S1_R]2,I_BQ</D84%/O=0XH78C!1FKZF
M^J]C?._E.*`?>D<_=/R6?NAWQ:\OO3L<O4)4\O/-5.K7NX:M0NFU;;#7.`V3
MX#P>AKJM[0C^//?2?`L'ZOK67;A-<B\:!+ZN:1WV%1Y6XAL]^R5-@C(>5M(U
MS2;LB/[RDOS4`(Z?<QP'."BA4UN*`,<^Q>)N8;NRGO@-NQ$-EDDJ+!%F<N%E
M=\SN*CN\][Q'8O_XS6L<Y5GYFT/ZF\.CXR(Z_J[X]:_7Q!9.4TP:0^+_]@DO
M[W#U'>;DCZ_4HJ_;V*G2)"T=\%)?4PJ%Q&L_(5W$8WX8\?+FZHLT6>H0%"65
MJ.5^C>XJJ[Q4R8<E\!MB*<Z25>KC7I5:]\&@&`MPRX@(T_$"C@\_SU_]J1)%
M3/:/KS?VW#&&1,T<+W&<G_]S%>;KTV3Y2$8S<9Y-GL-,XK-&QR:'C.#7R:14
M`,,J$Y1M>G%1M)%%OU#IO\/@&8&U3&)]6!+(V>23%&:=0QTA,+R1(6MSA<M!
MBD.3(`CI#,*+KKTPF,:GWF-(!D9*KFAT;/+&"'Z=0TH%,'PR0=GFUD8'4:7#
M:8P*-1A,N\&Y%\8X./?2F$SG,R7%9,(VN:4&7">56!(,FY3P.C3R_=5R%=&!
M.SK#B]`/<QC\N?#"]"<O6N%I_+C*LTO\A*-C)8F4&C:99`"]3B>%.!A.Z3&V
MB:70`$:P]^OJQX\A3DD)/ZP97,78W%39">V,'!(R4*D)CXPF<*6\E"J#&M"+
MFM&;WF'P#90P^*9?&'RS!V'P3>\P^`9D&*P!/.E-L!,H!#OI1["3/2#826^"
MG4`BV*<P#I>KI9)2+1F;)!+"J].F(0"&*")4;6HT9&"0X8;@PXIQ5>WO5N=^
M;5B-Z5[Y1S"5WT;4KGCV=U##F$_>LSX(-&6L!@$1O$80J`N`X8$(52<(U&5@
MD.%G+TV].%>2H25CDPQ">'4R-`3`D$&$JDV&ALRV9$A(>&%5?/3NY(A5\.RO
MT_FO9XF_HGLJDS@XC_,P7T_C19(NV<&5R5V6TZ,Z+1=ZZ-D@0F\W*#F,E9P3
MIB_2-HE*541T$5=&->TQ8TR&_6_NDZ?7`0YY>"$_M*,*^=6O',4-O@\I\CB_
M\I:XY;5<S`:E="`I@V0RS@FC`=;9(>64V,@B*NR.%J>$JZD73>,`/_\%KZ7.
M=>3L$D,"L\F,EA`@:HB12;A1"",FC8BX"W:4<>R6F!6XU?RS+2Z(0)44J/\-
M1,T+`$D["RKCLI:KXY=G7JZJ[I:<[7H7PFP3H"$$B@DB9%)*<&$RA`@0%7?!
MC@D!$E`P%Y%W+_"K]7=;;!#"*EG0^".(VA<AZFPTES*("KFHZ]-5FE*,8>9[
MT=^PE\J#@5S4%@-T8$LRR.1`\$(#KG-<BHLC+H^H@M/@P`<K/^,H^DN<?(GG
MV,N2&`?3+%MUUBT,Y.T.)S6PF\-*B3`($ID@;#-IFI434P]1S</?J"HJ=1%7
M_K,[4OV41*LX]]+U11CAM+T:KI"S2R()S"9Y6D*`2"-&IB)+I8&8BD.&%,'P
M!C\F:1[&]_2L\DI.%)FXY3FL$G1K*BN4!<0>)4`IB;[*4*6!N`HJ+#ED$V/S
M*>E'[Y-4O@+2DK++'2'$)F4:(H"8(L(E6?E@HJB4=4>(Z]5=%/H74>*U%^,E
M,G;)((#7I$)-`!`1NJ@D-.""B$DZ[&,V]QCF#QXICMDJ9W>M2>R2AT6EDN7^
MQL"!5J^CT`!$)`.8LJ75VIV3`\2544W;Y1H<G]CQ99\+\CO1<$8A:WLM3@JW
MO1[7$03!)!TZZ;I<,?\NEN>8BGO6T-4`,\[4)-TPI@-5S)=*#"!;VMAT7&%K
M-:,S983[MK/%11A[L1^2%I!DH>(00C]5)[=O#9P17L)5Z#GGW@"P;3)6JBA9
MH$H9E=KHEU(?R&&X29;A/-/0L"UD]9JE$&#C7F5#`@R)A+`Z.Q'S^?GM'!(5
MBO4!(T9T9.T30P*WRX^6(#":B-')-B6XS@\P:'/J90^3.*#_HOD(GKR(92W(
M3[TT79-!/KL0(''>4-=J.H`^[C12!)@H@J%='[0=&A(E1&9PR*<_X(TZ#$).
MXR<")DG75U@6OIHB-NDE`E=G4?WO8,@B`-59<RY$0@R$!=<I?O3"X/SY$<<9
M+B*GQ#^)K.7,2'*XK=1(74$P3%&A$R1'HK((<V$@O&GTQR9]ML-1CW:T8Y47
M>2VMG;[8)*1@N?%0<Z`#@QAD,A?F^#)\PL$TS@GF\"["'*"\H]$I6;VB:N1`
MXY:J4@-,T#&"V8D^9)Y.ABP'*,9`LHP4B$E%&@2?NIC]^-,%V0U!&QF(4:B#
M3AR(9OD#3D&%(8Y%Z9L+1LAY`+'V974^NYU<(DAK,I>A=Q=&84Z&U62VQC;2
M'I(HP&G&<_]IEFG,U6TRIJ]3=4Z9ZH+IG'H";E/R<CIY/[V<WD[/YVAR=8;F
MM[/3OWR<79Z=W\R_0F?G%]/3Z2TXKIHM(JH4'/'18#E1+@V1<_T6%FN*0%87
M)[Z?K,@X[=I;>V14IYF7282M=H=*P(WN42@)AD1*>(+4?4P8/7)I&.1AKS'@
M+#<BCTS8[NJ@"G!SG5`D"88\2G@"\J0K'*"P4()!G@)5-Y;*VXM,WG+\4<-N
MA2"Q,!@BZ1#*N`1K4?$RC/%L<9KB()0/ANHB=H<_77#-`<_F[V!X(0#5&3H3
M$7H*PV=",(APG2;!RL^+W"=KQE8O.HV\+`L7(0YT^Q2&VG9W+GJYU-S+,%(%
M0[I^>"4);U!4Q+*M3]S+DM[@I1<'5TF.R[';%<YGB[,P8V.TV>*[;X^.CLAD
M]*CE9F]M>PEP>KNT28-CK.J<9L/P=HY#,@,HIA;*X3A;Y::Q,"C,T)]_?\0V
M\7__W;<'Q.*.R'B:Q$\XS>F*_!F^(XUC14JKY1'SIF@[U_2V4A*+2F:P*6LT
MW=+9BK,#[<`@\';@N\]65-904)E3\OGH`!5+^^B1VX;1]S<+)E=W]3)ANR^C
MJ``WGT<123KGHQ$\,\;!H)#Q9-3U+-1L^NEXWJG=+#*>=39/+=348-"F][X1
ME)VB?GM#>[`;U'O_IZ[P5?DJRM9K\_K!6O.1NSFF!_M.-=V]1,?%\$L)7S3.
M$BHXITT?E*I^[+%ZAS"CBNB0C)*^.3HZ)O.#%#W1H[[_A8Z_H],`^G^4\9N:
MWBI_2-+P?W'P`^+?0J=$]=W;@S<G?*Q5_%C(AS232<#^D&PN>2(O)]J/.<OS
MBD[(Z(P2CTF=8;_X[3'[+?DGL?.(V?O)T:[FQYKR_#B@#C["8?G'OBS_N!<L
M_RB+CYR7'PDOWS`",V(5/[XH7DX'E-H4#B^G?7DYW0M>3M6\G!)>'A^\??N6
M_/][QJW-?P%EYUB3W2II@/("4$?,T=.?\FL]+1GGK-0`D[S[*>_WW_).7]SQ
M_Q?Z]KOO#]X<?7]P<GS"0^O;=P=OWKT[^,^3_WS9#)8\A"G;IY1)`WB25+CS
M*Q8%PVXU/L4#I/1*R6$8(Q_R`Z2UERZ+*9VD&$P473Y,*G=$]4AI5PL,[XRA
MJAXO#2`]7OHIC$DLIX\J\-,U$L>[8I9?OA*";#U^U9`!PQD),,$36$P,V#FG
M[I*4\=J5Z\5`LT5`6&O*4GSB-67A^A\,XNA.MNL7U25JD.XB:+8MA#JP"&>(
M5GP7QLKU@V'G6`8<GH!S8J7O,17G?5T/D(,.I#@[?C+L"`.H0R4#SH_`X),Q
MSH&G0F#TD\UEPVLOG:4L2UC`EFVN<<H28TJBMZFRY5P5/1QJ):\PT'1.SD%P
M!>DMZGMN!YLU-XBTY,E9)]7"GU&)=)7<T5#F@)Q^;0V@M)/`U-)MH[&COK78
M?FZB9:]9!!RS*.0;*%GK68T=J#I6K89S#O6"*=FTHIO\'3H5B_Q\R=\FHVKY
MHGO22J#IEEM25]0$ZZ@!9ID,:Q^JU3>1+/#MXY`(IE2RS#(#!UH$4VA`XI8>
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MS;T(9S?X"<<K>JQ$=T-9)FWU1*(:<N-8HE@4#)G4^-ID*@2!Y`BM8_^0)($B
M'[]8U!5GVF!EA"GE0+*E!:Z[+\UR9J&42P-91K@,?9H>D!Z(Q.D3^8_2&XG#
M"GF[IU4UL)O'5"7"8&BD0]C-Z,?D@7&I%3K-`JS3CLJ@@X)UAED,3GQD^>;\
MI_.KS^<PN'&:9/ELP4)DC>7S)))/Y^4*=F=@.N#-^9=,&DRLT4+LSKTR=IBT
M[,`*^L'@U8<TR3*";"&].=B0L,D<`;0Z56I_AA5CNL#:C&`2Z)&)H*\C\A]_
M@,&&V2-.O3R,[XMWUW3O^2KD;3)%"[O.&ZDPF`BC0]BF4R6/2@4@\ZD;G&%2
MAO1]T#,2]*+DD2X8%"`ESFMT[-Y1-H#?O)ZL4`!#+Q.4W7DZUV%9%X*-%@R>
MS7%$;-Y_P#%I"!'Q:Q(LPSBDC88F@E`3SE39ZC"[ET.-T;>1)A@N]H+;/7;`
ME`_0/5=GY/0:!F#PLQ/030._XV[4J/N$-?B2P1-?BDZJGA/6,P^5%WRQ_9*,
M$'7^UB6=D*8+54B;C1B8("3'UEDWHN-VZC\J=)(8"&,(]!1[&3[#_-_3^,(+
M4W9`9K;X'#_@X)XF'DG#)Q87IS&)D"O:@\N(M8U!R_MP6SK>VJH;:`T,F[=V
MH;-^\4#^"Z,PYB>GZ%+&E^(%"CX:+$U5#U*`R5=<)E)1CP`[4BY>ZE*,Z5HB
M=ICVCC,MQO?TI)VJRQ7#ZVX;<ZFRIWT=LF`+@R=729PT.P$U8Q3R-KFCA5UG
MD508U@!.!U/UO')Q-.'K0F/K137)R78Z"GB/%TF*VPF;R`3F.DV>PHP,#"Z2
ME..Y]9[%Y]R'V;%VZGT;-ZLS\$.,..]*MT4N'#;>,5MHV4[>Q3K1Q](>(D*(
MAT:44Y-``B3.-X/C29ZGX=TJI_E7;A/Z`'H2YZ0P(]9DE<GA!MBQ&E"'NMD(
MM'V-..?[MLBU">KHX#%;W65A$'HID+2L&T\O"`=.B7-AO"*^;69VO/77FO?Y
M<YYZ21J$,?%BFN-EUHO\._VB_;./.RVZ[OG)G7P.3-/;O8^2<YQ\^['LG:#W
M0Y7[Q1#O/8ZQ?.M:*FV_L4@A=XG>$05&4AD^P8$]T%QJ]'8F/:+#L8AVG`%L
M$B>`UJ8'D4'W'AD80#H`469K+B\5OO>RT*<;I6&TRJ57I[1:-GECZ$*=21H5
M,/''#*=P]D54$--!A^B.JO&U2ZX(@WL_X_#^@:"9/)$N_QY?K>C+!K,%0UV[
MX6-&R:'&;#)U.X?K!!YF"0ROMX+?>1VZ,(8*:YSV&:H9@ML&JEM%MW3:*3LT
MT!*RFSM<!+"9-[PN`89C0EC=1P*K2UU,#,J-KA+691AC-M/1.5D3=,*.#E`A
M0RHI>"QI0U,PA8HB)JNDRTZ+?6!"_S=6"YY,Y<,D("67YJK!LP)GNQ;>X_LP
MID,B$L_)'WQ\@"9+.`F+#;(.N$LUH,LOX"RI@"E-]$D%!/28`TK!,PG^L<IR
M=O3@-I&\TU2.\W%PFBSIH@-;#./9B1[9NM@-)FTD"W-<7,6X9L5W@_WD/F86
M)>5G[>MV'^ZR6J3-A\"L?!I,5VG7W\[J+6GWM$73TSC\2;[D$=!QM%J2NK-5
M2B(0]XN=0N*_ODC2\NZ4JA\TMV']!:&^[G7&(J8&P%!^"&H5<?WZDY)TD3@K
M=($-8\1NUSO@P6R6&@%`9XV#!GR66(!.:#7L@8R&-/)2-63^)`K=MYDM:L^C
MS+%/).G1S@'!P<`F`+[W<]\TG&L-0F\-O;P0/[##=@'I>SKX+M^CV#YR4S`V
M"J`M]"P`X[Y@[UM#/S=,FL,X'8/DK.KY,T[],,.SQ<_\S'[&6Y_HQ*-<UMJ9
M4QW<ZERI3-`Y?4S0M5E1BM>N5HPV!#;FA3P?MUS6(2\D.;=E@E!YH<RK+>:%
M/E[`.95B=X'=^&RK=$&='DJAQU'V;2/CQ,$*]7FLO!:D0-GA.=^5[K&'`65?
MP,4&DJ[<1?AT)0YK<EIL+9*AE9<]7$3)%UT>&K6*DQU@!7CA7K!`'DSL-``I
MWQ\F?1=50DP+7+)8$O`I.G96-<#!^_7G#`?3N+H2/O'S\(F_>:VFX!!#EH^3
M#G2TU;OWM`*&Q(.A=^9PD_E'='$Y^WF.+FYFG]#L^OQF<CN]^H`FI[?3G]@;
MYT`2,#7VJ.BF4NR'[*WMS5#H-AF'_[OYE+.]TY$+2[I1.M)WP+2R'3K7;H>U
M3Z$\06GY,?9X-QW$T]_2GWW:_:S(5^@UM$W*%Z_Z$)36NDS2//Q?MD<\6TSC
MG'A+5Y4F68:E>3IT2E9;D)$#C;:@U(##:A.8'7[6E.@H**S4D,?T8+!.?$9!
M-;D0"%L_N"4%W)FJ=23!L$H)KSN@IEN*?DVPS*3!]AF+TQ_L1'>Y5%0^\T?"
M(%X^1LD:8RX0)_%A]1L8+"PW46<+YN@D#LH5LMH&["P]C;Q0>OJWIPVKEP"'
MN->X&MC'`!B&#T&M/.G$KS+4-]9AT+?909SAN_PLS'RZBG6=XF6X6AIU+$(]
M=QVXP@UY'RY0`D-'4Z2ZGISNVZ&@4-W5SAU/NS6-B\Q=1<-A25O+A%N7FWQ;
MHMV&OA:L[>8,<ZW:X^FG;I5]3SB]2S(L6I\=#OU%)61K)Z>KYGW%D5G]VU_&
M!MRF(=0YIDX[*-,&$TM[0Q:S.&O-R=G$B-&XQET@\_.NR]/X"<?D:_*C0!H=
MMQ05P%>SLJ8`F(A=E-W<)UP"3BJB=ENB^>PV2V*J!2!39<?14.&0)A(*-`&3
M3P&W\VX#2UH(:2VHZ\[$YX/<:V]-+P33#.V^GZYP(!][;FO,+5'[.*PFKHDE
MP$3N`;\S7RI4T2/7Y8GYN3:P3.OFNX);;RM"W>_=;I\77.*A?KA%!\"T^T6@
MJ7L1QE[LCW!T06D(`)4-'#6@M,(*F.`\&+KNZ,+%]&IR=0KRZ`)QUL<X8.D0
MZQ=FRS.QLH0"!GHVN6OL1IVJ6B4PS#1%*L@-R/3X8QID'$R&!9NSSJ+-+'BL
MO$IR7(Z.#(JG*>Z*@R+0,NK594$R3@!03;28*I2C4AB,NL$$#CO$,EL8,$HN
M;O=E/#7HYJ-X8EEHSUAH<'9?Q"O$:<"BO()%*_,AP]9C#JB#P>T&@7LQKY'C
MELYK'@L3Z&Z-%J4ZN+E-/<J7V>39<9GB0HE!YR!6<]7OJIR0];\B'9#]L`*H
M]&F`,CLY#+[1QC6)`_HO>E?IR8MH1\!O_+:7QB0%TL^$U2?8!SC7>)2]ASZL
ML#D`>2=PGM^BL_/3F_/)_!Q-KQ";0D^NSO@/Y__S>?K3Y/+\ZG;NZ+J:V,4)
MZ2[2=$U".SMI8%ZK+468&1+[01<N@HAJ$!VB3<8\,JKC:%YFO0*\,-H/>)]:
M)1\VJT^++[RF]UY<'"D[3>(LB<*`_0=[7`IGQ/7BF%HQQO.BZDJ=;CUW)-M6
M7Y$=LS@:[\Z.81C,H&M,;SJ[T37;!ZAAG2W$U>W3UE1]`6T^`>YZYU8%1@^'
M1DFV2NGFYSR\C\-%Z-/C>GQ[DZ:$(?9\,FFZQ<_Y>^+&;[NHMT$P]J;Q;E'(
MH[7S`1A>1D@8[GAGF$Q7P(Y)7WO[@!&]SN+%:Q8VYJOETDO7-&+4/H`V7T#E
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MI:5)1M"-4;2QBFIF883U^>HNP_]<$7#G3P:[MG)QJV-1#>C&T%,BZYR%A@`[
M*;8J<<3EP8T4V@YI)SQR>9>D4D]H9,)@:644Q;ZG?6V;8+M*'<3WW^B>'M]]
MFRV4FWOEOU4;8MO;M)=>:"3W-PF'MC3HG+EC>M%]TH9O]DYJF[TS[6;O:+N^
MXP36R_"?JS`(\[7Y8I):Q69X-0%?C[`J>>=4[0&R,\5/*,-.:8&E,0Q>?:9O
MO9QG>;@D<S79K86VD$WNB`'6V=*4`,,/(:PV(S[S^Z25&`Q2W&#2^:]P[9%?
M%@S7NHACH&?W$J"A&\W;@!HE,`0S1=J]&,CT4$T1!NWF^)[.E&_P(\UF6?3S
M:S/J&>I:G53T<:<QP3!1!$/#/F@[$UJNBRIE($04YKWF2Y#L1(U/0(=/^)HX
MPT>A:UGA#+'D/E>YD:OZ1.9*,W`(/!B[.`4Z,X7JMN@IP'-8Z<Q[.7T6IM@G
M0,:C>MLB6,J+71],_::Y_6P"0A_Z-`6>5C!_\&)HK>+<2^G=.GH!DQ6)V=A#
MJV7UW(^9"XV#0&H5,"PUP]DY*E1H(:+&GQ&$P;4K_*6VI)4F,?G1YUM%?0:^
M_<W8388QS,EF2HQ^-L#P=2#P[GR-1M_&&F7#%@PZ7WAARB[`?L(>70NCT/KP
MN(>^30+W=JO.7&-E,)3MB[C-5:J/F`%4LP!E&^F6IC\:=1.I;1'L%I+8]<$;
M2$USSND[G@\C;1YQVS`B\]Q_P,$JPK-%U;KY32#B4RU5<M%>@UE,.IQ5FA)_
MR/`]Y,6D77X;]QM6IX.[*)[&!'',#SAO:KOT2M;XQ(]NT`1A$7XB?BZ+CR`O
M1PO:`Q7/SL3(HZ]N\L^B._K='?5$Q0TY?0<C$;36;RB!5MV!4,HY];30.KDU
MN2S4:!S&88XOPR?<N:/9-^::6W(46?NZ*HF?IF:<4W5[[!(NPR)QHG+K8I73
M:Z*UI^G.^<L*O=@]SB=<T'[,PA&UAS'L@VLH(SK560@DLGY.1@D+9@9YK4<3
M'UD+0SZ]K["C84(]`WGMK5']L,%0T=HPHI<CU;#"2,LY)7M#%>]]E#=6)K4;
M*T!'(N+MGT81\/2[ZYX#D^&&W8Q3MBT(\;!EJ%7G+6%T5[H7&JK<2_2)A8PU
M'/ZX0IGQ&<B%V5H1"&\'ERU\EMZ$]P\&%Q^&VW/4-(:Y+6D1_8Q!;`B#/-#P
MOWHD%RCUS_`BC''P'L?DA[PX#%`>?N9]H[;@C&RXH7@/]\2T-C``D,KFJ#OT
M+6Q0_A964&$&,3NU!$`9^H69`G)1K>OT!NHE^<LTQTO9<7A#7;NI@7JXTTP4
M9*`(AK1]T'834G4)VDA010T@9D')41N;S>_7U8\?0YP2$P_K2[K4/2'S2N5.
MLU+3<K)TQ5OS`W'+MYL/4*6&?J$Z0.),E?QQ&I,YXXKMAE>_XZL:[SWBDX_G
M#QCG'])D]4A/*VGN8F]OUNHABI$*H<'X+6V"B6DC.=)YXA;4J\U/.,N99]-X
MLEB$44@O.]';QF$0>O0==`(W\=EO)W'PWTD8YS\1<3INJ.+")E9+2G+\S]A]
MZ7DWA=1\`WK<;X!I1#MR3-BH8+0I9=BH;<"/WKN8VP;3Q?0M#N-^QM0PF'8R
MIC?MQE%3A]%$:H#,.Q&=DMU[\R8.-&_.JS2@C?Z-T+9I5JRQ52>!E*MD.ZR<
M';]_]"VTRNH'NW.4BS[M2`]PL3<><64`1J00;VM,*-'NV0GF]^M.!KO)%R\-
MBDV/#VS5=QKSA]M(P,QD:T<[^9+[VW.C%)7^5MU6GP'3">_.-_%.=/E:^3W+
M+PKD?;'ZJ='5LGR4G9_0^"F)2)'0V'Y#QNNZI2,#`TYNC!@[)ES(TVJ#H7-O
MR-*#.4^5-%R.WH39;Q<IQN7SL#T9*E9WS4^54SIVBG1!<U,!N'/UCHBB!9%%
M82&,4B(-EYUE4[K%Z7)`<^5JKMDH<L(T1E(=T.P3`)7&PRA<`.;:SYB><<#!
MA$P>O'M<HCX+Z?/M<="C3+267#/2T%4=235F0//6#+N4RD$AA]8ACH`,00>/
MP]D_?B*]`;U-R`;AQV,/]86?V(MYGJ)P1IG@">R#:3@[<*JS!<%/K9,FE9"6
MB)ZX#JBGHR<1,XX#<7$49_8E16BJ;+,M]'.HSG(S33#\[06WL]A`=>@M2\)-
MOY[R!W,U(.2,\S`(HQ5-9S2G=T/9\O/YLQ^M`AQ<D'JG'J_*-VG;.6=(\UO%
MLGVSD6Q;I?:8Q=%@_AB&X32,$;WI'$RC=DF;R:AD1EH+-XIH12'?B_Q5=47I
M_'J^VPO,9SCWPLCD!G-'TO859@G4]AWFEIAS1NFQR6XQ%](PPFCMEEZ!3[7K
M(96V?$1`!;FUZ2\2=4X>,WS=O;?',/<B-F@<\Y+CZ$QJW_><^/YJN6*O2-4O
M?>H+Q=B0(_[U=%1"34,K$%G;#WIG#K21;MSB=75L6^[7%98=*E)H`#RF;8:W
M\Z[,]H?EC(8KQ^;CE6/G`Y8.6,F(Y1CRD*4-3C-F0<?P^YIN5H$K_)S??L'1
M$_Z4Q/F#P>!FD%$H?9!Y`9CV1WJ+SKD]JAOM5D!9N(_$_QOVTMLOR2A%5=F"
M2_.6N\/971C:4U(WT0NX?+*W7":?EQ[2&&H-.)_K+F_):&IJGSE=PR]@];?[
MRNH+4JZC%1(W!IO3=8>WHS2UM,>,KL$7$/J[O24TD1VOC)@QX(2N.;PEH8GL
M/A-Z`U]`Z+>[S,;6R.%23%>OZ!43NM6C3<EFJ&TW+ULOEYK)V8Q4G1-M&%[A
MX?C"`.(6JO6*RH:KRT7)<EGDU6(;B-EDE3\D*5W"%P4,A3B\Q403L(),T$2G
MW"+U*@487=T9OLM/DYCXGI&XQG_*:?`K[UAR/Z=9ML+2HV)]C=A-+S/$P6:>
MF3X6G$>8K6!W'W#)0_X0!MW##XC)`_X0$9`=.*V3_/C"8.)6ZJ`HVW*J%UD+
MW?VA:1.P"4$]IF$W#Z[!Z1-33=>9<'6G4\S4G!.L/]8>R7!!'6C9]E+F;)5G
M9*X3A/']31)%%TE*_RAIK[OZV%X<$#<JL#'O`HN_Y+QM67&OW1S+AEA3>G'M
M[VJUO,.RI=$=?&=/6UVSF';4X/A'K+8U?A5BGGMIKIJ&[LK)3HO;R"$OXZE2
M?4P5T,GQ`2+-8>O#$;)1EL[#;.NT%CO\CKT1W`Z+:3/>V\%'G/=@N_:LW90^
M0$I@L6W\(/WT`H<L`5WI^XXBE?!+^]1I*8IJS&Y+\!GG36SWOG5RZG)),,V,
MSA_Y^MK9*JVN1_+UL_K,]/P9IWZ886DK&F#(:B,9[&BC#?2V`H?B0Z%W+YT7
M?W>T>;.G8W2[&T5\E'X>!W;'Z+(-INXH?4YJN1BF'[%A.I"CG-N62=$ZZ%L,
M.YTH"[ZS3V,.:3&-V0@['WEY35#FHB1H4[D7W@!KH::35(5W7-=IZ&.ZEK>P
MM8IL#&2?FO#P@MY11VN(`LZ(S)7KG9R_A38JU%&ICYB!?ZFXX+:N7F0$<-CL
M7_C*N('K#M;++;7W?@N?NVCS8R(`U>['+]I>;7^\ST,[G&G?]?U>Y-<5AV#=
MU45#[PUCKUK[P$(>M<GWQ/#BVOTP_Z%O/FQ;*J7/3AM_3Q![U?0'%?"H#;\7
M@A?7[(=X_X+W:Z#.,E_VWHZ1Z_^_XW,780<+2\9?!]7OC%ND.]HS`M/3V-Y)
M&M[)#-Y?`DQ&YR?IP5TQW;&?DB<)1SU5/_1,K\"S;!=G>@=]!\Z9WBV*R?Q,
M[X"/0&E)NW9P1ZM^DE8S"?ZQ*IZ'GBW*UBKR6")HC;=*H!7QA%+.=XVUT#II
M7#>R-NN]QQAXJ!&W?#$=D0ZS`"I"#44_D(H['`3R_#BGJS3%D@<5Z@*6AURJ
M0R)B7)T"9E('J)!S6LA71%!7SAL9<$4M@"8K[8VHTP*7%S.XPM44*?KE#"^\
M590C%I+^[JA8:P^G*R)&5PI0<2O`M8N^)NHZ@'233DDO832D+#_GKKUF(0:G
MRI#U59DB:Y+G:7BWRME*2IZ@:\]A?=2H,8D#L]K1Z<!L)&JHBB:#O#@HZLY5
MH_$BG-W@)QROL.1!A)8(H"J0(>OFT&$BI,]5/WJPPW)F\^OK-%F$PC*N_1E0
M^8I0=1<'B`SB0H[*=O:(:4+`^+[(6BD<TW2$`)6S'%LW14@AB4I11V5>/M"M
M>%^Q)0*HO&7(VJ5=RI6%[:BLR4PA*>M]&OO)$BM*72H,J/SU&#NOU=0T$%=!
M7Q=*?W"Y-52D%Y1NZ!1___4$3.$+80G?"R4C>BYFN8#9ZM'I`UW(GL;LK>MJ
M_8B,M,YP&CZQ_*^U@51GZ:R?.H"VL0WJ3D;67F9<136<GWK9`QDYT-?'@_?K
MSQG-BECU<!.?X.Q4;G]M`'6[!6C!LUV(VD"E$72W1E]3.RB,_X`VXX.-+4?U
M>X,?BUVGV>(JR7%V[:WIO%14FS)90'6GA=B==)0*]$`#4T&%#JP6=Q'&7NP/
M;7$";4"U-@!TSQ97F7+?XBA*$N3IO^B:PA.9'1/V\?U=,F9*L9?A,\S_+:KA
M/OJ`ZG@0[.X[K*2&Z6H,^Z%FYP!Q2Z@TA;XNC;D:>-;Z[@LO3%DO?Q9F?I1D
MJU18LVH-0'5I"%2Y"DT5$=-$&]7]/SYF,]T,L-G*3GP33GD.[Z@=5/\6JGV,
MAOZZ7/%!Q+YX4&92/JB?-3M`_+M[2D!'J5;@1*3=^;9+`M:^NN<$W(,+'"\R
M6AIY;"V&;I%DQ"6W7\Y5^#T*R#OP>@C/,U.B<SQD,EG,-%XLV_?Q*O@+XOU0
MUW=*_AJH?X$6L&\WHE\0^X<YOE/N5Y!>`//W_T[F'G%]9(^M341A<7O/+Z.Y
MY^ON?1,R<^2/N6"=BZM!0/@R'+CB7I"9)1<U?8:77AS4-XRO<#Y;T(T)^H;C
M;/'=MT='1Y,X..I4L;GJKT'B6ZM9\BWV;"5K>J(:[HV[LQ='JC59HO.(->EO
MG)P^XL]TTL?1S_`=04$G*"TWF`O%E8=K^G3ZIC@VQY"&V8%5H=LY`;MVKU.\
MP`0U/\`_)]T"SDY5U2A4`%M?*K3[5S$?^U;,Q[VJF(][6S'3OA4SW:N*F0*N
M&*O'9&%5VA#L`*NPB,I-XO&#U_P8=G<^J=.`55&F</>E;FH[DWTJJ*.V![4D
MPPRVJC[V;D8*#8@5I(>[+W5CVHQT:GM02WO7C*:]FY%"`V(%Z>'N2]V8-B.=
MVA[4TAXU(\TB6-_%/EB58P868*WH5[(&K.#!JAMCO`"KYS+)LO=XD:3X4Q@G
M:9BORQO89%;'KM]DQ.N+).4W@&^]9T&T&V($5A5NX0'`2IT$!&^2KND5G23.
M5A&[Z7B?8GY88G87A?>L*+);_)R_CTB<%^QV];8!JTJ'.P"P1LM-M<VNVV0I
MC)TR05AUHT&Y%Q4@&?G)!*%7P):CN_JO+LE/Y-?EK\@_Z($5\IO_`U!+`P04
M````"`!\>W5!R,5T6;H;``!IS0$`%0`<`&]X:7,M,C`Q,C`Y,S!?<')E+GAM
M;%54"0`#2SFM4$LYK5!U>`L``00E#@``!#D!``#M75MW&S>2?M]S]C]P/0^;
M?:`E2G8RSDEV#JV+PQE9U$ARDGGR:76#%";-AM(77?+K!^@+V3<T@+ZPB@KS
M8"LR@*ZJKZH`%`J%'_[VO')'C\0/*/-^?#-Y>_AF1#R;.=1;_OCFR\UX>G,R
MF[T9!:'E.9;+//+C&X^]^=O___=_C?A_/_S/>#SZYZ\S+R2^98?TD8S&8_YO
M/[C4^^U[\<>=%9`1_X87?/\<T!_?W(?AP_<'!T]/3V^?CM\R?WEP='@X.?CU
M\\6-?4]6UIAZXELV>9/U$J/4]9M\^/#A(/[7K&FEY?.=[V;?.#[(R%F/S/^5
M-K3/41+0[X.8O`MF6V$L*N5G1M(6XO_&6;.Q^-5X<C0^GKQ]#IPWF61C"?K,
M)==D,1)_?[F>K;_*GFGPUF:K`_$/!Z?,CE;$"Z>><^:%-'R9>0OFKV)".?'Q
M2/<^6?SX1O3C'YP<'7XX/A2?^XM.W_#E@<,>T-6#RX5QT(+"$^8%S*6.%1+G
MH^4*J=[<$Q(&*O*4'0>D[<KRN6#N24AMRVU-:.TH_5)]$_(_!8C!?#%_X)8H
MP#,2;?,(`U$[7]R$S/[MGKD.]S^G9$%M&K:BNG&DX61]8@7WYRY[:BWJR@#=
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M"4Q]Z[ZIF)B1,>G9Y@KK`%-D]4<8S$-H8JG7>V@JE5AK=F^B\\$G`=>7>*EQ
MP7]1Z$*>N2XYQ,D&$C1WB"/P7XO^AX>'D]%XE/7(_VAYSBCI/LKW3RG.:':9
M72#3%8$5YJND-?]U=O.UB<[I71"*4%0VD&O=$3<>_JOHJ]?UH`VQJ4CC4$]`
M[+=+]GC@$'H@Z!<_Q(R,#R=IH.<O_%=?$QJNR9**3WOAI;4B$LKKFY8IS:O"
MU+='S.>&RN'*!K5\NZ``U>!4VN+@(8Y;C.U[ZJYU9^&SE:DL4[DQ%2=Y^7(:
MM@["">?$M]P9MY7G?Y"71A0J;35AF"#$0<(W!!`9([=\6(7])DTTQ7Z$2NQU
M7$)*^XKXE'$6G%.^ZE"(O=164_['*.5?RS<$$%-.C2,H.G>MI02`4AM-P;]#
M)?A:/B$$?A+Y@L=S&MB6^R]B^<W*+V^N"<-[5#"HN(>;@G\AKOL/CSUY-\0*
MF$><61!$Q&^<BJ5]-+'Y%A4V6G*``^AGYO)].]_.GU.7[_\:@:FTU03D.X2`
M2/@&7*PF-GQ-'I@OXBCB4"EJQD/611.6OR*$I5D*<.C$6G+"7>J2^<T;B5)+
M32P^(,2BEF<X"*ZB.Y?:YRZS9)&`FG;:NSB$\J]A&-`]L=6*>7%DZ^:>,Q[,
MHS#.(.)&VNRD&COJXH-RFZTA$LA=8+(<3/9$Y_QWLLFDH;TN/#BWXU(!P*,B
M%NGZF.1:ZR*"<X,N8;X&CQ\.*NQ=\%\,$B179Z2M(^1'H_%HG>[#?\YW':5]
M1VGGKIJUL(*[&*0H&"\MZR%1+^*&0?:;LIZEO_Z:RZ(ZIQZGB7(S8`'5B*;K
M=>UL->UYFP8!%ZZ"BW(CR)BZ"1B%V$HMHWVZKJX@I(MU+2PJ;4'CZQ+95J0O
MX1`'""+54.0I\;_$L>VCY8H3YFEX8OG^"U^#_&RYD30`IM<7-!JO!LE(`CA`
MFWDB3XMOJ"Z)S&"*34`#\FH(ZOC!(>DKGSQ8U#E[?B!>0%)+EHA<TA8T)J^6
M?2.'.$`HN%&="0(X`F\X,=0(FY.[(/P?G8N$2RE1,44A"RTW;@D*$U^8T)!<
MT$?BS+BHO26]<TG"J=Q/J3J!ANO50.KQC,F,+IEG:UA2OAEHA%[7F*I\[;H]
M)7PUH@0<IM?%YK4@<D&M.^KR31<1*7G5E$?%)D:_.VS$N>UFTU0\.-QBCFJ]
MO6A3!]A0M#$`]>"AWK"F2>+!E?4BDOH5JT))8]B0=!>8FMG'`5%\[9L$H19$
MLL:P,>HN$#6SCP,BKD9^Q"??BM'+#4G67A>H83:X'6VI60@XL+J@'IDO3OA:
MB<JGI'P3742&V?UVFX2JK.(`X<IG3F2'Z36,EUAU+/?$M8*`+BAQ5*$AS=ZZ
MT`VSW^T"G:&`NJ(JNP)"5I;GB&NMV0S)M^'SQ2D-XFESOGC_[O#PD#-W*$'*
M9`!=L(;9&'<!RUQ,`^%UPKQ'XH<B:G)*[CC'$9=AB9:8CE1]KD1&U^;64?E`
MHNUHND@.LXWN@F1'`>)PKD4FPF9?*FNLB^$P67+]85AF'P=$VBO%#DO$HV'"
M&?WNBE]++,LX>M5#O.IHF/UTVWC5\!$J]:QWE>E.D@)(?*%I:L\GZ::+PS";
MYM9>KU$(,!C\U`Z#G_0Q&&8_W"L&/\%B,&N'P4P?@V%VP+UB,,.U#LCE*S>F
M!E6:Z4(RS,[6%))Z)G%`,'6<>&KCDYQ%G9EW8CW0<%-#L!RYD[76!628W:MA
MI*Z991RX7(O2'!YQSBS?H]XRF-IVM(I<D=5;*CU8@DBGHRY:P^Q0S=#2%P0.
MX#Y3C_EQ'GH2N)?`5&VF"\HP6TXS4&1,XH!`7HA0N0LQR&Y$`(.JXN+N;BA5
MV^R621'Z\`YSIMXZ7M`HA%[!1G'-I;Z>\?K.R['^G9?1-X6Q_F]_!^;5Y+V@
M"O\,G_'2[I"JW<D4\&48#6'JGS^!'SJU/E\"ONUBAH*^'+`N$H</60\5I<,:
ML>[MVDPND,6G\[D?L^S$X90KXL=WW:7)$GJ=0:\&F"9'F,@#(X9)<8)I%-[S
M7>0?FZ5B(W;53J!7";I@)N-_H"DJ/0,ITA"7>W(22F0>3]T/M)B,X6995PK;
M1"%7H,,<BIK.T+G^G0&1"F105'YJ:1N-_6#SPMM@H2&&;<)@9ASJSK!9X#T`
M`F,<LY;&T=@/-JVX#18:8M@F#&;&H>X,FRS<`R"#&4?O9]V&6QBMGK!)IZU/
MQ'=C]U*IJZ;<NC3V@$TN;8W54+N6@3!*'+0N/EEKV.S2CM@464:*B[I,8R\%
M&H\PG."U+,@(=0:G>*%S??[VKNG\;3/(B"U&FV%&WWSQK,BAO`WD*=S,XZR3
M-9&*H*^T-63DVG))<$T>B1>)DPY5V%K6&O*430%"8:W7S"T.)Y<G\A-C3D.-
MFOJFH,=M*A%+T"@SB@.*"VJ+VE,B88+XC_Q_,G*E!]'2]J"G;P:@*%G&@4R)
M(SU_!5QNKJ5IU%O%3F9BG;`@G"]B6\\IV`USY4MK>0?02FH&6*J9QF%2GWP6
M!%<^6TC3@0LM8`\Y]<5?P]:NFU&Z#O:6:6U$5;W@AO:@5;H,5FY*EG'8T#67
M'J=!E&T]Y=KIL@?!6$JS!!U%']!34;78F38CF'"Z(2X?<_F)>)P_EQ,\=5;4
MBY]W%"_"-@.FVQGV_-0(.C-YX,"PPJ"N]X,NAF:$C)3+5S.));/`!9^E50#F
M6\(>B+>#L,HI#DOB=/G$"L@I2?Z>>><6]>,SE/GBBW=/G*6X(.73Q]@;S#S.
M:_S@A0RQ+@/"'JP;`=M=;ECP3VY>-4][E5:P]=4,D:KET-R'?DA\J$>6(CX-
M[T4OF<>*[J49Q(;VL%D41G`JN8:;'"5I%\+I?R0+YI/R=4>^V.*[TT<:<#&?
M,S]AY]9ZEJYGV@T%FY)AA&X76>%PJ)<DW,SUTS#TZ5T4BLLDMTQ4`V=>R.7F
MQLK;>+&WQ3BPI=_,K+BME'"`O*']G,O@A)-+O8A3NSFE3)0XIZ5GSUP8'`'J
M6?[++"2KP$@=!OTB;-*/Z;IK:,EC4C'.0"J5CWQ_+@_/2EO#Y@BU@%;*,0Y8
M"HY+QW5#IP*U=\OP"ZI^(,LJ?F0Y@1^M@-HB4$G=*)1F=BE[P>8/&<&J*0$<
M%O8+H<M[3M7TD7.X))?1ZH[X\T5,>"[M20_%MH/!U@XT`K>;O#!FC7'B<]EQ
MY>H\Z^RQ]UK98R)Y+#_<_X[2`9'DD4FXUKQ*K-47]'9T2N&M6-RKV$@;J8RO
MHKD#'#*;H%*\#%WD)7_0@P$';JPD7@.KL,@UQ(1'08]J!9\C/%]C"8/P$_4Y
M8:L'YHE0\)3[0A4.]7UV"Y)Z'O+K7C17RC\3,7U*0*EOB@F+)@V3WR//.,EE
MA^+(]&]$HZ;=+D)1PT;^#!I?3<]&4!1]=A$@!4OY?1ZB0I^-*,D:[R(\,E[R
M%?A0U0>2SOBMJPP.7,&^LF8<N'8DW_U2)K:#?@@?/=*X!-CJYM]0Q0&T,&N^
MY;?#:$V=?T=!&.=9W#*)X\Y"8,01SH5X00Q-<O?[(3Y"N"9<D0,:DC1C^RIF
M\9K8;.G1AJ=^MO9UX"I3.CJV921PQ"YS%1U.(Y_/1@F]<5I0\NMSYF?7`)KF
M`?TQ@(M7:4\1IE)!#6C>@;9&5#H(:&)^)T@5<D&-::R.2?5)D6,R7^0J4=X0
MF[<4%2Q;&*W&F,#ES[H:L;;44"M`HKP]:X#VH-`5USI;_=:40))F=_9,?)L&
M9+Y(G_L,IJN&LKGRYK`W!/204#&[-1DWUHR2-X>N:==.QACK00V7D#)8_3H=
MX:LR4:"GCW81G:]'T-FX;8,Z@O)>`@5G'H+4><.@C@ELH!NM$LT#`0:>(!+P
M%885W)^[[*FFJM"W^E6%Q"BC>!A\V2!K#O630&JZP,Y,@J`X:Y^#_?'E2T"<
MF;=.;IK:(7U,7J5IYK#-0$C>_I""6)KK6@H*QX0XX!)D$'PZR'LW5BB%V*L(
MEGHVC5\SV1!\R_JQS6$^A>/<2]-\AY0V$GU:,;Z9_R,6_WPQXT!X2[&WGP8!
MD5X$5G4"/2<;%#.F+P1,*->?QC0MCVL:@[Y@LRU4FR6%`TVQ"Q#OUZ4)K%//
MR:(8N<#\W#]Q+2I-!C4<`[0JU[:P;R57'"I1=$:GY"[,GM2Z\LF*1BLM3U[;
M#_1`&L:9-\AOJ"?B[OGL069>6F4BU;NXY%)69R+WUIH$3--!0,^7MX5L.\FV
M#JP\$O^.!00^#E:M8K(67)JBH:YKK#T`CF-MS46]N61P^/@JW3/OD;/-?+E+
M4/0!/9QN@4,CBC72P`K</+PG_L:1->VU=#O#'C+WC663@+"".K7C!4/VPJPH
MMV?;?L0G#N7,W78PV//LOD$W$2`.)=`/-W:.?T,?K'<#VUQ0NUZ:0,)Q^OQN
M]R.2QH%@:[CU=$BB(2H<7H`3;A/BQ&5K\AG.69:)_/%:93_8ZFT=@&%&;&)%
M,_]BO`:(Q>:PV2#]8U<G#!R079,'ZR7-'M"`3-X<-A.D'\A4PG@%U3&UY=1Y
M2H4NH-:/2I@+;-=77WF_E96;C(]VTLPW#6=>WPVVZ%K_3KU).#B<NV"8;P7%
M7R)?\=%RA6]+TM/+FQ)98-QH"-BB;OU`W$9HNV[S]3Q/N3A]_X5++CX!,-*0
M2E_8PG!#JH9$3*_CZO#@FF&013Q07;DMZL8K23\6:^/)6&1Y6-Z+>,(K6JTL
M_V6^N*%+CRZH+8X)DXBDN`[%7&KG%TCKG.3O1N.1."QV61#YA/^/&'@TX3_<
MWI-1.O[(\IQ1^H6X;-WF&Z/-1T;KKP`^X.$O+2\]"=^D5PL=%E6Z-Z*?+U+=
MLMQ-XK7JQ:I^QH9\WJ0+!QLM$>K6I&6W7(\_<C9^&T*0K<B`3+KN524+3[@`
MH0E<F5,XJ*/Q%6<D_V;)VJ']M=:A'?$?LBX])K[$$8I;9NY+=#I"/KO(F/-$
M7?'H5CDU="-;E9F;#@)II/I`%IYQ;"4F!/9S/!9)8E7C^5!K/,?BMZ(]G$)F
M.6VIRVHV+EEC0(,JDJ2R'&EK2!-IAB!O%@IF$>C_NW%#=;#,&B:'M=;P+K[%
MEZ_;G/8'+"2O4Y,95?'ELO"%9/7MPZ`_I,7H%&4V%`0"VWD_SA^#YM+,JP8T
MJ36@]YD!C=(QXNWE>A3`54]D"1*(,JFAKB'DY+(6L2APLKGW<4U<<>0EWOH.
M-C=#KM+S->4DU'542-.30UF8J/H1'`*C_'8\=1YIP'P1"Q*;P<B-$Y.6/DDO
MIM^Y=!E_JL9.CVKM5%Q7ST:-370S[F@S\"@_\JO>6DD(U1>\RN):C;1[NZ8.
M`D-@:=^-;Z*[@/P>\0'/'FMC$)/C6GL2H=9-WU':&7`55N)#5<Y!VAQR)5DB
M2KERE+<'+<R@@**P9E2Q#/YRCMF9A/1L8O*N;$;MCR1&WV0_M2NB(KOXUI)7
MA:EU'Q;0)"\HW\@X?"NCOY]K[@)IF'T!7'A*5D-`.))7OH@:<V=!2%=\7I=E
M'94;@590&0*O>BG@0.B:\#D@(KFZTS%'+RJ+T^@'6NID"!RU984#VANR%.OA
M:_(@+G>GK+[HP:O9%[32R1`0&\D,"<RU)3N2R%A\KF1SAN@CN7(M+Y&!M*IC
MFY%`RZ(,H@+MY;F#"G%*?6)S0OI3C/*(H+53P!6D7KXX%*7\>*[>U*#L!5HQ
M90C`->6$`]1+\I3CTF<>_]%.`F,F"P#S84#+J0P!>UM)XM"#<XOZ<;[J9V*)
M':*@VT0!#/J#EC\9`GECV>U8Q"Q^U[0F7O:^SWA9\A'0:%E"0L^QLO*@D"L]
M^YXXD4OFB[7&)LECG)E<T8A4BYVY=RV>K/#3-],33I0[P7Z_L4NQN'KU*2P%
MAP``V)FD6:XR'_%MV4>D[0<Q^`(M"CN6M,5AGM2C(;G@FX)*GJ>I$>J/!!I'
M;41.8D*F0L*QT,H88$T,G$>AR'G,E5D\>Q9;1V($?S^?`(W+&NM%GV(%]JR2
MM#>9IZW<K)+GO`WB?!O)53[=H-47@=GR-8#RK<[T]N"+H:]N/S"HZS;"O=Z5
M=Q4I+L^>%D2NI-EFDIG[UW1YKY$[TGX\X&<#NBM$.P'NV+[Z5#S8[M:X\LJ=
MLBX;Z_0KH#OKE(:>M]:545$8_RE94(\X'XG'?PC3J'Z&96(%2H/7&D-EY!6;
M@-\B2_2@W@EH"2%?J!7TOE69U@VI%^67RBJWK[3Z(H"[E9(7;VIIL;K.`X`%
M=1VD^?BR_O$G2GPNL/N7"_)(W"EWCZJ`N*+S:X!5E]=\+2`,N.;B]4&5\%.V
MLJCLV1?#,1"@;*;-JO.-!EZQH3SS'J(PB#F<?":K.^*K,*WK@0E!$[VM!;*.
MP=PF$1EJ1\:H';UVU([*J"&$[=@8MN/7#MMQ";8C:-BRFU0SCZ_(HX3'['=)
MS/2CY8I7GF[N"0D_^2QZ$*DMBHU<]V%!(UI&B_D"Y#V)$T<\2[P0DKXY-/.F
MBP5UJ4A(%_>!J$,M\7((YXG9\6_Y%O#OC'KAS[RY6"NNM7\C.HFR]/\9T.A7
M;SK`AA01)CUKE%CN6+QW3Z0_-FCB^C#NR%2P.'0E1[6^AU%U`LU)[Q<DIL]U
M!=8^GF[;@7#[I3A%$`G7U;A[I1Q5#W'WT?I[&"+P:V*&"<77#`]:]B<M#]`8
M="\U0K#UZ!O;8@6@(KM(XN=KLE3!\KJ&"""K5[5:P>.+<U^+-S\;0MFY?]\)
M4>?H11*+C"EJ#(<46B"0<D4G*@(NAS*`1?R9>G05K1J%7&J#1<Q%FO."+A&,
M)-CWV7I6B[K89@=$720828#N6DSM?/.7W2GCDW^TBN)J86);:%/9`DZG(W#:
MF&S&+]ZAU^4?Q_X4T:L:@*AMY]$,-(^'UZ<O3D6RVC(6UL>72E6_Z9/E.VF2
MW*<XJVWF)0_.\,U](%W]#O$ET."6GD(-*&$<?B-_'RA:92\^/A";.[J?&?=W
M(I+S<LUEI3I.TQ@`--ZE![BY//#B>$V#W\Y]0F9>2+BD0T,4Z[N#EDEHCV&3
M+/`BF&G>+?%7+>POZ09:YZ"[U>5YQXO4+T1DAA-GRA<'UI)DQ)]2\<Z3)WM:
MN-5(H`4,VN.I*2$<$+>>]^,_?N8.1H1)XTE_TO>2JO83H+4-!EY+-<@4A[9,
MW7APXM2SF-[UD^B!;F=-A(=YT50/83,Y(,'."ZE#W4B<7]R(6^_QP>79L^U&
M#G'$VZN"A2A[8:I<8V>Z$F<B,FC[&5L[7`()?9]BQ%%90'9+ZJCR7,JZM,`0
M5YZ*U.@5%\!T02EW+3JEKBG0(&V-H4J`QBTB!;<X?%[#3?5<G#-_75V-EO9`
M&*[UFP%I*"/T&%^2AJRUQDZ@$;M>L,OQOL,92$513*I35.5!HO(4-9H,.$E-
MC&:I";9IJF+OU;H=EQRLVR?B/I+/S`OO-6:S5H,BFO0JF.HZ2WWAH7><-;S\
MBUC^[1/K!?_U6(BFR!YA+XEJ9]'FGY>&T=N.AFAB[1OQO+AV%?-S%DFOD[4<
M#/0L;%#$\\+:6<!S:=K=`8\'`STX&Q;P?$X[@M)EA?H]RN3[H\JC@'6/W@Z=
M5J\F7*>2F>8`D'E*;+5**VS%@;]@&H7WS*=_$-D966,/^`)D1I@5<I74DMC]
M#"7Q0O8)\S@]`4<D^2D4CB6[<I2P/@N"B$A/RDP'@2]"UEHIVLD+QRRKI#T)
M\K=&>=T=.&]L4'Q+,L(PG58KZDE/1BKO@3:5`AWBL*29X';%0#$=IG3-1YQ'
M8<#7=`[UEM?,=<^9+_ZQ[PP%Q<=`'R`U4I`^4T&;18_#A??(XV74<$EC@._`
MK@2'U8UAM+"(4.NUYD.<D7,36G[89;TI<^@J?H/MY;BW^A3L8A2/7G;`Z77X
M1BZ\!:%Q992,RX&\8^V78!?->/2P/4I(U%`L8)+]WVGDKS,BDWUA?G5S]DQ\
MFP;2N$J;@6`O<&Q/B5K+&(F.[.HR[NL1]`63G7%4M;+K92EWYCGP@<.NXDDM
M4U1J&%2%:[X#>]]F9Q18BM!>?0LP5.[-)%/.E4]M(B!:;"N&HTT(\%T4!`$>
M0\Q>W:JAB7]8186^1P.G8]O7="RAI2V9AUF$8P@3Z9,"X$M'NV$G_4.^^T?^
MG856$X*!,!9C,G0M!OT1!*3%M`1_;S;K6!2HT1@2H6LRZ$]'($VF%?!_`H-Y
M#=L5@X#H!/W1#?X=RSZ&*HG0`5B(]M=U[0/]J12@?1A"W;MUX$EJK+E,^ZY%
M5F//]VL5-'=*;,1Q_W97:^8;(K,OB;\%1':X)/Z:M"2W7'ASYHE-0$.9?$6?
MW8*DG@<DM=Y+Q#4^U"IIBPF-)AW+@R-A!0DHJ<MMK`I?:H,`A$95R@N_1#J.
MUU+W]Q!PETPTO7.PCP'M[RN@S!)Z=?<5:O@-ME>37_VI_7V%SCCM_>K^K@-6
M'=[270>)=YPZ_X[2]X3GBRQ4(M$,2=L_R16$1DDAR1?<@9LH.W]+8'\3!?U-
ME#][(O_^)LH^E?]UQ$CV:?M8\V#V:?O[M/U]VOX^;7^?MH_63O9I^W]BB]G!
MM'V3$%4+16XQSCX;OI78X%4)B0=^S3=`T,?J]S=`\!G,:]CYFMP`07_H@7_S
M.V#L4I[CGOZ+^...D\]_\Q]02P,$%`````@`?'MU0:\*2B-'"```!%```!$`
M'`!O>&ES+3(P,3(P.3,P+GAS9%54"0`#2SFM4$LYK5!U>`L``00E#@``!#D!
M``#M7%MSV[82?CZ=.?\!U<M)'VA*=NS6'KL=6TX:S;B66CEMWCH0"4DXI0`%
M`&7YWW<!DN)%)$72<L-4SH.'`G87N]^'RX):Y?*G]<)#*R(DY>RJTSOJ=A!A
M#G<IFUUU/HZMZW%_,.B@GW[\[S<(_EU^:UGHUT\#IHC`CJ(K@BP+^BZE,R<+
MC,`:DU>=N5++"]M^?'P\>CPYXF)F'W>[/?O3+W=C(]<)!"_6'F5_Y8GWSL_/
M;=,;B6Y)KB?"BTR?V+I[@B796(9>6B)/F528.2EY5VT4DL*G=M"9$J6YHF>!
M*(U$79*1D\0YFO&5#1T@WSNVNCWKI!>)^]*:8;S<J$RQG!C384>."N.,^8O\
M0%TE;/6T)#8(62!%!'4V>KN5T@K@@FZ6N<Z9GASOAI\&XXT"7U-YY/"%D>N>
MG^BIYI$%8>H]%XM;,L6^!PQ\]K%'IY2X':2PF!%UCQ=$+K%#2BQ%TQ,SQA56
M,)G#%MVV7%(VY=#PGTL]32X$]\@#>(STP\??!MMV=8=]RQU?>W?-W'=,4?4T
M`"MB8:QW$'6O.J42>CP8W8SHDBEEU+C5A86`+!2I)A\Q<U%@!R4,7=I9$PG#
MOB3ND/UHGI>"2#!CE.Z@(50,10J4'.PYOE=/)W8E5R5LB%"NC7N?,\D]ZF)%
MW!OLZ54ZGA.B9`!Z<7<QXL<`\QB0(2'D21LH-(("*Z]P1WB.L(#XYD11\'H'
M]FG98B).JA.!WJ2,?G?0Q&PPD\/I<`EGKQXU9T$4R!43\K:,D-@:XE,4VT-O
M/C+LNQ1D7FDQ``VG8\6=O^;<<R&7@K.,.E25T),O7TS3:26:-$M)N_]#H>57
MPG+61Q_+^7N//^Y81K%8,3UGU5>1-H>,O8,FY9XKTK/Z?+'$[`GRI[&_6&#Q
M!.N"SABD?PZ&M,IQN`_Y$)N-`$R'DI"IAKK%]'VOLS`J'8]+7\"-!ND1D$[3
M'N8$A0.9]"P<RBRT>#`4CX:BX0Z2T6-K!'.=J011<5,Q_C_DXJ^3ME#W(,$\
ML6[)1,5(AI^+83S/A5&G7%KQ(#%\:R7/PW>??;A<Q8CF]A;BV^OFXAMD4,E#
M-S!TD'B?!H@.ER9/A+WY#RP$3FT(Q2+%R/=RD3^-D$>A,;-%1^8.$O\SZ]I=
M4<F%/A=U%N)[^E2ZG@D2YC,3C\Z2MX?:6L4L'>>RI'.CR+PA*!X`Q2.@Q!`'
MR=SWUMB?2/+9AX#>K=)G:$Y?,0LGN2SH%"<V@@(K!P=TW9PQG7<VUBXFZVV6
MK.8))WH3/1W>;:(N,P]XXC5E-=0MYO1TGYP&HQT>HV'BGR0JW52,_UD6_U#Q
M<,$L2+B2X):+%(.]=74N3L@.%_^Z6\PM49AZ#?>G2+F8LZWK]G,VJ'"X5U(K
M\G*O5X/^XOQ9[,96BFG>>AVP!YK19N##(SP\1E*+,]-62,;QUKN#S:%TL`LH
MC5TO#]!>":);[P2RB*+>X6&Z_3XK?]NI(%>,_-8]/^_UU^N649QXI;:0'3+%
M-&Q=],M2KX/=9<KA[57AH&P7VKK`5R#A7[4QZ3^Z\.XW,D6F8.]"%X-==21=
M+#U=7F?:YH),KSJ:&2NJV?H30CM:+[Q(1)LN*=@S9&;1"`>.3&#A;%G9*B@$
M(WQ)A(*TQHZ<CPPHJK3Z*#$,TN/`4K7W$;*')W5#!A7BO6"L=]K^7H.$V5<W
MR,R$?:%0^_$H>PT8ED[=@-.K[87BO=T,D@PWK(JTX[+(\'.V=/(2`N="(;95
M?UE63AL4`M]QQY@J4=&?K$C/TDU6[]@ZZ1VMI1M[6L>)&(9Z3D1Z#9PH+X(M
M<,.XD%O;:Q-/R8TM*[95U9_2(N,R=[(Z^J'!^*45R\WAT"T-O*E0#5UEIB0U
M[P-%/57.]53IG3W3F6:.[/(B+*PVR8TNPOZSK%3Y>B*5KN;O&*_+RYIC61P^
M7764\&'-,>IY^OU>]-E4X%_`%D6Y^V!V4M<78?%TL+,&$F"%LME`D866`B!\
M,$R5KR5_%MQ?1H(41$I#!/R8J[_MDB/\I%VY)VHXU=F9?I\QG)Z^[7:[$%1W
M$V@=C9WA!7N9BKHF037K5<<1Q-7%@,F@%YQ!+BB>]A!VG[.5/@?`MULR@2[(
M0V4F#A-#WQ>ZGG8$T].0$&#07/TK``02N2D!MUV3E8_!-R+[.9$7R7VE(7ZH
M&.*'KS?$0<40!RT.<<?V4W&7>DZ`+IE\T9VI^B;48AK#[2(]^P92^O`XQT)_
MPQ9$646P>I"I,]2HOU0L0U_I,?5O`BL$E"?=BJ@^5&6H7+"-L>Q@J()T*Z(:
M5&6H7+"-L>Q@J(+T%X[JCDMY0^`>0'ZAC`MS*U`$;.MKPDCP%=4_(7[/Q8`Y
M?$$>\#J.L:%NC0O%/WJNO5L3X5!)AM/HU>[U(GF:E?0W#^F%#[%MG]/3M*2_
MZ;UO7S.S/\=L1@;L=^SYL7\PLV[!AY7YYNF.X@GUJ*)Q0+6U6DN=R0P?^'O*
M8#B*O?CW1MF+?17)UEWKJY<F/Y"UNO%@^XSB;:9:.^#@-_@7*K*QE]2Y6:EI
MEO'GVVG=?&A6K_E<8+)66@=+JCHR&VU!9^N"**U"S`954;AU038L^7KN#-XR
M\V\!9E-?LB>$<NRU#JITF53!<F\_XYEJK_(X>BT.9'<]5>[N55&CG>$6ULM4
MW*C;/SW-%><&2^+JK80P&7P%IMV?!2GDS5,L,\)/YENS1RS<,-J?3:`#-C(^
MP]@ROO>_C.TO?1G;44E5;VJT>L7OXB^'/KFON=',]I>>&]?N_WVIPO]6(_YA
M<'17R^]LI=-_$#J;*^)>KXC`,Q*]'!D)JDM@2@+:H5C_Z@GW3N@WLZ%6L)=V
M4'``CW\#4$L!`AX#%`````@`?'MU0;[5H`P?A0``-2<%`!$`&````````0``
M`*2!`````&]X:7,M,C`Q,C`Y,S`N>&UL550%``-+.:U0=7@+``$$)0X```0Y
M`0``4$L!`AX#%`````@`?'MU0<Q7T<GB"@``:'T``!4`&````````0```*2!
M:H4``&]X:7,M,C`Q,C`Y,S!?8V%L+GAM;%54!0`#2SFM4'5X"P`!!"4.```$
M.0$``%!+`0(>`Q0````(`'Q[=4'9"&V$%@P``&&A```5`!@```````$```"D
M@9N0``!O>&ES+3(P,3(P.3,P7V1E9BYX;6Q55`4``TLYK5!U>`L``00E#@``
M!#D!``!02P$"'@,4````"`!\>W5!AF\;Y4XI``!K;P(`%0`8```````!````
MI($`G0``;WAI<RTR,#$R,#DS,%]L86(N>&UL550%``-+.:U0=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`?'MU0<C%=%FZ&P``:<T!`!4`&````````0``
M`*2!G<8``&]X:7,M,C`Q,C`Y,S!?<')E+GAM;%54!0`#2SFM4'5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`'Q[=4&O"DHC1P@```10```1`!@```````$`
M``"D@:;B``!O>&ES+3(P,3(P.3,P+GAS9%54!0`#2SFM4'5X"P`!!"4.```$
:.0$``%!+!08`````!@`&`!H"```XZP``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Patents (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_OXIS_PatentsDetails1Abstract', window );"><strong>Patents Details 1</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2012</a></td>
        <td class="nump">$ 12,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2013</a></td>
        <td class="nump">4,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2014</a></td>
        <td class="nump">4,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2015</a></td>
        <td class="nump">4,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2016</a></td>
        <td class="nump">$ 1,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OXIS_PatentsDetails1Abstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>OXIS_PatentsDetails1Abstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>OXIS_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
